

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 973 746 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
24.09.2003 Bulletin 2003/39

(51) Int Cl.⁷: **C07D 215/54**, A61K 31/47,
C07D 401/12

(21) Application number: **98914417.5**

(86) International application number:
PCT/US98/06480

(22) Date of filing: **02.04.1998**

(87) International publication number:
WO 98/043960 (08.10.1998 Gazette 1998/40)

(54) **SUBSTITUTED 3-CYANO QUINOLINES**

SUBSTITUIERTE 3-CYANOCHINOLINE
3-CYANO QUINOLINES SUBSTITUEES

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **03.04.1997 US 826604**

(43) Date of publication of application:
26.01.2000 Bulletin 2000/04

(73) Proprietor: **Wyeth Holdings Corporation**
Madison, NJ 07940 (US)

(72) Inventors:
• **WISSNER, Allan**
Ardsey, NY 10502 (US)
• **JOHNSON, Bernard, Dean**
Stony Point, NY 10980 (US)
• **REICH, Marvin, Fred**
Suffern, NY 10901 (US)
• **FLOYD, Middleton, Brawner, Jr.**
Suffern, NY 10901 (US)
• **KITCHEN, Douglas, B.**
Schenectady, NY 12303 (US)
• **TSOU, Hwei-Ru**
New City, NY 10956 (US)

(74) Representative: **Mannion, Sally Kim, Dr.**
c/o Wyeth Laboratories,
Huntercombe Lane South,
Taplow
Maidenhead, Berkshire SL6 0PH (GB)

(56) References cited:
WO-A-96/09294 **WO-A-97/14681**

- **C. C. PRICE; V. BOEKELHEIDE: "A synthesis of substituted 4-aminoquinolines" J. AM. CHEM. SOC., vol. 68, 1946, pages 1246-50, XP002072256**
- **R. J. IFE: "Reversible Inhibitor of the Gastric (H1/K+)-ATPase. 3. 3-Substituted-4-(phenylamino)quinolines" J. MED. CHEM., vol. 35, no. 18, 1992, pages 3413-22, XP002072257 cited in the application**
- **REWCASTLE G W ET AL: "TYROSINE KINASE INHIBITORS. 5. SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS FOR 4- (PHENYLMETHYL)AMINO- AND 4-(PHENYLAMINO)QUINAZOLINES AS POTENT ADENOSINE 5-TRIPHOSPHATE BINDING SITE INHIBITORS OF THE TYROSINE KINASE DOMAIN OF THE EPIDERMAL GROWTH FACTOR RECEPTOR" JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 18, 1995, pages 3482-3487, XP000197136**
- **GAZIT A. ET AL.: "TYRPHOSTINS. 5. POTENT INHIBITORS OF PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE: STRUCTURE-ACTIVITY RELATIONSHIPS IN QUINOXALINES, QUINOLINES, AND INDOLE TYRPHOSTINS " J. MED. CHEM., vol. 39, no. 11, 1996, pages 2170-77, XP002072258 cited in the application**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 973 746 B1

Description

BACKGROUND OF THE INVENTION

[0001] This invention relates to certain substituted 3-cyano quinoline compounds as well as the pharmaceutically acceptable salts thereof. The compounds of the present invention inhibit the action of certain growth factor receptor protein tyrosine kinases (PTK) thereby inhibiting the abnormal growth of certain cell types. The compounds of this invention are therefore useful for the treatment of certain diseases that are the result of deregulation of these PTKs. The compounds of this invention are anti-cancer agents and are useful for the treatment of cancer in mammals. In addition, the compounds of this invention are useful for the treatment of polycystic kidney disease in mammals. This invention also relates to the manufacture of said 3-cyano quinolines, their use for the treatment of cancer and polycystic kidney disease, and the pharmaceutical preparations containing them.

[0002] Protein tyrosine kinases are a class of enzymes that catalyze the transfer of a phosphate group from ATP to a tyrosine residue located on a protein substrate. Protein tyrosine kinases clearly play a role in normal cell growth. Many of the growth factor receptor proteins function as tyrosine kinases and it is by this process that they effect signaling. The interaction of growth factors with these receptors is a necessary event in normal regulation of cell growth. However, under certain conditions, as a result of either mutation or overexpression, these receptors can become deregulated; the result of which is uncontrolled cell proliferation which can lead to tumor growth and ultimately to the disease known as cancer [Wilks A.F., *Adv. Cancer Res.*, 60, 43 (1993) and Parsons, J.T.; Parsons, S.J., *Important Advances in Oncology*, DeVita V.T. Ed., J.B. Lippincott Co., Phila., 3 (1993)]. Among the growth factor receptor kinases and their proto-oncogenes that have been identified and which are targets of the compounds of this invention are the epidermal growth factor receptor kinase (EGF-R kinase, the protein product of the erbB oncogene), and the product produced by the erbB-2 (also referred to as the neu or HER2) oncogene. Since the phosphorylation event is a necessary signal for cell division to occur and since overexpressed or mutated kinases have been associated with cancer, an inhibitor of this event, a protein tyrosine kinase inhibitor, will have therapeutic value for the treatment of cancer and other diseases characterized by uncontrolled or abnormal cell growth. For example, overexpression of the receptor kinase product of the erbB-2 oncogene has been associated with human breast and ovarian cancers [Slamon, D. J., et. al., *Science*, 244, 707 (1989) and *Science*, 235, 1146 (1987)]. Deregulation of EGF-R kinase has been associated with epidermoid tumors [Reiss, M., et. al., *Cancer Res.*, 51, 6254 (1991)], breast tumors [Macias, A., et. al., *Anticancer Res.*, 7, 459 (1987)], and tumors involving other major organs [Gullick, W.J., *Brit. Med. Bull.*, 47, 87 (1991)]. Because of the importance of the role played by deregulated receptor kinases in the pathogenesis of cancer, many recent studies have dealt with the development of specific PTK inhibitors as potential anti-cancer therapeutic agents [some recent reviews: Burke. T.R., *Drugs Future*, 17, 119 (1992) and Chang, C.J.; Geahlen, R.L., *J. Nat. Prod.*, 55, 1529 (1992)].

[0003] It is also known that deregulation of EGF receptors is a factor in the growth of epithelial cysts in the disease described as polycystic kidney disease [Du J., Wilson P. D., *Amer. J. Physiol.*, 269(2 Pt 1), 487 (1995); Nauta J., et al., *Pediatric Research*, 37(6), 755 (1995); Gattone V.H., et al., *Developmental Biology*, 169(2), 504 (1995); Wilson P.D., et al., *Eur. J. Cell Biol.*, 61(1), 131, (1993)]. The compounds of this invention, which inhibit the catalytic function of the EGF receptors, are consequently useful for the treatment of this disease.

[0004] The mitogen-activated protein kinase (MAPK) pathway is a major pathway in the cellular signal transduction cascade from growth factors to the cell nucleus. The pathway involves kinases at two levels: MAP kinase kinases (MAPKK), and their substrates MAP kinases (MAPK). There are different isoforms in the MAP kinase family. (For review, see Rony Seger and Edwin G. Krebs, *FASEB*, Vol. 9, 726, June 1995). The compounds of this invention can inhibit the action of two of these kinases: MEK, a MAP kinase kinase, and its substrate ERK, a MAP kinase. MEK is activated by phosphorylation on two serine residues by upstream kinases such as members of the *raf* family. When activated, MEK catalyzes phosphorylation on a threonine and a tyrosine residue of ERK. The activated ERK then phosphorylates and activates transcription factors in the nucleus, such as *fos* and *jun*, or other cellular targets with PXT/SP sequences. ERK, a p42 MAPK is found to be essential for cell proliferation and differentiation. Over-expression and/or over-activation of Mek or ERK has been found to be associated with various human cancers (For example, Vimala S. Sivaraman, Hsien-yu Wang, Gerard J. Nuovo, and Craig C. Malbon, *J. Clin. Invest.* Vol. 99, No. 7 April 1997). It has been demonstrated that inhibition of MEK prevents activation of ERK and subsequent activation of ERK substrates in cells, resulting in inhibition of cell growth stimulation and reversal of the phenotype of *ras*-transformed cells (David T. Dudley, Long Pang, Stuart J. Decker, Alexander J. Bridges, and Alan R. Saltiel, *PNAS*, Vol. 92, 7686, August 1995). Since, as demonstrated below, the compounds of this invention can inhibit the coupled action of MEK and ERK, they are useful for the treatment of diseases such as cancer which are characterized by uncontrolled cell proliferation and which, at least in part, depend on the MAPK pathway.


[0005] Epithelial Cell Kinase (ECK) is a receptor protein tyrosine kinase (RPTK) belonging to the EPH (Erythropoietin Producing Hepatoma) family. Although originally identified as an epithelial lineage-specific tyrosine kinase, ECK has subsequently been shown to be expressed on vascular endothelial cells, smooth muscle cells, and fibroblasts. ECK

is a type I transmembrane glycoprotein with the extracellular ligand-binding domain consisting of a cysteine-rich region followed by three fibronectin type III repeats. The intracellular domain of ECK possesses a tyrosine kinase catalytic domain that initiates a signal transduction cascade reflecting the ECK function. ECK binds and is subsequently activated by its counter-receptor, Ligand for Eph-Related Kinase (LERK)- 1, which is an immediate early response gene product readily inducible in a lineage-unrestricted manner with proinflammatory cytokines such as IL-1 or TNF. Soluble LERK-1 has been shown to stimulate angiogenesis in part by stimulating ECK in a murine model of corneal angiogenesis. Unlike their normal counterparts, tumor cells of various lineages constitutively express LERK-1 and this expression can further be upregulated by hypoxia and proinflammatory cytokines. Many of these tumor cells also express ECK at higher levels than their normal counterparts, thereby creating an opportunity for autocrine stimulation via ECK : LERK-1 interaction. The increased expression of both ECK and LERK-1 has been correlated with the transformation of melanomas from the noninvasive horizontal phase of growth into very invasive vertically growing metastatic melanomas. Together, the ECK : LERK-1 interaction is believed to promote tumor growth via its tumor growth promoting and angiogenic effects. Thus, the inhibition of the ECK tyrosine kinase activity mediating signaling cascade induced by its binding and cross-linking to LERK-1 may be therapeutically beneficial in cancer, inflammatory diseases, and hyperproliferative disorders. As is shown below, the compounds of this invention inhibit the tyrosine kinase activity of ECK and are therefore useful for the treatment of the aforementioned disorders.

[0006] Growth of most solid tumors is dependent on the angiogenesis involving activation, proliferation and migration of vascular endothelial cells and their subsequent differentiation into capillary tubes. Angiogenization of tumors allows them access to blood-derived oxygen and nutrients, and also provides them adequate perfusion. Hence inhibiting angiogenesis is an important therapeutic strategy in not only cancer but also in a number of chronic diseases such as rheumatoid arthritis, psoriasis, diabetic retinopathy, age-related macular degeneration, and so on. Tumor cells produce a number of angiogenic molecules. Vascular Endothelial Growth Factor (VEGF) is one such angiogenic factor. VEGF, a homodimeric disulfide-linked member of the PDGF family, is an endothelial cell-specific mitogen and is known to cause profound increase in the vascular endothelial permeability in the affected tissues. VEGF is also a senescence-preventing survival factor for endothelial cells. Almost all nucleated tissues in the body possess the capability to express VEGF in response to various stimuli including hypoxia, glucose deprivation, advanced glycation products, inflammatory cytokines, etc. Growth-promoting angiogenic effects of VEGF are mediated predominantly via its signaling receptor Kinase insert Domain containing Receptor (KDR).- The expression of KDR is low on most endothelial cells; however, activation with angiogenic agents results in a significant upregulation of KDR on endothelial cells. Most angiogenized blood vessels express high levels of KDR. KDR is a receptor protein tyrosine kinase with an extracellular VEGF-binding domain consisting of 7 immunoglobulin-like domains and a cytoplasmic domain containing the catalytic tyrosine kinase domain split by a kinase-insert region. Binding to VEGF causes dimerization of KDR resulting in its autophosphorylation and initiation of signaling cascade. Tyrosine kinase activity of KDR is essential for mediation of its functional effects as a receptor for VEGF. Inhibition of KDR-mediated functional effects by inhibiting KDR's catalytic activity is considered to be an important therapeutic strategy in the treatment of angiogenized disease states including cancer. As is shown below, the compounds of this invention inhibit the tyrosine kinase activity of KDR and are therefore useful for the treatment of the aforementioned disease states.

[0007] In addition to the above utilities some of the compounds of this invention are useful for the preparation of other compounds of this invention.

[0008] The compounds of this invention are certain substituted 3-cyano quinolines. Throughout this patent application, the quinoline ring system will be numbered as indicated in the formula below; the numbering for the quinazoline ring system is also shown :



[0009] No 3-cyano quinolines have been reported that have biological activity as inhibitors of protein tyrosine kinases. A 3-cyano quinoline with a 4-(2-methyl anilino) substituent having gastric (H⁺/K⁺)-ATPase inhibitory activity at high concentrations has been described [Ife R.J., et al., *J. Med. Chem.*, 35(18), 3413 (1992)].

[0010] There are quinolines that do not have the 3-cyano substituent and, unlike the compounds of this invention, are unsubstituted at the 4-position but are reported to be inhibitors of protein tyrosine kinases [Gazit A., et al., *J. Med.*


Chem., 39(11), 2170 (1996)]. A series of quinolines that have a 3-pyridyl substituent and no substituent at the 4-position have been described as inhibitors of platelet derived growth factor receptor kinase [Dolle R.E., et al., *J. Med. Chem.*, 372, 2627 (1994) and Maguire M.P., et al., *J. Med. Chem.*, 372, 129 (1994)]. The patent application WO 96/09294 describes inhibitors of protein tyrosine kinases that include 4-anilino quinolines with a large variety of substituents on positions 5-8 but which must also have a hydrogen atom at position 3. The US patent 5,480,883 describes quinoline derivatives that are inhibitors of protein tyrosine kinases but these derivatives do not have the unique combination of substituents, including the 3-cyano group, contained in the compounds of the present invention.

[0011] In addition to quinolines, certain quinazoline derivatives that are similar, in some respects, to the compounds of this invention are known to be inhibitors of protein tyrosine kinases. The application EP-92305703.8 describes 4-anilinoquinazolines that contain simple substituents such as chloro, trifluoromethyl, or nitro groups at positions 5 to 8. The application EP-93300270.1 is similar but with a much larger variety of substituents now allowed at positions 5 to 8. The application WO-9609294 describes compounds with similar substituents at positions 5 to 8 and with the substituent at to 4-position consisting of some polycyclic ring systems. Some simple substituted quinazolines are also described in the applications WO-9524190, WO-9521613, and WO-9515758. The applications EP-93309680.2 and WO-9523141 cover similar quinazoline derivatives where the aryl group attached at position 4 can be a variety of heterocyclic ring structures. The application EP-94305195.3 describes certain quinazoline derivatives that have alkenoylamino and alkynoylamino groups among the substituents at position 6 and a halogen atom at position 7. The application WO-9519774 describes compounds where one or more of the carbon atoms at positions 5-8 can be replaced with heteroatoms resulting in a large variety of bicyclic systems where the left-hand ring is a 5 and 6-membered heterocyclic ring; in addition, a variety of substituents are allowed on the left-hand ring. The application EP-682027-A1 describes certain pyrrolopyrimidine inhibitors of PTKs. The application WO-9519970 describes compounds in which the left-hand aromatic ring of the basic quinazoline structure has been replaced with a wide variety of different heterocyclic rings so that the resulting inhibitors are tricyclic. The application WO-94305194.6 describes quinazolines where an additional 5 or 6-membered heterocyclic ring with optional substitution is fused at positions 5 and 6.

[0012] In addition to the aforementioned patent applications, a number of publications describe 4-anilinoquinazolines: Fry, D.W., et. al., *Science*, 265, 1093 (1994), Rewcastle G.W., et. al., *J. Med. Chem.*, 38, 3482 (1995), and Bridges, A.J., et. al., *J. Med. Chem.*, 39, 267, (1996). There are no publications that describe 3-cyano quinolines as PTK inhibitors.

DESCRIPTION OF THE INVENTION

[0013] This invention provides a compound of formula 1:








wherein:



X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;
n is 0-1;

Y is -NH-, -O-, -S-, or -NR- ;

R is alkyl of 1-6 carbon atoms;

R₁, R₂, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphanyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, aminoalkyl of 1-4 carbon atoms, N-alkylaminoalkyl of 2-7 carbon atoms, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino,





R₅ is alkyl of 1-6 carbon atoms, alkyl optionally substituted with one or more halogen atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, nitro, cyano, or alkyl of 1-6 carbon atoms groups;

R₆ is hydrogen, alkyl of 1-6 carbon atoms, or alkenyl of 2-6 carbon atoms;

R₇ is chloro or bromo

R₈ is hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, or bromo;

Z is amino, hydroxy, alkoxy of 1-6 carbon atoms, alkylamino wherein the alkyl moiety is of 1-6 carbon atoms, dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, morpholino, piperazino, N-alkylpiperazino wherein the alkyl moiety is of 1-6 carbon atoms, or pyrrolidino;

m = 1-4, q = 1-3, and p = 0-3;

any of the substituents R₁, R₂, R₃, or R₄ that are located on contiguous carbon atoms can together be the divalent radical -O-C(R₈)₂-O-;

or a pharmaceutically acceptable salt thereof provided that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, then X is not 2-methylphenyl, and further provided that when Y is -NH-, R₃ is chlorine, R₁, R₂ and R₄ are hydrogen, and n is 0, then X is not phenyl or 3-chlorophenyl, and further provided that when Y is -NH-, R₁, R₂, and R₃ are hydrogen, R₄ is R₅-CONH(CH₂)_p-, R₅ is 2,6-dichlorophenyl, n is 1, and p is 0, then X is not pyridin-2-yl.

[0014] The pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.

[0015] In a further aspect of the invention there is provided pharmaceutical compositions comprising a compound of formula 1 as defined above provided that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, then X is not 2-methylphenyl, and further provided that when Y is -NH-, R₁, R₂, and R₃ are hydrogen, R₄ is R₅-CONH(CH₂)_p-, R₅ is 2,6-dichlorophenyl, n is 1, and p is 0, then X is not pyridin-2-yl; and a pharmaceutically acceptable carrier. In a yet further aspect of the invention there is provided a compound of formula 1 as defined above provided that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, then X is not 2-methylphenyl, and further provided that when Y is -NH-, R₁, R₂, and R₃ are hydrogen, R₄ is R₅-CONH(CH₂)_p-, R₅ is 2,6-dichlorophenyl, n is 1, and p is 0, then X is not pyridin-2-yl; for use as a therapeutic agent. In a still further aspect of the invention there is provided the use of a compound of formula 1 as defined above provided that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, then X is not 2-methylphenyl, and further provided that when Y is -NH-, R₁, R₂, and R₃ are hydrogen, R₄ is R₅-CONH(CH₂)_p-, R₅ is 2,6-dichlorophenyl, n is 1, and p is 0, then X is not pyridin-2-yl; in the preparation of a medicament for treating, inhibiting the growth of, or eradicating a neoplasm in a mammal in need thereof; or inhibiting the biological effects of a deregulated protein kinase in a mammal in need thereof. In another aspect of the invention there is provided the use of a compound of formula 1 as defined above provided that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, then X is not 2-methylphenyl; in the preparation of a medicament for use in treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal.


[0016] The alkyl portion of the alkyl, alkoxy, alkanoyloxy, alkoxymethyl, alkanoyloxymethyl, alkylsulphonyl, alkylsulphonamido, carboalkoxy, carboalkyl, alkanoylamino aminoalkyl, alkylaminoalkyl, N,N-dicycloalkylaminoalkyl, hydroxyalkyl, and alkoxyalkyl substituents include both straight chain as well as branched carbon chains. The cycloalkyl portions of N-cycloalkyl-N-alkylaminoalkyl and N,N-dicycloalkylaminoalkyl substituents include both simple carbocycles as well as carbocycles containing alkyl substituents. The alkenyl portion of the alkenyl, alkenoyloxymethyl, alkenyloxy, alkenylsulfonamido, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation. The alkynyl portion of the alkynyl, alkynoyloxymethyl, alkynylsulfonamido, alkynyloxy, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation. Carboxy is defined as a $-CO_2H$ radical. Carboalkoxy of 2-7 carbon atoms is defined as a $-CO_2R''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Carboalkyl is defined as a $-COR''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkanoyloxy is defined as a $-OCOR''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkanoyloxymethyl is defined as $R''CO_2CH_2-$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkoxymethyl is defined as $R''OCH_2-$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkylsulphonyl is defined as $R''SO_2-$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkylsulphonamido, alkenylsulfonamido, alkynylsulfonamido are defined as $R''SO_2NH-$ radical, where R'' is an alkyl radical of 1-6 carbon atoms, an alkenyl radical of 2-6 carbon atoms, or an alkynyl radical of 2-6 carbon atoms, respectively. N-alkylcarbamoyl is defined as $R''NHCO-$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. N,N-dialkylcarbamoyl is defined as $R''R'NCO-$ radical, where R'' is an alkyl radical of 1-6 carbon atoms, R' is an alkyl radical of 1-6 carbon atoms and R'' , and R' may be the same or different. When X is substituted, it is preferred that it is mono-, di-, or tri-substituted, with monosubstituted being most preferred. It is preferred that of the substituents R_1 , R_2 , R_3 , and R_4 , at least one is hydrogen and it is most preferred that two or three be hydrogen. An azacycloalkyl-N-alkyl substituent refers to a monocyclic heterocycle that contains a nitrogen atom on which is substituted a straight or branched chain alkyl radical. A morpholino-N-alkyl substituent is a morpholine ring substituted on the nitrogen atom with a straight or branch chain alkyl radical. A piperidino-N-alkyl substituent is a piperidine ring substituted on one of the nitrogen atoms with a straight or branch chain alkyl radical. A N-alkyl-piperidino-N-alkyl substituent is a piperidine ring substituted on one of the nitrogen atoms with a straight or branched chain alkyl group and on the other nitrogen atom with a straight or branch chain alkyl radical.

[0017] When any group contains an alkyl portion, the alkyl portion contains preferably 1-6 carbon atoms, more preferably 1-4 carbon atoms, particularly methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl or tert-butyl. When any group contains an alkenyl or alkynyl portion, the alkenyl or alkynyl portion contains preferably 2-6 carbon atoms, more preferably 2-4 carbon atoms.

[0018] The compounds of this invention may contain an asymmetric carbon; in such cases, the compounds of this invention cover the racemate and the individual R and S enantiomers, and in the case were more than one asymmetric carbon exists, the individual diastereomers, their racemates and individual enantiomers

[0019] Particularly preferred compounds of this invention are those in which X is optionally substituted phenyl or a pharmaceutically acceptable salt thereof, in particular X is a phenyl ring which may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxo, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino. Most preferably X is phenyl optionally mono-, di-, or tri-substituted with halogen.


[0020] Y is preferably the group $-NH-$. Group n is preferably 0. Groups R_1 and R_4 are preferably hydrogen. The group R_2 is preferably



The group R_3 is preferably hydrogen, alkoxy of 1-6 carbon atoms, or $Z \text{---} (C(R_6)_2)_q Y \text{---}$. The group R_6 is preferably hydrogen or alkyl of 1-6 carbon atoms. The group R_8 is preferably hydrogen, alkyl of 1-6 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, or morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms. The group Z is preferably dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, or morpholino. The group q is preferably 2, 3 or 4.

[0021] All of the preferred groups or moieties may be selected independently of any other preferred group.

[0022] A preferred sub-group of the compounds of this invention are those of Formula 1 wherein X is phenyl ring which may be optionally mono- di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino; n is 0-1; Y is -NH-; R₁ and R₄ are hydrogen; R₂ is



R₃ is hydrogen, alkoxy of 1-6 carbon atoms, or Z-(C(R₆)₂)_qY-; R₆ is hydrogen or alkyl of 1-6 carbon atoms; R₈ is hydrogen, alkyl of 1-6 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, or morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms;


Z is dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, or morpholino;

q = 1-4, and p = 0-3; or a pharmaceutically acceptable salt thereof.

[0023] The preparation of the compounds of this invention encompassed by Formula 5 is described below in Flow-sheet A where Y and n are as described above and X' is cycloalkyl or phenyl optionally substituted with one or more substituents selected from the group consisting of hydrogen, halogeno, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, halomethyl, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, trifluoromethyl, cyano, nitro, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, dialkylamino of 2 to 12 carbon atoms. R₁', R₂', R₃', and R₄' are each, independently, hydrogen, halogeno, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, trifluoromethyl, cyano, nitro, carboxy, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, alkoxyamino of 1-4 carbon atoms, dialkylamino of 2 to 12 carbon atom, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino, N-alkyl-carbamoyl of 1-6 carbon atoms, N,N-dialkylcarbamoyl of 2-12 carbon atoms. Any of the substituents R₁', R₂', R₃', or R₄' that are located on contiguous carbon atoms can together be the divalent radical -O-C(R₆)₂-O-. According to the sequence of reaction outlined in flowsheet A, a quinoline-3-carboxylic acid ester of Formula 2 is hydrolyzed with base to furnish a carboxylic acid of Formula 3. The carboxylic acid group of 3 is converted to an acyl imidazole by heating it with carbonyldiimidazole in an inert solvent such as dimethylformamide (DMF) followed by the addition of ammonia to give the amide 4. Dehydration of the amide functional group with a dehydrating agent such as trifluoroacetic anhydride in pyridine, phosphorous pentoxide in an inert solvent, or the like gives the 3-cyano quinolines, 5, of this invention. In those cases where any of the intermediates have an asymmetric carbon atom, they can be used as the racemate or as the individual R or S enantiomers in which case the compounds of this invention will be in the racemic or R and S optically active forms, respectively. The quinoline-3-carboxylic acid esters of Formula 2, the quinoline-3-carboxylic acids of Formula 3, and the quinoline-3-carboxylic amides of Formula 4 needed to prepare the compounds of this invention are either already known to the art or can be prepared by procedures known in the art as detailed in the following references:

Sarges, Reinhard; Gallagher, Andrea; Chambers, Timothy J.; Yeh, Li An, *J. Med. Chem.*, 36, 2828 (1993); Savini, Luisa; Massarelli, Paola; Pellerano, Cesare; Bruni, Giancarlo, *Farmaco*, 48(6), 805 (1993); Ife, Robert J.; Brown, Thomas H.; Keeling, David J.; Leach, Colin, J. *Med. Chem.*, 35, 3413 (1992); Hanifin, J. William; Capuzzi, Rosemary; Cohen, Elliott, *J. Med. Chem.*, 12(5), 1096 (1969); Marecki, Paul E.; Bambury, Ronald E., *J. Pharm. Sci.*, 73(8), 1141 (1984); Pellerano, C.; Savini, L.; Massarelli, P.; Bruni, G.; Fiaschi, A. I., *Farmaco*, 45(3), 269, (1990); Marecki, Paul E.; Bambury, Ronald E., *J. Pharm. Sci.*, 73(8), 114 (1984); patent application WO 8908105; US patent 4343804; US patent 3470186.

FLOWSHEET A




[0024] The preparation of the compounds of this invention encompassed by Formula 10 and Formula 11 are described below in Flowsheet B where Y, p, and n are as described above. X' is selected from the group consisting of cycloalkyl or phenyl optionally substituted with one or more substituents selected from the group consisting of hydrogen, halogeno, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino. Each R_9 is independently hydrogen, phenyl, or alkyl of 1-6 carbon atoms. The moieties $(R_{10})_k$ represent 1 to 3 substituents on the aromatic ring that can be the same or different and are selected independently from the group hydrogen, halogeno, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, trifluoromethyl, cyano, nitro, carboxy, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, alkoxyamino of 1-4 carbon atoms, dialkylamino of 2 to 12 carbon atom, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino, N-alkylcarbamoyl of 1-6 carbon atoms, N,N-dialkylcarbamoyl of 2-12 carbon atoms. R_{11} is a radical and is selected from the group:



45


50

FLOWSHEET B




[0025] The preparation of the compounds of this invention encompassed by Formula 18 is described below in Flow-sheet C where X, Y, n, R_1' , R_2' , R_3' , and R_4' are as described above. The substituted aniline of Formula 12 is heated with or without a solvent with the reagent 13 to give intermediate 14 as a mixture of isomers. Thermolysis of 14 in a high boiling solvent such as diphenyl ether at 200-350°C gives the 3-cyano quinolones of Formula 15; these intermediates may also exist in the 4-hydroxy quinoline tautomeric form. In those cases where R_4' is a hydrogen atom, the intermediates 15 may be formed as a mixture of two regioisomers. These isomers can be separated by methods well known in the art including, but not limited to, fractional crystallization and chromatographic methods. The separated isomers can then be converted separately to the compounds of the invention. Alternatively, the isomers can be separated at a later stage of the synthesis. Heating compounds 15 with or without solvent with a chlorinating agent such as phosphorous oxychloride or phosphorous pentachloride gives the 4-chloro-3-cyano quinolines of Formula 16. Condensation of 16 with a nucleophilic amine, aniline, mercaptan, thiophenol, phenol, or alcohol reagent of Formula 17 gives the 3-cyano quinolines of this invention of Formula 18; this condensation can be accelerated by heating the reaction mixture or by using basic catalysts such as trialkylamines, sodium hydride in an inert solvent, sodium or potassium alkoxides in an alcohol solvents, and the like. In those cases where the substituents X, R_1' , R_2' , R_3' , and R_4' may contribute an asymmetric carbon atom, the intermediates can be used as the racemate or as the individual R or S enantiomers in which case the compounds of this invention will be in the racemic or R and S optically active forms, respectively. In cases where the substituents X, R_1' , R_2' , R_3' , and R_4' may contribute more than one asymmetric carbon atoms, diastereomers may be present; these can be separated by methods well known in the art including, but not limited to, fractional crystallization and chromatographic methods.

FLOWSHEET C




[0026] The preparation of intermediate **21** (identical to intermediate **15** of Flowsheet C) can also be prepared as describe below in Flowsheet D. Heating the substituted aniline of Formula **19** with dimethylformamide dimethyl acetal with or without a solvent gives intermediates for Formula **20**. The reaction of **20** with one to ten equivalents of acetonitrile using a base such as sodium methoxide or the like in an inert solvent gives the 3-cyano quinolones, **21**, or the 3-cyano-4-hydroxy quinoline tautomers thereof which can be converted to the compounds of this invention using the procedures outlined above in Flowsheet C.

FLOWSHEET D



[0027] Formula 22 is given below wherein R₁, R₂, R₃, R₄, n, and X' are as defined above.



[0028] Where one or more of R₁, R₂, R₃, or R₄ of Formula 22 is a nitro group, it can be converted to the corresponding amino group by reduction using a reducing agent such as iron in acetic acid.

[0029] Where one or more of R₁, R₂, R₃, or R₄ of Formula 22 is an amino group, it can be converted to the corresponding dialkylamino group of 2 to 12 carbon atoms by alkylation with at least two equivalents of an alkyl halide of 1 to 6 carbon atoms by heating in an inert solvent.

[0030] Where one or more of R₁, R₂, R₃, or R₄ of Formula 22 is a methoxy group, it can be converted to the corresponding hydroxy group by reaction with a demethylating agent such as boron tribromide in an inert solvent or by heating with pyridinium chloride with or without solvent.

[0031] Where one or more of R₁, R₂, R₃, or R₄ of Formula 22 is an amino group, it can be converted to the corresponding alkylsulfonamido, alkenylsulfonamido, or alkynylsulfonamido group of 2 to 6 carbon atoms by the reaction with an alkylsulfonyl chloride, alkenylsulfonyl chloride, or alkynylsulfonyl chloride, respectively, in an inert solvent using a basic catalyst such as triethylamine or pyridine. Alternatively, when one or more of R₁, R₂, R₃, or R₄ of Formula 22 is an amino group, it can be converted to the corresponding alkenylsulfonamido group by the reaction with a reagent Cl-C(R'₆)₂-CHR'₆SO₂Cl, wherein R'₆ is hydrogen or alkyl of 1-4 carbon atoms, in an inert solvent using an excess of an organic base such as triethylamine.

[0032] Where two of R₁, R₂, R₃, or R₄ of Formula 22 are contiguous methoxy groups, the corresponding compound with contiguous hydroxy groups can be prepared by using a demethylating agent such as boron tribromide in an inert

solvent or by heating with pyridinium chloride with or without solvent.

[0033] Where two of R_1 , R_2 , R_3 , or R_4 of Formula **22** are contiguous hydroxy groups, they can be converted to the compound where together the two contiguous R_1 , R_2 , R_3 , or R_4 groups are the divalent radical $-O-C(R_8)_2-O-$ wherein R_8 is defined above by the reaction with a reagent, $J-C(R_8)_2-J$, wherein J is chloro, bromo, or iodo, and each J can be the same or different, using a base such as cesium carbonate or potassium carbonate in an inert solvent and heating as required.

[0034] Where one or more of R_1 , R_2 , R_3 , or R_4 of Formula **22** is an amino group, it can be converted to the corresponding alkylamino group of 1 to 6 carbon atoms by alkylation with one equivalent of an alkyl halide of 1 to 6 carbon atoms by heating in an inert solvent or by reductive alkylation using an aldehyde of 1 to 6 carbon atoms and a reducing agent such as sodium cyanoborohydride in a protic solvent such as water or alcohol, or mixtures thereof.

[0035] Where one or more of R_1 , R_2 , R_3 , or R_4 of Formula **22** is hydroxy, it can be converted to the corresponding alkanoyloxy group of 1-6 carbon atoms by reaction with an appropriate carboxylic acid chloride, anhydride, or mixed anhydride in an inert solvent using pyridine or a trialkylamine as a catalyst.

[0036] Where one or more of R_1 , R_2 , R_3 , or R_4 of Formula **22** is hydroxy, it can be converted to the corresponding alkenoyloxy group of 1-6 carbon atoms by reaction with an appropriate carboxylic acid chloride, anhydride, or mixed anhydride in an inert solvent using pyridine or a trialkylamine as a catalyst.


[0037] Where one or more of R_1 , R_2 , R_3 , or R_4 of Formula **22** is hydroxy, it can be converted to the corresponding alkynoyloxy group of 1-6 carbon atoms by reaction with an appropriate carboxylic acid chloride, anhydride, or mixed anhydride in an inert solvent using pyridine or a trialkylamine as a catalyst.

[0038] Where one or more of R_1 , R_2 , R_3 , or R_4 of Formula **22** is carboxy or a carboalkoxy group of 2-7 carbon atoms, it can be converted to the corresponding hydroxymethyl group by reduction with an appropriate reducing agent such as borane, lithium borohydride, or lithium aluminum hydride in an inert solvent; the hydroxymethyl group, in turn, can be converted to the corresponding halomethyl group by reaction in an inert solvent with a halogenating reagent such as phosphorous tribromide to give a bromomethyl group, or phosphorous pentachloride to give a chloromethyl group. The hydroxymethyl group can be acylated with an appropriate acid chloride, anhydride, or mixed anhydride in an inert solvent using pyridine or a trialkylamine as a catalyst to give the compounds of this invention with the corresponding alkanoyloxymethyl group of 2-7 carbon atoms, alkenoyloxymethyl group of 2-7 carbon atoms, or alkynoyloxymethyl group of 2-7 carbon atoms.

[0039] Where one or more of R_1 , R_2 , R_3 , or R_4 of Formula **22** is a halomethyl group, it can be converted to an alkoxymethyl group of 2-7 carbon atoms by displacing the halogen atom with a sodium alkoxide in an inert solvent.


[0040] Where one or more of R_1 , R_2 , R_3 , or R_4 of Formula **22** is a halomethyl group, it can be converted to an aminomethyl group, N-alkylaminomethyl group of 2-7 carbon atoms or N,N-dialkylaminomethyl group of 3-14 carbon atoms by displacing the halogen atom with ammonia, a primary, or secondary amine, respectively, in an inert solvent.

[0041] Where one or more of R_1 , R_2 , R_3 , or R_4 of Formula **22** is a $H_2N(CH_2)_p-$ group, it can be converted to the corresponding groups:




wherein R_5 and p are as defined above by reacting with phosgene in an inert solvent such as toluene in the presence of a base such as pyridine to give an isocyanate which, in turn, is treated with an excess of the alcohol R_5-OH or amines R_5-NH_2 or $(R_5)_2NH$, respectively.

[0042] Where one or more of R_1 , R_2 , R_3 , or R_4 of Formula **22** is a $HO-(CH_2)_p-$ group, it can be converted to the corresponding groups:



wherein R_5 and p are as defined above by the reaction, in an inert solvent using a basic catalyst such as pyridine, with an appropriate alkyl or phenyl chloroformate, $R_5-OCOCI$, alkyl or phenyl substituted isocyanate, $R_5-N=C=O$, or alkyl or phenyl substituted carboxylic acid chloride, R_5-COCl , respectively.

[0043] Where one or more of R_1 , R_2 , R_3 , or R_4 of Formula 22 is a $\text{HO}-(\text{CH}_2)_p$ -group, it can be converted to the corresponding group:



wherein R_5 and p are as defined above by the reaction, in an inert solvent using a basic catalyst such as pyridine, with a reagent $(\text{R}_5)_2\text{NCOC1}$.

[0044] Processes for the preparation of compounds of Formula 1 form further aspects of the present invention.

[0045] Representative compounds of this invention were evaluated in several standard pharmacological test procedures that showed that the compounds of this invention possess significant activity as inhibitors of protein tyrosine kinase and are antiproliferative agents. Based on the activity shown in the standard pharmacological test procedures, the compounds of this invention are therefore useful as antineoplastic agents. The test procedures used and results obtained are shown below.

Inhibition of Epidermal Growth Factor Receptor Kinase (EGF-R. membrane extract)

[0046] Representative compounds of the invention were evaluated for their ability to inhibit the phosphorylation of the tyrosine residue of a peptide substrate catalyzed by the enzyme epidermal growth factor receptor kinase in the standard pharmacological test procedure described below. The peptide substrate (RR-SRC) has the sequence arg-arg-leu-ile-glu-asp-ala-glu-tyr-ala-ala-arg-gly. The enzyme was obtained as a membrane extract of A431 cells (American Type Culture Collection, Rockville, MD). A431 cells were grown in T175 flasks to 80% confluency. The cells were washed twice with phosphate buffered saline (PBS) without Ca^{2+} . Flasks were rotated for 1.5 hours in 20 ml PBS with 1.0 mM ethylenediaminetetraacetic acid (EDTA) at room temperature and centrifuged at 600g for 10 minutes. The cells were solubilized in 1 ml per 5×10^6 cells of cold lysis buffer {10mM 4-(2-hydroxyethyl)-1-piperazineethane-sulfonic acid (HEPES), pH 7.6, 10 mM NaCl, 2mM EDTA, 1mM phenylmethyl-sulfonyl-fluoride (PMSF), 10 mg/ml aprotinin, 10 mg/ml leupeptin, 0.1 mM sodium orthovanadate} in a Dounce homogenizer with 10 strokes on ice. The lysate was centrifuged at 600g for 10 minutes first to clear cell debris and the supernatant further centrifuged at 100,000 g for 30 min at 4°C. The membrane pellet was suspended in 1.5 ml HNG buffer (50 mM HEPES, pH 7.6, 125 mM NaCl, 10% glycerol). The membrane extract was divided into aliquots, immediately frozen in liquid nitrogen and stored at -70°C.

[0047] Compounds to be evaluated were made into 10 mg/ml stock solutions in 100% dimethylsulfoxide (DMSO). Prior to experiment, stock solutions were diluted to 500 mM with buffer (30 mM Hepes pH 7.4) and then serially diluted to the desired concentration.

[0048] An aliquot of the A431 membrane extract (10 mg/ml) was diluted in 30 mM HEPES (pH 7.4) to give a protein concentration of 50 $\mu\text{g/ml}$. To 4 μl of enzyme preparation, EGF (1 μl at 12 $\mu\text{g/ml}$) was added and incubated for 10 min on ice followed by 4 μl of the test compound or buffer; this mix was incubated on ice for 30 min. To this was added the ^{33}P -ATP (10 mCi/ml) diluted 1:10 in assay buffer along with the substrate peptide at a concentration of 0.5 mM (control reactions get no test compound) and the reaction was allowed to proceed for 30 min at 30°C. The reaction was stopped with 10% TCA and left on ice for at least 10 min after which tubes were microcentrifuged at full speed for 15 min. The a portion of the supernatants were spotted on P81 phosphocellulose discs and washed twice in 1% acetic acid then water for 5 min each followed by scintillation counting. The inhibition data for representative compounds of the invention are shown below in TABLE 1. The IC_{50} is the concentration of test compound needed to reduce the total amount of phosphorylated substrate by 50%. The % inhibition of the test compound was determined for at least three different concentrations and the IC_{50} value was evaluated from the dose response curve. The % inhibition was evaluated with the following formula:

$$\% \text{ inhibition} = 100 - [\text{CPM}(\text{drug})/\text{CPM}(\text{control})] \times 100$$

where $\text{CPM}(\text{drug})$ is in units of counts per minute and is a number expressing the amount of radiolabeled ATP ($\text{g-}^{33}\text{P}$) incorporated onto the RR-SRC peptide substrate by the enzyme after 30 minutes at 30°C in the presence of test compound as measured by liquid scintillation counting. $\text{CPM}(\text{control})$ is in units of counts per minute and was a number expressing the amount of radiolabeled ATP ($\text{g-}^{33}\text{P}$) incorporated into the RR-SRC peptide substrate by the enzyme after 30 minutes at 30°C in the absence of test compound as measured by liquid scintillation counting. The CPM values

were corrected for the background counts produced by ATP in the absence of the enzymatic reaction. The IC₅₀ values reported in TABLE 1 are averages of the number of tests conducted.

TABLE 1

Inhibition of Epidermal Growth Factor Receptor Kinase (membrane extract)		
Compound	IC ₅₀ (uM)-	Number of Tests
Example 31	1.5 x 10 ⁻³	6
Example 35	0.20	4
Example 8	0.15	3
Example 15	6 x 10 ⁻⁴	1
Example 16	1.5 x 10 ⁻³	2
Example 17	9.0	2
Example 19	9.2 x 10 ⁻²	3
Example 18	2.1 x 10 ⁻⁵	3
Example 41	0.20	1
Example 42	1.5	3
Example 43	8.0	1
Example 45	1.67	3
Example 46	8.83	3
Example 47	0.13	5
Example 22	3.0	1
Example 50	5.0	1
Example 51	5 x 10 ⁻⁵	1
Example 52	1 x 10 ⁻²	1
Example 53	7 x 10 ⁻³	1
Example 54	7 x 10 ⁻³	1
Example 57	8 x 10 ⁻³	1
Example 58	2 x 10 ⁻³	1
Example 59	1 x 10 ⁻⁴	1

[0049] As shown by the data presented in TABLE 1, the compounds of this invention are effective inhibitors of the epidermal growth factor receptor kinase and are, as such, useful for the treatment of diseases such as cancer and polycystic kidney disease where deregulation of the kinase is a component of the disease.

Inhibition of Epidermal Growth Factor Receptor Kinase (EGF-R) using recombinant enzyme

[0050] Representative compounds of the invention were evaluated for their ability to inhibit the phosphorylation of the tyrosine residue of a peptide substrate catalyzed by the enzyme epidermal growth factor receptor kinase. The peptide substrate (RR-SRC) has the sequence arg-arg-leu-ile-glu-asg-ala-glu-tyr-ala-ala-arg-gly. The enzyme used in this assay is the His-tagged cytoplasmic domain of EGFR. A recombinant baculovirus (vHcEGFR52) was constructed containing the EGFR cDNA encoding amino acids 645 - 1186 preceded by Met-Ala-(His)₆. Sf9 cells in 100 mm plates were infected at an moi of 10 pfu/cell and cells were harvested 48 h post infection. A cytoplasmic extract was prepared using 1% Triton X-100 and applied to Ni-NTA column. After washing the column with 20 mM imidazole, HcEGFR was eluted with 250 mM imidazole (in 50 mM Na₂HPO₄, pH 8.0, 300 mM NaCl). Fractions collected were dialyzed against 10 mM HEPES, pH 7.0, 50 mM NaCl, 10% glycerol, 1μg/mL antipain and leupeptin and 0.1 mM Pefabloc SC. The protein was frozen in dry ice/methanol and stored -70°C.

[0051] Compounds to be evaluated were made into 10 mg/mL stock solutions in 100% dimethylsulfoxide (DMSO). Prior to experiment, stock solutions were diluted to 500 μM with 100% DMSO and then serially diluted to the desired concentration with HEPES buffer (30 mM HEPES pH 7.4).

[0052] For the enzyme reaction, 10 μL of each inhibitor (at various concentrations) were added to each well of a 96-well plate. To this was added 3 μL of enzyme (1:10 dilution in 10mM HEPES, pH 7.4 for final conc. of 1:120). This was allowed to sit for 10 min on ice and was followed by the addition of 5 μl peptide (80 μM final conc.), 10μl of 4X Buffer (Table A), 0.25 μL ³³P-ATP and 12 μL H₂O. The reaction was allowed to run for 90 min at room temperature and was followed by spotting the entire volume on to precut P81 filter papers. The filter discs were washed 2X with

0.5% phosphoric acid and radioactivity was measured using a liquid scintillation counter.

Table A

Reagent	Final	100 Rxns
1 M HEPES (pH 7.4)	12.5 mM	50 μ L
10mM Na ₃ VO ₄	50 μ M	20 μ L
1M MnCl ₂	10 mM	40 μ L
1mM ATP	20 μ M	80 μ L
³³ P-ATP	2.5 μ Ci	25 μ L

[0053] The inhibition data for representative compounds of the invention are shown below in TABLE 2. The IC₅₀ is the concentration of test compound needed to reduce the total amount of phosphorylated substrate by 50%. The % inhibition of the test compound was determined for at least three different concentrations and the IC₅₀ value was evaluated from the dose response curve. The % inhibition was evaluated with the following formula:

$$\% \text{ inhibition} = 100 - [\text{CPM}(\text{drug})/\text{CPM}(\text{control})] \times 100$$

where CPM(drug) is in units of counts per minute and is a number expressing the amount of radiolabeled ATP (g-³³P) incorporated onto the RR-SRC peptide substrate by the enzyme after 90 minutes at room temperature in the presence of test compound as measured by liquid scintillation counting. CPM(control) is in units of counts per minute and was a number expressing the amount of radiolabeled ATP (g-³³P) incorporated into the RR-SRC peptide substrate by the enzyme after 90 minutes at room temperature in the absence of test compound as measured by liquid scintillation counting. The CPM values were corrected for the background counts produced by ATP in the absence of the enzymatic reaction. The IC₅₀ values reported in TABLE 2 are averages of the number of tests conducted.

TABLE 2 (recombinant enzyme)

Inhibition of Epidermal Growth Factor Receptor Kinase		
Compound	IC ₅₀ (μ M)	Number of Tests
Example 88	0.08	1
Example 89	0.1	1
Example 99	0.03	1
Example 100	0.1	1
Example 101	0.1	1
Example 105	0.001	1
Example 126	0.4	1
Example 129	0.04	1
Example 130	0.1	1
Example 132	0.6	1
Example 133	0.006	1
Example 135	0.01	1
Example 138	0.0035	2
Example 139	0.5	1
Example 140	0.0006	2
Example 143	0.03	1
Example 144	0.065	2
Example 145	0.06	1
Example 146	0.03	1
Example 147	0.1	
Example 148	0.001	2
Example 151	0.5	1
Example 152	0.1	1
Example 154	0.15	2

TABLE 2 (recombinant enzyme) (continued)

Inhibition of Epidermal Growth Factor Receptor Kinase			
	Compound	IC ₅₀ (μM)	Number of Tests
5	Example 156	0.5	1
	Example 157	0.045	2
	Example 160	0.002	1
	Example 161	0.00035	2
10	Example 164	0.09	1
	Example 165	0.0005	2
	Example 166	0.02	1
	Example 169	0.005	1
	Example 170	0.06	1
15	Example 171	0.0065	2
	Example 172	0.005	2
	Example 173	0.03	1
	Example 174	0.2	1
	Example 175	0.3	1
20	Example 184	1.7	1
	Example 185	10	1
	Example 186	0.1	1
	Example 187	0.0007	2
25	Example 188	0.001	4
	Example 189	0.002	2
	Example 190	0.04	1
	Example 191	0.006	1
	Example 192	0.0006	1
30	Example 193	0.0019	2
	Example 194	0.0017	3
	Example 197	0.002	1
	Example 198	0.000008	2
35	Example 199	0.0005	2
	Example 200	0.02	1
	Example 203	0.0007	2
	Example 204	0.01	1
40	Example 205	0.1	1
	Example 208	0.0015	2
	Example 209	0.005	3
	Example 216	0.0006	2
	Example 217	0.002	2
45	Example 218	0.017	2
	Example 224	1.	1
	Example 227	0.01	1
	Example 255	0.1	1
50	Example 256	0.1	1
	Example 262	0.05	1
	Example 264	0.5	1
	Example 270	0.01	1
	Example 311	0.5	2
55	Example 62	0.4	1
	Example 63	10	1
	Example 64	10	1

TABLE 2 (recombinant enzyme) (continued)

Inhibition of Epidermal Growth Factor Receptor Kinase		
Compound	IC ₅₀ (μM)	Number of Tests
Example 312	0.05	1
Example 318	0.08	1
Example 313	0.4	1
Example 326	0.00005	1
Example 327	0.01	1
Example 328	0.0045	2
Example 329	0.00045	2
Example 330	0.00028	3
Example 331	0.1	1
Example 332	0.0009	1
Example 347	0.04	2
Example 358	0.1	1
Example 363	0.1	1
Example 360	0.5	1
Example 347	0.04	2
Example 383	0.007	1
Example 380	0.007	1
Example 395	0.5	1

Inhibition of Cancer Cell Growth as Measured by the Incorporation of [³H]-Thymidine

[0054] Representative compounds of this invention were evaluated for their ability to inhibit the growth of the cell lines described below in vitro. The inhibition is quantitated by measuring the decrease in the incorporation of radio-labeled thymidine when the cells are grown in the presence of the inhibitor. A431 and SKBR3 cell lines are obtained from American Type Culture Collection, Rockville, MD. Neu-3T3 cells are obtained by transfecting NIH 3T3 mouse fibroblasts with an activated rat Neu oncogene. NHEK cells are obtained from Clonetics (San Diego, CA). Cells were routinely grown in a humidified incubator in 5% CO₂ in air. These cell lines are dependent on growth factors which are ligands to the receptor tyrosine kinases that are the targets of the compounds of this invention, and have the following characteristics:

A431: human epidermoid carcinoma cells overexpressing EGFR
 Neu-3T3: NIH 3T3 cells transfected with activated Neu oncogene
 NHEK: EGF dependent normal human epidermal keratinocytes
 SKBR3: Human breast cancer cells overexpressing ErbB2 gene

[0055] The cell lines were grown in appropriate media as described below:

A431: Dulbecco's Modified Eagles Media, high glucose, BRL/Gibco (10% Fetal Bovine Serum (FBS), Glutamine, Penicillin-Streptomycin) Dulbecco, R., Freeman, G. *Virology* 8, 396 (1959).
 Neu-3T3: Dulbeccos Modified Eagles Media, high glucose (10% Fetal Bovine Serum, Glutamine, Penicillin-Streptomycin)
 SKBR3: Roswell Park Memorial Institute 1640 W/GLU (10% FBS, GLU, PS) Moore, G. E., Gerner, R. E. and Franklin, H. A. A.M.A., 199, 516 (1967).
 NHEK: Keratinocyte Growth Media, Clonetics Boyce, S.T. and Ham, R. G. *In Vitro* 17, 239 (Abstract No. 159) (1981)

[0056] Cells were seeded at 10,000 cells/well in 96 well plates in complete media and allowed to grow to log phase. At this stage the complete media was replaced with media containing 0.5% FBS (for cells growing in 10% FBS) or media lacking epidermal growth factor (EGF) (for cells growing in serum free media). After overnight incubation in low serum (or EGF lacking) media, the compounds to be evaluated were added and cells remained in the presence of compounds for 48 to 72 hours. Media with test compound was then removed and complete media was added back.

The cells were allowed to grow for 18 hours. This is followed by incubation in [³H]thymidine (1mCi/ml in serum/EGF media) for 4 hours. Cells were lysed in 0.5 M NaOH for at least 30 min at 37°C and radioactivity analyzed.

[0057] The cell growth inhibition data is provided below in TABLE 3. The IC₅₀ is the concentration of test compound needed to reduce the amount of [³H]thymidine incorporation by 50%. The % inhibition of the compound evaluated was determined for at least three different concentrations and the IC₅₀ value evaluated from the dose response curve. The % inhibition is evaluated with the following formula:

$$\% \text{ inhibition} = 100 - [\text{CPM}(\text{drug})/\text{CPM}(\text{control})] \times 100$$

where CPM(drug) is in units of counts per minute and is a number expressing the amount of [³H]thymidine incorporated into the DNA when cells are grown in the presence of test compound as measured by liquid scintillation counting. CPM (control) is in units of counts per minute and is a number expressing the amount of [³H]thymidine incorporated onto the DNA when cells are grown in the absence of test compound as measured by liquid scintillation counting.

TABLE 3

Inhibition of Cell Growth as Measured by the Incorporation of [³ H]-Thymidine (IC ₅₀)				
Compound	A431 (μM)	NEU-3T3 (μM)	NHEK (μM)	SKBR3 (μM)
Example 31	0.2		0.003	25
Example 15	35		4.0	
Example 41	1.5			
Example 42	7		0.01	
Example 43	10		4.0	
Example 44	15		1.5	
Example 33	18			
Example 45	0.15			
Example 46	1.0			
Example 47	1.5		0.03	
Example 20	35		0.65	
Example 3	>50		0.35	
Example 7	>50		4.5	
Example 8	40		0.2	
Example 13	50			
Example 14	0.1			
Example 23	0.1			
Example 16	1.8		0.06	
Example 17	25		9.0	
Example 19	15		2.0	
Example 18	0.00001		0.007	
Example 26	0.1	>50	0.4	>50
Example 22	0.15	>50	0.035	>50
Example 38	35			
Example 48	10			

[0058] As illustrated by the data presented in TABLE 3, the compounds of this invention are effective inhibitors of cancer cell growth and are therefore useful as antineoplastic agents.

Inhibition of Cancer Cell Growth as Measured by Cell Number

[0059] Human tumor cell lines were plated in 96-well plates (250 ml/well, 1-6 x 10⁴ cells/ml) in RPMI 1640 medium, containing 5% FBS (Fetal Bovine Serum). Twenty four hours after plating, test compounds were added at five log concentrations (0.01-100 mg/ml) or at lower concentrations for the more potent compounds. After 48 hours exposure to test compounds, cells were fixed with trichloroacetic acid, and stained with Sulforhodamine B according to the methods of Skehan et al (*J.Natl. Canc. Inst.* 1990, , 82:1107-1112. After washing with trichloroacetic acid, bound dye was

solubilized in 10 mM Tris base and optical density was determined using plate reader. Under conditions of the assay the optical density is proportional to the number of cells in the well. IC₅₀S (concentrations causing 50% inhibition of cell growth) were determined from the growth inhibition plots. These data are shown below in Tables 4-8. The cell lines were chosen since they overexpressed epidermal growth factor receptor (EGFR) (i.e. A431) or HER2/neu (SKBR3), or had little to no expression of these receptors (SW620, LOX, MCF7). Expression levels of these receptors were determined by antibody staining methods using EGFR or HER/neu directed antibodies and was similar to previously published data (Lewis et al., Cancer Immunol. Immunother., 1993, 37: 255-262). Other information about some of the cell lines used in these test procedures is available from the American Type Tissue Collection: Cell Lines and Hybridomas, 1994 Reference Guide, 8th Edition. In the Tables below, there may be separate entries for the same compound; this is an indication that the compound was tested more than one time. In the tables below, if a compound is missing a data value for a particular cell line, this is an indication that that compound was not tested against that cell line.

TABLE 4

Inhibition of Cancer Cell Growth as Measured by Cell Number (IC ₅₀ µg/ml)							
Example No.	HTB161	A27805	A2780DDP	MIP	SW620	COLO205	CX1
31	0.7933	2.03	1.165	0.7475	4.54	3.095	0.9695
15	33	33	33	33	33	33	33
41	7.87	7.726	6.255	4.089	14.65	6.133	7.252
42	5.18	6.434	8.223	11	31.18	5.966	9.131
43	0.5337	3.424	4.445	3.296	4.325	4.179	3.427
44	5.2	5.888	9.276	11.13	7.462	7.792	6.336
35	2.976	2.953	0.8381	0.6496	9.572		3.128
45	4.212	8.664	39.26	>100	>100	>100	89.66
46	9.586	7.406	5.856	5.597	>100		9.7
47	0.003947	0.05304	0.06454	0.06935	0.06723	0.07567	0.06179
3	3.645	4.065	5.1	1.214	9.554	8.934	4.342
7	2.123	4.656	4.905	2.392	5.837	4.83	4.878
8	98.81	0.9119	6.79	0.3541	2.503	2.489	7.549
13	97.14	9.937	56.95	7.803	100	45.84	>100
14	1.793	3.594	5.924	6.19	88.77	>100	8.899
23	5.039	1.548	7.544	33.89	>100	>100	4.859
16	0.6672	0.6018	0.5958	0.5336	>100		0.9775
17	7.887	9.799	60.35	100	>100	>100	81.9
38	3.195	4.578	6.56	7.754	31.72	6.429	5.622
39	0.5963	1.574	0.4968	6.104	4.429	1.996	5.407
40	0.6626	0.8827	2.497	0.7401	2.263	1.483	2.568
19	0.08544	0.001	0.001	0.001	0.006484	0.001	0.02891
18	0.4146	0.6284	0.8843	1.472	1.395	1.902	1.56
22	0.2478	0.0567	0.2112	0.3784	0.5262	4.302	0.775
48	70.9	40.18	58.88	63.34	>100	50.4	59.24
49	70.63	34.76	51.84	>100	>100	88.01	98.43
50	4.46	4.677	6.424	7.349	32.85	28.46	8.724
6	1.657	2.487	3.217	0.9502	4.713	5.513	3.024
9	0.3412	0.5424	0.5134	0.7313	1.937	2.565	0.9102

TABLE 5

Inhibition of Cancer Cell Growth as Measured by Cell Number (IC ₅₀ µg/ml)						
Example	CACO2	HCT15	LS174T	SW948	CCL228	MCF7
31	0.9255	0.7269	0.8852	5.477	4.909	5.656

EP 0 973 746 B1

TABLE 5 (continued)

Inhibition of Cancer Cell Growth as Measured by Cell Number (IC ₅₀ µg/ml)						
Example	CACO2	HCT15	LS174T	SW948	CCL228	MCF7
15	2.409	>33	>33	>33	>33	>33
41	2.111	4.213	2.924	14.12	18.48	24.84
42	3.84	6.714	5.971	17.17	8.934	6.142
43	2.58	0.8229	4.225	4.756	2.557	5.829
44	5.681	5.098	6.79	6.756	7.446	9.411
35	1.933	0.8809	0.8185	7.827	12.09	
45	0.9109	79.71	87.1	>100	>100	57.84
46	6.03	5.597	7.129	>100	54.01	
47	0.07006	0.03952	0.04683	0.06835	0.07154	0.07198
3	2.739	5.885	0.9281	0.8765	7.033	6.174
7	2.297	3.975	3.232	5.854	6.246	5.675
8	2.328	10.92	2.027	86.86	8.666	53.17
13	31.53	100	94.03	>100	>100	65
14	0.9885	6.628	39.29	>100	39.36	80.7
23	6.19	9.321	98.16	>100	95.33	47.91
16	0.7099	0.6409	0.4344	0.9284	4.383	
17	5.631	98.9	87.03	>100	>100	68.19
38	5.615	5.161	5.367	10.42	8.49	6
39	4.331	3.344	4.297	5.935	0.7774	6.642
40	0.7859	0.7268	1.346	4.467	0.9178	3.766
19	0.3773	0.002159	0.03099	0.09688	0.05037	0.05528
18	0.5761	1.672	1.593	1.937	1.171	2.169
22	0.4755	0.3723	0.8466	0.5934	0.2552	
48	30.1	83.6	48.48	>100	>100	79.3
49	42.15	97.36	>100	>100	99.04	57.45
50	4.886	8.535	7.684	17.9	6.787	7.138
6	0.8083	1.747	2.675	5.199	2.347	4.267
9	0.3407	0.9843	0.7118	3.3	0.7065	3.255

TABLE 6

Inhibition of Cancer Cell Growth as Measured by Cell Number (IC ₅₀ µg/ml)							
Example No.	B7474	T47D	LX1	A549	LOX	A431	NEC
31	1.577	3.331	6.88	2.269	0.8708	0.4339	2.231
15	>33	>33	>33	>33	>33	22.01	>33
41	6.261	8.503	48.74	24.96	0.961	0.8126	8.465
42	6.78	6.78	18.37	7.57	5.147	3.28	6.473
43	8.178	4.498	6.123	5.725	2.861	1.211	4.554
44	18.48	9.025	7.622	8.723	5.411	6.792	23.14
35	3.048	100	5.207	0.8654	0.6487	3.793	
45	86.76	30.04	100	100	9.06	2.609	72.08
46	32.91	>100	34.02	4.853	5.351	8.013	
47	0.2332	0.04675	0.07596	0.06786	0.06053	0.04457	0.06708
3	4.265	4.321	6.739	5.679	1.417	2.479	5.013
7	3.885	5.172	6.296	5.93	1.448	1.056	5.179

EP 0 973 746 B1

TABLE 6 (continued)

Inhibition of Cancer Cell Growth as Measured by Cell Number (IC ₅₀ µg/ml)							
Example No.	B7474	T47D	LX1	A549	LOX	A431	NEC
8	55.45	39.47	0.932	7.278	0.6472	9.585	9.299
13	98.79	47.74	>100	>100	>100	90.99	>100
14	20.55	7.388	69.61	7.685	2.812	1.499	8.278
23	61.44	7.85	100	9.99	7.918	8.98	37.94
16	0.8995	6.555	0.644	0.2136	0.3157	0.7664	
17	95.68	>100	>100	>100	74.16	38.06	>100
38	16.97	5.977	7.522	7.327	8.115	4.728	6.531
39	6.649	0.5526	1.257	4.164	0.278	3.709	0.534
40	5.784	3.304	2.709	3.488	1.154	0.6946	3.415
19	0.3246	0.007921	0.001275	0.05804	0.001	0.03393	0.005082
18	0.1522	1.315	1.117	1.611	0.08508	0.249	1.414
22	0.3138	0.7042	0.8101	0.3754	0.02253	0.04428	0.4923
48	99.89	>100	>100	>100	46.96	39.2	>100
49	87.09	71.23	>100	>100	55.1	100	85.32
50	7.166	5.418	7.205	6.816	4.696	7.346	6.887
6	3.756	3.264	5.55	4.445	0.8133	0.8448	4.171
9	0.4432	0.8375	0.06716	2.915	0.4382	0.4334	0.9521

TABLE 7

Inhibition of Cancer Cell Growth as Measured by Cell Number (IC ₅₀ µg/ml)						
Example No.	DU145	PC3	LNCAP	HL60	CCRF-CFM	SKBR3
31	0.5852	5.159	0.7721	0.8939	3.19	
15	18.01	>33	>33	>33	>33	>33
41	0.913	17.5	3.534	3.234	8.293	20.65
42	5.56	29.09	2.392	5.431	5.23	12.53
43	3.13	7.024	4.53	1.655	3.59	5.188
44	7.92	7.652	5.157	3.792	4.673	14.37
35	0.537	7.843		1.978	3.862	
45	8.939	88.92	57.79	>100	>100	60.53
46	3.635	>100		6.023	61.73	
47	0.06799	0.11 1	0.03366	0.06254	0.06796	0.04668
3	4.448	5.689	6.659	3.672	3.687	6.897
7	1.09	7.219	2.187	2.633	3.435	5.598
8	6.474	53.35	59.44	18.95	0.8227	38.26
13	65.79	>100	>100	70.25	>100	100
14	0.9097	41.24	8.979	4.044	7.603	43.61
23	41.89	100	6.633	6.388	6.797	48.01
16	0.1134	3.038		0.6964	0.7286	
17	7.806	>100	90.03	>100	>100	79.73
38	5.153	9.333	4.577	4.274	4.393	7.145
39	0.6365	5.697	3.479	2.97	0.8566	3.647
40	0.8375	5.645	2.692	0.7764	3.134	3.596
19	0.07054	0.05741	0.06975	0.07788	0.001	0.02646
18	0.3215	2.346	0.1462	1.427	1.038	1.852
22	0.2651	0.6952	0.7217	0.6077	0.4031	

EP 0 973 746 B1

TABLE 7 (continued)

Inhibition of Cancer Cell Growth as Measured by Cell Number (IC ₅₀ µg/ml)						
Example No.	DU145	PC3	LNCAP	HL60	CCRF-CFM	SKBR3
48	20.81	>100	40.65	44.65	>100	64.5
49	79.79	>100	52.39	48.39	>100	74.57
50	5.601	8.527	5.336	4.721	4.603	6.831
6	1.034	4.689	4.186	0.9471	2.572	4.204
9	0.3877	1.658	0.6608	0.7581	0.5509	0.8621

TABLE 8

Inhibition of Cancer Cell Growth as Measured by Cell Number (IC ₅₀ µg/ml)					
Example	A431	SKBR3	SW620	LOX	MCF7
156	3.77	7.43	7.91	67	7.57
158	2.97	0.80	4.08	2.44	5.44
155	4.30	3.28	7.55	6.08	7.49
258	5.42	50.45	36.21	10.72	9.69
261	0.61	0.80	2.92	1.32	7.50
260	0.06	0.08	0.32	0.26	9.98
154	0.07	0.05	0.55	0.44	2.57
262	0.04	0.06	0.56	0.07	0.09
151	0.09	0.07	<0.01	0.08	0.61
263	6.90	7.50	5.79	5.66	8.44
105	0.13	1.84	0.06	0.72	2.09
138	0.44	<0.01	3.52	1.12	3.51
186	37.61	21.48	62.56	46.36	42.49
163	7.02	7.28	47.28	64.22	17.45
162	6.87	7.15	33.54	8.13	16.35
187	0.06	0.06	0.05	0.07	0.42
108	6.6	6.34	14.55	6.85	7.97
168	1.57	1.38	9.10	1.76	5.94
109	38.85	30.67	40.8	35.09	37.91
270	14.34	46.12	47.99	0.06	27.06
270	6.95	>10	>10	>10	>10
41	0.24	0.48	2.23	1.33	6.86
44	6.29	7.46	6.61	6.58	17.96
35	0.51	0.93	6.40	4.10	40.86
47	<0.01	<0.01	<0.01	0.03	0.02
255	0.59	0.35	0.58	0.69	2.85
254	0.07	0.01	0.03	0.07	0.07
258	4.67	3.70	5.76	6.12	7.87
262	0.02	<0.01	N.A.	0.03	0.07
31	0.1	0.48	0.82	1.65	6.04
188	0.54	0.16	8.77	0.62	1.43
110	0.9	1.3	0.7	0.8	N.A.
311	0.8	0.7	1.0	2.8	N.A.
167	2.6	3.7	8.1	5.3	8.5
165	0.2	0.1	3.0	0.8	5.8
65	48	60	>100	84	84
188	0.4	0.5	0.7	0.3	0.8

EP 0 973 746 B1

TABLE 8 (continued)

Inhibition of Cancer Cell Growth as Measured by Cell Number (IC ₅₀ µg/ml)						
	Example	A431	SKBR3	SW620	LOX	MCF7
5	164	0.6	0.7	>100	0.9	57
	192	0.05	0.03	0.1		
	169	0.01	0.02	0.1		
	189	0.04	0.03	0.1		
10	62	0.01	0.3	0.3		
	194	0.1	0.2	0.2		
	193	0.01	0.003	0.1		
	99	0.3	0.1	4.4		
	101	>10	>10	>10		
15	100	0.1	0.1	0.8		
	161	0.1	0.04	0.2		
	227	0.02	0.2	0.1		
	166	0.02	0.02	0.04		
20	145	0.03	0.03	0.4		
	140	0.02	0.02	0.1		
	170	0.03	0.03	0.1		
	160	0.2	0.5	2.3		
	190	1.6	2.7	>5		
25	146	0.03	0.03	0.6		
	198	0.002	0.03	0.4		
	188	0.579	0.479	2.177		
	99	0.159	0.078	1.153		
30	191	0.048	0.060	0.084		
	190	1.733	0.494	4.882		
	164	0.322	0.684	>5		
	200	0.128	0.247	>5		
	203	0.048	0.1 1	1.733		
35	204	0.032	0.026	0.340		
	63	0.095	0.144	0.208		
	64	0.806	1.965	1.603		
	199	0.048	0.076	0.433		
40	61	0.341	1.094	1.066		
	312	0.491	2.255	3.534		
	184	0.158	0.300	0.463		
	185	0.340	1.108	2.182		
	112	>5	>5	>5		
45	111	3.046	3.324	2.019		
	197	0.121	0.197	0.266		
	205	0.049	0.243	>5		
	204	0.038	0.029	0.347		
50	157	3.26	2.601	4.17		
	229	0.469	>5	>5		
	174	0.345	0.298	>5		
	172	0.255	0.067	1.591		
	209	0.113	0.048	0.380		
55	208	0.067	0.038	0.453		
	148	0.195	0.043	0.260		
	175	0.144	0.180	4.948		

TABLE 8 (continued)

Inhibition of Cancer Cell Growth as Measured by Cell Number (IC ₅₀ µg/ml)					
Example	A431	SKBR3	SW620	LOX	MCF7
218	0.102	0.029	1.855		
217	0.050	0.019	1.387		
216	0.032	0.012	0.730		
76	2.206	1.886	2.310		
81	1.402	1.441	2.084		
216	0.024	0.015	0.240		
217	0.046	0.033	0.455		
218	0.044	0.047	1.235		
318	0.8	1.5	>10		
328	0.19	0.02	0.15	0.33	0.78
329	0.22	0.21	0.03	0.58	0.75
330	0.05	0.23	0.02	0.02	0.36
331	0.03	0.16	0.04	0.04	0.44
332	0.60	0.08	0.44	0.51	54.9
347	0.04	0.2	0.2		
358	0.5	0.7	4.1	2.5	7.8
363	0.07	0.06	0.08	0.08	0.8
391	0.34	0.4	5.23	0.10	6.53
392	0.46	2.61	73.3	1.99	3.66
393	0.45	0.84	2.25	0.85	4.0
396	0.3	0.2	2.7		

In Vivo Inhibition of the Growth of Human Epidermoid Tumors (A431)

[0060] Representative compounds of this invention (listed below) were evaluated in an *in vivo* standard pharmacological test procedure which measured its ability to inhibit the growth of human epidermoid tumors. Human epidermoid carcinoma cells A-431 (American Type Culture Collection, Rockville, Maryland # CRL-155) were grown *in vitro* as described above. BALB/c nu/nu female mice (Charles River, Wilmington, MA) were used in this *in vivo* standard pharmacological test procedure. A unit of 5×10^6 cells were injected SC into mice. When tumors attained a mass of between 100 and 150 mg, the mice were randomized into treatment groups (day zero). Mice were treated IP once a day either on days 1, 5, and 9 or on days 1 through 10 post staging with doses of either 80, 40 or 20 mg/kg/dose of the compound to be evaluated in 0.2% Klucel. Control animals received no drug. Tumor mass was determined every 7 days [(length X width²)/2] for 28 days post staging. Relative tumor growth (Mean tumor mass on days 7, 14, 21, and 28 divided by the mean tumor mass on day zero) is determined for each treatment group.

[0061] When evaluated in this test procedure, the compound of Example 18 (80 mg/kg administered on days 1, 5, and 9) reduced tumor size by 29% on day 7 and by 45% (p < 0.01) on day 14. Tumor growth was not reduced versus control when mice treated with the compound of Example 18 were evaluated on days 21 and 28.

[0062] The compound of Example 47 was similarly evaluated for its ability to inhibit the growth of human epidermoid tumors *in vivo* using the standard pharmacological test procedure described above. The results obtained are shown in Table 9.

TABLE 9

In Vivo Inhibition of the Growth of Human Epidermoid Tumors (A431) in Mice by the Compound of Example 47									
a	b	c	b	c	b	c	b b	c	e
Drug Treatment mg/kg/dose	Day 7	%T/C	Day 14	%T/C	Day 21	%T/C	Day 28	%T/C	S/T

EP 0 973 746 B1

TABLE 9 (continued)

In Vivo Inhibition of the Growth of Human Epidermoid Tumors (A431) in Mice by the Compound of Example 47									
a	b	c	b	c	b	c	b b	c	e
Placebo (Klucel)	4.68		9.09		11.51		13.67		10/10
Example 47 (100)	1.57	34(d)	3.36	37(d)	5.90	51	5.85	43	5/5
Example 47 (50)	2.05	44 (d)	5.04	55 (d)	10.02	87	14.01	102	5/5
Example 47 (10)	3.22	69	6.75	74	13.38	116	18.59	136	5/5
<p>a) Drugs administered IP on days 1 through 10 IP with exception of the placebo control which was administered on days 1 through 10 PO.</p> <p>b) Relative Tumor Growth = $\frac{\text{Mean Tumor Mass on Day 7, 14, 21, 28}}{\text{Mean Tumor Mass on Day 0}}$</p> <p>c) %T/C = $\frac{\text{Relative Tumor Growth of Treated Group}}{\text{Relative Tumor Growth of Placebo Group}} \times 100$</p> <p>d) Statistically (p < 0.05) significant; Student-t-test. significant reduction in Relative Tumor Growth of Treated Group, compared to Placebo Control.</p> <p>e) S/T = No. Survivors/No. Treated on Day +28 post tumor staging.</p>									

[0063] As shown in Table 9, the compound of Example 47 inhibited tumor growth; for example at 100 mg/kg (administered i.p. during days 1-10), tumor growth was inhibited by 66% at day 7, 63% at day 14, 49% at day 21, and 57% at day 28. Tumor growth inhibition also appeared to be dose dependent.

[0064] The compound of Examples 203, 204, and 205 were similarly evaluated for their ability to inhibit the growth of human epidermoid tumors *in vivo* using the standard pharmacological test procedure described above. The results obtained are shown in Table 10.

TABLE 10

In Vivo Inhibition of the Growth of Human Epidermoid Tumors (A431) in Mice by the Compounds of Examples 203, 204, and 205									
a	b	c	b	c	b	c	b	c	e
Drug Treatment mg/kg/ dose	Day	7 %T/C	Day 14	%T/C	Day 21	%T/C	Day 28	%T/C	S/T
Klucel (Placebo Control)	4.71		9.01		13.42		18.65		10/10
Example 203 (80 PO)	0.71	15	0.76	8	1.65	12	3.09	17	4/5
Example 203 (80 IP)	0.94	20	1.13	12	1.86	14	3.07	16	5/5
Example 204 (80 PO)	1.16	25	1.69	18	5.83	43	9.45	51	4/5
Example 204 (80 IP)	2.11	45	3.84	42	7.44	55	9.08	49	5/5
Example 205 (80 PO)	1.09	23	1.72	19	3.07	23	5.51	29	5/5

EP 0 973 746 B1

TABLE 10 (continued)

In Vivo Inhibition of the Growth of Human Epidermoid Tumors (A431) in Mice by the Compounds of Examples 203, 204, and 205									
a	b	c	b	c	b	c	b	c	e
Example 205 (80 IP)	1.43	30	2.27	25	5.06	38	11.38	61	5/5
a) All 80 PO doses administered on days 1 through 10. All 80 IP doses administered on days 1,5,9. b) $\text{Relative Tumor Growth} = \frac{\text{Mean Tumor Mass on Day 7, 14, 21, 28}}{\text{Mean Tumor Mass on Day 0}}$ c) $\%T/C = \frac{\text{Relative Tumor Growth of Treated Group}}{\text{Relative Tumor Growth of Placebo Group}} \times 100$ d) Statistical analysis (Student-t-test) of Log Relative Tumor Growth. All data had $p \leq 0.05$ indicating statistically significant reduction in Relative Tumor Growth of Treated Group, compared to Placebo Control. e) S/T = No. Survivors/No. Treated on Day +28 post tumor staging.									

[0065] As shown in Table 10, the compounds of Examples 203, 204, and 205 significantly inhibited tumor growth in animals that were treated with either drug relative to animals that did not receive any drug.

[0066] The compound of Examples 208, 216, and 217 were similarly evaluated for their ability to inhibit the growth of human epidermoid tumors *in vivo* using the standard pharmacological test procedure described above. The results obtained are shown in Table 11.

TABLE 11

In Vivo Inhibition of the Growth of Human Epidermoid Tumors (A431) in Mice by the Compounds of Examples 208, 216, and 217									
a	b	c	b	c	b	c	b	c	e
Drug Treatment mg/kg/dose	Day	7 %T/C	Day 14	%T/C	Day 21	%T/C	Day 28	%T/C	S/T
Klucel	5.74		14.99		17.90		24.85		8/10
Example 208 (80 PO)	0.40	6	0.99	6	1.46	8	2.63	10	5/5
Example 208 (80 IP)	0.82	14	2.29	15	4.80	26	8.09	32	5/5
Example 216 (80 PO)	0.40	6	1.02	6	2.20	12	5.28	21	5/5
Example 216 (80 IP)	0.84	14	1.81	12	3.06	17	4.92	19	5/5
Example 217 (80 PO)	1.73	30	5.01	33	7.84	43	10.54	42	5/5
Example 217 (80 IP)	1.47	25	5.50	36	9.20	51	14.04	56	5/5
a) All compounds administered IP received drug on days 1,5 and 9. All compounds administered PO were received on days 1 through 10. b) $\text{Relative Tumor Growth} = \frac{\text{Mean Tumor Mass on Day 7, 14, 21,28}}{\text{Mean Tumor Mass on Day 0}}$ c) $\%T/C = \frac{\text{Relative Tumor Growth of Treated Group}}{\text{Relative Tumor Growth of Placebo Group}} \times 100$ d) Statistical analysis (Student-t-test) of Log Relative Tumor Growth. All data had $p < 0.05$ indicating a statistically significant reduction in Relative Tumor Growth of Treated Group, compared to Placebo Control. e) S/T = No. Survivors/No. Treated on Day +28 post tumor staging.									

[0067] As shown in Table 11, the compounds of Examples 208, 216, and 217 significantly inhibited tumor growth in animals that were treated with either drug relative to animals that did not receive any drug.

Inhibition of Epithelial Cell Kinase (ECK)

[0068] In this standard pharmacological test procedure, a biotinylated peptide substrate is first immobilized on neutravidin-coated microtiter plates. The test drug, the Epithelial Cell Kinase (ECK), Mg^{++} , sodium vanadate (a protein tyrosine phosphatase inhibitor), and an appropriate buffer to maintain pH (7.2) are then added to the immobilized substrate-containing microtiter wells. ATP is then added to initiate phosphorylation. After incubation, the assay plates are washed with a suitable buffer leaving behind phosphorylated peptide which is exposed to horse radish peroxidase (HRP)-conjugated anti-phosphotyrosine monoclonal antibody. The antibody-treated plates are washed again and the HRP activity in individual wells is quantified as a reflection of degree of substrate phosphorylation. This nonradioactive format was used to identify inhibitors of ECK tyrosine kinase activity where the IC_{50} is the concentration of drug that inhibits substrate phosphorylation by 50%.

Table 12.

Inhibition of Epithelial Cell Kinase (ECK)					
Example No.	Eck IC_{50} (μM)	Example No.	Eck IC_{50} (μM)	Example No.	Eck IC_{50} (μM)
3	28.2318	139	> 56.1167	218	> 37.2833
6	> 25.0495	140	> 45.5063	227	> 41.8102
7	> 27.0834	141	> 68.8942	228	> 55.9011
8	< 0.0459	143	> 52.7983	232	> 52.8499
9	> 47.2500	144	> 54.5256	238	> 30.3251
13	> 27.0871	145	> 47.1809	239	> 29.8187
14	> 29.4814	147	43.1127	240	> 26.0261
15	< 0.0494	148	> 42.9277	241	7.2418
18	> 50.8587	149	> 63.9591	242	> 28.7018
19	24.0570	150	> 29.1800	243	> 26.7544
23	27.9110	151	> 50.8647	244	24.7647
35	> 61.8563	152	> 29.4811	246	0.0060
39	28.0756	153	> 27.0856	248	25.1091
40	27.1597	154	< 0.0571	249	> 28.1069
41	> 58.8616	155	> 67.4992	254	> 21.0084
42	> 53.5719	156	> 30.6466	255	> 44.6478
43	> 54.7360	157	> 42.6439	256	> 51.8403
44	> 62.6253	158	> 49.6401	257	> 53.2765
45	> 60.5418	159	> 23.1000	258	> 28.7853
46	> 61.8563	160	< 0.0589	259	> 29.9940
47	> 24.2548	161	> 46.0299	260	> 28.4576
48	> 59.6363	162	> 35.0508	261	> 152.9052
49	> 51.9184	163	> 31.7158	262	> 27.1887
65	> 22.8676	164	> 57.0776	264	> 62.4317
76	0.4663	165	> 59.1017	265	> 55.1861
81	0.4247	166	> 46.1361	266	51.7585
82	50.9606	167	> 70.3482	267	> 59.6363
83	> 46.0299	168	> 31.8167	268	> 56.5274
84	0.4495	169	40.9500	269	> 50.8298
85	0.0411	170	11.8953	270	< 0.0569
86	> 46.4177	171	> 40.6174	275	> 61.0225
87	> 42.2913	174	39.1850	276	> 65.5010
88	> 60.1793	175	> 37.0096	277	> 62.8176
89	> 28.5714	176	0.0100	278	> 54.0237

Table 12. (continued)

Inhibition of Epithelial Cell Kinase (ECK)					
Example No.	Eck IC ₅₀ (μM)	Example No.	Eck IC ₅₀ (μM)	Example No.	Eck IC ₅₀ (μM)
97	> 28.6533	177	0.0057	279	> 62.2396
100	41.8064	186	> 22.1590	280	> 30.3689
105	> 26.0960	187	> 41.9842	281	0.0033
108	> 23.4577	188	> 38.6548	282	0.0029
109	> 25.2334	189	> 44.4543	283	9.1534
110	> 43.2526	190	39.7298	284	32.7505
112	> 22.8154	191	41.9842	288	0.0014
125	42.4719	192	39.6495	290	> 28.1069
126	< 0.0402	193	47.4091	291	> 20.8711
127	> 42.4719	194	> 48.9213	292	0.0018
128	> 44.5931	197	42.8894	293	32.6449
129	22.7169	200	38.2844	294	0.0020
130	> 25.8933	202	> 58.3494	295	> 29.8182
131	> 24.0269	203	2.2031	302	28.0756
	> 58.7544	204	20.7485	303	> 22.7118
133	> 72.9129	205	40.3963	305	> 42.8266
134	> 32.8623	208	> 40.1317	307	> 61.0128
135	> 57.3394	209	> 37.9930	308	> 63.7552
136	> 67.8656	216	> 40.4535	311	> 21.1730
138	> 58.0720	217	0.1148	319	0.001

Inhibition of Kinase insert Domain containing Receptor (KDR: the catalytic domain of the VEGF receptor)

[0069] In this standard pharmacological test procedure, KDR protein is mixed, in the presence or absence of a inhibitor compound, with a substrate peptide to be phosphorylated (a copolymer of glutamic acid and tyrosine, E:Y :: 4: 1) and other cofactors such as Mg⁺⁺ and sodium vanadate (a protein tyrosine phosphatase inhibitor) in an appropriate buffer to maintain pH (7.2). ATP and a radioactive tracer (either P³²- or P³³- labeled ATP) is then add to initiate phosphorylation. After incubation, the radioactive phosphate associated with the acid-insoluble fraction of the assay mixture is then quantified as reflection of substrate phosphorylation. This radioactive format was used to identify inhibitors of KDR tyrosine kinase activity where the IC₅₀ is the concentration of drug that inhibits substrate phosphorylation by 50%.

Table 13:

Inhibition of Kinase insert Domain containing Receptor (KDR)			
Example - NO.	KDR IC ₅₀ μg/mL	Example No .	KDR IC ₅₀ μg/mL
9	>30	241	>30
18	>30	242	>30
49	>30	243	>30
76	0.7	244	>30
82	3	246	>10
84	0.3	248	10
85	0.3	249	>10
86	3	250	>10
87	3	275	>30
97	0.1	276	>30
127	10	277	>30
128	8	278	>30

Table 13: (continued)

Inhibition of Kinase insert Domain containing Receptor (KDR)			
Example - NO.	KDR IC ₅₀ µg/mL	Example No .	KDR IC ₅₀ µg/mL
145	>30	279	>30
154	>30	280	>30
160	30	281	3
176	3	282	2
177	0.05	283	30
208	10	284	30
209	30	288	10
216	30	290	10
217	30	291	10
218	>30	292	10
229	0.2	293	10
232	>30	294	6
233	>30	295	10
234	>30	305	30
238	>30	307	30
239	>30	308	30
240	>30	319	0.5

Mitogen Activated Protein Kinase (MAPK) Assay

[0070] To evaluate inhibitors of the MAP (mitogen activated protein) kinase a two component coupled standard pharmacological test procedure, which measures phosphorylation of a serine/threonine residue in an appropriate sequence in the substrate in the presence and absence of a putative inhibitor, was used. Recombinant human MEK 1 (MAPKK) was first used to activate recombinant human ERK2 (MAPK) and the activated MAPK (ERK) was incubated with substrate (MBP peptide or MYC peptide) in the presence of ATP, Mg²⁺ and radiolabeled ³³P ATP. The phosphorylated peptide was captured on a P 81 phosphocellulose filter (paper filter or embedded in microtiter plate) washed and counted by scintillation methods.

[0071] The peptide substrates used in the assay are MBP, peptide substrate (APRTPGGRR), or synthetic Myc substrate, (KKFELLTPPLSPSRR•5 TFA. The recombinant enzymes used were prepared as GST fusion proteins of human ERK 2 and human MEK 1. Inhibitor samples were prepared as 10X stocks in 10% DMSO and an appropriate aliquot was used to deliver either 10 µg/ml for a single point screening dose or 100, 10, 1, and 0.1 µM final concentration for a dose response curve. Final DMSO concentrations were less than or equal to 1%.

[0072] The reaction was run as follows in 50 mM Tris kinase buffer, pH 7.4 in a reaction volume of 50 µl. The appropriate volume of kinase buffer and inhibitor sample was added to the tube. Appropriate dilution of enzyme was delivered to give 2-5 µg recombinant MAPK (Erk) per tube. The inhibitor was incubated with MAPK (Erk) for 30 min at 0 deg. C. Recombinant Mek (MAPKK) (0.5-2.5 µg) or fully activated Mek (0.05-0.1 units) was added to activate the Erk and incubated for 30 min at 30° C. Then substrate and gamma ³³P ATP was were added to give a final concentration of 0.5- 1 mM MBPP or 250-500 µM Myc; 0.2-0.5 µCi gamma P 33 ATP/tube; 50 µM ATP final concentration. Samples were incubated at 30°C for 30 minutes and the reaction was stopped by adding 25 µl of ice cold 10 %TCA .After samples were chilled on ice for 30 min, 20 µl of sample was transferred onto P 81 phosphocellulose filter paper or appropriate MTP with embedded P 81 filter. Filter papers or MTP were washed 2 times with a large volume of 1% acetic acid, then 2 times with water. The filters or MTP were briefly air dried before addition of scintillant and samples were counted in the appropriate scintillation counter set up for reading ³³P isotope. Samples included a positive control (activated enzyme plus substrate); a no enzyme control; a no substrate control; samples with different concentrations of putative inhibitor, and samples with reference inhibitors (other active compounds or non-specific inhibitors such as staurosporine or K252 B).

[0073] The raw data was captured as cpm. Sample replicates were averaged and corrected for background count. Mean cpm data was tabulated by group and % inhibition by a test compound was calculated as (corrected cpm control-corrected. cpm sample/control) X 100 = % inhibition. If several concentrations of inhibitor were tested, IC₅₀ values (the concentration which gives 50% inhibition) were determined graphically from the dose response curve for % inhibition

EP 0 973 746 B1

or by an appropriate computer program. In the Table below, there may be separate entries for the same compound; this is an indication that the compound was evaluated more than one time.

Table 14:

Mitogen Activated Protein Kinase (MAPK) Assay					
Example	IC ₅₀ (μM)	Example	IC ₅₀ (μM)	Example	IC ₅₀ (μM)
3	>100	47	>100	131	>100
6	>100	48	10	131	>100
7	25	49	>100	132	>100
8	>100	49	>100	133	>100
9	>100	50	>100	134	>100
13	>100	61	>100	134	80
14	>100	62	2	135	10
15	>100	62	20	135	30
16	3.3	63	>100	135	>100
16	34	64	>100	136	70
17	>100	64	3	136	>100
18	>100	65	40	136	>100
19	29	76	<1	138	2.3
23	>100	81	0.1	138	38
31	8	82	5.5	139	35
31	<1	83	1.8	140	>100
31	2	83	25	141	35
35	2.5	84	<1	143	40
35	9	84	<1	144	40
38	45	85	<1	145	35
39	40	85	<1	146	6
40	>100	85	0.2	147	80
41	1.4	86	1.8	149	2
43	30	86	2	149	4
44	18	87	<1	150	>100
45	>100	87	<1	150	>100
46	>100	87	2	152	<1
46	>100	87	30	152	40
46	>10	88	<10	153	>100
46	>30	88	>50	154	20
46	>100	89	2.5	155	3
46	>100	89	4	155	<1
47	<1	89	>50	156	>100
47	<1	89	2	157	90
47	>100	99	40	158	<1
47	9.2	100	20	158	<1
47	7	101	20	158	<1
47	1.3	105	>100	158	0.3
47	8	108	>100	159	>100
47	10	110	40	160	30
47	8	111	100	161	55
47	9	112	>100	162	35
47	20	117	40	163	>100
47	5	117	28	164	>100
47	<1	125	>100	165	>100
47	1	126	>100	166	>100

EP 0 973 746 B1

Table 14: (continued)

Mitogen Activated Protein Kinase (MAPK) Assay					
Example	IC ₅₀ (μM)	Example	IC ₅₀ (μM)	Example	IC ₅₀ (μM)
47	<1	127	6	167	>100
47	5	129	60	168	80
47	<1	130	>100	169	>100
47	2	130	>100	170	>100
47	>100	130	>100	171	100
172	90	252	100	280	>100
173	8	254	<1	281	2.5
174	2.5	254	<1	281	2.5
176	>100	254	9	282	>100
177	40	254	<0.5	282	>100
186	3	255	<1	283	>100
186	7	255	<1	284	4
186	2.5	255	0.2	288	16
187	>100	255	10	290	3
188	<1	255	<1	291	>100
188	50	255	2	292	>100
188	30	255	10	293	>100
189	50	255	0.2	294	9
190	12	256	95	295	50
191	40	256	3	296	3.5
191	>100	257	>100	298	<1
192	>100	258	4	299	>100
192	>100	258	1	300	20
193	50	258	<1	301	12
194	>100	259	3	303	>100
197	35	259	>50	305	>100
198	15	259	>100	311	2
198	7	259	>100	311 1	70
200	>100	260	55	311	2.5
203	<1	261	<1	312	>100
203	<1	261	<1	313	>100
203	0.8	261	<1	318	70
204	35	261	5	319	<1
205	>100	262	4	319	<1
208	13	262	1.2	323	15
209	9	263	80	324	100
229	<1	264	3	325	>100
229	<1	264	1	326	35
232	>100	264	3	327	10
232	45	264	8	327	3
232	>100	265	20	327	>100
233	80	266	>100	328	>100
234	>100	268	15	329	>100
238	>100	269	5	330	>100
239	>100	269	<1	331	>100
240	10	269	3	332	25
241	>100	269	8	332	<50
242	10	270	>100	333	10

Table 14: (continued)

Mitogen Activated Protein Kinase (MAPK) Assay					
Example	IC ₅₀ (μ M)	Example	IC ₅₀ (μ M)	Example	IC ₅₀ (μ M)
243	>100	270	>100	339	65
244	>100	275	>100	339	50
246	35	276	>100	340	>100
248	8	277	>100	340	>100
249	15	278	>100	341	>100
250	10	279	>100	342	>100
343	60	363	25	383	>100
344	>100	364	>100	384	>100
345	>100	365	>100	385	90
348	>100	366	<1	386	>100
348	80	366	10	387	>100
349	>100	366	4	388	25
349	>100	366	3	388	50
351	32	366	50	389	>100
353	40	366	4	390	>100
354	>100	374	<1	391	>100
355	45	374	2	392	40
356	>100	377	>100	393	40
357	>100	379	40	394	>100
358	18	380	>100	395	15
359	>100	381	>100	396	50
362	>100	382	>100		

[0074] Based on the results obtained for representative compounds of this invention, the compounds of this invention are antineoplastic agents which are useful in treating, inhibiting the growth of, or eradicating neoplasms. In particular, the compounds of this invention are useful in treating, inhibiting the growth of, or eradicating neoplasms that express EGFR such as those of the breast, kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, or lung. In addition, the compounds of this invention are useful in treating, inhibiting the growth of, or eradicating neoplasms of the breast that express the receptor protein produced by the erbB2 (Her2) oncogene.

[0075] The compounds of this invention may formulated neat or may be combined with one or more pharmaceutically acceptable carriers for administration. For example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solution or suspension containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 0.05 up to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight. Pharmaceutical compositions comprising a compound of Formula 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier form a further aspect of the present invention.

[0076] The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 1000 mg/kg of animal body weight, optionally given in divided doses two to four times a day, or in sustained release form. For most large mammals the total daily dosage is from about 1 to 1000 mg, preferably from about 2 to 500 mg. Dosage forms suitable for internal use comprise from about 0.5 to 1000 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

[0077] The compounds of this invention may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such

as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

[0078] The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

[0079] In some cases it may be desirable to administer the compounds directly to the airways in the form of an aerosol.

[0080] The compounds of this invention may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0081] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

[0082] For the treatment of cancer, the compounds of this invention can be administered in combination with other antitumor substances or with radiation therapy. These other substances or radiation treatments can be given at the same or at different times as the compounds of this invention. These combined therapies may effect synergy and result in improved efficacy. For example, the compounds of this invention can be used in combination with mitotic inhibitors such as taxol or vinblastine, alkylating agents such as cisplatin or cyclophosphamide, antimetabolites such as 5-fluorouracil or hydroxyurea, DNA intercalators such as adriamycin or bleomycin, topoisomerase inhibitors such as etoposide or camptothecin, and antiestrogens such as tamoxifen.

[0083] The preparation of representative examples of the compounds of this invention is described below.

Example 1

1,4-Dihydro-7-methoxy-4-oxo-3-quinolinecarbonitrile

[0084] A mixture of 30.2 g (245.2 mmol) of 3-methoxy aniline and 41.5 g (245.2 mmol) of ethyl(ethoxymethylene) cyanoacetate was heated in the absence of solvent to 140°C for 30 minutes. To the resulting oil was added 1200 ml of Dowtherm. The solution was refluxed with stirring under nitrogen for 22 hours. The mixture was cooled to room temperature and solid was collected and washed with hexanes. The solid was recrystallized from acetic acid to give 17 g of 1,4-dihydro-7-methoxy-4-oxo-3-quinolinecarbonitrile: mass spectrum (electrospray, m/e): M+H 200.9.

Example 2

4-Chloro-7-methoxy -3-quinolinecarbonitrile

[0085] A mixture of 4.0 g (20 mmol) of 1,4-dihydro-7-methoxy-4-oxo-3-quinolinecarbonitrile and 8.3 g (40 mmol) of phosphorous pentachloride was heated at 165°C for 3 hours. The mixture was diluted with hexanes and the solid was collected. The solid was mixed with brine and dilute sodium hydroxide solution and extracted several times with a mixture of tetrahydrofuran and ethyl acetate. The solution was dried over magnesium sulfate and filtered through a pad of silica gel giving 3.7 g of 4-chloro-7-methoxy -3-quinolinecarbonitrile as a white solid: mass spectrum (electrospray, m/e): M+H 218.9.

Example 3

4-[(3-Bromophenyl)amino]-7-methoxy -3-quinolinecarbonitrile

[0086] A solution of 2.97 g (13.6 mmol) of 4-chloro-7-methoxy -3-quinolinecarbonitrile and 4.67 g (27.2 mmol) of 3-bromo aniline in 76 ml of methoxyethanol was refluxed under nitrogen for 5 hours. The solution was cooled and diluted with ether. Solid was collected and washed with ether. The solid was stirred with a hot mixture of ethyl acetate and sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. Solvent was removed and the residue was recrystallized from a chloroform - ethyl acetate mixture giving 1.6 g of 4-[(3-bromophenyl)

amino]-7-methoxy -3-quinolinecarbonitrile as a white solid: mass spectrum (electrospray, m/e): M+H 354.1, 356.1.

Example 4

1,4-Dihydro-7-methoxy-6-nitro-4-oxo-3-quinolinecarbonitrile

[0087] To a suspension of 10 g (49.6 mmol) of 1,4-dihydro-7-methoxy-4-oxo-3-quinolinecarbonitrile in 160 ml of trifluoroacetic anhydride was added 6 g (74.9 mmol) of ammonium nitrate over a period of 3 hours. The mixture was stirred an additional two hours. Excess anhydride was removed at reduced pressure at 45°C. The residue was stirred with 500 ml of water. The solid was collected and washed with water. The solid was dissolved in 1000 ml of boiling acetic acid and the solution was treated with decolorizing charcoal. The mixture was filtered and concentrated to a volume of 300 ml. Cooling gave a solid which was collected giving 5.4 g of 1,4-dihydro-7-methoxy-6-nitro-4-oxo-3-quinolinecarbonitrile as a brown solid: mass spectrum (electrospray, m/e): M+H 246.

Example 5

4-Chloro-7-methoxy-6-nitro -3-quinolinecarbonitrile

[0088] A mixture of 5.3 g (21.6 mmol) of 1,4-dihydro-7-methoxy-6-nitro-4-oxo-3-quinolinecarbonitrile and 9 g (43.2 mmol) of phosphorous pentachloride was heated at 165°C for 2 hours. The mixture was diluted with hexanes and the solid was collected. The solid was dissolved in 700 ml ethyl acetate and washed with cold dilute sodium hydroxide solution. The solution was dried over magnesium sulfate and filtered through a pad of silica gel giving 5.2 g of 4-chloro-7-methoxy-6-nitro-3-quinolinecarbonitrile as a tan solid.

Example 6

4-[(3-Bromophenyl) amino] -7-methoxy-6-nitro -3-quinolinecarbonitrile

[0089] A solution of 5.2 g (19.7 mmol) of 4-chloro-7-methoxy-6-nitro-3-quinolinecarbonitrile and 3.7 g (21.7 mmol) of 3-bromo aniline in 130 ml of methoxyethanol was refluxed under nitrogen for 4 hours. The reaction mixture was poured into dilute sodium bicarbonate solution. Solid was collected and washed with water and dried in air. The solid was chromatographed on silica gel eluting with chloroform-ethyl acetate 9:1. Solvent was removed from product fractions giving 1.2 g of 4-[(3-bromophenyl)amino]-7-methoxy-6-nitro-3-quinolinecarbonitrile as a yellow solid: mass spectrum (electrospray, m/e): M+H 399.0, 402.0.

Example 7

6-Amino-4-[(3-bromophenyl)amino] -7-methoxy -3-quinolinecarbonitrile

[0090] A mixture of 2.05 g (5.1 mmol) of 4-[(3-bromophenyl)amino]-7-methoxy-6-nitro-3-quinolinecarbonitrile, 1.37 g (25.7 mmol) of ammonium chloride, and 0.86 g (15.4 mmol) of powdered iron was stirred at reflux in 26 ml water and 26 ml methanol for 2 hours. The mixture was diluted with ethyl acetate and the hot mixture was filtered. The organic layer was separated from the filtrate and dried over magnesium sulfate. The solvent was removed and the residue was chromatographed on silica gel eluting with mixtures of chloroform and ethyl acetate. Product fractions were combined to give 1.3 g of 6-amino-4-[(3-bromophenyl)amino]-7-methoxy -3-quinolinecarbonitrile as a yellow solid: mass spectrum (electrospray, m/e): M+H 369.1, 371.1.

Example 8

N-[4-[(3-Bromophenyl)amino]-3-cyano-7-methoxy -6-quinoliny]-2-butyramide

[0091] To a solution of 1.44 g (17.14 mmol) of 2-butyric acid and 2.26 g (16.5 mmol) of isobutyl chloroformate in 30 ml of tetrahydrofuran at 0°C, with stirring, was added 3.1 g (3.4 mmol) of N-methyl morpholine. This solution of the mixed anhydride was added to a stirred solution of 1.13 g (3.06 mmol) of 6-amino-4-[(3-bromophenyl)amino]-7-methoxy-3-quinolinecarbonitrile in 30 ml tetrahydrofuran in three portions over a 24 hour period. The solvent was removed. The residue was stirred with dilute sodium bicarbonate solution. Solid was collected and washed with water and ether. This was recrystallized from 1-butanol. The resulting solid was taken up in hot tetrahydrofuran and filtered through silica gel. The filtrate was concentrated and diluted with hexanes to give 0.71 g of N-[4-[(3-bromophenyl)amino]-3-cy-

ano-7-methoxy -6-quinoliny]-2-butyramide as a yellow powder: mass spectrum (electrospray, m/e): M+H 437.1, 438.1.

Example 9

N-[4-[(3-Bromophenyl)amino]-3-cyano-7-methoxy-6-quinoliny]-2-propenamide

[0092] To a solution of 1.5 g (4.06 mmol) of 6-Amino-4-[(3-bromophenyl)amino]-7-methoxy-3-quinolinecarbonitrile and 0.45 ml of N-methylmorpholine in 30 ml of tetrahydrofuran was added at 0°C, under nitrogen, with stirring, 0.42 g (4.7 mmol) of acryloyl chloride over a 15 minute period. After 1 hour at 0°C, the solution was diluted with 200 ml ethyl acetate. The mixture was washed with saturated sodium bicarbonate solution and then dried over magnesium sulfate. The solvent was removed. The residue was chromatographed on silica gel eluted with chloroform-ethyl acetate mixtures to give 0.5 g of the title compound as a light yellow solid powder: mass spectrum (electrospray, m/e): M+H 423.1, 425.1

Example 10

2-Cyano-3-(4-nitrophenylamino)acrylic Acid Ethyl Ester

[0093] 4-Nitroaniline (60.0g, 0.435mol) and ethyl(ethoxymethylene) cyanoacetate (73.5g, 0.435mol) were mixed mechanically in a flask. The mixture was heated at 100°C for 0.5h after it had melted and resolidified. A 114 g portion of the crude product was recrystallized from dimethylformamide to give 44.2g of yellow crystals; mp 227-228.5°C.

Example 11

1,4-Dihydroquinoline-6-Nitro-4-oxo -3-carbonitrile

[0094] A slurry of 25.0g (95.8mmol) of 2-cyano-3-(4-nitrophenylamino)acrylic acid ethyl ester in 1.0L of Dowtherm A was heated at 260°C under N₂ for 12.5h. The cooled reaction was poured into 1.5L of hexane. The product was collected, washed with hexane and hot ethanol and dried in vacuo. There was obtained 18.7g of brown solid. An analytical sample was obtained by recrystallization from dimethylformamide/ethanol: mass spectrum (electrospray, rule): M+H 216.

Example 12

4-Chloro-6-nitro-3-quinolinecarbonitrile

[0095] A mixture of 31.3g (0.147mol) of 6-nitro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile and 160mL of phosphorous oxychloride was refluxed for 5.5h. The phosphorous oxychloride was removed in vacuo and the residue was poured over ice and neutralized with sodium bicarbonate. The product was collected, washed with water and dried in vacuo (50°C). There was obtained 33.5g of tan solid; solid: mass spectrum (electrospray, m/e): M+H 234.

Example 13

4-[(3-Bromophenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0096] A mixture of 17.0g (73.1mmol) of 4-chloro-6-nitro-3-quinolinecarbonitrile and 15.1g (87.7mmol) of 3-bromoaniline in 425mL of ethanol was refluxed for 5h. Saturated sodium bicarbonate was added and then all volatile material was removed in vacuo. The residue was slurried with hexane and the product was collected and washed with hexane. The crude product was washed with water and dried in vacuo (60°C). There was obtained 22.5g of yellow solid. An analytical sample was obtained by recrystallization from ethyl acetate; mp 258-259°C.

Example 14

6-Amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile

[0097] A mixture of 4.00g (10.8mmol) of 4-[(3-bromophenyl)amino]-6-nitro-3-quinolinecarbonitrile and 12.2g (54.2mmol) of SnCl₂ dihydrate in 160mL of ethanol was refluxed under N₂ for 1.3h. After cooling to 25°C, ice water and sodium bicarbonate were added and the mixture was stirred for 2h. Extraction with chloroform, treatment with Darco, drying (magnesium sulfate) and solvent removal gave 3.9g of brown crystals: mass spectrum (electrospray, m/

e): M+H 339.

Example 15

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-2-butyramide

[0098] Isobutyl chloroformate(0.788g, 5.75mmol) and N-methylmorpholine(0.581g, 5.75mmol) were added to an ice cold solution of 0.485g (5.75mmol) of 2-butyric acid in 20mL of tetrahydrofuran under N₂. After stirring for 10min, a solution of 1.50g (4.42mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 10mL of tetrahydrofuran was added and the mixture was stirred overnight at 25°C. A second equivalent of preformed mixed anhydride was then added. After 6h, the reaction was poured into saturated sodium bicarbonate and brine. The product was collected and washed with hot ethyl acetate and ethanol and dried in vacuo to give 0.638g of yellow solid; mp 283-285°C(dec).

Example 16

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny] acetamide

[0099] Triethylamine (0.359g, 3.55mmol) and acetyl chloride (0.277mg, 3.55mmol) were added to an ice cold solution of 1.00g (2.96mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 8mL of methylene chloride and 6mL of tetrahydrofuran under N₂. After stirring overnight at 25°C, volatile material was removed, and the residue was slurried with water and collected. Recrystallization from ethanol gave 0.543g of brown solid; mp 258-261°C(dec).

Example 17

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny] butanamide

[0100] Triethylamine (0.359g, 3.55mmol) and butyryl chloride (0.380g, 3.55mmol) were added to an ice cold solution of 1.00g (2.96mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 12mL of tetrahydrofuran under N₂. After stirring overnight at 25°C, volatile material was removed, and the residue was slurried with water and collected. The residue was washed with boiling methanol and dried in vacuo to give 0.773g of brown powder; mp 276-277°C(dec).

Example 18

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-2-propenamide

[0101] Triethylamine (0.359g, 3.55mmol) and acryloyl chloride (0.321g, 3.55mmol) were added to an ice cold solution of 1.00g (2.96mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 12 mL of tetrahydrofuran under N₂. After stirring overnight at 25°C, volatile material was removed and the residue was slurried with water and collected. Recrystallization from ethanol gave 0.580g of brown solid: mass spectrum (electrospray, m/e): M+H 393, 395.

Example 19

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-2-chloroacetamide

[0102] Triethylamine(0.359g, 3.55mmol) and chloroacetyl chloride (0.402g, 3.55mmol) were added to an ice cold solution of 1.00g (2.96mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 12mL of tetrahydrofuran under N₂. After stirring overnight at 25°C, volatile material was removed and the residue was slurried in water and collected. Recrystallization from methanol gave 0.540g of tan solid: mass spectrum (electrospray, m/e): M+H 415, 417.

Example 20

4-[(3,4-Dibromophenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0103] A mixture of 6.20g (26.6mmol) of 4-chloro-6-nitro-3-quinolinecarbonitrile and 8.00g (31.9mmol) of 3,4-dibromoaniline in 160mL of ethanol was refluxed under N₂ for 5h. Saturated sodium bicarbonate was added and volatile material was removed. The residue was slurried with hexane, collected, washed with hexane and water and dried. The insoluble material was repeatedly extracted with boiling ethyl acetate and the solution was then filtered through silica gel. The solvent was removed to give 3.80g of green solid: mass spectrum (electrospray, m/e): M+H 449.

Example 216-Amino-4-[(3,4-dibromophenyl)amino]-3-quinolinecarbonitrile

[0104] A mixture of 4.90g (10.9mmol) of 4-[(3,4-dibromophenyl)amino]-6-nitro-3-quinolinecarbonitrile and 12.4g (54.7mmol) of SnCl₂ dihydrate in 200mL of ethanol was refluxed under N₂ for 1.5h. After cooling to 25°C, the reaction was diluted with ice water, neutralized with sodium bicarbonate and stirred for 2h. This solution was then extracted with chloroform, treated with Darco, dried(magnesium sulfate) and evaporated. After drying in vacuo(40°C), there was obtained 1.25g of brown solid: mass spectrum (electrospray, m/e): M+H 417, 419, 421.

Example 22N-[4-[(3,4-dibromophenyl)amino]-3-cyano-6-quinoliny]-2-butyname

[0105] Isobutyl chloroformate (0.984g, 7.18mmol) and N-methylmorpholine (0.725g, 7.18mmol) were added to an ice cold solution of 0.604g (7.18mmol) of 2-butyneic acid in 25mL of tetrahydrofuran. After 10min, a solution of 1.20g (2.87mmol) of 6-amino-4-[(3,4-dibromophenyl)amino]-3-quinolinecarbonitrile in 12mL of tetrahydrofuran was added dropwise. After stirring overnight at 25°C, volatile material was removed and the residue was slurried in water and filtered. The crude product was washed with boiling EtOAc and ethanol and dried in vacuo(50°C) to give 0.651g of brown solid: mass spectrum (electrospray, m/e): M+H 485.

Example 236-Nitro-4[(3-trifluoromethylphenyl)amino]-3-quinolinecarbonitrile

[0106] A mixture of 10.6g (45.7mmol) of 4-chloro-6-nitro-3-quinolinecarbonitrile and 8.82g (54.8mmol) of 3-(trifluoromethyl)aniline in 270 mL of ethanol was refluxed under N₂ for 5h. The reaction was diluted with ethanol, neutralized with satd sodium bicarbonate and evaporated. The residue was slurried with hexane, collected, washed with hexane and water and dried in vacuo(60°C) to give 10.9g of yellow solid. A 2.00g sample was recrystallized from ethanol to give 1.20g of bright yellow solid; mp 260-261°C.

Example 246-Amino-4[(3-trifluoromethylphenyl)amino]-3-quinolinecarbonitrile

[0107] A slurry of 6.00g(16.8mmol) of 6-nitro-4-[(3-trifluoromethylphenyl)amino]-3-quinolinecarbonitrile and 18.9g (83.3mmol) of SnCl₂ dihydrate in 240 mL of ethanol was refluxed under N₂ for 1h. After cooling to 25°C, the reaction was diluted with ice water, neutralized with sodium bicarbonate and stirred for 2h. The product was extracted with chloroform, treated with Darco, dried(magnesium sulfate) and evaporated. The residue was filtered through silica gel (10% methanol in chloroform), evaporated and dried in vacuo(40°C) to give 4.87g of brown solid: mass spectrum (electrospray, m/e): M+H 329.

Example 25N-[4-[(3-Trifluoromethylphenyl)amino]-3-cyano-6-quinoliny]-2-butyname

[0108] Isobutyl chloroformate (1.56 g, 11.4mmol) and N-methylmorpholine (1.15 g, 11.4mmol) were added to an ice cold solution of 0.961 g (11.4mmol) of 2-butyneic acid in 40mL of tetrahydrofuran under N₂. After stirring for 10min a solution of 1.50g (4.57mmol) of 6-amino-4-[(3-trifluoromethylphenyl)amino]-3-quinolinecarbonitrile in 12mL of tetrahydrofuran was added dropwise. After stirring at 25°C overnight, volatile material was removed and the residue was slurried in water and filtered. The crude product was washed 3 times with small portions of hot ethyl acetate and then dried in vacuo (45°C) to give 0.831 g of yellow solid: mass spectrum (electrospray, m/e): M+H 395.

Example 263-Carbethoxy-4-hydroxy-6,7-dimethoxyquinoline

[0109] A mixture of 30.6 g of 4-aminoveratrole and 43.2 g of diethyl ethoxymethylene-malonate was heated at 100

for 2 h and at 165°C for 0.75 h. The intermediate thus obtained was dissolved in 600 ml of diphenyl ether, and the resulting solution was heated at reflux temperature for 2 h, cooled, and diluted with hexane. The resulting solid was filtered, washed with hexane followed by ether, and dried to provide the title compound as a brown solid, mp 275-285°C.

5 Example 27

3-Carbethoxy-4-chloro-6,7-dimethoxyquinoline

10 [0110] A mixture of 28.8 g of 3-carbethoxy-4-hydroxy-6,7-dimethoxyquinoline and 16.6 ml of phosphorous oxychloride was stirred at 110°C for 30 min, cooled to 0°C, and treated with a mixture of ice and ammonium hydroxide. The resulting grey solid was filtered, washed with water and ether, and dried, mp 147-150°C.

Example 28

4-[(3-Bromophenyl)amino]-6,7-dimethoxy-3-quinolinecarboxylic Acid, Ethyl Ester

15 [0111] A mixture of 14.8 g of 3-carbethoxy-4-chloro-6,7-dimethoxyquinoline, 9.46 g of 3-bromoaniline, 4.05 ml of pyridine, and 150 ml of ethanol was refluxed for 30 min, evaporated to remove ethanol, and partitioned with dichloromethane-aq sodium bicarbonate. The organic layer was washed with water, dried, and concentrated. The residue was recrystallized from ethanol to give a white solid, mp 155-158°C.

Example 29

4-[(3-Bromophenyl)amino]-6,7-dimethoxy-3-quinolinecarboxylic Acid

25 [0112] A mixture of 13 g of 4-[(3-bromophenyl)amino]-3-quinolinecarboxylic acid, ethyl ester, 15 ml of 10 N sodium hydroxide, and 300 ml of ethanol was refluxed for 2 h. After evaporation of most ethanol, the residue was diluted with water and acidified with sodium dihydrogen phosphate to pH 7. The resulting white solid was filtered, washed with water, and dried, mp 282-285°C.

Example 30

4-[(3-Bromophenyl)amino]-6,7-dimethoxy-3-quinolinecarboxamide

35 [0113] A mixture of 4.03 g of 4-[(3-bromophenyl)amino]-6,7-dimethoxy-3-quinolinecarboxylic acid, 3.24 g of carbonyldiimidazole, and 100 ml of dimethylformamide was heated at 55 for 30 m, cooled to 0°C, and saturated with ammonia gas. After warming to 25 the resulting solution was stirred for 45 m, heated at 50, and evaporated to remove dimethylformamide. The residue was stirred with water, and the resulting solid was filtered, washed with water, and dried. Recrystallization from acetone gave a grey solid, mp 239-242°C.

Example 31

4-[(3-Bromophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile

45 [0114] To a stirred mixture of 3.02 g of 4-[(3-bromophenyl)amino]-6,7-dimethoxy-3-quinolinecarboxamide, 2.43 ml of pyridine, and 22.5 ml of dichloromethane at 0°C was added 3.18 ml of trifluoroacetic anhydride during 3 min. The reaction mixture was warmed to 25°C, stirred for 60 min, and concentrated. The residue was dissolved in 38 ml of methanol. The resulting solution was treated with 15 ml of 5 N NaOH at 25°C. After 5 m the solution was acidified with carbon dioxide and evaporated free of methanol. The residue was partitioned with dichloromethane-water. The organic layer was washed with water, dried, and evaporated to give a white solid. Recrystallization from ethyl acetate-hexane gave mp 224-228°C.

Example 32

Ethyl 2-cyano-3-(3,4-dimethoxyphenylamino)acrylate

55 [0115] A mixture of 7.66 g of 4-aminoveratrole, 8.49 g of ethyl ethoxymethylenecyanoacetate, and 20 ml of toluene was heated at 100°C for 90 min. The toluene was evaporated to give a solid, mp 150-155°C.

Example 331,4-Dihydro-6,7-dimethoxy-4-oxo-3-quinolinecarbonitrile

[0116] A mixture of 40 g of ethyl 2-cyano-3-(3,4-dimethoxyphenylamino)acrylate and 1.2 L of Dowtherm® A was refluxed for 10 h, cooled, and diluted with hexane. The resulting solid was filtered, washed with hexane followed by dichloromethane, and dried; mp 330-350°C (dec).

Example 344-Chloro-6,7-dimethoxy -3-quinolinecarbonitrile

[0117] A stirred mixture of 20 g of 1,4-dihydro-6,7-dimethoxy-4-oxo-3-quinolinecarbonitrile and 87 ml of phosphorous oxychloride was refluxed for 2 h, cooled, and evaporated free of volatile matter. The residue was stirred at 0°C with dichloromethane-water as solid sodium carbonate was added until the aqueous layer was pH 8. The organic layer was separated, washed with water, dried and concentrated. Recrystallization from dichloromethane gave a solid, mp 220-223°C.

Example 354-[(3-Fluorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0118] A mixture of 1.00 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.89 g of 3-fluoroaniline, 0.32 ml of pyridine, and 12 ml of ethoxyethanol was stirred at reflux temperature for 4 h. The mixture was cooled and partitioned with dichloromethane and aqueous sodium bicarbonate. The organic layer was washed with water, dried and evaporated. The residue was recrystallized from ethyl acetate to give a solid, mp 226-230°C.

Example 36Methyl 2-(dimethylaminomethyleneamino)benzoate

[0119] To a stirred solution of 7.56 g of methyl anthranilate in 50 ml of dimethylformamide at 0°C was added 5.6 ml of phosphorous oxychloride during 15 m. The mixture was heated at 55 for 45 m, cooled to 0, and diluted with dichloromethane. The mixture was basified at 0°C by slow addition of cold 1N NaOH to pH 9. The dichloromethane layer was separated, washed with water, dried and concentrated to an oil.

Example 371,4-Dihydro-4-oxo-3-quinolinecarbonitrile

[0120] A stirred mixture of 1.03 g of methyl 2-(dimethylaminomethyleneamino)benzoate, 0.54 g of sodium methoxide, 1.04 ml of acetonitrile, and 10 ml of toluene was refluxed for 18 h. The mixture was cooled, treated with water, and brought to pH 3 by addition of dilute HCl. The resulting solid was extracted with ethyl acetate. The extract was washed with water, dried and evaporated. The residue was recrystallized from ethanol to give a solid, mp 290-300°C.

Example 384-(Cyclohexylamino)-6,7-dimethoxy-3-quinolinecarbonitrile

[0121] A solution of 1.24g (5 mmole) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 1.14 ml (0.99g;10 mmole) of cyclohexylamine, and 0.4 ml (0.39g) of pyridine in 10 ml of methyl cellosolve was refluxed in an oil bath at 148°C for 3 hours. The reaction was poured into 25 ml of saturated aqueous sodium bicarbonate, and the resulting solid was filtered. This solid was dissolved in methylene chloride, and the solution was passed through Magnesol. Hexanes were added to the filtrate, and this solution was evaporated on a hot plate until crystals formed. Cooling gave 1.54 g of 4-(cyclohexylamino)-6,7-dimethoxy-3-quinolinecarbonitrile melting at 193-195 °C: mass spectrum (electrospray, m/e): M+H 312.1.

Example 394-[(3-Bromophenyl)amino]-6,7-dihydroxy-3-quinolinecarbonitrile

5 **[0122]** 5.11 g of 4-[(3-bromophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile and 30.74 g of pyridine hydrochloride were intimately mixed and then heated under nitrogen at 207 °C for an hour. On cooling the reaction was treated with about 100 ml of water and the solid was filtered. This solid was digested with methyl cellulose and washed with ether to give 3.00 g of 4-[(3-bromophenyl)amino]-6,7-dihydroxy-3-quinolinecarbonitrile: mass spectrum (electro-spray, m/e): M+H 356, 358.

Example 408-[(3-Bromophenyl)amino]-[1,3]-dioxolo[4,5-g]quinoline-7-carbonitrile

15 **[0123]** A mixture of 2.17g (6.09 mmole) of 4-[(3-bromophenyl)amino]-6,7-dihydroxy-3-quinolinecarbonitrile, 0.59ml (1.18g; 9.14 mmole) of bromochloromethane and 2.98g (9.14 mmole) of cesium carbonate in 20 ml of N, N-dimethylformamide was heated and stirred for 2 hours in an oil bath at 111°C. The reaction was poured into 75 ml of water and extracted with four 50ml portions of methylene chloride. The combined methylene chloride extracts were washed with several portions of water. This solution was taken to an oil *in vacuo* and this was dissolved in ethyl acetate. This solution
20 was washed repeatedly with water, then with brine. The solution was dried over anhydrous magnesium sulfate, and taken to a solid *in vacuo* to give 0.95 g of 8-[(3-bromophenyl)amino]-[1,3]-dioxolo[4,5-g]quinoline-7-carbonitrile, m.p. 201-205 °C: mass spectrum (electrospray, m/e): M+H 368.1, 370.1.

Example 414-[(3-Chlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile

25 **[0124]** A mixture of 0.5 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.51 g of 3-chloroaniline, 0.16 ml of pyridine, and 6 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 6 h. The mixture was cooled and partitioned with dichloromethane and aqueous sodium bicarbonate. The organic layer was washed with water, dried and evaporated. The residue was recrystallized from ethyl acetate-hexanes to give 0.37 g of 4-[(3-chlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as a solid, mp 214-217°C.

Example 424-[(3-Trifluoromethylphenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile

35 **[0125]** A mixture of 1.24 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 1.61 g of 3-trifluoromethylaniline, 0.4 ml of pyridine, and 15 ml of ethoxyethanol was stirred, under nitrogen, at reflux temperature for 5 h. The mixture was cooled and partitioned with dichloromethane and aqueous sodium bicarbonate. The organic layer was washed with water, dried and evaporated. The residue was recrystallized from ethyl acetate-hexanes to give 1.34 g of 4-[(3-trifluoromethylphenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as a solid, mp 190-193°C.

Example 434-[(3,4-Dimethoxyphenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile

45 **[0126]** A mixture of 1.0 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 1.22 g of 3,4-dimethoxyaniline, 0.32 ml of pyridine, and 12 ml of ethoxyethanol was stirred, under nitrogen, at reflux temperature for 5 h. The mixture was cooled and partitioned with dichloromethane and aqueous sodium bicarbonate. The organic layer was washed with water, dried and evaporated. The residue was recrystallized from ethyl acetate to give 0.96 g of 4-[(3,4-dimethoxyphenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as a solid, mp 230-240°C.

Example 444-[(Methylphenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile

55 **[0127]** A mixture of 0.86 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.86 g of N-methylaniline, 0.32 ml of

pyridine, and 12 ml of ethoxyethanol was stirred, under nitrogen, at reflux temperature for 24 h. The mixture was cooled and partitioned with dichloromethane and aqueous sodium bicarbonate. The organic layer was washed with water, dried and evaporated. The residue was recrystallized from ethyl acetate-hexanes to give 0.54 g of 4-[(methylphenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as a solid, mp 137-141°C.

Example 45

4-[(3-Cyanophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0128] A mixture of 0.5 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.47 g of 3-aminobenzonitrile, 0.16 ml of pyridine, and 12 ml of ethoxyethanol was stirred, under nitrogen, at reflux temperature for 22 h. The mixture was cooled and partitioned with dichloromethane and aqueous sodium bicarbonate. The organic layer was washed with water, dried and evaporated. The residue was recrystallized from ethyl acetate-hexanes to give 0.59 g of 4-[(3-cyanophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as a solid, mp 285-288°C.

Example 46

4-[(4-Fluorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0129] A mixture of 0.5 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.44 g of 4-fluoroaniline, 0.16 ml of pyridine, and 6 ml of ethoxyethanol was stirred, under nitrogen, at reflux temperature for 4 h. The mixture was cooled and partitioned with dichloromethane and aqueous sodium bicarbonate. The organic layer was washed with water, dried and evaporated. The residue was recrystallized from ethyl acetate to give 0.59 g of 4-[(4-fluorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as a solid, mp 282-285°C.

Example 47

4-[(3-Bromophenyl)amino]-6,7-diethoxy-3-quinolinecarbonitrile

[0130] A mixture of 0.36 g of 4-[(3-bromophenyl)amino]-6,7-dihydroxy-3-quinolinecarbonitrile, 0.32 ml of ethyl iodide and 0.55 g of potassium carbonate in 4 ml of dimethylsulfoxide was stirred for 3 hours in an oil bath with heating. Most of the solvent was removed at reduced pressure. The mixture was mixed with ethyl acetate and water. The organic layer was washed with water and dried over magnesium sulfate. Solvent was removed to give 0.23 g of 4-[(3-bromophenyl)amino]-6,7-diethoxy-3-quinolinecarbonitrile which after recrystallization from ethyl acetate gave mp = 173-175°C.

Example 48

4-[(3-(hydroxymethyl)phenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0131] A mixture of 1.0 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.98 g of 3-aminobenzyl alcohol, 0.32 ml of pyridine, and 12 ml of ethoxyethanol was stirred, under nitrogen, at reflux temperature for 3 h. The mixture was cooled and partitioned with dichloromethane and aqueous sodium bicarbonate. The organic layer was washed with water, dried and evaporated. The residue was washed with hot methanol to give 1.16 g of 4-[(3-(hydroxymethyl)phenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as a solid, mp 250-255°C.

Example 49

4-(3-Bromophenoxy)-6,7-dimethoxy-3-quinolinecarbonitrile

[0132] A mixture of 0.16 g of 88% KOH and 1.73 g of 3-bromophenol at 50°C was treated with 0.50 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile. The resulting mixture was heated to 170°C during 30 min, cooled, and treated at 0°C with 40 ml of 0.1 N NaOH. The solid which resulted was filtered, washed with water, and dissolved in methylene chloride. The solution was washed with 0.5 N NaOH and water, dried, and concentrated. The resulting solid was recrystallized from methylene chloride-hexane to give 4-(3-bromophenoxy)-6,7-dimethoxy-3-quinolinecarbonitrile as a white solid, mp 187-190°C.

Example 504-[(4-Bromophenyl)sulfanyl]-6,7-dimethoxy-3-quinolinecarbonitrile

[0133] To 1.89 g of 4-bromothiophenol at 25 under argon was added 0.16 g of 88% KOH. The resulting mixture was heated at 85°C for 15 minutes, treated with 0.50 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, and heated at 140°C for 1 hour and 160°C for 15 minutes. The mixture was cooled and stirred at 0°C with 40 ml of 0.1 N NaOH. The resulting solid was filtered, washed with water, and dissolved in methylene chloride. The solution was washed with 0.2 N NaOH and water, dried, and concentrated. The residue which resulted was recrystallized from ethyl acetate to give 4-[(3-bromophenyl)sulfanyl]-6,7-dimethoxy-3-quinolinecarbonitrile as a an off-white solid, mp 173-175°C.

Example 51N-[4-[(3-Bromophenyl)amino]-3-cyano -6-quinoliny]-3(E)-chloro-2-propenamide and**Example 52**N-[4-[(3-Bromophenyl)amino]-3-cyano -6-quinoliny]-3(Z)-chloro-2-propenamide

[0134] A mixture of 3 g (28.2 mmol) of *cis*-3-chloro acrylic acid and 3.3 ml (37.5 mmol) of oxalyl chloride in 30 ml of methylene chloride containing one drop of dimethylformamide was stirred for 2.5 hours. The solvent was removed to give the acid chloride as a mixture of *cis* and *trans* isomers. To a solution of 0.5 g (1.5 mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile and 0.24 g (1.8 mmol) of N,N-diisopropylethylamine in 5 ml tetrahydrofuran was added at 0°C, under nitrogen, with stirring, 0.21 g (1.7 mmol) of 3-chloro acryloyl chloride isomer mixture over a 4 minute period. After 40 min at 0°C, the solution was diluted with ether. The solid was collected and dissolved in a mixture of tetrahydrofuran and ethyl acetate. The mixture was washed with brine and then dried over magnesium sulfate. The solvent was removed. The residue was chromatographed on silica gel eluted with chloroform-ethyl acetate. Two products were obtained. The less polar product is N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-3(E)-chloro-2-propenamide: mass spectrum (electrospray, m/e): M+H 424.9, 427.0. The more polar product is N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-3(Z)-chloro-2-propenamide: mass spectrum (electrospray, m/e): M+H 425.0, 427.0.

Example 53N-[4-[(3-Bromophenyl)amino]-3-cyano -6-quinoliny]-2-methyl-2-propenamide

[0135] To a solution of 0.5 g (1.48 mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile and 0.194 g (1.92 mmol) of triethylamine in 6 ml tetrahydrofuran was added at 0°C, under nitrogen, with stirring, 0.21 g (1.92 mmol) of 2-methyl acryloyl chloride over a 10 minute period. The solution was stirred at room temperature overnight. The mixture was poured into water. The solid was collected and air dried. The solid was washed with boiling ethyl acetate and air dried giving 0.32 g of N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-2-methyl-2-propenamide : mass spectrum (electrospray, m/e): M+H 407, 409.

Example 54N-[4-[(3,4-Dibromophenyl)amino]-3-cyano-6-quinoliny]-2-propenamide

[0136] To a solution of 0.75 g (1.79 mmol) of 6-amino-4-[(3,4-dibromophenyl)amino]-3-quinolinecarbonitrile and 0.22 g (2.15 mmol) of triethylamine in 10 mL of tetrahydrofuran was added dropwise 0.195 g (2.15 mmol) of acryloyl chloride. After stirring overnight at 25°C, volatile material was removed and the residue was slurried in water and solid was collected. The crude product was washed with boiling ethyl acetate dried in vacuo (50°C) to give 0.609 g of brown solid: high resolution mass spectrum (m/e): 470.9457.

Example 55N-[4- [(5-bromo-3-pyridinyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0137] A mixture of 249 mg (1 mmole) of 3-cyano-4-chloro-6,7-dimethoxy quinoline, 346 mg (2 mmoles) of 3-amino-5-bromo pyridine and 20 mg (about 0.1 mmole) of p-toluene-sulfonic acid monohydrate in 5 ml of 2-methoxy ethanol

was stirred and refluxed in an oil bath at 153°C for 7 hours. On cooling overnight to room temperature, the solid was filtered and washed with ethanol, then with ether to give 287 mg (74.5%) of N-[4-[(5-bromo-3-pyridinyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile, which melted at 272-275° C. mass spectrum (electrospray, m/e) M+H = 384.9, 386.8.

Example 56

4-[(3-Bromophenyl)amino]-6,7-bis(methoxymethoxy)-3-quinolinecarbonitrile

[0138] A mixture of 0.36 g of 4-[(3-bromophenyl)amino]-6,7-dihydroxy-3-quinolinecarbonitrile, 0.30 ml of 2-chloromethyl methyl ether and 0.55 g of potassium carbonate in 4 ml of dimethylformamide was stirred for 6 hours at 0°C. Most of the solvent was removed at reduced pressure. The mixture was mixed with ethyl acetate and water and the pH was adjusted to 8 with dilute hydrochloric acid. The organic layer was washed with water and dried over magnesium sulfate. Solvent was removed to give 4-[(3-bromophenyl)amino]-6,7-bis(methoxymethoxy)-3-quinolinecarbonitrile which was purified by column chromatography on silica gel. : mass spectrum (electrospray, m/e): M+H 356, 358.

Example 57

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-hydroxy-2-butyramide

[0139] Isobutyl chloroformate (0.214g, 1.57mmol) and N-methylmorpholine (0.190g, 1.88mmol) were added to an ice cold solution of 0.336g (1.57mmol) of 4-(tert-butyl dimethyl-silyloxy)-2-butyric acid in 15mL of tetrahydrofuran under N₂. After stirring for 30min, it was transferred to an additional funnel plugged with a glass wool and added dropwise to a solution of 0.4g (1.18mmol) of 6-amino-4-[(3-bromo-phenyl)amino]-3-quinolinecarbonitrile in 3mL of tetrahydrofuran and 1.5ml of pyridine. The mixture was stirred at 25°C for 1h. The reaction solution was poured into ethyl acetate and washed with saturated sodium bicarbonate and brine. The product was collected and purified by flash column chromatography (60% ethyl acetate in hexane) to give 0.220g of N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-(tert-butyl-dimethylsilyloxy)-2-butyramide as a yellow solid (35%); ESMS m/z 535.1 (M+H⁺); mp °C(dec).

[0140] N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-(tert-butyl-dimethyl-silyloxy)-2-butyramide (0.120g, 0.224mmol) was dissolved in a 25ml solution (acetic acid:tetrahydrofuran:water=3:1:1) and stirred overnight at 25°C. The reaction was poured into ethyl acetate and washed with saturated sodium bicarbonate and brine. The product was collected, washed with ethyl acetate, and dried in vacuo to give 0.085g of yellow solid (90%); ESMS m/z 421.2 (M+H⁺); mp 253-254°C(dec).

Example 58

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-morpholino-2-butyramide

[0141] Isobutyl chloroformate (0.161 g, 1.18 mmol) and N-methylmorpholine (0.150 g, 1.48 mmol) were added to an ice cold solution of 0.250g (1.48mmol) of 4-morpholino-2-butyric acid in 10mL of tetrahydrofuran under N₂. After stirring for 30min, a solution of 0.250g (0.74mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 8mL of pyridine was added and the mixture was stirred at 0°C for 2h. The reaction was quenched with ice water and then poured into saturated sodium bicarbonate and brine. The product was collected, washed with ethyl acetate, and dried in vacuo to give 0.096g (27%) of yellow solid; ESMS m/z 490.1 (M+H⁺); mp 112-115 °C.

Example 59

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-2-butyramide

[0142] Isobutyl chloroformate (0.260g, 1.91mmol) and N-methylmorpholine (0.594g, 5.88mmol) were added to an ice cold solution of 0.370g (2.94mmol) of 4-dimethylamino-2-butyric acid in 50mL of tetrahydrofuran under N₂. After stirring for 30min, a solution of 0.500g (0.147mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 10mL of pyridine was added and the mixture was stirred at 0°C for 2h. The reaction was quenched with ice water, and then poured into saturated sodium bicarbonate and brine. The product was collected, washed with ethyl acetate, and dried in vacuo to give 0.144g (21%) of yellow solid; ESMS m/z 448.0 (M+H⁺); mp 114-118 °C.

Example 60N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinolinyl]-4-methoxy-2-butynamide

[0143] Isobutyl chloroformate (0.410g, 3.0mmol) and N-methylmorpholine (0.910g, 9.0mmol) were added to an ice cold solution of 0.680g (6.0mmol) of 4-methoxy-2-butynoic acid in 20mL of tetrahydrofuran under N₂. After stirring for 30min, a solution of 0.500g (0.147mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 10mL of pyridine was added and the mixture was stirred at 0°C for 2h. The reaction was quenched with ice water, and then poured into saturated sodium bicarbonate and brine. The product was collected, washed with ethyl acetate, and dried in vacuo to give 0.200g (35%) of yellow solid; ESMS m/z 435.1 (M+H⁺); mp 198-202 °C(dec).

Example 614-(3-Bromophenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0144] A stirred mixture of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile (0.69 g, 2.5 mmol), 3-bromobenzylamine (0.78 g, 3.5 mmol), diisopropylethyl amine (1.05 ml, 6.0 mmol), and 7.5 ml of ethoxyethanol was refluxed for 4 h, cooled, and stirred with a mixture of hexane and water containing 0.4 g of potassium carbonate for 3 h. The resulting solid was filtered, washed with water, and dried. Recrystallization from acetone- hexane gave 0.73 g of off-white solid, mp 156-159°C.

Example 624-(3-Phenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0145] In the manner of Example 61 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with benzylamine gave the title compound as an off-white solid, mp 150-153°C.

Example 634-(3,4-Dimethoxyphenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0146] In the manner of Example 61 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 3,4-dimethoxybenzylamine gave the title compound as a tan solid, mp 200-204°C.

Example 644-(3,4-Dichlorophenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0147] In the manner of Example 61 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 3,4-dichlorobenzylamine gave the title compound as a tan solid, mp 163-165°C.

Example 654-Methoxy-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide

[0148] To a solution of 1.0 g (2.95 mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile and 0.57 g (4.42 mmol) of diisopropylethyl amine at 0°C with stirring was added 0.43 g (3.24 mmol) of 4-methoxycrotonyl chloride. After 1.5 hr at 0°C, the mixture was poured into a saturated solution of sodium bicarbonate and then extracted with ethyl acetate. The organic solution was dried over magnesium sulfate and the solvent was removed. The residue was recrystallized from 1-butanol giving 1.3 g of 4-Methoxy-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide as a yellow solid: mass spectrum (electrospray, m/e,): M+H 436.4, 438.9.

Example 664-(3-Chloro-propoxy)-5-methoxy -benzoic acid methyl ester

[0149] A mixture of 102.4 g (411.7 mmol) of 3-chloropropyl p-toluene sulfonate, 75 g (411.7 mmol) of 4-hydroxy-

5-methoxy -benzoic acid methyl ester, 75.7 g (547.5 mmol) of potassium carbonate, and 1.66 g (4.1 mmol) of methyl-tricapryl ammonium chloride in 900 ml of acetone was stirred rapidly at reflux for 18 hr. The mixture was filtered and the solvent was removed giving 106 g of the title compound after recrystallization from a chloroform-hexane mixture.

5 Example 67

4-(2-Chloro-ethoxy)-5-methoxy -benzoic acid methyl ester

[0150] By using an identical method as above 77 g of 4-hydroxy-5-methoxy -benzoic acid methyl ester, 99.2 g of 2-chloroethyl p-toluene sulfonate, 77.7 g of potassium carbonate, and 1.7 g (4.1 mmol) of methyl-tricapryl ammonium chloride was converted to 91.6 g of the title compound: mass spectrum (electrospray, m/e,): M+H 245.0

Example 68

4-(3-Chloro-propoxy)-5-methoxy-2-nitro-benzoic acid methyl ester

[0151] To a solution of 100 g (386.5 mmol) 4-(3-chloro-propoxy)-5-methoxy -benzoic acid methyl ester in 300 ml acetic acid was added dropwise 100 ml of 70% nitric acid. The mixture was heated to 50°C for 1 hr and then poured into ice water. The mixture was extracted with chloroform. The organic solution was washed with dilute sodium hydroxide and then dried over magnesium sulfate. The solvent was removed. Ether was added and the mixture was stirred until solid was deposited. The solid was collected by filtration giving 98 g of 4-(3-Chloro-propoxy)-5-methoxy-2-nitro-benzoic acid methyl ester as white crystals : mass spectrum (electrospray, m/e,): M+H 303.8; 2M+NH₄ 623.9.

Example 69

4-(2-Chloro-ethoxy)-5-methoxy-2-nitro-benzoic acid methyl ester

[0152] By using an identical method as above 85 g of 4-(2-Chloro-ethoxy)-5-methoxy-benzoic acid methyl ester was nitrated to give 72 g of the title compound: mass spectrum (electrospray, m/e,): 2M+NH₄ 595.89

Example 70

2-Amino-4-(3-chloro-propoxy)-5-methoxy-benzoic acid methyl ester

[0153] A mixture of 91 g (299.6 mmol) of 4-(3-chloro-propoxy)-5-methoxy-2-nitro-benzoic acid methyl ester and 55.2 g (988.8 mmol) of iron was mechanically stirred at reflux in a mixture containing 60.1 g ammonium chloride, 500 ml water, and 1300 ml methanol for 5.5 hr. The mixture was concentrated and mixed with ethyl acetate. The organic solution was washed with water and saturated sodium bicarbonate. The solution was dried over magnesium sulfate and filtered through a short column of silica gel. The solvent was removed and the residue mixed with 300 ml of ether-hexane 2:1. After standing 73.9 g of the title compound was obtained as a pink solid : mass spectrum (electrospray, m/e): 2M-HCl+H 511.0; M+H 273.8

Example 71

2-Amino-4-(2-chloro-ethoxy)-5-methoxy-benzoic acid methyl ester

[0154] A mixture of 68.2 g (235.4 mmol) of 4-(2-chloro-ethoxy)-5-methoxy-2-nitro-benzoic acid methyl ester and 52.6 g (941.8 mmol) of iron was mechanically stirred at reflux in a mixture containing 62.9 g ammonium chloride, 393 ml water, and 1021 ml methanol for 15 hr. The mixture was concentrated and mixed with ethyl acetate. The organic solution was washed with water and saturated sodium bicarbonate. The solution was dried over magnesium sulfate and filtered through a short column of silica gel. The solution was concentrated to 200 ml and diluted with 250 of hot hexane. After standing 47.7 g of the title compound was obtained as a solid : mass spectrum (electrospray, m/e) M+H 259.8.

Example 72

7-(2-Chloro-ethoxy)-4-hydroxy-6-methoxy-quinoline-3-carbonitrile

[0155] A mixture of 25 g (96.3 mmol) of 2-amino-4-(2-chloro-ethoxy)-5-methoxy-benzoic acid methyl ester and 17.2

g (144.4 mmol) of dimethylformamide dimethylacetal was heated to reflux for 1.5 hr. Excess reagents were removed at reduced pressure leaving 30.3 g of a residue which was dissolved in 350 ml of tetrahydrofuran.

In a separate flask, to a stirred solution of 80.9 ml of 2.5M n-butyl lithium in hexane in 300 ml of tetrahydrofuran at -78°C was added dropwise 8.3 g (202.1 mmol) of acetonitrile over 40 min. After 30 min, the above solution of amidine was added dropwise over 45 min at -78°C. After 1 hr, 27.5 ml of acetic acid was added and the mixture was allowed to warm to room temperature. The solvent was removed and water was added. Solid was collected by filtration and washed with water and ether. After drying in vacuum, 18.5 g of the title compound was obtained as a tan powder: mass spectrum (electrospray, m/e) M+H 278.8.

Example 73

7-(3-Chloro-propoxy)-4-hydroxy-6-methoxy-quinoline-3-carbonitrile

[0156] By using the above method, starting with 6.01 g of the corresponding amidine, 1.58 g of acetonitrile, and 15.35 ml of n-butyl lithium solution, 3.7 g of the title compound was obtained as a tan powder: mass spectrum (electrospray, m/e) M+H 292.8; 2M+H 584.2

Example 74

7-(3-Chloro-propoxy)-4-chloro-6-methoxy-quinoline-3-carbonitrile

[0157] A mixture of 3.5 g (12 mmol) of 7-(3-chloro-propoxy)-4-hydroxy-6-methoxyquinoline-3-carbonitrile and 28 ml of phosphorous oxychloride was refluxed for 1.5 hr. Excess reagent was removed at reduced pressure. The residue was mixed with ice cold dilute sodium hydroxide and ethyl acetate. The mixture was extracted with a combination of ethyl acetate and tetrahydrofuran. The combined extracts were washed with a saturated solution of sodium bicarbonate, dried over magnesium sulfate, and filter through a short column of silica gel. Solvents were removed giving 3.2 g of the title compound as a pink solid that is used with additional purification.

Example 75

7-(3-Chloro-ethoxy)-4-chloro-6-methoxy-quinoline-3-carbonitrile

[0158] A solution of 8 g (28.7 mmol) of 7-(3-chloro-ethoxy)-4-hydroxy-6-methoxy-quinoline-3-carbonitrile and 18.2 g (143.5 mmol) of oxalyl chloride in 80 ml of methylene chloride containing 0.26 g of dimethylformamide was stirred at reflux for 2.5 hr. The solvent was removed. The residue was mixed with cold dilute sodium hydroxide and extracted several time with ethyl acetate and tetrahydrofuran. The combined extracts were dried over magnesium sulfate and the solution was passed through a short silica gel column. The solvents were removed giving 6.0 g of the title compound as an off-white solid that is used without additional purification.

Example 76

4-(4-Chloro-2-fluoro-phenylamino)-7-(3-chloro-propoxy)-6-methoxy-quinoline-3-carbonitrile

[0159] A mixture of 3.1 g (9.96 mmol) of 7-(3-Chloro-propoxy)-4-chloro-6-methoxyquinoline-3-carbonitrile, 1.6 g (10.96 mmol) of 4-chloro-2-fluoro-aniline, and 1.2 g (10 mmol) of pyridine hydrochloride in 31 ml of 2-ethoxyethanol was stirred at reflux for 1.5 hr. The mixture was poured into saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic solution was dried and solvent was removed. The residue was purified on a silica gel column eluting with chloroform-ether mixtures to give 2.88 g of the title compound as an off-white solid powder: mass spectrum (electrospray, m/e) M+H 419.7.

Example 77

7-(2-Chloro-ethoxy)-4-(3-hydroxy-4-methyl-phenylamino)-6-methoxy-quinoline-3-carbonitrile

[0160] By using the above method, starting with 3 g of 7-(2-chloro-ethoxy)-4-chloro-6-methoxy-quinoline-3-carbonitrile, 1.37 g of 3-hydroxy-4-methyl-aniline, and 1.2 g of pyridine hydrochloride in 31 ml of 2-ethoxyethanol, 2.6 g of the title compound was obtained as a crystalline solid: mass spectrum (electrospray, m/e) M+H 383.9.

Example 78

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-7-(3-chloropropoxy)-6-methoxy-quinoline-3-carbonitrile

[0161] By using the above method, starting with 3 g of 7-(3-chloro-propoxy)-4-chloro-6-methoxy-quinoline-3-carbonitrile, 2.35 g of the methyl carbonate of 4-chloro-2-fluoro-5-hydroxy-aniline, and 1.1 g of pyridine hydrochloride in 30 ml of 2-ethoxyethanol, 1.7 g of the title compound was obtained as a crystalline solid: mass spectrum (electrospray, m/e) M+H 435.8, 437.8.

Example 79

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-7-(2-chloro-ethoxy)-6-methoxy-quinoline-3-carbonitrile

[0162] By using the above method, starting with 3 g of 7-(2-chloro-ethoxy)-4-chloro-6-methoxy-quinoline-3-carbonitrile, 2.46 g of the methyl carbonate of 4-chloro-2-fluoro-5-hydroxy-aniline, and 1.18 g of pyridine hydrochloride in 31 ml of 2-ethoxyethanol, 2.2 g of the title compound was obtained as a tan solid: mass spectrum (electrospray, m/e) M+H 421.9.

Example 80

4-(4-Chloro-2-fluoro-phenylamino)-7-(3-dimethylamino-propoxy)-6-methoxy-quinoline-3-carbonitrile

[0163] A mixture of 1 g (2.38mmol) of 4-(4-Chloro-2-fluoro-phenylamino)-7-(3-chloro-propoxy)-6-methoxy-quinoline-3-carbonitrile and 0.07 g of sodium iodide in 17.85 ml of 2M dimethylamine in tetrahydrofuran was placed in a sealed tube and heated to 125°C for 3.5 hr. The solvent was removed and the residue was mixed with warm ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. Solvent was removed and ether was added. One standing, the crystals were deposited giving 0.93 g of the title compound as a white solid: mass spectrum (electrospray, m/e) M+H 428.9.

Example 81

4-(4-Chloro-2-fluoro-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile

[0164] A mixture of 1 g (2.38mmol) of 4-(4-Chloro-2-fluoro-phenylamino)-7-(3-chloro-propoxy)-6-methoxy-quinoline-3-carbonitrile, 3.1 g (35.7 mmol) of morpholine, and 0.07 g of sodium iodide in 20 ml ethylene glycol dimethyl ether refluxed for 7 hr. The solvent was removed and the residue was mixed with warm ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. Solvent was removed and ether-hexane was added. One standing, the crystals were deposited giving 1.1 g of the title compound as a off-white solid: mass spectrum (electrospray, m/e) M+H 470.9.

Example 82

7-(2-Dimethylamino-ethoxy)-4-(3-hydroxy-4-methylphenylamino)-6-methoxy-quinoline-3-carbonitrile

[0165] A mixture of 1 g (2.38mmol) of 7-(2-chloro-ethoxy)-4-(3-hydroxy-4-methylphenylamino)-6-methoxy-quinoline-3-carbonitrile and 0.078 g of sodium iodide in 19.5 ml of 2M dimethylamine in tetrahydrofuran was placed in a sealed tube and heated to 125°C for 14 hr. The solvent was removed and the residue was mixed with warm ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. Solvent was removed and the residue was chromatographed on silica gel eluting with ethyl acetate-methanol-triethylamine 70:30:2.5 giving 0.89 g of the title compound as a light yellow solid: mass spectrum (electrospray, m/e) M+H 393.0; (M+2H)⁺ 196.9.

Example 83

4-(3-Hydroxy-4-methyl-phenylamino)-6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinoline-3-carbonitrile

[0166] A mixture of 1 g (2.38mmol) of 7-(2-chloro-ethoxy)-4-(3-hydroxy-4-methylphenylamino)-6-methoxy-quinoline-3-carbonitrile, 3.4 g (39 mmol) of morpholine, and 0.08 g of sodium iodide in 22 ml ethylene glycol dimethyl ether

refluxed for 34 hr. The solvent was removed and the residue was mixed with warm ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. Solvent was removed and the residue was chromatographed on silica gel eluting with ethyl acetate-methanol-triethylamine 70:30:2.5 giving 1.05 of the title compound as a light orange solid: mass spectrum (electrospray, m/e) M+H 435.0; (M+2H)⁺ 218.0.

Example 84

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-7-(3-dimethylaminopropoxy)-6-methoxy-quinoline-3-carbonitrile

[0167] A mixture of 0.8 g (1.83 mmol) of 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-7-(3-chloro-propoxy)-6-methoxy-quinoline-3-carbonitrile and 0.055 g of sodium iodide in 15.6 ml of 2M dimethylamine in tetrahydrofuran was placed in a sealed tube and heated to 125°C for 2.5 hr. The solvent was removed and the residue was mixed with warm ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. Solvent was removed and the residue was treated with ethyl acetate-ether depositing a solid and giving 0.51 g of the title compound as a off-white solid: mass spectrum (electrospray, m/e) M+H 445.0; (M+2H)⁺ 243.4.

Example 85

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile

[0168] A mixture of 0.8 g (1.83 mmol) of 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-7-(3-chloro-propoxy)-6-methoxy-quinoline-3-carbonitrile, 2.4 g (27.5 mmol) of morpholine, and 0.11 g of sodium iodide in 15 ml ethylene glycol dimethyl ether refluxed for 7 hr. The solvent was removed and the residue was mixed with warm ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. Solvent was removed and the residue was recrystallized from ethyl acetate-carbon tetrachloride giving 0.63 of the title compound as a light tan solid: mass spectrum (electrospray, m/e) M+H 487.0; (M+2H)⁺ 243.9.

Example 86

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-7-(2-dimethylamino-ethoxy)-6-methoxy-quinoline-3-carbonitrile

[0169] A mixture of 0.8 g (1.83 mmol) of 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-7-(2-chloro-ethoxy)-6-methoxy-quinoline-3-carbonitrile and 0.11 g of sodium iodide in 16.1 ml of 2M dimethylamine in tetrahydrofuran was placed in a sealed tube and heated to 135°C for 14 hr. The solvent was removed and the residue was mixed with warm ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. Solvent was removed and the residue was chromatographed on silica gel eluting with ethyl acetate-methanol-triethylamine 60:40:3 giving 0.41 g of the title compound as a tan solid: mass spectrum (electrospray, m/e) M+H 430.9; (M+2H)⁺ 216.0.

Example 87

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinoline-3-carbonitrile

[0170] A mixture of 0.8 g (1.83 mmol) of 4-(4-chloro-2-fluoro-5-hydroxyphenylamino)-7-(2-chloroethoxy)-6-methoxy-quinoline-3-carbonitrile, 2.4 g (27.5 mmol) of morpholine, and 0.11 g of sodium iodide in 15 ml ethylene glycol dimethyl ether heated in a sealed tube at 135°C for 12 hr. The solvent was removed and the residue was mixed with warm ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. Solvent was removed and the residue was chromatographed on silica gel eluting with ethyl acetate-methanol-triethylamine 70:30:1 giving 0.43 g of the title compound as a tan solid: mass spectrum (electrospray, m/e) M+H 470.0; (M+2H)⁺ 237.0.

Example 88

N-[3-Cyano-4-(3-fluorophenylamino)quinolin-6-yl]acrylamide

[0171] A solution of 1.00 g (3.60 mmol) of 6-amino-4-(3-fluorophenylamino)quinoline-3-carbonitrile in 12 mL of THE under N₂ was chilled in ice. Triethylamine (0.436 g, 4.32 mmol) was added followed by 0.393 g (4.32 mmol) of acryloyl chloride and the reaction was stirred at 25°C overnight. The solvent was removed and the residue was slurried with

water and filtered. The crude product was washed with water, dried, washed with hot ethyl acetate and dried in vacuo (50°C). This yielded 0.862 g of N-[3-cyano-4-(3-fluorophenylamino)quinolin-6-yl]acrylamide as a brown solid: mass spectrum (electrospray, m/e): M+H 333.1.

5 Example 89

6,7-Dimethoxy-4-(3-nitrophenylamino)quinoline-3-carbonitrile

10 [0172] A solution of 0.500 g (2.00 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile and 0.332 g (2.41 mmol) of 3-nitroaniline in 6 mL of methyl cellosolve was refluxed under N₂ for 8 hr. Methanol was added, followed by satd NaHCO₃ (pH 8) and volatile material was removed. The residue was slurried with water, collected by filtration and dried. Recrystallization from ethanol gave 0.480 g of 6,7-dimethoxy-4-(3-nitrophenylamino)quinoline-3-carbonitrile as yellow crystals: mass spectrum (electrospray, m/e): M+H 351.0.

15 Example 90

4-(3-Bromophenylamino)-6-ethoxy-7-methoxyquinoline-3-carbonitrile

20 [0173] A mixture of 1.00 g (3.82 mmol) of 4-chloro-6-ethoxy-7-methoxyquinoline-3-carbonitrile and 0.788 g (4.58 mmol) of 3-bromoaniline in 20 mL of ethanol was refluxed under N₂ for 7 h. Saturated NaHCO₃ was added, volatile material was removed and the residue was azeotroped with ethanol. The crude product was slurried with hexane, filtered, washed with water and dried. Recrystallization from ethanol gave 1.31 g of 4-(3-bromophenylamino)-6-ethoxy-7-methoxyquinoline-3-carbonitrile as tan crystals: mass spectrum (electrospray, m/e): M+H 397.9, 399.8.

25 Example 91

4-Chloro-6-ethoxy-7-methoxyquinoline-3-carbonitrile

30 [0174] A mixture of 7.95 g (32.6 mmol) of 6-ethoxy-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carbonitrile and 50 mL of phosphorous oxychloride was refluxed for 3h 40 min. The phosphorous oxychloride was removed in vacuo and the residue was slurried with ice water. Solid NaHCO₃ was added (pH8) and the product was collected by filtration, washed well with water and dried in vacuo (40°C). The yield was 7.75 g of 4-chloro-6-ethoxy-7-methoxyquinoline-3-carbonitrile as a tan solid: mass spectrum (electrospray, m/e): M+H 262.8, 264.8.

35 Example 92

6-Ethoxy-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carbonitrile

40 [0175] A solution of 10.2 g (45.3 mmol) of methyl 2-amino-5-ethoxy-4-methoxy benzoate and 10.8 g (90.7 mmol) of dimethylformamide dimethyl acetal in 50 mL of dimethylformamide was refluxed for 3 h. Volatile material was removed and the residue was azeotroped with toluene and dried in vacuo to give the formamidine as a purple syrup. n-Butyllithium (100 mmol) in hexane was diluted with 60 mL of tetrahydrofuran at -78°C. A solution of 4.18 g (102 mmol) of acetonitrile in 80 mL of tetrahydrofuran was added over 15 min and the solution was stirred for 20 min. The crude formamidine was dissolved in 80 mL of tetrahydrofuran and added dropwise to the cold solution over 0.5 h. After stirring for 2h, the reaction was quenched at -78°C with 13 mL of acetic acid. It was allowed to warm to room temperature and volatile material was removed in vacuo. The residue was slurried with water and the crude product was collected by filtration washed with water and dried. This material was then washed with chloroform and dried to give 7.95 g of 6-ethoxy-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carbonitrile as yellow crystals: mass spectrum (electrospray, m/e): M-H 243.2.

50 Example 93

Methyl 2-Amino-5-ethoxy-4-methoxybenzoate

55 [0176] A mixture of 17.0 g (66.7 mmol) of methyl 5-ethoxy-4-methoxy-2-nitrobenzoate, 13.1 g (233 mmol) of powdered iron and 17.7 g (334 mmol) of ammonium chloride in 95 mL of water and 245 mL of methanol was refluxed for 4.5 h. An additional 13.1 g of iron was added followed by refluxing for 2.5 h. Then an additional 13.1 g of iron and 17.7 g of ammonium chloride was added and refluxing was continued for 12 h. The reaction was filtered through Celite and

methanol was removed from the filtrate. The filtrate was extracted with chloroform and the extracts were treated with Darco, evaporated and dried in vacuo (50°C). The yield was 11.0 g of methyl 2-amino-5-ethoxy-4-methoxybenzoate as tan crystals: mass spectrum (electrospray, m/e): M+H 225.9.

5 Example 94

Methyl 5-Ethoxy-4-methoxy-2-nitrobenzoate

10 [0177] A mixture of 15.0 g (74.1 mmol) of methyl 3-ethoxy-4-methoxybenzoate in 45 mL of acetic acid was treated with 15 mL of conc nitric acid dropwise over 12 min. The reaction was kept at 55°C for 45 min, cooled to 25°C and poured into ice water. The product was extracted into methylene chloride and the extracts were washed with water and dil sodium hydroxide, dried and evaporated. The yield was 17.8 g of methyl 5-ethoxy-4-methoxy-2-nitrobenzoate as yellow crystals: mass spectrum (electrospray, m/e): M+H 256.0.

15 Example 95

Methyl 3-Ethoxy-4-methoxybenzoate

20 [0178] A mixture of 24.3 g (134 mmol) of methyl 3-hydroxy-4-methoxybenzoate, 36.8 g (267 mmol) of anhyd potassium carbonate and 31.4 g (201 mmol) of ethyl iodide in 500 mL of dimethylformamide was stirred at 100°C for 5.5 h. An additional amount of ethyl iodide (31.4 g) and potassium carbonate (18.4 g) was added and heating was continued for 2 h more. The reaction was filtered and volatile material was removed from the filtrate in vacuo. The residue was slurried with water and filtered to collect the product which was washed with water and dried. Recrystallization from heptane gave 15.6 g of methyl 3-ethoxy-4-methoxybenzoate as white crystals: mass spectrum (electrospray, m/e): M+H 210.9.

Example 96

Methyl 3-Hydroxy-4-methoxybenzoate

30 [0179] A solution of 30.8 g (183 mmol) of 3-hydroxy-4-methoxybenzoic acid and 6 mL of conc sulfuric acid in 600 mL of methanol was refluxed overnight. Most of the solvent was removed and the remaining solution was poured into 600 mL of water containing 25 g of sodium bicarbonate. The product was extracted into ether, treated with Darco, dried and evaporated. The yield was 31.8 g of methyl 3-hydroxy-4-methoxybenzoate as pale yellow crystals.

35 Example 97

6-Ethoxy-4-(3-hydroxy-4-methylphenylamino)-7-methoxyquinoline-3-carbonitrile

40 [0180] A mixture of 1.00 g (3.82 mmol) of 4-chloro-6-ethoxy-7-methoxyquinoline-3-carbonitrile and 0.563 g (4.58 mmol) of 3-hydroxy-4-methylaniline in 20 mL of ethanol was refluxed under N₂ for 8 h. Saturated NaHCO₃ was added, volatile material was removed and the residue was azeotroped with ethanol. The crude product was slurried with hexane, filtered, washed with water and cold ethanol and dried. Recrystallization from ethanol gave 0.632 g of 6-ethoxy-4-(3-hydroxy-4-methylphenylamino)-7-methoxyquinoline-3-carbonitrile as light yellow crystals: mass spectrum (electrospray, m/e): M+H 349.9.

Example 98

4-Bromo-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide

50 [0181] A solution of 1.65 grams (0.01 mole) of 4-bromo crotonic acid (Giza Braun, J. Am. Chem. Soc. 52, 3167 1930) in 15ml of dichloromethane was treated with 1.74 ml (0.02 moles) of oxalyl chloride and 1 drop of N, N- dimethylformamide. After an hour the solvents were removed on the rotary evaporator. The residual oil was taken up in 25 ml of tetrahydrofuran, and 3.39 grams of 6-Amino-4-(3-bromo-phenylamino)-quinoline-3-carbonitrile in 25 ml of tetrahydrofuran was added dropwise. This was followed by the dropwise addition of 1.92 ml (0.011 moles) of diisopropylethylamine. After the addition of 25 ml of water and 50 ml of ethyl acetate, the layers were separated. The organic layer was dried over anhydrous sodium sulfate, and taken to a solid *in vacuo*. This solid was digested for an hour with refluxing ethyl acetate then filtered from the ethyl acetate while still hot. Thus was obtained 3.31 grams (68%) of 4-bro-

mo-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide.

Example 99

5 4-Dimethylamino-but-2-enoic acid [4-(3-bromophenylamino)-3-cyano-quinolin-6-yl]-amide

[0182] Fifteen milliliters of a 2 molar solution of dimethylamine in tetrahydrofuran was cooled in an ice bath and a solution of 729 mg (1.5 mmoles) of 4-bromo-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide in 5 ml of N, N-dimethylformamide was added dropwise. Stirring and cooling were continued for 2 hours. Then 25 ml of water and 15 ml of ethyl acetate were added. The layers were separated and the organic layer was extracted with an addition 25 ml of water. The combined aqueous layers were extracted with 2-25 ml portions of 1:1 tetrahydrofuran-ethyl acetate. The combined organic layers were absorbed onto silica gel and chromatographed on silica gel. The column was eluted with a gradient of 1:19 to 1:4 methanol-methylene chloride. Obtained was 381 mg (56%) of 4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide which melted at 209-211 deg. : mass spectrum (electrospray, m/e): M+H 225.5, 226.2.

Example 100

20 4-Diethylamino-but-2-enoic acid [4-(3-bromophenylamino)-3-cyano-quinolin-6-yl]-amide

[0183] A solution of 3.15 ml (30 mmoles) of diethylamine in 15 ml of tetrahydrofuran was cooled in an ice bath and a solution of 729 mg (1.5 mmoles) of 4-bromo-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide in 5 ml of N,N-dimethylformamide was added dropwise. Stirring and cooling were continued for 2 hours. Then 25 ml of water and 15 ml of ethyl acetate were added. The layers were separated and aqueous layer was extracted with 2-15 ml portions of 1:1 tetrahydrofuran-ethyl acetate. The combined organic layers were absorbed onto silica gel and chromatographed on silica gel. The column was eluted with a gradient of 1:19 to 1:4 methanol-methylene chloride to give 367 mg (51%) of 4-Diethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide. The compound melted at 141-145 deg: mass spectrum (electrospray, m/e): M+H 478.0, 480.0.

30 Example 101

4-Methylamino-but-2-enoic acid [4-(3-bromophenylamino)-3-cyano-quinolin-6-yl]-amide

[0184] Fifteen milliliters of a 2 molar solution of methylamine in tetrahydrofuran was cooled in an ice bath and a solution of 729 mg (1.5 mmoles) of 4-bromo-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide in 5 ml of N, N-dimethylformamide was added dropwise. Stirring and cooling were continued for 2 hours. Then 25 ml of water and 15 ml of ethyl acetate were added. The layers were separated aqueous layer was extracted with 2-15 ml portions of 1:1 tetrahydrofuran-ethyl acetate. The combined organic layers were absorbed onto silica gel and chromatographed on silica gel. The column was eluted with a gradient of 1:19 to 1:1 methanol-methylene chloride. Obtained was 210 mg (32%) of 4-Methylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide which slowly went to a tar in the range of 194-202 deg. : mass spectrum (electrospray, m/e): M+H 437.9; M+2H 219.5.

Example 102

45 2-Cyano-3-(2-methyl-4-nitrophenyl)acrylic Acid Ethyl Ester

[0185] A mixture of 2-methyl-4-nitroaniline (38.0 g, 250 mmol), ethyl (ethoxymethylene)-cyanoacetate (50.8 g, 300 mmol), and 200 ml of toluene was refluxed for 24 h, cooled, diluted with 1:1 ether-hexane, and filtered. The resulting white solid was washed with hexane-ether and dried to give 63.9 g, mp 180-210°C.

Example 103

1,4-Dihydroquinoline-8-methyl-6-nitro-3-carbonitrile

55 [0186] A stirred mixture of 64 g (230 mmol) of 2-cyano-3-(2-methyl-4-nitrophenyl)acrylic acid ethyl ester and 1.5 L of Dowtherm A was heated at 260°C for 12 h, cooled, diluted with hexane, and filtered. The grey solid thus obtained was washed with hexane and dried to give 51.5 g, mp 295-305°C.

Example 1044-Chloro-8-methyl-6-nitro-3-quinolinecarbonitrile

[0187] A stirred mixture of 1,4-dihydroquinoline-8-methyl-6-nitro-3-carbonitrile (47 g, 200 mmol) and 200 ml of phosphorous oxychloride was refluxed for 4 h. The phosphorous oxychloride was removed in vacuo, and the residue was stirred with methylene chloride at 0°C and treated with a slurry of ice and sodium carbonate. The organic layer was separated and washed with water. The solution was dried and concentrated to a volume of 700 ml. The product was precipitated by the addition of hexane and cooling to 0°C. The white solid was filtered off and dried to give 41.6 g, mp 210-212°C.

Example 1054-[(3-Bromophenyl)amino]-8-methyl-6-nitro-3-quinolinecarbonitrile

[0188] A stirred mixture of 4-chloro-8-methyl-6-nitro-3-quinolinecarbonitrile (14.8 g, 60 mmol), 3-bromoaniline (12.4 g, 72 mmol), pyridine hydrochloride (6.93 g, 60 mmol), and 180 ml of ethoxyethanol was refluxed for 1.5 h, cooled, poured into a stirred mixture of water and an amount of sodium carbonate to give a pH of 8-9. The resulting yellow solid was filtered, washed with water, dried, digested in boiling ether, filtered, and dried to give 22.6 g, mp 263-267°C.

Example 1064-[(3-Bromophenyl)-N-acetylamino]-8-methyl-6-nitro-3-quinolinecarbonitrile

[0189] A stirred mixture of 4-[(3-bromophenyl)amino]-8-methyl-6-nitro-3-quinolinecarbonitrile (15.3 g, 40 mmol), 0.37 g (3 mmol) of dimethylaminopyridine, 40 ml of acetic anhydride, and 80 ml of pyridine was refluxed for 3 h and concentrated at 50°C under vacuum. The residue was stirred with methylene chloride and 0.1 N HCl. After filtration through Celite, the organic layer was washed with water, dried and concentrated. The residue was subjected to chromatography on silica gel with 1% acetic acid in methylene chloride to give 11.2 g of an amber glass, NMR (CDCl₃) δ 2.29 (N-acetyl group).

Example 1078-Bromomethyl-4-[(3-bromophenyl)-N-acetylamino]-6-nitro-3-quinolinecarbonitrile

[0190] A stirred mixture of 4-[(3-bromophenyl)-N-acetylamino]-8-methyl-6-nitro-3-quinolinecarbonitrile (10.6 g, 25 mmol), N-bromosuccinimide (6.68 g, 37.5 mmol), 0.30 g of dibenzoyl peroxide, and 200 ml of carbon tetrachloride was refluxed for 2h, treated with an additional 0.30 g of dibenzoyl peroxide, and refluxed an additional 2.5 h, cooled, diluted with methylene chloride, and stirred with aqueous sodium bisulfite. The organic layer was separated and washed successively with water, sodium bicarbonate solution, and water. The solution was dried and evaporated to give 15 g of a white foam, NMR (CDCl₃) δ 5.19 (dd, CH₂Br).

Example 1084-[(3-Bromophenyl)amino]-8-dimethylaminomethyl-6-nitro-3-quinolinecarbonitrile

[0191] To a stirred solution of dimethylamine in THF (2.0 M; 115 ml; 230 mmol) at 0°C was added a solution of 8-bromomethyl 4-[(3-bromophenyl)-N-acetylamino]-6-nitro-3-quinolinecarbonitrile (11.6 g, 23 mmol) in 115 ml of THF during 15 m. After warming to 25°C the mixture was stirred for 2h. The THF was evaporated off, and the residue was refluxed in 230ml of methanol with 12.7 g (92 mmol) of potassium carbonate for 1 h. The mixture was cooled, saturated with CO₂, and concentrated. The residue was partitioned with methylene chloride and water. The organic layer was washed with water, dried, and concentrated. The residue was subjected to chromatography on silica gel with methylene chloride-ethyl acetate-methanol-triethylamine to give 6.0 g yellow solid, mp 223-226°C.

Example 1096-Amino-4-[(3-bromophenyl)amino]-8-dimethylaminomethyl-3-quinolinecarbonitrile

[0192] A stirred mixture of 4-[(3-bromophenyl)amino]-8-dimethylaminomethyl-6-nitro-3-quinolinecarbonitrile (5.98 g, 14.1 mmol), iron powder (2.76 g, 49 mg-atoms), acetic acid (5.67 ml, 99 mmol), and 70 ml of methanol was refluxed for 2 h and then evaporated to remove methanol. The residue was stirred with water for 10 m, and the orange solid was filtered off and washed with 2% acetic acid. The total filtrate was basified to pH 10 with 5 N sodium hydroxide. The resulting precipitate was extracted with methylene chloride. The extract was washed with water, dried, and concentrated. The residue was subjected to chromatography on silica gel with ethyl acetate-methanol-triethylamine to give 3.34 g of amber solid; mass spectrum (electrospray, m/e) M+H 396.2, 398.1.

Example 110N-{4-[(3-Bromophenyl)amino]-3-cyano-8-dimethylaminomethyl-6-quinolinyl}-2-butyramide

[0193] To a stirred mixture of 2-butyric acid (0.42 g, 5.0 mmol) and N-methylmorpholine (0.66 ml, 6.0 mmol) in 4.0 ml of THF at 0°C was added i-butyl chloroformate (0.52 ml, 4.0 mmol) during 10 m. After 10 m a solution of 6-amino-4-[(3-bromophenyl)amino]-8-dimethylaminomethyl-3-quinolinecarbonitrile (0.79 g, 2.0 mmol) in 4.0 ml of THF was added during 60 s. The mixture was warmed to 25°C, stirred for 2 h, and diluted with water. The pH was adjusted to 9-10 with potassium carbonate, and the resulting solid was filtered off, washed with water, stirred with methylene chloride, and filtered. The latter filtrate was concentrated to give a solid which was subjected to chromatography on silica gel with methylene chloride-ethyl acetate-methanol-triethylamine to give an amber solid; mass spectrum (electrospray, m/e) M+H 462, 464.

Example 111N-{4-[(3-Bromophenyl)amino]-3-cyano-8-dimethylaminomethyl-6-quinolinyl}-2-propenamide

[0194] To a stirred solution of 6-amino-4-[(3-bromophenyl)amino]-8-dimethylaminomethyl-3-quinolinecarbonitrile (0.20 g, 0.50 mmol) and N,N-diisopropylethylamine (0.13 ml, 0.75 mmol) in 3.4 ml of THF at 0°C was added acryloyl chloride (0.045 ml, 0.55 mmol) during 5 m. After stirring for 3 h at 0°C the mixture was diluted with sodium bicarbonate solution. The resulting solid was filtered off, washed with water, dried, and subjected to chromatography on silica gel with methylene chloride-ethyl acetate-methanol-triethylamine to give a yellow solid; mass spectrum (electrospray, m/e) M+H 449.9, 452.0.

Example 112N-{4-[(3-Bromophenyl)amino]-3-cyano-8-dimethylaminomethyl-6-quinolinyl} acetamide

[0195] To a stirred mixture of 6-amino-4-[(3-bromophenyl)amino]-8-dimethylaminomethyl-3-quinolinecarbonitrile (0.20 g, 0.50 mmol) and 1.5 ml of acetic acid at 25°C was added 0.14 ml (1.5 mmol) of acetic anhydride. After 60 m volatile matter was evaporated off under vacuum. The residue was stirred with sodium bicarbonate solution. The resulting solid was filtered off, washed with water, dried, and recrystallized from isopropanol-hexane to give a light yellow solid, mp 162-167°C.

Example 113N'-[2-Carboethoxy-4,5-bis(2-methoxyethoxy)phenyl]-N,N-dimethylformamidine

[0196] To a stirred solution of 15.7 g (50 mmol) of ethyl 2-amino-4,5-bis(2-methoxyethoxy)-benzoate (Pfizer patent WO 96130347) in 50 ml of DMF at 0°C was added phosphorous oxychloride (5.6 ml, 60 mmol) during 15 m. The resulting solution was heated at 55°C for 45 m, cooled, diluted with methylene chloride, and treated at 0°C with 200 ml of N/1 sodium hydroxide during 2 m. The organic layer was separated and washed at 0°C with water. The solution was dried and evaporated with added toluene present to give 18.4 g of amber oil; NMR (CDCl₃) δ 3.02 (s, Me₂N).

Example 1141,4-Dihydroquinoline-5,6-bis(2-methoxyethoxy)-3-carbonitrile

[0197] To a stirred solution of n-butyllithium (44 ml of 2.5 M in hexane; 110 mmol) in 65 ml of THE at -78°C was added a solution of acetonitrile (5.85 ml, 112 mmol) in 110 ml of THF during 10 m. After stirring at -78°C for 15 m, the mixture was treated with a solution of N'-[2-carbethoxy-4,5-bis(2-methoxyethoxy)phenyl]-N,N-dimethylformamidine in 75 ml of THF during 20 m. After 30 m at -78°C the stirred mixture was treated with acetic acid (14.3 ml, 250 mmol). The mixture was warmed to 25°C and stirred for 2 h. The mixture was evaporated to dryness, and diluted with water. The resulting white solid was filtered, washed with water, and dried to give 10.7 g; mass spectrum (electrospray, m/e) M+H 319.2.

Example 1154-Chloro-5,6-bis(2-methoxyethoxy)-3-quinolinecarbonitrile

[0198] A stirred mixture of 1,4-dihydroquinoline-5,6-bis(2-methoxyethoxy)-3-carbonitrile (9.68 g, 30.4 mmol) and 30 ml of phosphorous oxychloride was refluxed for 1.5 h. The resulting solution was concentrated under vacuum, and the residue was stirred with methylene chloride at 0°C as ice-water and sodium carbonate were added until pH of mixture was 8-9. The organic layer was separated, washed with water, dried and concentrated to give a tan solid; mass spectrum (electrospray, m/e) M+H 337.1, 339.1.

Example 1164-f (3-Ethynylphenyl)amino]-5,6-bis(2-methoxyethoxy)-3-quinolinecarbonitrile

[0199] A stirred mixture of 4-Chloro-5,6-bis(2-methoxyethoxy)-3-quinolinecarbonitrile (2.52 g, 7.5 mmol), pyridine hydrochloride (0.87 g, 9.0 mmol), 3-ethynylaniline (1.06 g, 9.0 mmol), and ethoxyethanol (22 ml) was refluxed for 1.5 h, cooled, diluted with water containing potassium carbonate to give pH~9, and extracted with ethyl acetate. The extract was washed well with water, dried, and concentrated. The resulting solid was recrystallized from ethyl acetate to give an off-white solid, mp 150-153°.

Example 1174-[3-Dimethylaminophenyl)amino]-5,6-bis(2-methoxyethoxy)-3-quinolinecarbonitrile

[0200] A stirred mixture of 4-Chloro-5,6-bis(2-methoxyethoxy)-3-quinolinecarbonitrile (0.67 g, 2.0 mmol), pyridine (0.39 ml, 4.8 mmol), 3-dimethylaminoaniline dihydrochloride (0.50 g, 2.4 mmol), and ethoxyethanol (6.0 ml) was refluxed for 2 h, cooled, and partitioned with ethyl acetate and water containing potassium carbonate to give pH~9-10. The organic layer was washed with water, dried and concentrated. The residue was chromatographed on silica gel with methylene chloride-ethyl acetate-methanol to give an amber glass; mass spectrum (electrospray, m/e) M+H 437.0.

Example 1184-[(3-Acetylphenyl)amino]-5,6-bis(2-methoxyethoxy)-3-quinolinecarbonitrile

[0201] In the manner of Example 116, 4-Chloro-5,6-bis(2-methoxyethoxy)-3-quinolinecarbonitrile was reacted with 3-aminoacetophenone to give the title compound; recrystallized from ethanol to give off-white solid, mp 250-253 (dec).

Example 119Methyl 4-methoxy-3-(3-morpholin-4-yl-propoxy))benzoate

[0202] A stirred mixture of methyl isovanillate (22.6 g, 124 mmol), N-(3-chloropropyl)-morpholine (25.4 g, 155 mmol), potassium carbonate (18.8 g, 136 mmol), tetrabutylammonium iodide (0.92 g, 2.5 mmol), and 248 ml of 2-butanone was refluxed for 20 h. The 2-butanone was evaporated off, and the residue was stirred with water at 0°C. The resulting white solid was filtered off, washed successively with water and hexane, and dried; mp 90-94°C.

Example 120Methyl 4-methoxy-5-(3-morpholin-4-yl-propoxy))-2-nitrobenzoate

[0203] To a stirred solution of methyl 4-methoxy-3-(3-morpholin-4-yl-propoxy))benzoate (30.9 g, 100 mmol) in 100 ml of acetic acid at 25°C was added 50 ml of 70% nitric acid during 30 m. The solution was heated to 45°C at which point the reaction started and was self-sustaining at that temperature. After a total of 1.5 h at 45-50°C the mixture was cooled to 0°C, treated with ice-water and 240 g (1.75 mol) of potassium carbonate, and extracted with ethyl acetate. The extract was washed with water, dried, and concentrated to give a yellow solid, mp 78-82°C.

Example 121Methyl 2-amino-4-methoxy-5-(3-morpholin-4-yl-propoxy))benzoate

[0204] A solution of methyl 4-methoxy-3-(3-morpholin-4-yl-propoxy))-2-nitrobenzoate (32.5 g, 91.7 mmol) in 110 ml of methanol and 220 ml of ethyl acetate was hydrogenated at 55 psi in the presence of 2.0 g of 10% Pd on carbon catalyst at 25°C. After 4 h the mixture was filtered, and the filtrate was evaporated to dryness. The residue was recrystallized from acetone-hexane to give a tan solid, mp 78-82°C.

Example 122Ethyl 2-(dimethylaminomethyleneamino)-4-methoxy-5-(3-morpholin-4-yl-propoxy))benzoate

[0205] A mixture of methyl 2-amino-4-methoxy-5-(3-morpholin-4-yl-propoxy))benzoate (6.49 g, 20 mmol) and dimethylformamide dimethyl acetal (4.25 ml, 30 mmol) was heated at 100°C for 1.5 h. All volatile materials were evaporated off directly at 70°C to give a syrup; mass spectrum (electrospray, m/e) M+H 380.5.

Example 1231,4-Dihydroquinoline-7-methoxy-6-(3-morpholin-4-yl-propoxyl)-4-oxo-3-carbonitrile

[0206] To a stirred solution of n-butyllithium (17.6 ml of 2.5 M in hexane; 44 mmol) in 26 ml of THF at -78°C was added a solution of acetonitrile (1.85 ml, 45 mmol) in 44 ml of THF during 10 m. After stirring at -78°C for 15 m, the mixture was treated with a solution of ethyl 2-(dimethylaminomethyleneamino)-4-methoxy-5-(3-morpholin-4-yl-propoxy))benzoate (7.6 g, 20 mmol) in 30 ml of THF during 20 m. After 90 m at -78°C the mixture was treated with carbon dioxide while warming slowly to 25°C and then evaporated to dryness. The residue was partitioned with n-butanol (200 ml) and half-saturated NaCl solution (40 ml). The organic layer was separated, washed with saturated NaCl solution, and evaporated to dryness. The resulting solid was triturated successively with boiling acetone and methanol, filtered, and dried to give a tan solid, mp 255-260°C.

Example 1244-Chloro-7-methoxy-6-(3-morpholin-4-yl-propoxy))-3-quinolinecarbonitrile

[0207] A stirred mixture of 1,4-Dihydroquinoline-7-methoxy-6-(3-morpholin-4-yl-propoxy))-4-oxo-3-carbonitrile (4.75 g, 13.8 mmol), 0.10 ml of DMF, and 55 ml of thionyl chloride was refluxed for 3 h. Volatile matter was removed by evaporation at 30°C, and the residue was stirred at 0°C with a mixture of methylene chloride and water containing potassium carbonate to give pH 9-10. The organic layer was separated, washed with water, dried and concentrated to give a brown solid; mass spectrum (electrospray, m/e) M+H 362.4, 364.4.

Example 1254-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholin-4-yl-propoxy))-3-quinolinecarbonitrile

[0208] A stirred mixture of 4-chloro-7-methoxy-6-(3-morpholin-4-yl-propoxy))-3-quinolinecarbonitrile (1.8 g, 5.0 mmol), 3-chloro-4-fluoroaniline (0.87 g, 6.0 mmol), pyridine hydrochloride (1.15 g, 10 mmol), and 15 ml of ethoxyethanol was refluxed for 2 h, cooled, and stirred with hexane and water containing potassium carbonate to give pH 10. The resulting brown solid was filtered off, washed with water and hexane, and dried. Recrystallization from ethanol gave

an off-white solid, mp 240-244°C.

Example 126

4-[(3-Bromophenyl)amino]-7-methoxy-(3-morpholin-4-yl-propoxy))-3-quinolinecarbonitrile

[0209] In the manner of Example 125, 4-chloro-7-methoxy-6-(3-morpholin-4-yl-propoxy))-3-quinolinecarbonitrile was reacted with 3-bromoaniline to give the title compound; recrystallized from methanol to give an off-white solid, mp 208-212°C.

Example 127

4-[(4-Chloro-2-fluorophenyl)amino]-7-methoxy-6-(3-morpholin-4-yl-propoxy))-3-quinolinecarbonitrile

[0210] In the manner of Example 125, 4-chloro-7-methoxy-6-(3-morpholin-4-yl-propoxy))-3-quinolinecarbonitrile was reacted with 4-chloro-2-fluoroaniline to give the title compound; recrystallized from methanol to give an off-white solid, mp 207-212°C.

Example 128

4-[(3-Hydroxy-4-methylphenyl)amino]-7-methoxy-6-(3-morpholin-4-yl-propoxy))-3-quinolinecarbonitrile

[0211] In the manner of Example 125, 4-chloro-7-methoxy-6-(3-morpholin-4-yl-propoxy))-3-quinolinecarbonitrile was reacted with 3-hydroxy-4-methylaniline to give the title compound; recrystallized from ethyl acetate to give an amber solid, mp 222-227°C (dec).

Example 129

N-3-Cyano-4-[(3-iodophenyl)amino]-6-quinoliny]-2-propenamide

[0212] Dissolved 500 mg (1.29 mmol) 6-amino-4-[(3-iodophenyl)amino]-3-quinolinecarbonitrile in 1.0 ml of DMF and added 6 ml THE. Chilled to 0°C under N₂ and added 200 µl (1.43 mmol) triethyl amine and 120 µl (1.44 mmol) acryloyl chloride. Removed ice bath at 15 minutes. At 1.5 hours stripped solvent. Slurried residue with water and dilute sodium bicarbonate. Collected, washed with water, air dried. Boiled solids in ethyl acetate. Filtered off solids, removed solvent of the filtrate, and dried in vacuo, giving 391 mg of orange-brown solid: mass spectrum (electrospray m/e): M+H = 441.1.

Example 130

6-Amino-4-[(3-iodophenyl)amino]-3-quinolinecarbonitrile

[0213] A mixture of 6.70g (16.1 mmol) 4-[(3-iodophenyl)amino]-6-nitro-3-quinolinecarbonitrile, 300 ml ethanol, and 18.2 g (80.5 mmol) SnCl₂ dihydrate was heated to reflux under N₂. Removed heat at 2 hours, added ice water. Added sodium bicarbonate until pH was basic, forming a thick yellow mixture. Stirred for 2.5 hours. Extracted with chloroform, stirred organic portion with Darco and filtered through magnesium sulfate. Stripped solvent and dried in vacuo, giving 3.48g of yellow-brown solid: mass spectrum (electrospray m/e): M+H = 387.0.

Example 131

4-[(3-Iodophenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0214] A mixture of 3.10 ml (25.7 mmol) 3-iodoaniline, 200 ml ethanol, and 5.00 g (21.4 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile was heated to reflux under N₂ for 3.5 hours. Cooled and made basic with a saturated sodium bicarbonate. Stripped solvents and azeotroped with ethanol. Slurried residue with hexane and collected. Air dried, washed solids with water, and dried in vacuo. Dissolved solids in 400 ml ethyl acetate, stirred with Darco, filtered and removed solvent. Dried solids in vacuo to give 7.38 g of yellow solid: mass spectrum (electrospray m/e): M+H = 417.0.

Example 132N-{3-Cyano-4-[(3-methylphenyl)amino]-6-quinolinyl}-2-butyramide

[0215] Dissolved 597 mg (7.10 mmol) 2-butyric acid in 25 ml THF under N₂ and chilled to 0°C. Added 950 µl (7.30 mmol) isobutyl chloroformate and 780 µl (7.10 mmol) N-methylmorpholine and stirred for 10 minutes. Added dropwise a solution of 778 mg (2.84 mmol) 6-amino-4-[(3-methylphenyl)amino]-3-quinolinecarbonitrile, stirred for 15 minutes at 0°C and then at 25°C overnight. Stripped solvent and slurried residue with water, drying the gummy solid in vacuo briefly. Boiled solid in ethyl acetate and collected. Recrystallized from DMF, using ethanol to crash out the product, and dried in vacuo, giving 401 mg of yellow-brown solid: mass spectrum (electrospray m/e): M+H = 341.2.

Example 1336-Amino-4-[(3-methylphenyl)amino]-3-quinolinecarbonitrile

[0216] Added 253 mg 10% palladium on carbon to a round bottom flask under N₂ and covered catalyst with 140 ml ethanol. To this added 2.49 g (8.18 mmol) 6-nitro-4-[(3-methylphenyl)amino]-3-quinolinecarbonitrile and 640 µl (20.4 mmol) anhydrous hydrazine. The mixture was heated to reflux for 2 hours 15 minutes and filtered hot through celite. Stripped solvent and dried in vacuo, giving 2.455 g of yellow solid: mass spectrum (electrospray m/e): M+H = 275.2.

Example 1346-Nitro-4-[(3-methylphenyl)amino]-3-quinolinecarbonitrile

[0217] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 200 ml ethanol, and 2.75 ml (25.7 mmol) 3-toluidine was heated to reflux for 4.5 hours. Cooled and added a saturated sodium bicarbonate until pH was basic. Stripped solvents and azeotroped with ethanol. Slurried with hexane, collected, and air dried. Washed with water and dried in vacuo. Boiled in ethyl acetate, stirred with Darco and filtered. Stripped solvent and dried in vacuo to give 4.82 g of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 305.2.

Example 135N-4-[(3-Chlorophenyl)amino]-3-cyano-6-quinolinyl-2-propenamide

[0218] Dissolved 430 mg (1.46 mmol) 6-amino-4-[(3-chlorophenyl)amino]-3-quinolinecarbonitrile in 4 ml DMF, added 10 ml THF and chilled to 0°C under N₂. Added 224 µl (1.60 mmol) triethylamine and 133 µl (1.60 mmol) acryloyl chloride. Removed ice bath at 15 minutes, reaction complete at this time, but stirred overnight at 25°C. Stripped solvent, added a dilute sodium bicarbonate to the residue and collected solids. Washed with water and dried in vacuo. Boiled in ethyl acetate, collected solids and dried in vacuo, giving 200 mg of orange solid: mass spectrum (electrospray m/e): M+H = 349.0, 351.0.

Example 1366-Amino-4-[(3-chlorophenyl)amino]-3-quinolinecarbonitrile

[0219] A mixture of 6.30 g (19.4 mmol) 4-[(3-chlorophenyl)amino]-6-nitro-3-quinolinecarbonitrile, 300 ml ethanol, and 21.9 g (97 mmol) SnCl₂ dihydrate were heated to reflux under N₂. Removed heat at 2.5 hours, added ice water and made basic with sodium bicarbonate. Stirred for 2 hours and extracted with chloroform. Dried organic layer with sodium sulfate, filtered, stripped solvent and dried residue in vacuo, giving 5.74 g of yellow-brown solid: mass spectrum (electrospray m/e): M+H = 295.1, 297.1.

Example 1374-[(3-Chlorophenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0220] A mixture of 10.0 g (42.9 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 260 ml ethanol, and 5.40 ml 3-chloroaniline was heated to reflux under N₂. Removed heat at 4 hours, cooled to 25°C and added saturated sodium bicarbonate until the pH was basic. Stripped solvents and azeotroped with ethanol. Slurried residue with hexane, collected

solid, and air dried. Washed solids with water and dried in vacuo. Dissolved in boiling ethyl acetate, stirred with Darco, and filtered. Stripped solvent and dried residue in vacuo, giving 6.5g of yellow solid: mass spectrum (electrospray m/e): M+H = 325.0, 327.0.

Example 138

N-{3-Cyano-4-[(3-methoxyphenyl)amino]-6-quinoliny]-2-propenamide

[0221] Dissolved 500 mg (1.72 mmol) 6-amino-4-[(3-methoxyphenyl)amino]-3-quinolinecarbonitrile in 2 ml hot DMF, added 6 ml THF, and chilled to 0°C. Added 264 µl (1.90 mmol) triethylamine and 158 µl (1.90 mmol) acryloyl chloride. Removed ice bath at 15 minutes. Stripped solvent at 2 hours. Washed residue with dilute sodium bicarbonate, collected solids, washed with water, and air dried. Boiled solids in ethyl acetate, collected and dried in vacuo, giving 288 mg of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 345.2.

Example 139

N- {3-Cyano-4-[(3-methoxyphenyl)amino]-6-quinoliny} -2-butynamide

[0222] Dissolved 362 mg (4.31 mmol) acid in 20 ml THF under N₂ and chilled to 0°C. Added 560 µl (4.30 mmol) isobutyl chloroformate and 475 µl (4.31 mmol) N-methylmorpholine and stirred for 10 minutes. Dissolved 500 mg (1.72 mmol) 6-amino-4-[(3-methoxyphenyl)amino]-3-quinolinecarbonitrile in 2 ml hot DMF and added 10 ml THF. Added this to the mixed anhydride dropwise, stirred for 15 minutes at 0°C and at 25°C overnight. Stripped solvent, slurried residue with water, collected solids, and air dried. Recrystallized from ethyl acetate and dried in vacuo, giving 270 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 357.1.

Example 140

N-{3-cyano-4-[(3-methoxyphenyl)amino]-6-quinoliny]-4-piperidino-2-butynamide

[0223] Partially dissolved 1.21 (7.22 mmol) 4-piperidino-2-butynoic acid in 100 ml THF and chilled to 0°C under N₂. Added 955 µl (8.67 mmol) N-methylmorpholine and 750 µl (5.78 mmol) isobutyl chloroformate. Stirred for 40 minutes and added a solution of 840 mg (2.89 mmol) 6-amino-4-[(3-methoxyphenyl)amino]-3-quinolinecarbonitrile dissolved in 10 ml hot pyridine. At 2 hours, poured into ice water and made basic with saturated sodium bicarbonate. Extracted with ethyl acetate, dried with sodium sulfate, and stripped down to a small volume, which was loaded onto a column of silica gel. Eluted with 10% methanol/ethyl acetate, stripped solvent of desired fractions, and dried in vacuo, giving 970 mg of green solid: mass spectrum (electrospray m/e): M+H = 440.1.

Example 141

6-Amino-4-[(3-methoxyphenyl)amino]-3-quinolinecarbonitrile

[0224] 325 mg of 10% palladium on carbon was added to a round bottom flask under N₂ and covered with 165 ml ethanol. Added 3.29 g (10.3 mmol) 4-[(3-methoxyphenyl)-amino]-6-nitro-3-quinolinecarbonitrile and 800µl anhydrous hydrazine and heated mixture to reflux. At 1.5 hours, filtered hot through celite, stripped solvent and dried in vacuo, giving 2.876 g of yellow solid: mass spectrum (electrospray m/e): M+H = 291.2.

Example 142

4-[(3-methoxyphenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0225] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 200 ml ethanol, and 3.0 ml (26.0 mmol) m-anisidine was heated to reflux under N₂. Removed heat at 4.5 hours and made basic with saturated sodium bicarbonate. Stripped solvents and azeotroped with ethanol. Slurried with hexane and collected crystals. Washed with water, dried in vacuo. Dissolved 5.94 g of crude product in 320 ml boiling ethyl acetate, stirred with Darco, filtered, stripped solvent, and dried in vacuo, giving about 5 g of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 291.1.

Example 143

N-{4-[(3-Chloro-4-fluoro-phenyl)amino]-3-cyano-6-quinoliny}-2-butyramide

[0226] Dissolved 336 mg (4.00 mmol) 2-butyric acid in 20 ml of THF and chilled to 0°C under N₂. Added 520 µl (4.00 mmol) isobutyl chloroformate and 440 µl (4.00 mmol) N-methylmorpholine and stirred for 10 minutes. Added a solution of 500 mg (1.60 mmol) 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-3-quinolinecarbonitrile, stirred for 15 minutes at 0°C and then at 25°C overnight. Stripped solvent, washed with water, collected and dried in vacuo. Recrystallized from ethyl acetate, giving 148 mg of a yellow solid: mass spectrum (electrospray m/e): M+H = 379.1, 381.1.

Example 144

N-{4-[(3-Chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny}-2-propenamide

[0227] Dissolved 1.00 g (3.20 mmol) 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-3-quinolinecarbonitrile in 2 ml hot DMF, added 12 ml THF and chilled to 0°C under N₂. Added 490 µl (3.52 mmol) triethyl amine and 295 µl (3.52 mmol) acryloyl chloride. Removed ice bath at 15 minutes, and at 1.5 hours stripped solvent. Slurried residue with a dilute sodium bicarbonate, collected solids, and washed with water. Recrystallized from ethyl acetate, giving 215 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 367.1, 369.1.

Example 145

N- 4-[(3-Chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny) -4-dimethylamino-2-butenamide

[0228] Dissolved 1.50 g (4.80 mmol) 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-3-quinolinecarbonitrile in 50 ml THF, added 836 µl (4.80 mmol) N,N-diisopropylethylamine, and chilled to 0°C under N₂. Added 500 µl (4.80 mmol) 4-bromo-but-2-enoyl chloride and after 1 hour dropwise added the mixture to 10 ml of a 2M solution (19 mmol) of dimethylamine in THF cooled to -78°C. At 2 hours, added 5 ml (9.5 mmol) more of dimethyl amine solution and warmed to 25°C. After 1 hour, poured onto a cold solution of sodium bicarbonate. Extracted with ethyl acetate, dried organics with brine and sodium sulfate, reduced to small volume and loaded onto a column of silica gel. Eluted with 70% methanol/ethyl acetate, stripped solvent of desired fractions and dried in vacuo, giving 427 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 424.0, 426.0.

Example 146

N-{ 4-[(3-Chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny}-4-diethylamino-2-butenamide

[0229] Added 500 µl (4.80 mmol) 4-bromo-but-2-enoyl chloride to a solution of 1.50 g (4.80 mmol) 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-3-quinolinecarbonitrile and 836 µl (4.80 mmol) N,N-diisopropylethylamine in 50 ml THF at 0°C under N₂. At 1 hour added the mixture dropwise to 1.26 ml (24 mmol) diethylamine in 11 ml THF chilled to -78°C. Removed dry ice bath after complete addition, and at 2 hours, 45 minutes poured onto a mixture of ice and saturated sodium bicarbonate. Extracted with ethyl acetate, dried organic layer with brine and sodium sulfate, and stripped solvent. Loaded compound onto a column of silica gel, eluted with 35% methanol/ethyl acetate, stripped solvent from desired fractions, and dried in vacuo, giving 292 mg of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 452.4, 454.4.

Example 147

N-{4-[(3-Chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny} -4-morpholino-2-butenamide

[0230] Added 500 µl (4.80 mmol) 4-bromo-but-2-enoyl chloride to a solution of 1.50 g (4.80 mmol) 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-3-quinolinecarbonitrile and 836 µl (4.80 mmol) N,N-diisopropylethylamine in 50 ml THF at 0°C under N₂. At 1 hour added the mixture dropwise to 2.09 ml (24 mmol) morpholine in 10 ml THF at 0°C. Removed ice bath upon complete addition and at 3 hours, poured reaction onto a mixture of ice and saturated sodium bicarbonate. Extracted with ethyl acetate, dried organic layer with brine and sodium sulfate, and stripped solvent. Loaded compound onto a column of silica gel, eluted with 12% methanol/ethyl acetate, stripped solvent from desired fractions, and dried in vacuo, giving 798 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 466.4, 468.4.

Example 148

N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinolinyl}-2-morpholin-4-ylmethyl-2-propenamide

[0231] Partially dissolved 1.37 g (8.00 mmol) 2-morpholin-4-ylmethyl-2-propenoic acid in 50 ml THF and chilled to 0°C under N₂. Added 1.06 ml (9.6 mmol) N-methylmorpholine and 833 µl (6.4 mmol) isobutyl chloroformate. Stirred at 0°C for 1 hour and added a solution of 1.00 g (3.20 mmol) 6-amino-4-[(3-chloro-4-fluorophenyl)-amino]-3-quinolinecarbonitrile in 5 ml pyridine. Stirred overnight at 25°C. Poured onto a mixture of ice and saturated sodium bicarbonate, extracted with ethyl acetate, dried organic layer with brine and sodium sulfate, and stripped solvent to a small volume. Loaded onto a column of silica gel, eluted with 1% methanol/ethyl acetate, stripped solvent from desired fractions and dried under vacuum, giving 139 mg of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 465.8, 468.0.

Example 149

6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-3-quinolinecarbonitrile

[0232] A mixture of 5.360 g (15.6 mmol) 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-3-quinolinecarbonitrile, 250 ml ethanol, and 17.67 g (78.2 mmol) SnCl₂ dihydrate was heated to reflux under N₂. Removed heat at 1.5 hours and added ice water. Made basic with sodium bicarbonate. Stirred for 2 hours extracted with chloroform. Added brine to the separatory funnel to help separate layers. Stirred organic layer with Darco and dried with sodium sulfate. Filtered, stripped solvent and dried in vacuo, giving 4.460 g of yellow-brown solid: mass spectrum (electrospray m/e): M+H = 312.9, 315.0.

Example 150

4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0233] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 200 ml ethanol, and 3.75 g (25.8 mmol) 3-chloro-4-fluoroaniline was heated to reflux under N₂. Removed heat at 3.5 hours and added a solution of saturated sodium bicarbonate until mixture was basic. Stripped solvents and azeotroped with ethanol. Slurried residue with hexane, collected solids, washed with water and dried in vacuo. Dissolved solids in 250 ml boiling ethyl acetate, stirred with Darco, and filtered. Stripped solvent and dried in vacuo, giving 6.036 g of yellow solid: mass spectrum (electrospray m/e): M+H = 343.1, 345.1.

Example 151

N-{4-[(4-Bromophenyl)amino]-3-cyano-6-quinolinyl}-2-propenamide

[0234] Dissolved 500 mg (1.47 mmol) 6-amino-4-[(4-bromophenyl)amino]-3-quinolinecarbonitrile in 1 ml hot DMF, added 6 ml THF and chilled to 0°C under N₂. Added 226 µl (1.62 mmol) triethylamine and 135 µl (1.62 mmol) acryloyl chloride. Removed ice bath at 15 minutes. At 1.5 hours, stripped solvent, slurried residue in dilute sodium bicarbonate, collected solids, and dried in vacuo. Boiled solids in ethyl acetate, collected, and dried in vacuo, giving 194 mg of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 393.1, 395.1.

Example 152

6-Amino-4-[(4-bromophenyl)amino]-3-quinolinecarbonitrile

[0235] A mixture of 3.10 g (8.40 mmol) 4-[(4-bromophenyl)amino]-6-nitro-3-quinolinecarbonitrile, 155 ml ethanol, and 9.47 g (42.0 mmol) SnCl₂ dihydrate was heated to reflux under N₂. After 4 hours, removed heat and added ice water. Made basic with sodium bicarbonate and stirred for 2 hours. With mixture still basic, extracted with chloroform, stirred organic layer with Darco and dried with sodium sulfate. Filtered, stripped solvent and dried in vacuo, giving 2.265 g of brown-yellow solid: mass spectrum (electrospray m/e): M+H = 339.0, 341.0.

Example 1534-[(4-Bromophenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0236] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 200 ml ethanol, and 4.42 g (25.8 mmol) p-bromoaniline was heated to reflux under N₂ for 3 hours. Removed heat and added saturated sodium bicarbonate until basic. Stripped solvents and azeotroped with ethanol. Slurried residue with hexane, collected solids, and air dried. Washed with water and dried in vacuo. Boiled in 1.4 liters ethyl acetate, and without completely dissolving all solids, stirred with Darco, and filtered. Stripped solvent and dried in vacuo, giving 3.524 g of yellow solid: mass spectrum (electrospray m/e): M+H = 369, 370.9.

Example 154N-{3-Cyano-4-[(3,4-difluorophenyl)amino]-6-quinoliny]-2-propenamide

[0237] Dissolved 1.00g (3.37 mmol) 6-amino-4-[(3,4-difluorophenyl)amino]-3-quinolinecarbonitrile in 2 ml DMF, added 12 ml THF, and chilled to 0°C under N₂. Added 517 µl (3.71 mmol) triethylamine and 310 µl (3.72 mmol) acryloyl chloride. Removed ice bath a 15 minutes. At 3.5 hours stripped solvent and slurried residue with dilute sodium bicarbonate. Collected solids, washed with water, and air dried. Boiled in ethyl acetate, collected solids and dried in vacuo, giving 332 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 351.1.

Example 1556-Amino-4-[(3,4-difluorophenyl)amino]-3-quinolinecarbonitrile

[0238] A mixture of 4.53 g (13.9 mmol) 4-[(3,4-difluorophenyl)amino]-6-nitro-3-quinolinecarbonitrile, 200 ml ethanol and 15.72 g (69.4 mmol) SnCl₂ dihydrate was heated to reflux under N₂. Removed heat at 1.5 hours, added ice water and made basic with sodium bicarbonate. Stirred for 2 hours and extracted with chloroform. Stirred organic layer with Darco, dried with sodium sulfate and filtered. Stripped solvent and dried in vacuo, giving 3.660 g of yellow-green solid: mass spectrum (electrospray m/e): M+H = 297.1.

Example 1564-[(3,4-Difluorophenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0239] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 250 ml ethanol and 2.55 ml (25.8 mmol) 3,4-difluoroaniline was heated to reflux under N₂. Removed heat at 3.5 hours and made basic with saturated sodium bicarbonate. Stripped solvents and azeotroped with ethanol. Slurried residue with hexane, collected solids and air dried. Washed with water and dried in vacuo. Dissolved in ethyl acetate, stirred with Darco, filtered, stripped solvent and dried in vacuo, giving 5.02 g of yellow solid: mass spectrum (electrospray m/e): M+H = 327.1.

Example 157N-(4-f(3-Chloro-4-thiophenoxyphenyl)amino)-3-cyano-6-quinoliny]-2-butynamide

[0240] Dissolved 314 mg (3.72 mmol) 2-butyric acid in 40 ml THF under N₂. Chilled to 0° and added 409 µl (3.72 mmol) N-methylmorpholine and 485 µl (3.72 mmol) isobutyl chloroformate and stirred for 10 minutes. Added dropwise a solution that was prepared by dissolving 1.00 g (2.48 mmol) 6-amino-4-[(3-chloro-4-thiophenoxyphenyl)amino]-3-quinolinecarbonitrile in 2.0 ml hot DMF and adding 20 ml THF. Stirred mixture for 15 minutes at 0° and 25°C overnight. To drive reaction to completion, added 1.24 mmol of the mixed anhydride (104 mg acid, 136 µl NMM, and 161 µl isobutyl chloroformate) in 15 ml THF. Stirred overnight. Stripped solvent, dried in vacuo. Recrystallized from ethyl acetate, dried in vacuo, giving 284 mg of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 469.2, 471.2.

Example 1586-Amino-4-[(3-chloro-4-thiophenoxyphenyl)amino]-3-quinolinecarbonitrile

[0241] A mixture of 6.753 g (15.6 mmol) 4-[(3-chloro-4-thiophenoxyphenyl)amino]-6-nitro-3-quinolinecarbonitrile,

250 ml ethanol, and 17.66 g (78.0 mmol) SnCl_2 dihydrate was heated to reflux under N_2 . Removed heat at 2 hours, added large volume of ice water, and made basic with sodium bicarbonate. Stirred for 2 hours and with mixture still basic, extracted with chloroform. Stirred organic layer with Darco, dried with sodium sulfate, filtered, stripped solvent and dried in vacuo, giving 5.996 g of yellow-brown solid: mass spectrum (electrospray m/e): $\text{M}+\text{H} = 403.1, 405.1$.

Example 159

4-[(3-Chloro-4-thiophenoxyphenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0242] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 250 ml ethanol, and 6.07 g (25.6 mmol) 3-chloro-4-thiophenoxyaniline was heated to reflux under N_2 . Removed heat at about 8 hours, made basic with saturated sodium bicarbonate, stripped solvents and azeotroped with ethanol. Slurried residue with hexane and collected solids. Washed with water and dried in vacuo. Dissolved nearly completely in 400 ml ethyl acetate, stirred with Darco and filtered. Stripped solvent and boiled in hexane to remove last of the excess aniline. Dried in vacuo, giving 6.90 g of red solid: mass spectrum (electrospray m/e): $\text{M}+\text{H} = 433.1, 435.1$.

Example 160

N-[3-Cyano-4-[(3-cyanophenyl)amino]-6-quinolinyl]-2-propenamide

[0243] Dissolved 729 mg (2.56 mmol) 6-amino-4-[(3-cyanophenyl)amino]-3-quinolinecarbonitrile in 2 ml hot DMF, added 12 ml THF and cooled to 0°C under N_2 . Added 392 μl (2.81 mmol) triethylamine and 234 μl (2.81 mmol) acryloyl chloride. Removed ice bath after 15 minutes and stripped solvent at 2 hours. Washed residue with water and collected solids. Recrystallized from ethyl acetate and dried in vacuo, giving 318 mg of yellow solid: mass spectrum (electrospray m/e): $\text{M}+\text{H} = 340.1$.

Example 161

N-[3-Cyano-4-[(3-cyanophenyl)amino]-6-quinolinyl]-4-piperidino-2-butyramide

[0244] Partially dissolved 1.46 g (8.75 mmol) 4-piperidino-2-butyric acid in 100 ml THF and chilled to 0°C under N_2 . Added 1.16 ml (10.5 mmol) N-methylmorpholine and 911 μl (7.00 mmol) isobutyl chloroformate and stirred for 30 minutes. Added a solution of 1.00 g (3.50 mmol) 6-amino-4-[(3-cyanophenyl)amino]-3-quinolinecarbonitrile in 8 ml pyridine. At 3.5 hours poured onto ice bath and made basic with saturated sodium bicarbonate. Extracted with ethyl acetate, dried organic layers with magnesium sulfate, filtered, and reduced solvent to a small volume. Loaded compound onto a column of silica gel and eluted with 7% methanol/ethyl acetate. Stripped solvent from desired fractions and dried in vacuo, giving 1.008 g of off-white solid: mass spectrum (electrospray m/e): 435.0.

Example 162

6-Amino-4-[(3-cyanophenyl)amino]-3-quinolinecarbonitrile

[0245] Added 100 mg of 10% palladium on carbon to a round bottom flask under N_2 and covered with 50 ml ethanol. Added 1.00g (3.17 mmol) 4-[(3-cyanophenyl)amino]-6-nitro-3-quinolinecarbonitrile and 250 μl (7.39 mmol) anhydrous hydrazine and heated to reflux. Removed heat at 2 hours and filtered hot through celite. Stripped solvent and dried in vacuo, giving 887 mg of yellow solid: mass spectrum (electrospray m/e): $\text{M}+\text{H} = 286.2$.

Example 163

4-[(3-Cyanophenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0246] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 200 ml ethanol, and 3.04 g (25.8 mmol) 3-aminobenzonitrile was heated to reflux. Removed heat at 3.5 hours and made basic with saturated sodium bicarbonate. Stripped solvents and air dried. Slurried residue with hexane and collected solids. Washed with water and dried in vacuo. Boiled in large volume ethyl acetate, collected solids and dried in vacuo, giving 5.15 g of yellow-brown solid: mass spectrum (electrospray m/e): 316.0.

Example 164N-{3-Cyano-4-[(3-ethynylphenyl)amino]-6-quinolinyl}-2-butyramide

[0247] Dissolved 370 mg (4.40 mmol) 2-butyric acid in 20 ml THF under N₂ and chilled to 0°C. Added 484 µl (4.40 mmol) N-methylmorpholine and 572 µl (4.40 mmol) isobutyl chloroformate and stirred for 10 minutes. Added a solution of 500 mg (1.76 mmol) 6-amino-4-[(3-ethynylphenyl)amino]-quinoline-3-carbonitrile in 1 ml DMF and 10 ml THF. Removed ice bath at 15 minutes and stirred overnight at 25°C. Stripped solvent, slurried residue with water, collected solids, and dried in vacuo. Boiled in ethyl acetate, collected solids and dried in vacuo, giving 494 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 350.9.

Example 165N-{3-Cyano-4-[(3-ethynylphenyl)amino]-6-quinolinyl}-2-propenamide

[0248] Dissolved 1.00g (3.52 mmol) 6-amino-4-[(3-ethynylphenyl)amino]-3-quinolinecarbonitrile in 2 ml hot DMF, added 12 ml THF and chilled to 0°C under N₂. Added 539 µl (3.87 mmol) triethylamine and 322 µl (3.87 mmol) acryloyl chloride. Removed ice bath at 15 minutes and stripped solvent at 1.5 hours. Slurried residue in water, collected solids and air dried overnight. Recrystallized from ethyl acetate, dried in vacuo, giving 302 mg of orange solid: mass spectrum (electrospray m/e): 339.1.

Example 166N-{3-cyano-4-[(3-ethynylphenyl)amino]-6-quinolinyl}-4-piperidino-2-butyramide

[0249] Partially dissolved 1.03 g (6.16 mmol) 4-piperidino-2-butyric acid in 70 ml THF and chilled to 0° under N₂. Added 812 µl (7.38 mmol) N-methylmorpholine and 640 µl (4.92 mmol) isobutyl chloroformate. After 0.5 hour stirring, added a solution of 700 mg (2.46 mmol) 6-amino-4-[(3-ethynylphenyl)amino]-3-quinolinecarbonitrile dissolved in 5 ml pyridine. At 1 hours poured onto ice bath and made basic with a saturated solution of sodium bicarbonate. Extracted with ethyl acetate, dried organics with sodium sulfate, reduced to a small volume and loaded onto a column of silica gel. Eluted with 8% methanol in ethyl acetate. Stripped solvent of desired fractions and dried in vacuo, giving 641 mg of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 434.2.

Example 1676-Amino-4-[(3-ethynylphenyl)amino]-3-quinolinecarbonitrile

[0250] A mixture of 2.00g (6.36 mmol) 4-[(3-ethynylphenyl)amino]-6-nitro-3-quinolinecarbonitrile, 100 ml ethanol, and 7.19 g (31.8 mmol) SnCl₂ dihydrate was heated to reflux under N₂. Removed heat at 3.5 hours and added ice water. Made basic with sodium bicarbonate and stirred for 2 hours. Extracted with chloroform, stirred organic layer with Darco, dried with sodium sulfate, filtered, stripped solvent, and dried in vacuo, giving 1.737 g of yellow-brown solid: mass spectrum (electrospray m/e): M+H = 285.2.

Example 1684-[(3-Ethynylphenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0251] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 200 ml ethanol, and 3.82 g (32.6 mmol) 3-ethynylaniline was heated to reflux under N₂. Removed heat at 3.5 hours and added a solution of saturated sodium bicarbonate until basic. Stripped solvents and azeotroped with ethanol. Slurried residue with hexane and collected solids. Washed with water and dried in vacuo. Dissolved in ethyl acetate, stirred with Darco, filtered, stripped solvent and dried in vacuo, giving 4.544 g of yellow solid: mass spectrum (electrospray m/e): M+H = 315.1.

Example 169

N-{4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-piperidino-2-butyramide}

[0252] Partially dissolved 1.23 g (7.37 mmol) 4-piperidino-2-butyric acid in 40 ml THF and chilled to 0°C under N₂. Added 973 µl (8.4 mmol) N-methylmorpholine and 768 µl (5.9 mmol) isobutyl chloroformate. Stirred 10 minutes and added a solution of 1.00 g (2.95 mmol) 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 2 ml DMF and 10 ml THF. Removed ice bath at 15 minutes and at 5 hours added 2.95 mmol more of mixed anhydride (.493 g acid, 487 µl NMM, and 384 µl isobutyl chloroformate), stirred overnight at 25°C. Stripped solvent, slurried residue with water, and collected solids. Boiled in ethyl acetate and collected. Dissolved in 20% methanol/chloroform and coated 5 g of silica gel. Flash chromatographed with 20% methanol/ethyl acetate, stripped solvent of desired fractions and dried in vacuo, giving 122 mg of brown solid: mass spectrum (electrospray m/e): M+H = 488.0, 489.9.

Example 170

N-{4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-propylamino-2-butyramide}

[0253] Partially dissolved 1.28 g (7.0 mmol) 4-dipropylamino-2-butyric acid in 100 ml THF and chilled to 0°C under N₂. Added 974 µl (8.85 mmol) N-methylmorpholine 768 µl (5.90 mmol) isobutyl chloroformate and stirred for 30 minutes. Added a solution of 1.00 g (2.95 mmol) 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 8 ml pyridine. At two hours, quenched with ice water and extracted with ethyl acetate. Dried organic layer with magnesium sulfate, reduced solvent to a small volume and loaded onto a column of silica gel. Eluted with ethyl acetate, stripped solvent from desired fractions and dried in vacuo, giving 764 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 504, 506.4.

Example 171

N-{4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-2-morpholin-4-ylmethyl-2-propenamide}

[0254] Partially dissolved 1.26 g (7.37 mmol) 2-morpholin-4-ylmethyl-2-propenoic acid in 40 ml THF and chilled to 0°C under N₂. Added 810 µl (7.37 mmol) N-methylmorpholine and 950 µl (7.37 mmol) isobutyl chloroformate. After stirring 10 minutes, added a solution of 1.00 g (2.95 mmol) 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 2.5 ml DMF and 20 ml THF. Stripped solvent at 2 hours, slurried residue with water, collected solids, and dried in vacuo. Recrystallized from ethyl acetate and dried in vacuo, giving 334 mg of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 492, 494.3.

Example 172

N-{4-[(3-Bromo-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-2-butenamide}

[0255] Made 2.25 mmol of 5-bromo-but-2-enoyl chloride by mixing 386 µl (2.25 mmol) trimethylsilyl 4-bromo-but-2-enoate, 10 ml methylene chloride, 294 µl (3.38 mmol) oxalyl chloride, and 2 drops of DMF. After bubbling had subsided, removed solvent and dissolved in 10 ml THF. This solution was added to a mixture of 800 mg (2.25 mmol) 6-amino-4-[(3-bromo-4-fluorophenyl)amino]-3-quinolinecarbonitrile, 50 ml THF, and 392 µl (2.25 mmol) N,N-diisopropylethylamine chilled to 0°C under N₂. At 1 hour, added dropwise to a solution of 5.62 ml of 2.0M dimethyl amine in THF (11.2 mmol) at -78°C. Removed dry ice bath after complete addition. After 2 hours, poured into a cold solution of sodium bicarbonate, extracted with ethyl acetate, dried organic layer with sodium sulfate and reduced solvent to a small volume. Loaded onto a column of silica gel and eluted with 50% methanol/ethyl acetate. Stripped solvent of desired fractions and dried in vacuo, giving 386 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 467.9, 469.9.

Example 173

N-{4-[(3-Bromo-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-diethylamino-2-butenamide}

[0256] Made 2.25 mmol of 5-bromo-but-2-enoyl chloride by mixing 386 µl (2.25 mmol) trimethylsilyl 4-bromo-but-2-enoate, 10 ml methylene chloride, 294 µl (3.38 mmol) oxalyl chloride, and 2 drops of DMF. After bubbling had subsided, removed solvent and dissolved in 10 ml THF. This solution was added to a mixture of 800 mg (2.25 mmol)

6-amino-4-[(3-bromo-4-fluorophenyl)amino]-3-quinolinecarbonitrile, 50 ml THF, 3 ml DMF (failed to dissolve amine) and 392 μ l (2.25 mmol) N,N-diisopropylethylamine chilled to 0°C under N₂. Removed ice bath at 20 minutes. At 1 hour added dropwise to a solution of 1.2 ml (11.2 mmol) diethylamine in 4.4 ml THF chilled to -78°C. Removed dry ice bath after complete addition and stirred for 3 hours. Poured into a mixture of ice and saturated sodium bicarbonate, extracted with ethyl acetate, dried organic layer with sodium sulfate and reduced solvent to a small volume. Loaded compound onto a column of silica gel, eluted with 30% methanol/ethyl acetate, stripped solvent from desired fractions and dried in vacuo, giving 321 mg of yellow-brown solid: mass spectrum (electrospray m/e): M+H = 496.0, 497.9.

Example 174

N-[4-[(3-Bromo-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-morpholino-2-butenamide

[0257] Made 2.25 mmol of 5-bromo-but-2-enoyl chloride by mixing 386 μ l (2.25 mmol) trimethylsilyl 4-bromo-but-2-enoate, 10 ml methylene chloride, 294 μ l (3.38 mmol) oxalyl chloride, and 2 drops of DMF. After bubbling had subsided, removed solvent and dissolved in 10 ml THF. This solution was added to a mixture of 800 mg (2.25 mmol) 6-amino-4-[(3-bromo-4-fluorophenyl)amino]-3-quinolinecarbonitrile, 50 ml THF, and 392 μ l (2.25 mmol) N,N-diisopropylethylamine chilled to 0°C under N₂. At 1 hour, added the mixture dropwise to a solution of 1 ml (11.2 mmol) morpholine in 4.5 ml THF chilled to 0°C. After complete addition, removed the ice bath, and at 2 hours poured onto a mixture of ice and saturated sodium bicarbonate. Extracted with ethyl acetate, dried organic layer with sodium sulfate and reduced solvent to a small volume. Loaded onto a column of silica gel, eluted with 12% methanol/ethyl acetate, stripped solvent from desired fractions and dried in vacuo, giving 369 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 509.9, 511.9.

Example 175

N-[4-[(3-Bromo-4-fluorophenyl)amino]-3-cyano-7-methoxy-6-quinoliny]-4-morpholino-2-butenamide

[0258] Made 2.07 mmol of 5-bromo-but-2-enoyl chloride by mixing 363 μ l (2.07 mmol) trimethylsilyl 4-bromo-but-2-enoate, 8 ml methylene chloride, 270 μ l (3.10 mmol) oxalyl chloride and 2 drops of DMF. Removed solvent when bubbling subsided and dissolved in 10 ml THF. The acid chloride solution was added to a mixture of 800 mg (2.07 mmol) 6-amino-4-[(3-bromo-4-fluorophenyl)amino]-7-methoxy-3-quinolinecarbonitrile, 50 ml THF, and 721 μ l (4.14 mmol) N,N-diisopropylethylamine chilled to 0°C under N₂. At 1.5 hours added this mixture to a solution of 900 μ l (10.4 mmol) morpholine in 4.3 ml THF at 0°C. Warmed to 25°C after complete addition, and at 2 hours added 900 μ l more morpholine. At 3 hours, poured onto a mixture of ice and saturated sodium bicarbonate, extracted with ethyl acetate, dried with sodium sulfate, and reduced solvent to a small volume. Loaded compound onto a column of silica gel, eluted with 12% methanol/ethyl acetate, stripped solvent from desired fractions, and dried in vacuo, giving 287 mg of orange-brown solid: mass spectrum (electrospray m/e): M+H = 539.9, 541.9.

Example 176

4-[(3-Bromophenyl)amino]-7-ethoxy-6-methoxy-3-quinolinecarbonitrile

[0259] A mixture of 500 mg (1.90 mmol) 4-chloro-7-ethoxy-6-methoxy-3-quinolinecarbonitrile, 20 ml ethanol, and 250 μ l (2.28 mmol) 3-bromoaniline was heated to reflux under N₂. At 3 hours, added 103 μ l (0.95 mmol) and 10 ml ethanol and refluxed overnight. Removed heat and made basic with saturated sodium bicarbonate. Stripped solvent, slurried residue with hexane, collected solids, and dried. Washed with water and dried in vacuo, giving 554 mg of tan solid: mass spectrum (electrospray m/e): M+H = 398, 399.8.

Example 177

7-Ethoxy-4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-3-quinolinecarbonitrile

[0260] A mixture of 500 mg (1.90 mmol) 4-chloro-7-ethoxy-6-methoxy-3-quinolinecarbonitrile, 30 ml ethanol, and 281 mg (2.28 mmol) 3-hydroxy-4-methylaniline was heated to reflux under N₂ overnight. Removed heat and made basic with saturated sodium bicarbonate. Stripped solvents and slurried residue in hexane. Collected solids, washed with water, and dried in vacuo, giving 364 mg off-white solid: mass spectrum (electrospray m/e): M+H = 349.9.

Example 1784-Chloro-7-ethoxy-6-methoxy-3-quinolinecarbonitrile

[0261] Mixed 122 mg (0.50 mmol) 7-ethoxy-1,4-dihydro-6-methoxy-4-oxo-3-quinolinecarbonitrile and 2.0 ml methylene chloride under N₂ and kept temperature near 25°C. Added 218 µl (2.5 mmol) oxalyl chloride and 10 µl (0.125 mmol) DMF. Stirred overnight, diluted with chloroform and stirred in saturated sodium bicarbonate until basic. Separated layers and dried organics with magnesium sulfate, stripped solvent and dried in vacuo, giving 117 mg of tan solid: mass spectrum (electrospray m/e): M+H = 262.8, 264.8.

Example 1797-Ethoxy-1,4-dihydro-6-methoxy-4-oxo-3-quinolinecarbonitrile

[0262] Added 54.0 ml (135 mmol) n-butyl lithium to 150 ml THF and chilled to -78°C under N₂. Added dropwise over 20 minutes 7.05 ml (135 mmol) acetonitrile in 200 ml THF. Stirred 15 minutes and added a solution of 17.99 g (64.2 mmol) methyl 4-ethoxy-5-methoxy-2-(dimethylaminomethyleneamino)benzoate in 150 ml THF dropwise over 20 minutes. Let stir for 0.5 hour at -78°C. Added 11.0 ml (193 mmol) acetic acid and warmed gradually to 25°C. After 2.5 hours, stripped solvent, slurried residue with water, collected solids and dried in vacuo, giving 13.025 g of yellow solid: mass spectrum (electrospray m/e): M+H = 245.2.

Example 180Methyl 4-ethoxy-5-methoxy-2-(dimethylaminomethyleneamino)benzoate

[0263] A mixture of 15.056 g (66.9 mmol) methyl 2-amino-4-ethoxy-5-methoxybenzoate and 14.1 ml (100 mmol) N, N-dimethylformamide dimethylacetal was heated to 100°C under N₂. At 4.5 hours added 4.7 ml (33.3 mmol) more DMF/DMA and removed heat at 5 hours. Stripped solvent, azeotroped with toluene, and dried in vacuo, giving 18.211 g of grey-brown solid: mass spectrum (electrospray m/e): M+H = 281.3.

Example 181Methyl 2-amino-4-ethoxy-5-methoxybenzoate

[0264] A mixture of 24.110 g (94.5 mmol) methyl 4-ethoxy-5-methoxy-2-nitrobenzoate, 15.81 g (283 mmol) iron powder, 25.28 g (472 mmol) ammonium chloride, 135 ml water, and 350 ml methanol was heated to reflux under N₂. At both 3 and 5.5 hours added the same amount of iron and ammonium chloride. Removed heat at 6.5 hours, added ethyl acetate and saturated sodium bicarbonate, filtered through celite and separated layers. Washed organic layer with saturated sodium bicarbonate, dried with magnesium sulfate, stripped solvent, and dried in vacuo, giving 17.594 g of pink solid: mass spectrum (electrospray m/e): M+H = 226.2.

Example 182Methyl 4-ethoxy-5-methoxy-2-nitrobenzoate

[0265] Dissolved 5.00g (23.7 mmol) methyl 4-ethoxy-3-methoxybenzoate in 25 ml acetic acid under N₂ and added 6.1 ml (95.1 mmol) 69% nitric acid dropwise over 30 minutes. Heated to 50°C for 1.5 hours and poured onto ice bath. Extracted with chloroform, washed with dilute sodium hydroxide solution and filtered through magnesium sulfate. Stripped solvent and dried in vacuo, giving 5.268 g of off-white solid: mass spectrum (electrospray m/e): M+H = 255.8.

Example 183Methyl 4-ethoxy-3-methoxybenzoate

[0266] A mixture of 25.0 g (137 mmol) methyl vanillate, 38.87 g (274 mmol) potassium carbonate, 500 ml DMF, and 16.5 ml (206 mmol) ethyl iodide was heated to 100°C under N₂. At 2.5 hours, cooled and removed solids. Stripped solvent, and partitioned between water and methylene chloride. Stripped solvent and dried in vacuo, giving 25.85 g of white solid: mass spectrum (EI m/e): M = 210.0.

Example 184

N-[4-[(3-Chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-(Z)-2-butenamide

[0267] A mixture of 0.05g (0.118mmol) N-[4[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-2-butyne and 6mg of Lindlar catalyst in 10ml of methanol was hydrogenated at room temperature overnight. The mixture was filtered through a pad of Celite. After the solvent was removed, the residue was purified by thin-layer chromatography eluted with 30% methanol in ethyl acetate. The product was dried to give 0.018g (36%) pale yellow solid; HRMS m/z 423.1270 (M⁺).

Example 185

N-[4-[(3-Chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-methoxy-(Z)-2-butenamide

[0268] A mixture of 0.05g (0.118mmol) N-[4[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-methoxy-2-butyne and 6mg of Lindlar catalyst in 15mL of methanol was hydrogenated at room temperature for 5.5hrs. The mixture was filtered through a pad of Celite. The solvent was removed to give 0.05g (99.7%) yellow solid; HRMS m/z 410.0928 (M⁺).

Example 186

4-[[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-amino]-2-methylene-4-oxo-butanoic acid

[0269] Itaconic anhydride (0.14g, 1.25mmol) was added portionwise to a solution of 0.1 g (0.30mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 2mL of ethyl acetate under N₂. After stirring at room temperature overnight, the reaction solution was added into ice water and hexane. The product was collected, washed with water, ether and hexane, and dried in vacuo to give 0.09g (68%) of yellowish brown solid; ESMS m/z 451.2 (M+H⁺).

Example 187

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-diethylamino-2-butyne

[0270] Isobutyl chloroformate (0.261g, 1.91mmol) was dropwise added into an ice cold solution of 4-diethylamino-2-butyne (0.456g, 2.94mmol) and N-methylmorpholine (0.294g, 2.94mmol) in 50mL of tetrahydrofuran under N₂. After stirring for 30min, a solution of 0.5g (1.47mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 3mL of pyridine was added dropwise and the mixture was stirred at 0°C for 2hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by thin-layer chromatography eluted with 15% methanol in ethyl acetate. The product was collected, and dried in vacuo to give 0.2g (28.5%) of pale greenish yellow solid; ESMS m/z 476.2, 478.2 (M+H⁺); mp 133-135 °C.

Example 188

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-(N-ethylpiperazino)-2-butyne

[0271] Isobutyl chloroformate (0.785g, 5.75mmol) was dropwise added into an ice cold solution of 4-(N-ethylpiperazino)-2-butyne (1.75g, 8.85mmol) and N-methylmorpholine (1.3453g, 13.3mmol) in 50mL of tetrahydrofuran under N₂. After stirring for 30min, a solution of 1.5g (4.42mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 10mL of pyridine was added dropwise and the mixture was stirred at 0°C for 2hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by flash column chromatography. The product fractions were collected, and dried in vacuo to give 1.07g (46%) of light brown solid; ESMS m/z 517.1, 519.1 (M+H⁺); mp 161°C (dec).

Example 189

N-[4-[(3-Chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-diethylamino-2-butyne

[0272] Isobutyl chloroformate (0.061g, 0.448mmol) was dropwise added into an ice cold solution of 4-diethylamino-

2-butynoic acid (0.104g, 0.672mmol) and N-methylmorpholine (0.068g, 0.672mmol) in 1 of tetrahydrofuan under N₂. After stirring for 30min, a solution of 0.1 g (0.32mmol) of 6-amino-4-[(3-chloro-4-fluorophenyl)-amino]-3-quinolinecarbonitrile in 1.5mL of pyridine was added dropwise and the mixture was stirred at 0°C for 1.5hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by thin-layer chromatography eluted with 15% methanol in ethyl acetate. The product was collected, and dried in vacuo to give 0.046g (32%) of light brown solid; ESMS m/z 450.2, (M+H⁺); mp 117-120 °C.

Example 190

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-(N-methylpiperazino)-2-butynamide

[0273] Isobutyl chloroformate (0.785g, 5.75mmol) was dropwise added into an ice cold solution of 4-(N-methylpiperazino)-2-butynoic acid (1.65g, 8.85mmol) and N-methylmorpholine (1.36g, 13.3mmol) in 1 of tetrahydrofuan under N₂. After stirring for 30min, a solution of 1.5g (4.42mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 10mL of pyridine was added dropwise and the mixture was stirred at 0°C for 2hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by thin-layer chromatography eluted with 15% methanol in ethyl acetate. The product was collected, and dried in vacuo to give 0.37 (16%) of yellow solid; ESMS m/z 503, 505, (M+H⁺); mp 190 °C (dec).

Example 191

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-(N-isopropyl-N-methylamino)-2-butynamide

[0274] Isobutyl chloroformate (0.785g, 5.75mmol) was dropwise added into an ice cold solution of 4-(N-isopropyl-N-methylamino)-2-butynoic acid (1.4g, 8.84mmol) and N-methylmorpholine (0.94g, 9.3mmol) in 80mL of tetrahydrofuan under N₂. After stirring for 30min, a solution of 1.5g (4.42mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 15mL of pyridine was added dropwise and the mixture was stirred at 0°C for 2hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by flash column chromatography. The product fractions were collected, and dried in vacuo to give 0.65 (31%) of reddish brown solid; ESMS m/z 476.0, 478.0 (M+H⁺); mp 124-126°C.

Example 192

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-diisopropylamino-2-butynamide

[0275] Isobutyl chloroformate (0.785g, 5.75mmol) was dropwise added into an ice cold solution of 4-diisopropylamino-2-butynoic acid (1.65g, 8.85mmol) and N-methylmorpholine (0.94g, 9.3mmol) in 100mL of tetrahydrofuan under N₂. After stirring for 30min, a solution of 1.5g (4.42mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 15mL of pyridine was added dropwise and the mixture was stirred at 0°C for 2hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by flash column chromatography. The product fractions were collected, and dried in vacuo to give 1.08 (48%) of light brown solid; ESMS m/z 504.1, 506.1 (M+H⁺); mp 130°C (dec).

Example 193

N-[4-[(3-Chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-2-butynamide

[0276] Isobutyl chloroformate (0.85g, 6.2 mmol) was dropwise added into an ice cold solution of 4-dimethylamino-2-butynoic acid (1.85g, 14.4mmol) and N-methylmorpholine (1.5g, 14.8mmol) in 100mL of tetrahydrofuan under N₂. After stirring for 30min, a solution of 1.5g (4.79mmol) of 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-3-quinolinecarbonitrile in 15mL of pyridine was added dropwise and the mixture was stirred at 0°C for 2hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by flash column chromatography. The product fractions were collected, and dried in vacuo to give 0.47 (23%) of reddish brown solid; ESMS m/z 422.0 (M+H⁺); mp 225°C (dec).

Example 194

N-[4-[(3-Chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-methoxy-2-butyramide

[0277] Isobutyl chloroformate (0.85g, 6.2 mmol) was dropwise added into an ice cold solution of 4-methoxy-2-butyric acid (1.1 g, 9.6mmol) and N-methylmorpholine (1.02g, 10mmol) in 100mL of tetrahydrofuran under N₂. After stirring for 30min, a solution of 1.5g (4.79mmol) of 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-3-quinolinecarbonitrile in 15mL of pyridine was added dropwise and the mixture was stirred at 0°C for 3hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by flash column chromatography. The product fractions were collected, and dried in vacuo to give 0.73 (37%) of light yellowish brown solid; ESMS m/z 409(M+H⁺); mp 170-171).

Example 195

4-[(3-Bromo-4-fluorophenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0278] A mixture of 3.8g (16.33mmol) of 4-chloro-6-nitro-3-quinolinecarbonitrile and 3.7g (20mmol) of 3-bromo-4-fluoroaniline in 200mL of ethanol was refluxed for 3hr. After the solvent was removed, the residue was dissolved in ethyl acetate and washed with sodium bicarbonate. The product was collected as a pale yellow solid, 6.5g (71%); ESMS m/z 387.3, 389.2, mp 269-270°C (dec).

Example 196

6-amino-4-[(3-Bromo-4-fluorophenyl)amino]-3-quinolinecarbonitrile

[0279] A mixture of 8g (20.67mmol) of 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-3-quinolinecarbonitrile, 4g (72.35mmol) of iron dust and 8.9g (165.36mmol) of ammonium chloride in 240mL of methanol and water (2:1 ratio) was refluxed for 4hr. The mixture was filtered hot and washed with methanol and water. The product precipitated from the filtrate upon cooling. The solid was collected and dried in vacuo to give 5.8g (79%) yellowish brown solid; ESMS m/z 356.8, 358.8, mp 210-212°C.

Example 197

N-[4-[(3-Bromo-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-2-butyramide

[0280] Isobutyl chloroformate (0.373g, 2.73 mmol) was dropwise added into an ice cold solution of 4-dimethylamino-2-butyric acid (0.8g, 6.3mmol) and N-methylmorpholine (0.658g, 6.5mmol) in 80mL of tetrahydrofuran under N₂. After stirring for 30min, a solution of 10.65g (2.1mmol) of 6-amino-4-[(3-bromo-4-fluorophenyl)amino]-3-quinolinecarbonitrile in 10mL of pyridine was added dropwise and the mixture was stirred at 0°C for 2.5hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by flash column chromatography. The product fractions were collected, and dried in vacuo to give 0.33 (33%) of yellow solid; ESMS m/z 465.9, 467.9(M+H⁺); mp 228-231°C.

Example 198

4-Dimethylamino-but-2-enoic acid [4-(3-bromophenylamino)-3-cyano-7-methoxy-quinolin-6yl]-amide

[0281] To a mixture of 1.9 g (5.1 mmol) of 4-[(3-bromophenyl)amino]-7-methoxy-6-amino-3-quinolinecarbonitrile and 5.3 ml (31 mmol) of Hunig's base in 110 ml of dry THF at 0° C, with stirring, was added a THF solution containing 5.7 g (31 mmol) of 4-bromo crotonyl chloride dropwise. The mixture was stirred for additional 0.5 hour after addition. 100 ml of saturated sodium chloride solution was added to the reaction mixture, then it was extracted with ethyl acetate. The ethyl acetate solution was dried over sodium sulfate and then was added to 40 ml of dimethyl amine solution (2.0 M in THF) at 0°C dropwise. The solution was stirred an additional 0.5 hour. The mixture was poured into diluted sodium bicarbonate solution. The organic layer was separated and dried over sodium sulfate. Chromatography gave 1.4 g of beige solid; mass spectrum (electrospray, m/e): M+H 480.0 and 481.9.

Example 1994-Diethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide

[0282] To a mixture of 0.5 g (1.36 mmol) of 4-[(3-bromophenyl)amino]-7-methoxy-6-amino-3-quinolinecarbonitrile and 0.48 ml (2.7 mmol) of Hunig's base in 50 ml of dry THF at 0° C, with stirring, was added a THF solution containing 0.50 g (2.7 mmol) of 4-bromo crotonyl chloride dropwise. The mixture was stirred for additional 0.5 hour after addition and then was added to a solution of 4.2 ml (40.8 mmol) diethyl amine in 50 ml of THF at 0°C dropwise. The solution was stirred for an additional 0.5 hour. The mixture was poured into diluted sodium bicarbonate solution. The organic layer was separated and dried over sodium sulfate. Chromatography gave 0.2 g of white solid: mass spectrum (electrospray, m/e): M+H 508.1 and 510.8.

Example 2004-Morpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide

[0283] To a mixture of 0.69 g (1.87 mmol) of 4-[(3-Bromophenyl)amino]-7-methoxy-6-amino-3-quinolinecarbonitrile and 0.98 ml (5.6 mmol) of Hunig's base in 50 ml of dry THF at 00C, with stirring, was added a THF solution containing 0.86 g (5 mmol) of 4-bromocrotonyl chloride dropwise. The mixture was stirred for a additional 0.5 hour and then was added to a solution of 4.89 ml (56 mmol) morpholine in 50 ml THF at 0°C dropwise. The solution was stirred an additional 0.5 hour and then the mixture was poured into diluted sodium bicarbonate solution. The organic layer was separated and dried over sodium sulfate. The residue was chromatographed to give 0.38 g of grey solid: mass spectrum (electrospray, m/e): M+H 521.9 and 523.8.

Example 2014-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-6-nitro-quinoline-3-carbonitrile

[0284] A mixture of 4.4 g (16.7 mmol) of 4-chloro-7-methoxy -6-nitro-3-quinolinecarbonitrile and 2.67 g (18.3 mmol) of 3-chloro-4-fluoro aniline in 110 ml of methoxyethanol was refluxed under nitrogen for 4 hours. The reaction mixture was diluted with ethyl acetate and wash with sodium bicarbonate solution and sodium chloride solution. The organic layer was dried over sodium sulfate and then the solvent was removed under vacuum. The residue was chromatographed on silica gel eluting with mixture of ethyl acetate and methanol to give 3 g yellow solid: mass spectrum (electrospray, m/e): 372.9.

Example 2026-Amino-4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinoline-3-carbonitrile

[0285] A mixture of 4.88 g (13 mmol) of 4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-nitro-quinoline-3-carbonitrile, 5.2 g (97.5 mmol) of ammonium chloride, and 3.3 g (58.5 mmol) iron was stirred at reflux in 60 ml of water and 60 ml of methanol for 4.5 hours. The mixture was diluted with 500 ml of hot ethyl acetate and the hot mixture was filtered. The filtration was washed with saturated sodium chloride solution and then the organic layer was dried over sodium sulfate. The solvent was removed and the residue was chromatographed on silica gel eluting with mixture of ethyl acetate and methanol to give 3.38 g of yellow solid: mass spectrum (electrospray, m/e): M+H 343.4.

Example 2034-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide

[0286] To a mixture of 1.08 g (3.1 mmol) of 4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-amino-quinoline-3-carbonitrile and 1.7 ml (9.7 mmol) of Hunig's base in 30 ml of dry THF at 0° C, with stirring, was added a THF solution containing 1.99 g (9.3 mmol) of 4-bromo crotonyl chloride dropwise. The mixture was stirred for additional 0.5 hour at 0°C under nitrogen. 50 ml of saturated sodium chloride solution was introduced to the reaction mixture, then it was extracted with ethyl acetate. The ethyl acetate solution was separated and dried over sodium sulfate and then it was added to 31 ml of dimethyl amine solution (2.0 M in THF) at 0°C dropwise. After addition, the solution was stirred for another hour at room temperature. The mixture was poured into diluted sodium bicarbonate solution. The organic layer was separated and the residue was chromatographed to give 0.86 grams of white solid: mass spectrum (elec-

trospray, m/e):

Example 204

4-Diethylamino-but-2-enoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide

[0287] To a mixture of 1.1 g (3.2 mmol) of 4-[3-chloro-4-fluorophenyl]amino]-7-methoxy-6-amino-3-quinolinecarbonitrile and 2.24 ml (12.8 mmol) of Hunig's base in 40 ml of dry THF at 0° C, with stirring, was added a THF solution containing 2.34 g (12.8 mmol) of 4-bromo crotonyl chloride dropwise. The mixture was stirred for additional 0.5 hour at 0°C. 50 ml of saturated sodium chloride solution was added to the reaction mixture and then it was extracted with ethyl acetate. The ethyl acetate solution was dried over sodium sulfate and added to a solution of 6.6 ml (64 mmol) diethyl amine in 5 ml of THF at 0°C dropwise. The solution was stirred an additional hour at 0°C. The mixture was poured into diluted sodium bicarbonate solution. The organic layer was separated and dried over sodium sulfate. The residue was chromatographed and followed by recrystallization to give 0.62 grams of white solid: mass spectrum (electrospray, m/e): M+H 482.0.

Example 205

4-Morpholin-4-yl-but-2-enoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide

[0288] To a mixture of 1.2 g (3.5 mmol) of 4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-amino-quinoline-3-carbonitrile and 2.44 ml (14 mmol) of Hunig's base in 50 ml of dry THF at 0° C, with stirring, was added a THF solution containing 2.57 g (14 mmol) of 4-bromo crotonyl chloride dropwise. The mixture was stirred for an additional hour at 0°C. 50 ml of saturated sodium chloride solution was added to the reaction mixture, then it was extracted with ethyl acetate. The ethyl acetate solution was dried over sodium sulfate and then was added to a solution of 4.58 ml (52.5 mmol) morpholine in 5 mL of THF at 0°C dropwise. The solution was stirred an overnight at 0°C. The mixture was poured into diluted sodium bicarbonate solution. The organic layer dried over sodium sulfate. Chromatography gave 0.83 grams off-white solid: mass spectrum (electrospray, m/e): M+H 496.0.

Example 206

4-(3-Bromo-4-fluoro-phenylamino)-7-methoxy-6-nitro-quinoline-3-carbonitrile

[0289] A mixture of 3.52 g (9.7 mmol) of 4-chloro-7-methoxy -6-nitro-3-quinolinecarbonitrile and 2.0 g (10.7 mmol) of 3-bromo-4-fluoro aniline in 150 ml of methoxyethanol was refluxed under nitrogen for 5.5 hours. The reaction mixture was diluted with ethyl acetate and wash with sodium bicarbonate solution and sodium chloride solution. The organic layer was dried with sodium sulfate and then solvent was removed under vacuum. The residue was chromatographed on silica gel eluting with mixture of ethyl acetate and methanol to give 3 g of yellow solid: mass spectrum (electrospray, m/e): 416.8 and 418.8.

Example 207

6-Amino-4-(3-bromo-4-fluoro-phenylamino)-7-methoxy-quinoline-3-carbonitrile

[0290] A mixture of 2.9 g (6.95 mmol) of 4-[(3-bromo-4-fluorophenyl)amino]-7-methoxy-6-nitro-quinoline-3-carbonitrile, 6.5 g (121.6 mmol) of ammonium chloride and 4.05 g (73 mmol) of iron in 50 ml of water and 50 ml of methanol for 6 hours. The mixture was diluted with hot ethyl acetate and the hot mixture was filtered. The filtration was washed with saturated sodium chloride solution then the organic layer was dried over sodium sulfate. The solvent was removed and the residue was chromatographed on silica gel eluting with mixture of ethyl acetate and methanol to give 2.11 g of light yellow solid: mass spectrum (electrospray, m/e): M+H 386.7 and 388.8.

Example 208

4-Dimethylamino-but-2-enoic acid [4-(3-bromo-4-fluorophenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide

[0291] To a mixture of 0.77 g (1.98 mmol) of 4-(3-bromo-4-fluorophenyl)amino]-7-methoxy-6-amino-quinoline-3-carbonitrile and 3.5 ml (20 mmol) of Hunig's base in 35 ml of dry THF at 0° C, with stirring, was added a THF solution containing 2.2 g (12 mmol) of 4-bromo crotonyl chloride dropwise. The mixture was stirred for additional 30 minutes

at 0°C. 50 ml of saturated sodium chloride solution was added to the reaction mixture, then it was extracted with ethyl acetate. The ethyl acetate solution was dried over sodium sulfate and then was added to 15 ml of dimethyl amine (2.0 M in THF) at 0°C dropwise. The solution was stirred an additional hour at room temperature. The mixture was poured into diluted sodium bicarbonate solution. The organic layer was dried over sodium sulfate and the solvent was removed under vacuum. The residue was chromatographed gave 0.55g beige solid: mass spectrum (electrospray, m/e): M+H 498.0 and 500.0.

Example 209

4-Diethylamino-but-2-enoic acid [4-(3-bromo-4-fluorophenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide

[0292] To a mixture of 0.77 g (1.98 mmol) of 4-[(3-bromo-4-fluorophenyl)amino]-7-methoxy-6-amino-quinoline-3-carbonitrile and 3.5 ml (20 mmol) of Hunig's base in 35 ml of dry THF at 0° C, with stirring, was added a THF solution containing 2.2 g (12 mmol) of 4-bromo crotonyl chloride dropwise. The mixture was stirred for additional 30 minutes at 0°C. 50 ml of saturated NaCl solution was added to the reaction mixture, then it was extracted with ethyl acetate. The ethyl acetate solution was dried over sodium sulfate and then was added to a solution of 3.1 ml (30 mmol) of diethyl amine in 5 ml of THF at 0°C dropwise. The solution was stirred an additional hour at 0°C and 30 minutes at room temperature. The mixture was poured into diluted sodium bicarbonate solution. The organic layer was dried over sodium sulfate and solvent was removed under vacuum. The residue was chromatographed to give 0.4 g off-white solid: mass spectrum (electrospray, m/e): M+H 525.9 and 527.9.

Example 210

7-Ethoxy-4-hydroxy-quinoline-3-carbonitrile

[0293] A mixture of 10 g (73 mmol) of 3-ethoxy aniline and 12.3 g (73 mmol) of ethyl (ethoxymethylene) cyanoacetate was heated in 90 ml of Dowther at 140°C for 7 hours. To this mixture was added 250 ml of Dowther. The solution was stirred and refluxed under nitrogen for 12 hours with periodically distilling out the eliminated ethanol. The mixture was cooled to room temperature and the solid was collected and washed with hexane. The crude solid was treated with boiling ethanol and then filtered to give 9.86 g of brown solid: mass spectrum (electrospray, m/e): M+H 214.7.

Example 211

7-Ethoxy-4-hydroxy-6-nitro-quinoline-3-carbonitrile

[0294] To a suspension of 5 g (23 mmol) of 7-Ethoxy-4-hydroxy-quinoline-3-carbonitrile in 75 ml of trifluoroacetic anhydride was added 5.5 g (69 mmol) of ammonium nitrate over a period of 6 hours at room temperature. Excess anhydride was removed at reduced pressure at 45°C. The residue was stirred with 300 ml of water. The solid was collected and treated with boiling ethanol to give 3.68 g of tin solid: mass spectrum (electrospray, m/e) M+H 259.8.

Example 212

4-Chloro-7-ethoxy-6-nitro-quinoline-3-carbonitrile

[0295] A mixture of 3.45 g (13 mmol) of 7-Ethoxy-4-hydroxy-6-nitro-quinoline-3-carbonitrile, 5.55 g (26 mmol) of phosphorous pentachloride, and 10 ml of phosphorous oxychloride was refluxed for 3 hours. The mixture was diluted with hexane and the solid was collected. The solid was dissolved in 500 ml of ethyl acetate and washed with cold diluted sodium hydroxide solution. The solution was dried over magnesium sulfate and filtered through a pad of silica gel. The solvent was removed giving 2.1 g of beige solid: mass spectrum (electrospray, m/e) M+H 277.7.

Example 213

4-(3-Bromo-phenylamino)-7-ethoxy-6-nitro-quinoline-3-carbonitrile

[0296] A mixture of 2.1 g (7.6 mmol) of 4-chloro-7-ethoxy-6-nitro-3-quinolinecarbonitrile and 0.91 ml (8.3 mmol) of 3-bromo aniline in 100 ml ethanol was refluxed under nitrogen for 4.5 hours. The reaction mixture was poured into diluted sodium bicarbonate solution. Ethanol was removed under vacuum. The mixture was diluted with ethyl acetate and the organic layer was separated and dried over sodium sulfate. The solution was concentrated and solid was

collected and then washed with hexane. Upon drying, 2.6 g of yellow solid obtained: mass spectrum (electrospray, m/e) M+H 412.8 and 414.9.

Example 214

6-Amino-4-(3-bromo-phenylamino)-7-ethoxy-quinoline-3-carbonitrile

[0297] A mixture of 2.5 g (6 mmol) of 4-[(3-bromophenyl)amino]-7-ethoxy-6-nitro-quinoline-3-carbonitrile, 2.4 g (45 mmol) of ammonium chloride, and 1.5 g (27 mmol) iron was stirred at reflux in 40 ml of water and 40 ml of methanol for 4 hours. The mixture was diluted with 500 ml of hot ethyl acetate and the hot mixture was filtered. The filtration was washed with saturated sodium chloride solution and then the organic layer was dried over sodium sulfate. The solution was concentrated and 1.5 g of beige solid was collected: mass spectrum (electrospray, m/e): M+H 382.8 and 384.8.

Example 215

4-Bromo-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide

[0298] To a mixture of 1.34 g (3.5 mmol) of 4-[3-bromo-phenylamino]-7-ethoxy-6-amino-3-quinolinecarbonitrile and 3.66 ml (21 mmol) of Hunig's base in 80 ml of dry THF at 0°C, with stirring, was added a THF solution containing 3.85 g (21 mmol) of 4-bromo crotonyl chloride dropwise. The mixture was stirred for additional 30 minutes at 0°C. 50 ml of saturated sodium chloride solution was added to the reaction mixture, then it was extracted with ethyl acetate. The ethyl acetate solution was dried over sodium sulfate and then the drying agent was filtered off. This solution was used without further characterization.

Example 216

4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide

[0299] A one-third portion of the solution from example 18 was added dropwise to 8.75 ml (17.5 mmol) of dimethyl amine at 0°C. The mixture was stirred for an additional 30 minutes at 0°C. The mixture was diluted with sodium bicarbonate solution and then the organic layer was separated and dried. The solvent was removed under vacuum and the residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and methanol giving 0.32 g beige solid: mass spectrum (electrospray, m/e) M+H, 494.0 and 496.0

Example 217

4-Diethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide

[0300] A one-third portion of the solution from example 18 was added dropwise to a solution of 1.81 ml (17.5 mmol) of diethyl amine in 5 ml of THF at 0°C. The mixture was stirred for an additional 30 minutes at 0°C. The mixture was diluted with sodium bicarbonate solution and then the organic layer was separated and dried. The solvent was removed under vacuum and the residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and methanol giving 0.22 g beige solid: mass spectrum (electrospray, m/e) M+H, 522.0 and 524.0.

Example 218

4-Morpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide

[0301] A one-third portion of the solution from example 18 was added dropwise to a solution of 1.57 ml (18 mmol) of morpholine in 5 ml of THF at 0°C. The mixture was stirred for an additional 30 minutes at 0°C. The mixture was diluted with sodium bicarbonate solution and then the organic layer was separated and dried. The solvent was removed under vacuum and the residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and methanol giving 0.37 g white solid: mass spectrum (electrospray, m/e) M+H, 535.9 and 538.0.

Example 2198-Methoxy-4-hydroxy-6-nitro-quinoline-3-carbonitrile

[0302] A mixture of 12.6 g (75 mmol) of 2-methoxy-4-nitro aniline and 12.7 g (75 mmol) of ethyl (ethoxymethylene) cyanoacetate was heated in 100 ml of Dowther at 120°C for overnight and 180°C for 20 hours. To this mixture was added 300 ml of Dowther. The solution was stirred and refluxed under nitrogen for 12 hours with periodically distilling out the eliminated ethanol. The mixture was cooled to room temperature and the solid was collected and washed with hexane. The crude solid was treated with boiling ethanol and then filtered to give 12 g of brown solid: mass spectrum (electrospray, m/e): M+H 245.8.

Example 2204-Chloro-8-methoxy-6-nitro-quinoline-3-carbonitrile

[0303] A mixture of 4 g (16 mmol) of 8-Methoxy-4-hydroxy-6-nitro-quinoline-3-carbonitrile, 6.66 g (32 mmol) of phosphorous pentachloride, and 15 ml of phosphorous oxychloride was refluxed for 2.5 hours. The mixture was diluted with hexane and the solid was collected. The solid was dissolved in 500 ml of ethyl acetate and washed with cold diluted sodium hydroxide solution. The solution was dried over magnesium sulfate and filtered through a pad of silica gel. The solvent was removed giving 2.05 g of tan solid: mass spectrum (electrospray, m/e) M+H 263.7.

Example 2216-nitro-4-(3-bromo-phenylamino)-8-methoxy-quinoline-3-carbonitrile

[0304] A mixture of 1.9 g (7.6 mmol) of 4-chloro-8-methoxy-6-nitro-quinoline-3-carbonitrile and 0.86 ml (8.3 mmol) of 3-bromo aniline in 95 ml ethanol was refluxed under nitrogen for 5 hours. The reaction mixture was poured into diluted sodium bicarbonate solution. Ethanol was removed under vacuum. The mixture was diluted with ethyl acetate and the organic layer was separated and dried over sodium chloride. The solution was concentrated and solid was collected and then washed with hexane. Upon drying, 2.3 g of yellow solid obtained: mass spectrum (electrospray, m/e) M+H 398.8 and 400.8.

Example 2226-Amino-4-(3-bromo-phenylamino)-8-methoxy-quinoline-3-carbonitrile

[0305] A mixture of 2.15 g (5 mmol) of 4-[(3-bromophenyl)amino]-8-methoxy-6-nitroquinoline-3-carbonitrile, 1.95 g (37.5 mmol) of ammonium chloride, and 1.26 g (22.5 mmol) iron was stirred at reflux in 40 ml of water and 40 ml of methanol for 3 hours. The mixture was diluted with 500 ml of hot ethyl acetate and the hot mixture was filtered. The filtration was washed with saturated sodium chloride solution and then the organic layer was dried over sodium sulfate. The solution was concentrated and 0.43 g of dark yellow solid was collected: mass spectrum (electrospray, m/e): M+H 368.9 and 370.9.

Example 2234-Bromo-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-8-methoxy-quinolin-6-yl]-amide

[0306] To a mixture of 1.05 g (2.8 mmol) of 4-[(3-bromophenyl)amino]-8-methoxy-6-amino-3-quinolinecarbonitrile and 3.9 ml (22.4 mmol) of Hunig's base in 50 ml of dry THF at 0°C, with stirring, was added a THF solution containing 4.11 g (22.4 mmol) of 4-bromo crotonylchloride dropwise. The mixture was stirred for additional 1 hour at 0°C. 50 mL of saturated sodium chloride solution was added to the reaction mixture, then it was extracted with ethyl acetate. The ethyl acetate solution was dried over sodium sulfate and then the drying agent was filtered off. This solution was used without further characterization.

Example 2244-Dimethylamino-but-2-enoic acid 14-(3-bromo-phenylamino)-3-cyano-8-methoxy-quinolin-6-yl]-amide

[0307] A one-third portion of the solution from example 26 was added dropwise to a solution of 7 ml (14 mmol) of dimethyl amine (2.0 M in THF) at 0°C. The mixture was stirred for an additional 30 minutes at 0°C. The mixture was diluted with sodium bicarbonate solution and then the organic layer was separated and dried. The solvent was removed under vacuum and the residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and methanol giving 0.22 g tin solid: mass spectrum (electrospray, m/e) M+H, 480.0 and 482.0.

Example 2254-Diethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-8-methoxy-quinolin-6-yl]-amide

[0308] A one-third portion of the solution from example 26 was added dropwise to a solution of 1.4 ml (14 mmol) of diethyl amine in 5 ml of THF at 0°C. The mixture was stirred for an additional 30 minutes at 0°C. The mixture was diluted with sodium bicarbonate solution and then the organic layer was separated and dried. The solvent was removed under vacuum and the residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and methanol giving 95 mg tin solid: mass spectrum (electrospray, m/e) M+H, 509.9 and 511.0.

Example 2264-Morpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-8-methoxy-quinolin-6-yl]-amide

[0309] A one-third portion of the solution from example 26 was added dropwise to a solution of 1.2 ml (14 mmol) of morpholine in 5 ml of THF at 0°C. The mixture was stirred for an additional 30 minutes at 0°C. The mixture was diluted with sodium bicarbonate solution and then the organic layer was separated and dried. The solvent was removed under vacuum and the residue was chromatographed on silica gel eluting with a mixture of ethyl acetate and methanol giving 0.21 g yellow solid: mass spectrum (electrospray, m/e) M+H, 522.0 and 524.0.

Example 2274-Dimethylamino-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinol-6-yl]-amide

[0310] Isobutyl chloroformate 6.9 ml (5.4 mmol) and N-methylmorpholine 1.19 ml (10.8 mmol) were added to an ice-cold solution of 1.37 g (10.8 mmol) of 4-dimethylamino-2-butyric acid in 60 ml of THF. After stirring for 10 minutes, a solution of 1 g (2.7 mmol) 4-[(3-bromophenyl)amino]-7-methoxy-6-amino-quinoline-3-carbonitrile in 10 ml of pyridine was introduced. The reaction mixture was stirred overnight at 0°C. The solvent was evaporated and the residue was stirred in diluted sodium bicarbonate. The solution was then extracted with ethyl acetate. The ethyl acetate solution was dried and removed under vacuum. The residue was chromatographed to give 0.18 g of tin solid: mass spectrum (electrospray, m/e) 478.0 and 480.0.

Example 2284-(4-Chloro-2-fluoro-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0311] A mixture of 2.0 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 1.46 g of 4-chloro-2-fluoroaniline, 0.925 g of pyridine hydrochloride, and 125 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 1 h. The mixture was cooled and added to 1000 ml of water. To this mixture was added sodium carbonate to pH 9. The product was collected, washed with water, and dried to give 2.61 g of 4-(4-chloro-2-fluoro-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile as a solid, mp 139-141°C; mass spectrum (electrospray, m/e): M+H 357.9.

Example 2294-(3-Hydroxy-4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0312] A mixture of 2.98 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 1.85 g of 5-amino-o-cresol, 1.39 g of pyridine hydrochloride, and 200 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 1 h. The

mixture was cooled and added to 1000 ml of water. To this mixture was added sodium carbonate to pH 9. The product was collected, washed with water, and dried to give 3.27 g of 4-(3-hydroxy-4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile as a solid, mp 222-224°C; mass spectrum (EI, m/e): M 335.1269.

5 Example 230

4-Hydroxy-6,7,8-trimethoxy-quinoline-3-carbonitrile

[0313] A mixture of 4.82 g of methyl 3,4,5-trimethoxyanthranilate in 20 ml of N,N-dimethyl-formamide dimethyl acetal was refluxed for 18 hours and concentrated in vacuo. The crude amidine product was used in the next step without further purification. To 25 ml of tetrahydrofuran at -78°C was added 17.6 ml of 2.5M n-butyllithium in hexanes. Then 2.35 ml of acetonitrile in 45 ml of tetrahydrofuran was added dropwise. The mixture was stirred at -78°C for 15 minutes. Then a solution of the crude amidine in 30 ml of tetrahydrofuran was added dropwise. The mixture was stirred at -78°C for 30 minutes, then 5.7 ml of acetic acid was added. The mixture was warmed to room temperature, and 100 ml of water was added. The product was collected, washed with water, and dried to give 4.14 g of 4-hydroxy-6,7,8-trimethoxyquinoline-3-carbonitrile as a solid, mp 280°C (decomposed); mass spectrum (electrospray, m/e): M+H 261.2.

Example 231

4-Chloro-6,7,8-trimethoxy-quinoline-3-carbonitrile

[0314] A stirred mixture of 1.30 g of 4-hydroxy-6,7,8-trimethoxy-quinoline-3-carbonitrile, 10 ml of phosphorous oxychloride, and 1 drop of N,N-dimethylformamide was refluxed for 10 minutes and evaporated free of volatile matter. The residue was stirred with 20 ml of 5% methyl alcohol in ethyl acetate. The product was collected and dried to give 1.12 g of 4-chloro-6,7,8-trimethoxy-quinoline-3-carbonitrile as a solid, mp 161-163°C; mass spectrum (EI, m/e): M 278.0452.

Example 232

4-(3-Dimethylamino-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile

[0315] A mixture of 0.279 g of 4-chloro-6,7,8-trimethoxy-quinoline-3-carbonitrile, 0.23 g of N,N-dimethyl-1,3-phenylenediamine dihydrochloride, 0.2 ml of pyridine, and 15 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 100 ml of water. To this mixture was added sodium carbonate to pH 9. The product was collected, washed with water, and dried to give 0.251 g of 4-(3-dimethylamino-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile as a solid, mp 142-144°C; mass spectrum (EI, m/e): M 378.1685.

Example 233

4-(3-Hydroxy-4-methyl-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile

[0316] A mixture of 0.279 g of 4-chloro-6,7,8-trimethoxy-quinoline-3-carbonitrile, 0.148 g of 5-amino-o-cresol, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 100 ml of water. To this mixture was added sodium carbonate to pH 9. The product was collected, washed with water, and dried to give 0.279 g of 4-(3-hydroxy-4-methylphenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile as a solid, mp 200°C (decomposed); mass spectrum (EI, m/e): M 365.1356.

Example 234

4-(4-Chloro-2-fluoro-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile

[0317] A mixture of 0.279 g of 4-chloro-6,7,8-trimethoxy-quinoline-3-carbonitrile, 0.177 g of 4-chloro-2-fluoroaniline, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 100 ml of water. To this mixture was added sodium carbonate to pH 9. The product was extracted with ethyl acetate, washed with water, dried and concentrated in vacuo. The solid thus obtained was chromatographed on silica gel eluting with hexanes-ethyl acetate 9:1 to 2:1. Solvent was removed from product fractions giving 0.261 g of 4-(4-chloro-2-fluoro-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile as a yellow solid: mp 166-168°C; mass spectrum (EI, m/e): M 387.0777.

Example 2352-(Dimethylamino-methyleneamino)-3,6-dimethoxy-benzoic acid methylester

[0318] A mixture of 3.46 g of 2-amino-3,6-dimethoxybenzoic acid (Manouchehr Azadi-Ardakani and Timothy W. Wallace, Tetrahedron, Vol. 44, No. 18, pp. 5939 to 5952, 1988) in 20 ml of N,N-dimethylformamide dimethyl acetal was refluxed for 18 hours and concentrated in vacuo. To the residue was added 180 ml of ethyl acetate. The mixture was filtered, and 200 ml of hexanes was added to the filtrate. The mixture was then concentrated to 100 ml. The product was collected and dried to give 3.25 g of 2-(dimethylamino-methyleneamino)-3,6-dimethoxy-benzoic acid methylester as a solid, mp 81-83°C; mass spectrum (EI, m/e): M 266.1263.

Example 2364-Hydroxy-5,8-dimethoxy-quinoline-3-carbonitrile

[0319] To 12.5 ml of tetrahydrofuran at -78°C was added 8.8 ml of 2.5M n-butyllithium in hexanes. Then 1.18 ml of acetonitrile in 25 ml of tetrahydrofuran was added dropwise. The mixture was stirred at -78°C for 15 minutes. Then a solution of 2-(dimethylamino-methyleneamino)-3,6-dimethoxy-benzoic acid methylester in 62 ml of tetrahydrofuran was added dropwise. The mixture was stirred at -78°C for 10 minutes, then warmed to room temperature in 15 minutes. Acetic acid (3 ml) was added, followed by 200 ml of water. The product was collected, washed with water, and dried to give 1.57 g of 4-hydroxy-5,8-dimethoxy-quinoline-3-carbonitrile as a solid, mp 300-305°C; mass spectrum (EI, m/e): M 230.0685.

Example 2374-Chloro-5,8-dimethoxy-quinoline-3-carbonitrile

[0320] A stirred mixture of 1.30 g of 4-hydroxy-5,8-dimethoxy-quinoline-3-carbonitrile, 10 ml of phosphorous oxychloride, and 2 drops of N,N-dimethylformamide was refluxed for 10 minutes and evaporated free of volatile matter. The residue was stirred with 50 ml of water. The product was collected and dried to give 1.74 g of 4-chloro-5,8-dimethoxy-quinoline-3-carbonitrile as a solid, mp 165-167°C; mass spectrum (EI, m/e): M 248.0346.

Example 2384-(4-Chloro-2-fluoro-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile

[0321] A mixture of 0.148 g of 4-chloro-5,8-dimethoxy-3-quinolinecarbonitrile, 0.102 g of 4-chloro-2-fluoroaniline, and 5 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 50 ml of water. To this mixture was added sodium carbonate to pH 9. The product was collected, washed with water, dried, and washed with 10 ml of hexanes-ethyl acetate (4:1) to give 0.168 g of 4-(4-chloro-2-fluoro-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile as a solid, mp 197-199°C; mass spectrum (EI, m/e): M 329.7609.

Example 2394-(3-Hydroxy-4-methyl-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile

[0322] A mixture of 0.148 g of 4-chloro-5,8-dimethoxy-3-quinolinecarbonitrile, 0.087 g of 5-amino-o-cresol, and 5 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 50 ml of water. To this mixture was added sodium carbonate to pH 9. The product was collected, washed with water, dried, and washed with 10 ml of hexanes-ethyl acetate (4:1) to give 0.168 g of 4-(3-hydroxy-4-methyl-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile as a solid, mp 240-242°C; mass spectrum (EI, m/e): M 335.1260.

Example 2404-(3-Bromo-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile

[0323] A mixture of 0.148 g of 4-chloro-5,8-dimethoxy-3-quinolinecarbonitrile, 0.12 g of *m*-bromoaniline, and 5 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to

50 ml of water. To this mixture was added sodium carbonate to pH 9. The product was collected, washed with water, dried, and washed with 10 ml of hexanes-ethyl acetate (4:1) to give 0.213 g of 4-(3-bromo-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile as a solid, mp 72-74°C; mass spectrum (EI, m/e): M 383.0265.

5 Example 241

4-(3-Bromo-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile

10 [0324] A mixture of 0.167 g of 4-chloro-6,7,8-trimethoxy-3-quinolinecarbonitrile, 0.12 g of m-bromoaniline, and 5 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 50 ml of water. To this mixture was added sodium carbonate to pH 9. The product was collected, washed with water, dried, and washed with 10 ml of hexanes-ethyl acetate (4:1) to give 0.212 g of 4-(3-bromo-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile as a solid, mp 211-213°C; mass spectrum (EI, m/e): M 413.0377.

15 Example 242

4-(3-Dimethylamino-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile

20 [0325] A mixture of 0.148 g of 4-chloro-5,8-dimethoxy-3-quinolinecarbonitrile, 0.146 g of N,N-dimethyl-1,3-phenylenediamine dihydrochloride, 0.2 ml of pyridine, and 5 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. Then the mixture was partitioned between ethyl acetate and saturated sodium chloride solution. The organic layer was dried and concentrated in vacuo. The residue thus obtained was chromatographed on silica gel eluting with ethyl acetate. Solvent was removed from product fractions giving 0.160 g of 4-(3-dimethylamino-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile as a solid, mp 103-105°C; mass spectrum (EI, m/e): M 348.1588.

25 Example 243

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile

30 [0326] A mixture of 0.223 g of 4-chloro-5,8-dimethoxy-3-quinolinecarbonitrile, 0.22 g of the methyl carbonate of 4-chloro-2-fluoro-5-hydroxy-aniline, and 15 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 100 ml of water. To this mixture was added sodium carbonate to pH 9. The product was collected, washed with water, and dried.
The solids thus obtained were dissolved in a mixture of 30 ml of methyl alcohol and 20 ml of acetone. To this mixture
35 was added 1.5 ml of 28-30% ammonium hydroxide solution. The mixture was heated at 50°C for 30 minutes and concentrated. The product was collected, washed with ethyl acetate, and dried to give 0.237 g of 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile as a solid, mp 240°C (decomposed); mass spectrum (electrospray, m/e): M+H 373.9.

40 Example 244

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile

45 [0327] A mixture of 0.279 g of 4-chloro-6,7,8-trimethoxy-3-quinolinecarbonitrile, 0.22 g of the methyl carbonate of 4-chloro-2-fluoro-5-hydroxy-aniline, and 15 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 100 ml of water. To this mixture was added sodium carbonate to pH 9. The product was collected, washed with water, and dried. The solids thus obtained were dissolved in a mixture of 30 ml of methyl alcohol and 20 ml of acetone. To this mixture was added 1.5 ml of 28-30% ammonium hydroxide solution. The mixture was heated at 50°C for 30 minutes and concentrated. The product was collected, washed with
50 ethyl acetate, and dried to give 0.162 g of 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile as a solid, mp 223-225°C; mass spectrum (EI, m/e): M 403.0731.

Example 245

4-(3-Hydroxy-2-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

55 [0328] A mixture of 0.249 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.123 g of 3-amino-o-cresol, 20 mg of pyridine hydrochloride, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes.

The mixture was cooled and added to 40 ml of water. To this mixture was added sodium carbonate and concentrated hydrogen chloride to adjust pH to 7. The product was collected, washed with water, and dried to give 0.174 g of 4-(3-hydroxy-2-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile as a solid, mp 255-257°C; mass spectrum (electrospray, m/e): M+H 335.9.

Example 246

4-(2-Hydroxy-6-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0329] A mixture of 0.249 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.123 g of 2-amino-m-cresol, 20 mg of pyridine hydrochloride, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 40 ml of water. To this mixture was added sodium carbonate and concentrated hydrogen chloride to adjust pH to 7. The product was collected, washed with water, and dried to give 0.216 g of 4-(2-hydroxy-6-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile as a solid, mp 245-247°C; mass spectrum (electrospray, m/e): M+H 336.1363.

Example 247

3-(3-Cyano-6,7-dimethoxy-quinolin-4-ylamino)-benzamide

[0330] A mixture of 0.249 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.136 g of 3-aminobenzamide, 20 mg of pyridine hydrochloride, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 40 ml of water. To this mixture was added sodium carbonate and concentrated hydrogen chloride to adjust pH to 7. The product was collected, washed with water, and dried to give 0.321 g of 3-(3-cyano-6,7-dimethoxy-quinolin-4-ylamino)-benzamide as a solid, mp 253-255°C; mass spectrum (electrospray, m/e): M 349.1301.

Example 248

4-(3-Bromo-4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0331] A mixture of 0.249 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.186 g of 3-bromo-4-methylaniline, 20 mg of pyridine hydrochloride, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 40 ml of water. To this mixture was added sodium carbonate and concentrated hydrogen chloride to adjust pH to 7. The product was collected, washed with water, and dried to give 0.286 g of 4-(3-bromo-4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile as a solid, mp 292-294°C; mass spectrum (EI, m/e): M 397.0446.

Example 249

4-(3-Chloro-4-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0332] A mixture of 0.249 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.144 g of 4-amino-2-chlorophenol, 20 mg of pyridine hydrochloride, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 40 ml of water. To this mixture was added sodium carbonate and concentrated hydrogen chloride to adjust pH to 7. The product was collected, washed with water, and dried to give 0.256 g of 4-(3-chloro-4-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile as a solid, mp 230-232°C; mass spectrum (EI, m/e): M 355.0719.

Example 250

6,7-Dimethoxy-4-(2-methylsulfanyl-phenylamino)-quinoline-3-carbonitrile

[0333] A mixture of 0.249 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.139 g of 2-(methylmercapto)aniline, 20 mg of pyridine hydrochloride, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 40 ml of water. To this mixture was added sodium carbonate and concentrated hydrogen chloride to adjust pH to 7. The product was collected, washed with water, and dried to give 0.184 g of 6,7-dimethoxy-4-(2-methylsulfanylphenylamino)-quinoline-3-carbonitrile as a solid, mp 245-247°C; mass

spectrum (EI, m/e): M 351.1051.

Example 251

Methyl 2-(dimethylaminomethyleneamino)-4,5-diethoxybenzoate

[0334] To a stirred solution of methyl 2-amino-4,5-diethoxybenzoate (4.79 g, 20 mmol) in 20 ml of DMF at 0°C was added phosphorous oxychloride (2.24 ml, 24 mmol) during 15 m. The mixture was warmed to 55°C and stirred for 45 m. The resulting solution was diluted with methylene chloride, cooled to 0°C, and treated with 80 ml of precooled N/1 sodium hydroxide during 5 m. The organic layer was separated and washed at 0°C with water. The solution was dried and concentrated to give an amber oil; NMR (CDCl₃) δ 3.00(s, Me₂N).

Example 252

1,4-Dihydroquinoline-6,7-diethoxy-4-oxo-3-carbonitrile

[0335] To a stirred solution of n-butyllithium (17.6 ml of 2.5 M in hexane; 44 mmol) in 25 ml of THF at -78°C was added a solution of acetonitrile (2.35 ml, 45 mmol) in 44 ml of THF during 10 m. After stirring at -78°C for 15 m, the mixture was treated with a solution of ethyl 2-(dimethylaminomethyleneamino)-4,5-diethoxybenzoate (5.83 g, 19.8 mmol) in 30 ml of THF during 30 m. After 30 m at -78°C the mixture was treated with 5.7 ml (100 mmol) of acetic acid and evaporated to dryness. The residue was stirred in water, and the resulting precipitate was filtered off, washed with water, and dried to give 4.01 g of off-white solid; NMR (DMSO-d₆) δ 8.58(s, 2-H).

Example 253

4-Chloro-6,7-diethoxy-3-quinolinecarbonitrile

[0336] In the manner of Example 115 treatment of 1,4-dihydroquinoline-6,7-diethoxy-4-oxo-3-carbonitrile with phosphorous oxychloride gave the title compound as a pink solid, mp 170-175°C.

Example 254

4-[3-Chloro-4-(phenylthio)phenylamino]-6,7-diethoxy-3-quinolinecarbonitrile

[0337] In the manner of Example 105 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 3-chloro-4-(phenylthio)aniline gave the title compound as a tan solid, mp 88-94°C.

Example 255

4-[3-Chloro-4-(phenylthio)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0338] In the manner of Example 105 reaction of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile with 3-chloro-4-(phenylthio)aniline gave the title compound as a tan solid, mp 124-130°C.

Example 256

4-(3-Chloro-4-fluorophenylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0339] In the manner of Example 105 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 3-chloro-4-fluoroaniline gave the title compound as an off-white solid, mp 194-198°C.

Example 257

4-(3-acetylphenylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0340] In the manner of Example 105 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 3-aminoacetophenone gave the title compound as an off-white solid, mp 191-194°C.

Example 258

4-(N-Methylphenylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0341] In the manner of Example 105 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with N-methylaniline gave the title compound as a tan solid, mp 153-155°C.

Example 259

4-(Phenylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0342] In the manner of Example 105 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with aniline gave the title compound as a tan solid, mp 168-170°C.

Example 260

4-(4-fluorophenylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0343] In the manner of Example 105 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 4-fluoroaniline gave the title compound as a tan solid, mp 177-181°C.

Example 261

4-(4-Fluoro-2-methylphenylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0344] In the manner of Example 105 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 4-fluoro-3-methylaniline gave the title compound as a tan solid, mp 105-108°C.

Example 262

4-(3-Chlorophenylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0345] In the manner of Example 105 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 4-fluoroaniline gave the title compound as a tan solid, mp 188-190°C.

Example 263

4-(3-Fluorophenylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0346] In the manner of Example 105 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 3-fluoroaniline gave the title compound as a tan solid, mp 192-195°C.

Example 264

4-(3-Aminophenylamino)-6,7-dimethoxy-3-quinolinecarbonitrile

[0347] A stirred mixture of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile (3.73 g, 15 mmol), 1,3-diaminobenzene (4.86 g, 45 mmol), pyridine (1.21 ml, 15 mmol), and 45 ml of ethoxyethanol was refluxed for 30 m, cooled, and stirred with aqueous sodium bicarbonate. The resulting solid was filtered, washed with water, and dried. Recrystallization from ethanol gave a brown solid, mp 222-228°C.

Example 265

4-(3-Acetamidophenylamino)-6,7-dimethoxy-3-quinolinecarbonitrile

[0348] To a stirred solution of 4-(3-aminophenylamino)-6,7-dimethoxy-3-quinolinecarbonitrile (0.96 g, 3.0 mmol) in 9.0 ml of acetic acid at 25°C was added 0.85 ml (9.0 mmol) of acetic anhydride. After 2 h the solution was evaporated to dryness, and the residue was stirred with methanol. This solution was evaporated, and the residue was recrystallized

from ethanol to give 0.50 g of amber solid, mp 147-150°C.

Example 266

5 4-[3-(2-Butynoylamino)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0349] Isobutyl chloroformate (0.26 ml, 2.0 mmol) and N-methylmorpholine (0.22 ml, 2.0 mmol) were added to an ice-cold solution of 2-butynoic acid (0.21 g, 2.5 mmol) in 8.5 ml of THF. After 10 m a suspension of 4-(3-aminophenylamino)-6,7-dimethoxy-3-quinolinecarbonitrile (0.32 g, 1.0 mmol) in 6.5 ml of THF was added, and the resulting mixture was stirred at 25°C for 16 h and diluted with water. The resulting solid was filtered off, washed with water, dried, and recrystallized from methanol to give 0.12 g of off-white solid, mp 193-196°C.

Example 267

15 4-[3-(Hydroxymethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0350] A stirred mixture of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile (7.46 g, 30 mmol), 3-aminobenzyl alcohol (7.39 g, 60 mmol), pyridine (2.43 ml, 30 mmol), and 90 ml of ethoxyethanol was refluxed for 5 h, cooled, and stirred with aqueous sodium bicarbonate. The resulting solid was filtered, washed with water, and dried. Recrystallization from methanol gave a brown solid, mp 250-255°C.

Example 268

25 4-[3-(Chloromethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0351] To 14 ml of DMF was added phosphorous trichloride (0.70 ml, 8.0 mmol) with stirring at 25-30°C. After 60 m, the mixture was cooled to 0°C, and a suspension of 4-[3-(hydroxymethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile (1.34 g, 4.0 mmol) in 6 ml of DMF was added. The mixture was warmed to 25°C, stirred 15 m, recooled in ice bath, and partitioned with methylene chloride-aqueous sodium bicarbonate. The organic layer was washed with water, dried, and concentrated to give 1.15 g of an amber solid; NMR (CDCl₃) δ 4.79(s, CH₂Cl).

Example 269

35 4-[3-(Acetylthiomethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0352] To a stirred solution of 4-[3-(chloromethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile (0.97 g, 2.7 mmol) in 5.4 ml of DMF was added potassium thioacetate (0.93 g, 8.1 mmol) at 25°C. After 30 m the mixture was partitioned with methylene chloride and water. The organic layer was washed with water, dried, and concentrated. The residue was recrystallized from ethyl acetate to give 0.43 g of yellow solid, mp 172-177°C.

Example 270

45 4-[3-(Thiomethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile

[0353] A stirred mixture of 4-[3-(acetylthiomethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile (1.23 g, 3.13 mmol), 12.5 ml of concentrated ammonium hydroxide, 63 ml of ethanol, and 32 ml of DMF was heated at 85°C for 2.5 h and then concentrated to dryness. The residue was partitioned with methylene chloride and water. The organic layer was washed with water, dried, and concentrated. The residue was subjected to chromatography on silica gel with methylene chloride-ethyl acetate-methanol to give an off-white solid; mass spectrum (electrospray, m/e) M+H 352.1.

Example 271

50 2-(Dimethylamino-methyleneamino)-3-methoxy-benzoic acid methyl ester

[0354] A reaction mixture of 5.0 g (29.9 mmol) of 2-amino-3-methoxy-benzoic acid in 25.0 mL of DMF-DMA was heated at 100-105°C for 2.5 hr, and then the solvent was removed to give a red-purple viscous oil. After standing in a refrigerator, the oil solidified to give 5.8 g of the product as a red-purple solid in 82.8 % yield, mass spectrum (electrospray, m/e): M+H 236.9

Example 2721,4-Dihydro-8-methoxy-4-oxo-3-quinolinecarbonitrile

[0355] To 35.0 mL of THF was added 26.6 mL (66.4 mmol) of n-BuLi solution during 5 min at -78° C. To the stirred solution was added a solution of 3.55 mL (67.9 mmol) of CH₃CN in 65 mL of THF during 10 min which time the solution became white suspension, and then continued to stir for 15 min at -78° C. To the suspension was added a solution of 5.8 g (24.5 mmol) of 2-(Dimethylamino-methyleneamino)-3-methoxy-benzoic acid methyl ester in 45 mL of THF during 30 min, and then continued to stir 30 min at -78° C during which time the mixture gradually became clear. The solution was quenched with 8.5 mL of HOAc. The resulting thick slurry was stirred and warmed to room temperature. After most of the solvent was evaporated, the residue was diluted with cold water. The separate solid was collected by filtration and washed with water. After drying in vacuo, this afforded 3.8 g of the product as an off white solid in 77.6 % of yield, m.p. 270° C (dec.), mass spectrum (electrospray, m/e): M+H 201.1

Example 2734-Chloro-8-methoxy-3-quinolinecarbonitrile

[0356] A mixture of 3.8 g (19 mmol) of 1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarbonitrile and 40 mL of phosphorous oxochloride and 5 drops of DMF was refluxed for 0.5 hours. The mixture was evaporated to dryness and diluted with hexanes. The solid was collected and mixed with cold dilute sodium carbonate solution and extracted several times with ethyl acetate. The organic layer was dried over sodium sulfate and filtered through a pad of silica gel. Removal of the solvent gave 3.8 g of 4-chloro-8-methoxy-3-quinolinecarbonitrile as an off white solid in 91 % yield, mass spectrum (electrospray, m/e): M+H 219.1.

Example 2744-[(3-Bromophenyl)amino]-8-methoxy -3-quinolinecarbonitrile

[0357] A solution of 328.0 mg (1.5 mmol) of 4-chloro-8-methoxy -3-quinolinecarbonitrile, 309.7 mg (1.8 mmol) of 3-bromoaniline and 173.3 mg (1.5 mmol) of pyridine hydrochloride in 15 ml of 2-ethoxyethanol was refluxed under nitrogen for 0.5 hours. The solvent was removed and the residue was diluted with water followed by neutralization to pH 7-8 with diluted sodium carbonate solution. The precipitate was collected and washed with ether and dried in vacuo to give 476.1 mg (89.6%) of the product as a yellow solid, m.p. 210-212° C; mass spectrum (electrospray, m/e): M+H 353.8, 355.8.

Example 2754-(4-Chloro-2-fluoro-phenylamino)-8-methoxy-quinoline-3-carbonitrile

[0358] Using an analogous procedure to that described in Example 274. A reaction mixture of 328.0 mg (1.5 mmol) of 4-chloro-8-methoxy -3-quinolinecarbonitrile, 173.3 mg (1.5 mmol) of pyridine hydrochloride and 240.0 mg (1.7 mmol) of 2-fluoro-4-chloro-aniline in 15 mL of 2-ethoxyethanol was heated at 100° C for 2 hr. After the work up, 431.3 mg (87.9%) of the product was obtained as an off white solid, m.p. 127° C (dec.), mass spectrum (electrospray, m/e): M+H 327.8, 329.9.

Example 2764-(3-Hydroxy-4-methyl-phenylamino)-8-methoxy-quinoline-3-carbonitrile

[0359] Using an analogous procedure to that described in Example 274. A reaction mixture of 328.0 mg (1.5 mmol) of 4-chloro-8-methoxy -3-quinolinecarbonitrile, 173.3 mg (1.5 mmol) of pyridine hydrochloride and 203.2 mg (1.7 mmol) of 3-hydroxy-4-methylaniline in 15 mL of 2-ethoxyethanol was heated at 100 ° C for 1.5 hr. After the work up, 407.7 mg (89.4%) of the product was obtained as a yellow solid, m.p. 148-150°C, mass spectrum (electrospray, m/e): M+H 306.9.

Example 2774-(3-Dimethylamino-phenylamino)-8-methoxy-quinoline-3-carbonitrile

[0360] Using an analogous procedure to that described in Example 274. A reaction mixture of 250.0 mg (1.1 mmol) of 4-chloro-8-methoxy-3-quinolinecarbonitrile, 273.3 mg (3.0 mmol) of pyridine and 261.4 mg (1.25 mmol) of 3-dimethylaminoaniline hydrochloride in 10 mL of 2-ethoxyethanol was heated at 100°C for 1.5 hr. The work up gave 294.8 mg (73.4%) of the product as a deep greenish yellow solid, m.p. 222-225° C, mass spectrum (electrospray, m/e): M+H 319.0.

Example 2784-(4-Bromo-3-hydroxy-phenylamino)-8-methoxy-quinoline-3-carbonitrile

[0361] Using an analogous procedure to that described in Example 274. A reaction mixture of 250.0 mg (1.1 mmol) of 4-chloro-8-methoxy-3-quinolinecarbonitrile, 131.7 mg (1.1 mmol) of pyridine hydrochloride and 286.7 mg (1.3 mmol) of 4-bromo-3-hydroxy-aniline in 10 mL of 2-ethoxyethanol was heated at 100° C for 1.5 hr. The work up gave 374.1 mg (88.6 %) of the product as a pink solid, m.p. 146° C (dec.), mass spectrum (electrospray, rule): M+H 369.9.

Example 2794-(3-Hydroxy-4-methoxy-phenylamino)-8-methoxy-quinoline-3-carbonitrile

[0362] Using an analogous procedure to that described in Example 274. A reaction mixture of 200.0 mg (0.92 mmol) of 4-chloro-8-methoxy-3-quinolinecarbonitrile, 105.7 mg (0.92 mmol) of pyridine hydrochloride and 140.6 mg (1.0 mmol) of 5-amino-2-methoxyphenol in 10 mL of 2-ethoxyethanol was heated at 100° C for 2 hr. The work up gave 261.6 mg (89.0 %) of the product as a deep yellow solid, m.p. 138-140° C (dec.), mass spectrum (electrospray, m/e): M+H 321.9.

Example 2808-Methoxy-4-(2,4,6-trifluoro-phenylamino)-quinoline-3-carbonitrile

[0363] Using an analogous procedure to that described in Example 274. A reaction mixture of 200.0 mg (0.92 mmol) of 4-chloro-8-methoxy-3-quinolinecarbonitrile, 105.7 mg (0.92 mmol) of pyridine hydrochloride and 148.6 mg (1.0 mmol) of 2,4,6-trifluoro-aniline in 10 mL of 2-ethoxyethanol was heated at 100° C for 2 hr. The work up gave 112.6 mg (37.4 %) of the product as a yellow solid, m.p. 297° C (dec.), mass spectrum (electrospray, m/e): M+H 330.0.

Example 2814-(3-hydroxy-4-methyl-phenylamino)-7-methoxy-quinoline-3-carbonitrile

[0364] To a suspension of 200 mg (0.91 mmol) of 4-chloro-7-methoxy-3-quinolinecarbonitrile and 135.5 mg (1.10 mmol) of 5-amino-o-cresol in 10 mL of 2-ethoxy ethanol was added 105.6 mg (0.91 mmol) of pyridine hydrochloride. The resulting reaction mixture was refluxed for 1 hr, and then the solvent was removed to give a residue. To the residue was added about 30 mL of water and neutralized to pH 7-8 by addition of diluted sodium carbonate solution. The precipitate was collected by filtration and washed with water and ether. After drying in vacuo, this afforded 277 mg (99 %) of the product as a yellow solid, m.p. >250° C, mass (electrospray, m/e): M+H 305.9.

Example 2824-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-7-methoxy-quinoline-3-carbonitrile

[0365] The method of Example 281 was used with 218.6 mg (1.0 mmol) of 4-chloro-7-methoxy-3-quinolinecarbonitrile, 263.5 mg (1.2 mmol) of the aniline and 115.6 mg (1.0 mmol) of pyridine hydrochloride in 10 mL of 2-ethoxyethanol. This afforded a red oil residue. To the residue were added 10 mL of methanol and 1 mL of NH₄OH (28-30%). The resulting mixture was heated at 50° C for 30 min, and then the solvent was removed to give a residue. To the residue was added water. The separated solid was collected by filtration and washed with water and ether/ethyl acetate (1:1). After drying in vacuo, 142.1 mg (41.4 %) of the product was obtained as a brown solid, m.p. 240°C (dec.); mass

(electrospray, m/e): M+H 343.9, 345.8.

Example 283

4-(4-Chloro-2-fluoro-phenylamino)-6-methoxy-quinoline-3-carbonitrile

[0366] The method of Example 281 was used with 218.6 mg (1 mmol) of 4-chloro-6-methoxy-3-quinolinecarbonitrile, 174.7 mg (1.2 mmol) of 4-chloro-2-fluoro-aniline and 115.6 mg (1 mmol) of pyridine hydrochloride in 10 mL of 2-ethoxyethanol. This afforded 319.8 mg of the product as a yellow solid, m.p. >250° C, mass (electrospray, m/e): M+H 325.9, 327.9

Example 284

4-(3-Hydroxy-4-methyl-phenylamino)-6-methoxy-quinoline-3-carbonitrile

[0367] To a suspension of 218.6 mg (1.0 mmol) of 4-chloro-6-methoxy-3-quinolinecarbonitrile and 147.8 mg (1.20 mmol) of 5-amino-o-cresol in 10 mL of 2-ethoxyethanol was added 115.6 mg (1.0 mmol) of pyridine hydrochloride. The resulting reaction mixture was refluxed for 1 hr, and then the solvent was removed to give a residue. To the residue was added about 30 mL of water and neutralized to pH 7-8 by addition of diluted sodium carbonate solution. The precipitate was collected by filtration and washed with water and ether. After drying in vacuo, this afforded 278.3 mg (91 %) of the product as a yellow solid, m.p. >250° C (dec.), mass (electrospray, m/e): M+H 305.9.

Example 285

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-6-methoxy-quinoline-3-carbonitrile

[0368] The method of Example 282 was used with 218.6 mg (1.0 mmol) of 4-chloro-6-methoxy-3-quinolinecarbonitrile and 263.5 mg (1.2 mmol) of the aniline (cat 800906) in 10 mL of 2-ethoxyethanol was added 115.6 mg (1.0 mmol) of pyridine hydrochloride. This afforded a dark oil residue. To the residue was added 10 mL of methanol and 1 mL of NH₄OH (28-30 %). The resulting mixture was heated at 50° C for 30 min, and then the solvent was removed and the residue was triturated with water and ether in an ice bath. The separated solid was filtered off and washed with water and ether. After drying in vacuo, 83.2 mg (24.2 %) of the product was obtained as a light brown solid, m.p. 228-230° C, mass (electrospray, m/e): M+H 343.8, 345.8.

Example 286

4-(3,5-Dichloro-4-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0369] A reaction mixture of 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 213.6 mg (1.2 mmol) of 4-amino-2,6-dichlorophenol and 115.6 mg (1 mmol) of pyridine hydrochloride in 10 mL of 2-ethoxyethanol was refluxed under N₂ for 1 hr. After removal of the solvent, the residue was diluted with water and neutralized to pH 7-8 with diluted sodium carbonate solution. The precipitate was filtered and washed with water and ether/ ethyl acetate (1:1). After drying in vacuo, this yielded 346.7 mg (88.8 %) of the product as a yellow solid, m.p. >250° C, mass (electrospray, m/e): M+H 389.8, 391.8.

Example 287

4-(2-Hydroxy-4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0370] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 10 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 147.8 mg (1.2 mmol) of 6-amino-m-cresol to give 287.5 mg (85.8 %) of the product as a light brown solid, m.p. >250° C, mass (electrospray, m/e): M+H 335.9.

Example 2884-(4-Hydroxy-3,5-dimethyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0371] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 10 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 164.6 mg (1.2 mmol) of 4-amino-2,5-dimethylphenol to give 232.9 mg (66.7 %) of the product as a light brown solid, m.p. 234-236° C, mass (electrospray, m/e): M+H 349.9.

Example 2894-(3-Cyano-6,7-dimethoxy-quinolin-4-ylamino)-benzamide

[0372] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 10 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 163.4 mg (1.2 mmol) of 4-amino-benzamide to give 255.7 mg (73.4 %) of the product as a light yellow solid, m.p. >250° C, mass (electrospray, m/e): M+H 348.9.

Example 2904-(5-Chloro-2-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0373] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 15 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 172.3 mg (1.2 mmol) of 2-amino-chlorophenol to give 326.4 mg (91.9 %) of the product as a yellow solid, m.p. >250° C, mass (electrospray, m/e): M+H 355.8.

Example 2914-(3,5-Dibromo-4-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0374] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 15 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 320.3 mg (1.2 mmol) of 4-amino-2,6-dibromophenol to give 427.1 mg (89.2 %) of the product as a gray solid, m.p. >250° C, mass (electrospray, m/e): M+H 479.7, 481.6.

Example 2924-(4-Hydroxy-2-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0375] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 15 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 147.8 mg (1.2 mmol) of 4-amino-m-cresol to give 304.6 mg (90.9 %) of the product as a salmon solid, m.p. >250° C, mass (electrospray, m/e): M+H 335.9

Example 2936,7-Dimethoxy-4-(pyridin-3-ylamino)-quinoline-3-carbonitrile

[0376] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 15 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 112.9 mg (1.2 mmol) of 3-amino-pyridine to give 60.6 mg (19.8 %) of the product as an orange solid, m.p. 231-233° C, mass (electrospray, m/e): M+H 306.8.

Example 2946,7-Dimethoxy-4-(3-methylsulfanyl-phenylamino)-quinoline-3-carbonitrile

[0377] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 15 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 167.1 mg (1.2 mmol) of 3-(methylthio)aniline to give 134.1 mg (38.2 %) of the product as an off white solid, m.p. >250°C, mass (electrospray, m/e): M+H 351.9.

Example 2954-(2-Hydroxy-5-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0378] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, in 15 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 147.8 mg (1.2 mmol) of 2-amino-p-cresol to give 315.0 mg (94.0 %) of the product as a yellow solid, m.p. 198-200° C, mass (electrospray, m/e): M+H 335.8.

Example 2964-(2-Chloro-4-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0379] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 15 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 270.1 mg (1.5 mmol) of 4-amino-3-chlorophenol to give 299.2 mg (84.3 %) of the product as a light brown solid, m.p. >250° C, mass (electrospray, m/e): M+H 355.8, 357.8.

Example 2972-(3-Cyano-6,7-dimethoxy-quinolin-4-ylamino)-benzamide

[0380] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 12 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 177.0 mg (1.3 mmol) of anthranilamide to give 292.4 mg (84.0 %) of the product as a deep yellow solid, m.p. 238-240.5° C, mass (electrospray, m/e): M+H 348.9.

Example 2986,7-Dimethoxy-4-(4-methylsulfanyl-phenylamino)-quinoline-3-carbonitrile

[0381] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 12 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 181.0 mg (1.3 mmol) of 4-(methylmercapto)-aniline to give 334.1 mg (95.2%) of the product as a yellow solid, m.p. 235-237° C, mass (electrospray, m/e): M+H 351.9, 352.9, 353.8, 354.9.

Example 2994-[4-(2-Hydroxy-ethyl)-phenylamino]-6,7-dimethoxy-quinoline-3-carbonitrile

[0382] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 12 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 178.3 mg (1.3 mmol) of 4-aminophenethyl alcohol to give 327.8 mg (93.9 %) of the product as an off white yellow solid, m.p. 208-210° C, mass (electrospray, m/e): M+H 349.9.

Example 3004-(2,4-Dihydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0383] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 12 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 210.0 mg (1.3 mmol) of 4-aminoresorcinol to give 330.4 mg (98.0 %) of the product as a deep purple solid, m.p. >250°C, mass (electrospray, m/e): M+H 337.9.

Example 3014-[2-(2-Hydroxy-ethyl)-phenylamino]-6,7-dimethoxy-quinoline-3-carbonitrile

[0384] Using an analogous procedure to that described in Example 286, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 12 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 178.3 mg (1.3 mmol) of 2-aminophenethyl alcohol to give 218.4 mg (64.4 %) of the product as a pink solid, m.p. 159-162° C, mass (electrospray, m/e): M+H 349.9.

Example 3024-(3-Bromophenylamino)-6,7-dihydroxy-3-quinolinecarbonitrile

[0385] A stirred mixture of 4-(3-bromophenylamino)-6,7-dimethoxy-3-quinolinecarbonitrile (15.4 g, 40 mmol) and 100 g of pyridine hydrochloride was heated at 210°C for 20 m, cooled to 0°C, treated with 100 ml of concentrated ammonium hydroxide, and concentrated to dryness. The residue was stirred with 1 L of water, and the resulting amber solid was filtered off, washed with water, and dried; mass spectrum (electrospray, m/e) M+H 356.1, 358.1.

Example 3034-(3-Bromophenylamino)-6,7-di-n-propoxy-3-quinolinecarbonitrile

[0386] To a stirred mixture of 4-(3-bromophenylamino)-6,7-dihydroxy-3-quinolinecarbonitrile (1.07 g, 3.0 mmol), potassium carbonate (1.66 g, 12.0 mmol), and 12 ml of DMF at 0°C was added 1-iodopropane (1.17 ml, 12.0 mmol). The mixture was warmed to 25°C, stirred for 5 h, and then partitioned at 0° C with ethyl acetate and water containing HCl to give pH~8. The organic layer was separated, washed with water, dried, and concentrated. The residue was subjected to chromatography on silica gel with methylene chloride-ethyl acetate-acetic acid to give an amorphous solid; mass spectrum (electrospray, m/e) M+H 440.2, 442.2.

Example 3044-[(3-Bromophenyl)-N-acetylamino]-6,7-dihydroxy-3-quinolinecarbonitrile

[0387] A solution of 4-(3-bromophenylamino)-6,7-dihydroxy-3-quinolinecarbonitrile (1.78 g, 5.0 mmol), dimethylaminopyridine (60 mg, 0.50 mmol), 5.0 ml of acetic anhydride, and 10 ml of pyridine was stirred at reflux temperature for 1.5 h and concentrated to dryness. The residue was stirred with 50 ml of methanol, 5 ml of water, and sodium bicarbonate (2.1 g, 25 mmol) at 25°C for 16 h and concentrated to dryness. The residue was stirred with water containing acetic acid to give pH~4-5, and the resulting solid was filtered off, washed with water, and dried. A solution of the resulting solid in THF was passed through a pad of silica gel; the filtrate was concentrated to give a tan solid; mass spectrum (electrospray, m/e) M-H 396.3, 398.3.

Example 3054-(3-Bromophenylamino)-6,7-di-n-butoxy-3-quinolinecarbonitrile

[0388] A stirred mixture of 4-[(3-bromophenyl)-N-acetylamino]-6,7-dihydroxy-3-quinolinecarbonitrile (0.40 g, 1.0 mmol), 1-bromobutane (0.41 g, 3.0 mmol), potassium carbonate (0.30 g, 2.2 mmol), and 2.0 ml of DMF was stirred at 65-70°C for 5 h, concentrated to dryness, and partitioned with ethyl acetate and water containing acetic acid to give pH~6. The organic layer was washed with water, dried and concentrated. The residue was stirred with potassium

carbonate (0.55 g, 4.0 mmol), and 10 ml of methanol at reflux temperature for 60 m and then evaporated to dryness. The residue was partitioned with methylene chloride and water saturated with carbon dioxide (pH~8-9). The organic layer was separated and washed with water, dried, and concentrated. A solution of the residue in 60:30:1 heptane-ethyl acetate-acetic was filtered through a pad of silica gel. The filtrate was evaporated to give an amorphous solid; mass spectrum (electrospray, m/e) M+H 467.9, 469.9.

Example 3064-Chloro-7-methoxy-3-quinolinecarbonitrile

[0389] In the manner of Example 115 treatment of 1,4-dihydroquinolin-7-methoxy-4-oxo-3-carbonitrile with phosphorous oxychloride gave the title compound as a tan solid; mass spectrum (electrospray, m/e) M+H 219.2, 221.2.

Example 3074-(4-Chloro-2-fluorophenylamino)-7-methoxy-3-quinolinecarbonitrile

[0390] In the manner of Example 274 reaction of 4-chloro-7-methoxy-3-quinolinecarbonitrile with 4-chloro-2-fluoroaniline gave the title compound as an amber solid, mp 208-210°C.

Example 3084-(4-Chloro-2-fluorophenylamino)-7-hydroxy-3-quinolinecarbonitrile

[0391] In the manner of Example 302 reaction of 4-(4-chloro-2-fluorophenylamino)-7-methoxy-3-quinolinecarbonitrile with pyridine hydrochloride at 210°C gave the title compound, mp 295-305°C.

Example 3094-[(4-Chloro-2-fluorophenylamino)-N-acetylamino]-7-hydroxy-3-quinolinecarbonitrile

[0392] In the manner of Example 304 peracetylation of 4-(4-chloro-2-fluorophenylamino)-7-hydroxy-3-quinolinecarbonitrile with acetic anhydride in the presence of dimethylaminopyridine followed by de-O-acetylation with sodium bicarbonate in aqueous methanol gave the title compound as an amber solid, mp 182-191°C.

Example 3104-(4-Chloro-2-fluorophenylamino)-7-ethoxy-3-quinolinecarbonitrile

[0393] In the manner of Example 305 alkylation of 4-[(4-Chloro-2-fluorophenylamino)-N-acetylamino]-7-hydroxy-3-quinolinecarbonitrile with ethyl iodide in the presence of potassium carbonate in DMF followed by de-N-acetylation with potassium carbonate in aqueous methanol gave the title compound as a white solid, mp 221-224°C.

Example 3114-[(3-Bromophenyl)amino]-6,7-bis(2-methoxyethoxy)-3-quinolinecarbonitrile

[0394] In the manner of Example 305 alkylation of 4-(3-bromophenylamino)-6,7-dihydroxy-3-quinolinecarbonitrile with 2-bromoethyl methyl ether in the presence of potassium carbonate in DMF gave the title compound as a light yellow solid, mp 135-138°C.

Example 3124-(4-Hydroxy-2-methyl-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile

[0395] A mixture of 0.3 g of 4-chloro-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile derivative, 0.12 g of 4-amino-m-cresol, 0.1 g of pyridine hydrochloride and 4 ml of 2-ethoxy ethanol was stirred under nitrogen at reflux temperature for 1.5 hr. The mixture was cooled and added to the mixture of ethyl acetate and saturated solution

of sodium bicarbonate, stirred for 15 minutes. Following separation of layers, the organic layer was dried over anhydrous sodium sulfate, filtered and filtrate was evaporated to yield dark oil. The oil was purified by silica gel flash chromatography utilizing a gradient of methylene chloride/methanol (95:5 to 90:10) to give 0.23 g of the title compound as a tan solid, mp 120-126°C; mass spectrum (electrospray, m/e): M+H 449.

Example 313

4-(3-Bromo-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile

[0396] The method of Example 312 was used as well as 0.3 g of 4-chloro-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile, 0.12 ml of 3-bromo aniline, 0.1 g of pyridine hydrochloride and 4.0 ml of 2-ethoxy ethanol. This afforded an oil which was purified by silica gel flash chromatography utilizing a gradient of methylene chloride/methanol (96:4 to 92:8) to give 0.22 g of the title compound as an off white solid, mp 115-118 °C; mass spectrum (ES, m/e): M+H499.

Example 314

6-Methoxy-4-(2-methylsulfanyl-phenylamino)-7-(3-morpholin-4-yl-propoxyl-quinoline-3-carbonitrile

[0397] The method of Example 312 was used as well as 0.3 g of 4-chloro-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile, 0.14 ml of 2-(methyl mercapto) aniline, 0.1 g of pyridine hydrochloride and 4.0 ml of 2-ethoxy ethanol. This afforded an oil which was purified by silica gel flash chromatography [methylene chloride/methanol (96:4)] to give 0.16 g of the title compound as an off white solid, mp 179-180 °C; mass spectrum (ES, m/e): M+H465.

Example 315

4-(4-Hydroxy-3,5-dimethyl-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile

[0398] The method of Example 312 was used as well as 0.25 g of 4-chloro-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile, 0.12 ml of 4-amino, 2-5 dimethyl phenol , 0.1 g of pyridine hydrochloride and 4.0 ml of 2-ethoxy ethanol. This afforded an oil which was purified by silica gel flash chromatography utilizing a gradient of methylene chloride/methanol (96:4 to 92:8) to give 0.20 g of the title compound as a tan foam, mp 122-125 °C; mass spectrum (ES, m/e): M+H481.

Example 316

4-(2-Aminophenylmethyamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0399] In the manner of Example 61 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 2-aminobenzylamine gave the title compound as an off-white solid, mp 173-177°C.

Example 317

4-(3,4-Difluorophenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile

[0400] In the manner of Example 61 reaction of 4-chloro-6,7-diethoxy-3-quinolinecarbonitrile with 3,4-difluorobenzylamine gave the title compound as a tan solid, mp 167-169°C.

Example 318

4-Methoxy-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide

[0401] To a solution of 1 g (3.17 mmol) of 5-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile and 0.6 g of diisopropylethylamine in 21 ml of tetrahydrofuran was added 0.47 g (3.5 mmol) of 4-methoxycrotonoyl chloride at 0°C with stirring. After 1.5 hr at 0°C another 0.15 g of acid chloride was added. The mixture was diluted with 75 ml of tetrahydrofuran and stirred with a mixture of brine and saturated sodium bicarbonate. 50 ml of ethyl acetate was added and the organic layer was separated and dried over magnesium sulfate. Solvent was removed and the residue was purified by chromatography on silica gel. Recrystallization from 1-butanol gave 1.25 g of a yellow powder; mass spec-

trum (electrospray, m/e): M+H 415.0 and 415.9.

Example 319

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0402] A mixture of 0.25 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.195 g of 4-chloro-2-fluoro-5-hydroxy-aniline, 0.116 g of pyridine hydrochloride, and 3 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 1 h. The mixture was cooled and added to 10 ml of water. To this mixture was added sodium carbonate until pH 9. The product was collected, washed with water, and dried to give 0.327g of 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile as a solid, dec > 260°C ; mass spectrum (electrospray, m/e): M+H 373.9.

Example 320

7-benzyloxy-4-hydroxy-6-methoxy-quinoline-3-carbonitrile

[0403] To a stirred solution of 26.9 ml of n-butyllithium (2.5 M in hexane) in 50 ml of THF at -78°C was added a 3.51 ml of acetonitrile in 20 ml of THF during 10 min. After stirring at -78°C for 30 min, the mixture was treated with 10 g of L17741-150 (B. Floyd) in 20 ml of THF during 5 min. After 15 min at -78°C the stirred mixture was warmed to 0°C for a further 30 min. It was then treated with 5 ml of acetic acid, warmed to 25°C and stirred for 30 min. The mixture was evaporated to dryness, and diluted with aqueous sodium bicarbonate. The resulting off-white solid was filtered, washed with water, ethyl acetate and ether. After drying, 4.5 g of 7-benzyloxy-4-hydroxy-6-methoxy-quinoline-3-carbonitrile was obtained as an off-white solid, dec >255°C ; mass spectrum (electrospray, m/e) M+H 307.

Example 321

7-benzyloxy-4-chloro-6-methoxy-quinoline-3-carbonitrile

[0404] To a stirred suspension of 1 g of 7-benzyloxy-4-hydroxy-6-methoxy-quinoline-3-carbonitrile in 10 ml of methylene chloride was added 5 ml of oxalyl chloride (2M in methylene chloride), and 2 drops of N,N-dimethylformamide. The mixture was refluxed for 20 min and to it was slowly added aqueous sodium bicarbonate until the bubbling ceased. Following separation of the layers, the organic layer was evaporated to a small volume, then passed through a plug of magnesol. Elution with 50 ml methylene chloride, followed by evaporation provided 0.6 g of 7-benzyloxy-4-chloro-6-methoxy-quinoline-3-carbonitrile as a pale yellow solid, mp 282-284°C; mass spectrum (electrospray, m/e) M+H 325.

Example 322

7-Benzyloxy-4-(4-chloro-2-fluoro-phenylamino)-6-methoxy-quinoline-3-carbonitrile

[0405] A mixture of 0.200 g of 7-benzyloxy-4-chloro-6-methoxy-quinoline-3-carbonitrile 0.108 g of 4-chloro-2-fluoroaniline, 0.071 g of pyridine hydrochloride, and 3 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 1 h. The mixture was cooled and added to 10 ml of water. To this mixture was added sodium carbonate until pH 9. The product was collected, washed with water, and dried to give 0.150g of 7-Benzyloxy-4-(4-chloro-2-fluoro-phenylamino)-6-methoxy-quinoline-3-carbonitrile hydrochloride as a solid, mp 241-243°C ; mass spectrum (electrospray, m/e): M+H 433.9.

Example 323

4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-7-methoxy-6-(3-morpholin-4-yl)-propoxyl-quinoline-3-carbonitrile

[0406] A mixture of 0.35 g of 4-chloro-7-methoxy-6-(3-morpholin-4-yl-propoxy)-3-quinolinecarbonitrile, 0.188 g of 4-chloro-2-fluoro-5-hydroxyaniline, 0.112 g of pyridine hydrochloride, and 4 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 1 h. The mixture was cooled and added to 10 ml of water. To this mixture was added sodium carbonate until pH 9. The product was collected, washed with water, and dried to give 0.210g of 4-(4-Chloro-2-fluoro-5-hydroxy-phenylamino)-7-methoxy-6-(3-morpholin-4-yl)-propoxyl-quinoline-3-carbonitrile as a solid, mp 125-128°C ; mass spectrum (electrospray, m/e): M+H 487.0.

Example 324

4-(3-acetylphenylamino)-6,7-dimethoxy-3-quinolinecarbonitrile

[0407] In the manner of Example 274 reaction of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile with 3-aminoacetophenone gave the title compound as a tan solid, mp 204-206°C.

Example 325

4-(3-Bromophenylamino)-6,7-di-methoxymethyl-3-quinolinecarbonitrile

[0408] In the manner of Example 305 treatment of 4-(3-bromophenylamino)-6,7-dihydroxy-3-quinolinecarbonitrile with potassium carbonate and chloromethyl ether in dimethylformamide gave the title compound as a yellow solid: mp = 113-116°C.

Example 326

N-[4-(3-Bromo-phenylamino)-3-cyano-quinolin-6-yl]-3-chloro-(E) acrylamide and

Example 327

N-[4-(3-Bromo-phenylamino)-3-cyano-quinolin-6-yl]-3-chloro-(Z)-acrylamide

[0409] To a solution of 0.5 g (1.47 mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile and 0.24 g (1.8 mmol) of diisopropylethyl amine in 3 ml of tetrahydrofuran at 0°C with stirring was added 0.21 g (1.7 mmol) of 3-chloro-acryloyl chloride (cis/trans mixture) in 2 ml of tetrahydrofuran. After 40 min at 0°C, the mixture was poured into a saturated solution of sodium bicarbonate and then extracted ether. The organic solution was dried over magnesium sulfate and the solvent was removed. The residue chromatographed on silica gel giving 0.16 g of N-[4-(3-bromophenylamino)-3-cyano-quinolin-6-yl]-3-chloro-(E) acrylamide: mass spectrum (electrospray, m/e,): M+H 424.9, 427.0, and 0.12 g of N-[4-(3-bromo-phenylamino)-3-cyanoquinolin-6-yl]-3-chloro-(Z) acrylamide: mass spectrum (electrospray, m/e,): M+H 425.0, 427.0

Example 328

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinolinyl]-4-morpholino-2-butyramide

[0410] Isobutyl chloroformate (0.161g, 1.18mmol) was dropwise added into an ice cold solution of 4-morpholino-2-butyric acid (0.25g, 1.48mmol) and N-methylmorpholine (0.15g, 1.48mmol) in 8mL of tetrahydrofuran under N₂. After stirring for 30min, a solution of 0.25g (0.74mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 6mL of pyridine was added dropwise and the mixture was stirred at 0°C for 2hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by thin-layer chromatography eluted with 15% methanol in ethyl acetate. The product was collected, and dried in vacuo to give 0.096g (27%) of yellow solid; : mass spectrum (electrospray, m/e,) 490.1, 492.1 (M+H⁺); mp 145-148°C.

Example 329

N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinolinyl]-4-dimethylamino-2-butyramide

[0411] Isobutyl chloroformate (0.342g, 2.5mmol) was dropwise added into an ice cold solution of 4-dimethylamino-2-butyric acid (0.9g, 3.8mmol) and N-methylmorpholine (0.384g, 3.8mmol) in 50mL of tetrahydrofuran under N₂. After stirring for 30min, a solution of 0.644g (1.9mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 10mL of pyridine was added dropwise and the mixture was stirred at 0°C for 2.5hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by thin-layer chromatography eluted with 15% methanol in ethyl acetate. The product was collected, and dried in vacuo to give 0.144g (21%) of yellow solid; : mass spectrum (electrospray, m/e,): 447.9, 450.2 (M+H⁺); mp 180 °C (dec.).

Example 330N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-methoxy-2-butyramide

[0412] Isobutyl chloroformate (0.432g, 3.2mmol) was dropwise added into an ice cold solution of 4-methoxy-2-butyric acid (0.72g, 6.32mmol) and N-methylmorpholine (0.959g, 9.78mmol) in 20mL of tetrahydrofuran under N₂. After stirring for 30min, a solution of 0.5g (1.58mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 8mL of pyridine was added dropwise and the mixture was stirred at 0°C for 2hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by thin-layer chromatography eluted with 5% methanol in chloroform. The product was collected, and dried in vacuo to give 0.27g (41%) of yellow solid; : mass spectrum (electrospray, m/e,): 435.1, 437.0 (M+H⁺); mp 197°C (dec.).

Example 331N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-t-butyldimethylsiloxy-2-butyramide

[0413] Isobutyl chloroformate (0.214g, 1.57mmol) was dropwise added into an ice cold solution of 4-t-butyldimethylsiloxy-2-butyric acid (0.336g, 1.57mmol) and N-methylmorpholine (0.19g, 1.88mmol) in 15mL of tetrahydrofuran under N₂. After stirring for 30min, the reaction mixture was added dropwise into a solution of 0.4g (1.18mmol) of 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile in 3mL of tetrahydrofuran and 1.5mL of pyridine and stirred at 0°C for 1hr. The reaction was quenched with ice water, poured into saturated sodium bicarbonate and brine, and extracted with ethyl acetate. The ethyl acetate layer was concentrated and purified by column chromatography eluted with 60% ethyl acetate in hexane. The product was collected, and dried in vacuo to give 0.22g (35%) of yellow solid; : mass spectrum (electrospray, m/e,): 535.1189 (M⁺).

Example 332N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinolmyn-4-hydroxy-2-butyramide

[0414] N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinoliny]-4-t-butyldimethylsiloxy-2-butyramide (60mg, 0.122mmol) was dissolved in a solution of acetic acid, tetrahydrofuran and water (3:1:1) and stirred overnight at room temperature. The solution was diluted with ethyl acetate and washed with saturated sodium bicarbonate and brine. The ethyl acetate was concentrated to give 42.2mg (90%) of yellow solid; mass spectrum (electrospray, m/e,): 421.0311 (M⁺).

Example 3334-(3-Hydroxymethyl-2-methylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile

[0415] A mixture of 0.248 g (1 mmol) of 4-chloro-6,7-dimethoxy-quinoline-3-carbonitrile, 0.151 g (1.1 mmol) of 3-amino-2-methylbenzyl alcohol, 0.116 g (1 mmol) pyridine hydrochloride and 12 ml of 2-ethoxyethanol was heated in a 138-140°C oil bath for 6 hours; progress of the reaction was monitored by TLC. When TLC indicated the disappearance of starting material, the reaction was cooled and concentrated *in vacuo* to a thick oil. To this oil was added 50 ml of water followed by 5 ml of 1M NaHCO₃, approximately pH 8. The resulting precipitate was collected, washed with water and diethyl ether, and dried *in vacuo* at 65°C to give 0.32 g (91.5%) of the desired product as light tan crystals. MP 123-125°C; : mass spectrum (electrospray, m/e,): 349.9(M+H)⁺.

Example 3344-(2-Amino-4,5-dimethylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile

[0416] A mixture of 0.248 g (1 mmol) of 4-chloro-6,7-dimethoxy-quinoline-3-carbonitrile, 0.410 g (3.0 mmol) of 4,5-dimethyl-1,2-diphenylenediamine, 0.116 g (1 mmol) pyridine hydrochloride and 12 ml of 2-ethoxyethanol was heated in a 138-140°C oil bath for 1 hour; progress of the reaction was monitored by TLC. When TLC indicated the disappearance of starting material, the reaction was cooled and concentrated *in vacuo* to a thick oil. To this oil was added 50 ml of water followed by 5 ml of 1M NaHCO₃, approximately pH 8. The resulting precipitate was collected, washed with water and diethyl ether, and dried *in vacuo* at 65°C to give 0.587 g of the desired product (impure). The impure

product was digested with 50 ml of chloroform and 50 ml of ethyl acetate for 0.5 hour, collected, washed with chloroform and dried to give 0.307 g (88%) of the desired pure product as yellow crystals. MP 260-262°C; : mass spectrum (electrospray, m/e,): 348.1582(HR).

Example 335

4-(4-Ethylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile

[0417] A mixture of 0.248 g (1 mmol) of 4-chloro-6,7-dimethoxy-quinoline-3-carbonitrile, 0.14 ml (1.1 mmol) of 4-ethylaniline, 0.116 g (1 mmol) pyridine hydrochloride and 12 ml of 2-ethoxyethanol was heated in a 138-140°C oil bath for 1 hour, progress of the reaction was monitored by TLC. When TLC indicated the disappearance of starting material, the reaction was cooled and concentrated *in vacuo* to a thick oil. To this oil was added 50 ml of water followed by 5 ml of 1 M NaHCO₃, approximately pH 8. The resulting precipitate was collected, washed with water and diethyl ether, and dried *in vacuo* at 65°C to give 0.325 g (97.5%) of the desired product as light cream crystals. MP 248-250°C; : mass spectrum (electrospray, m/e,): 333.1462.

Example 336

4-(4-Chloro-2-methylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile

[0418] A mixture of 0.248 g (1 mmol) of 4-chloro-6,7-dimethoxy-quinoline-3-carbonitrile, 0.156 g (1.1 mmol) of 4-chloro-2-methylaniline, 0.116 g (1 mmol) pyridine hydrochloride and 12 ml of 2-ethoxyethanol was heated in a 138-140°C oil bath for 24 hours; progress of the reaction was monitored by TLC. After 24 hours an additional 0.156 g of 4-chloro-2-methylaniline was added and the heating continued for 24 hours. When TLC indicated the disappearance of starting material, the reaction was cooled and concentrated *in vacuo* to a thick oil. To this oil was added 50 ml of water followed by 5 ml of 1M NaHCO₃, approximately pH 8. The gummy solid was dissolved in chloroform and passed through a pad of hydrous magnesium silicate. The liquid was concentrated *in vacuo* and the residue triturated 5 times with hexane. The resulting precipitate was collected, washed with hexane, and dried *in vacuo* at 65°C to give 0.250 g (71%) of the desired product as brown crystals. MP 227-229°C; : mass spectrum (electrospray, m/e,): 353.8(M+H)⁺.

Example 337

6,7-Dimethoxy-4-(3-phenoxyphenylamino)quinoline-3-carbonitrile

[0419] A mixture of 0.248 g (1 mmol) of 4-chloro-6,7-dimethoxy-quinoline-3-carbonitrile, 0.204 g (1.1 mmol) of 3-phenoxyaniline, 0.116 g (1 mmol) pyridine hydrochloride and 12 ml of 2-ethoxyethanol was heated in a 138-140°C oil bath for 3 hours; progress of the reaction was monitored by TLC. When TLC indicated the disappearance of starting material, the reaction was cooled and concentrated *in vacuo* to a thick oil. To this oil was added 50 ml of water followed by 5 ml of 1 M NaHCO₃, approximately pH 8. The resulting precipitate was collected, washed with water and diethyl ether, and dried *in vacuo* at 65°C to give 0.309 g (78%) of the desired product as cream crystals. MP 253-254°C; : mass spectrum (electrospray, m/e,): 397.0(M+H)⁺.

Example 338

4-(4-Chloro-3-trifluoromethylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile

[0420] A mixture of 0.248 g (1 mmol) of 4-chloro-6,7-dimethoxy-quinoline-3-carbonitrile, 0.215 g of 4-chloro-3-trifluoromethylaniline, 0.116 g (1 mmol) pyridine hydrochloride and 12 ml of 2-ethoxyethanol was heated in a 138-140°C oil bath for 1.5 hours; progress of the reaction was monitored by TLC. When TLC indicated the disappearance of starting material, the reaction was cooled and concentrated *in vacuo* to a thick oil. To this oil was added 50 ml of water followed by 5 ml of 1M NaHCO₃, approximately pH 8. The resulting precipitate was collected, washed with water and diethyl ether, and dried *in vacuo* at 65°C to give 0.266 g (65.5%) of the desired product as cream crystals. MP 265-267°C; : mass spectrum (electrospray, m/e,): 408.2(M+H)⁺.

Example 339

4-(3-Hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0421] Using the method described in Example 105, 0.7 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile and 0.38 g of 3-aminophenol was converted to 0.83 g of the title compound: mass spectrum (electrospray, m/e,): 321.9, 322.8 (M+H)⁺

Example 340

4-(4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0422] Using the method described in Example 105, 0.7 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile and 0.317 g of 4-methylphenol was converted to 0.79 g of the title compound: MP = 128-130°C.

Example 341

4-(3-Hydroxy-4-methyl-phenylamino)-8-methoxy-6-nitro-quinoline-3- carbonitrile

[0423] Using the method described in Example 105, 0.5 g of 4-chloro-8-methoxy-6-nitro-3-quinolinecarbonitrile and 0.28 g of 3-hydroxy-4-methylphenol was converted to 0.3 g of the title compound: mass spectrum (electrospray, m/e,): 350.9, 351.9 (M+H)⁺

Example 342

4-(4-chloro-2-fluoro-phenylamino)-8-methoxy-6-nitro-quinoline-3- carbonitrile

[0424] Using the method described in Example 105, 0.5 g of 4-chloro-8-methoxy-6-nitro-3-quinolinecarbonitrile and 0.25 ml of 4-chloro-2-fluoro phenol was converted to 0.08 g of the title compound: mass spectrum (electrospray, m/e,): 372.8, 374.8 (M+H)⁺

Example 343

4-(3-hydroxy-4-methoxy-phenylamino)-8-methoxy-6-nitro-quinoline-3- carbonitrile

[0425] Using the method described in Example 105, 0.5 g of 4-chloro-8-methoxy-6-nitro-3-quinolinecarbonitrile and 0.31 g of 3-hydroxy-4-methoxy phenol was converted to 0.21 g of the title compound: mass spectrum (electrospray, m/e,): 366.9, 367.9 (M+H)⁺

Example 344

6-Amino-4-(3-hydroxy-4-methyl-phenylamino)-8-methoxy-quinoline-3-carbonitrile

[0426] Using the method described in Example 196, 0.2 g of 4-(3-hydroxy-4-methyl-phenylamino)-8-methoxy-6-nitro-quinoline-3-carbonitrile and 0.1 g of iron was converted to 0.14 g of the title compound: :MP = 227°C (dec)

Example 345

6-Amino-4-(3-hydroxy-4-methoxy-phenylamino)-8-methoxy-quinoline-3- carbonitrile

[0427] Using the method described in Example 196, 0.1 g of 4-(3-hydroxy-4-methoxyphenylamino)-8-methoxy-6-nitro-quinoline-3-carbonitrile and 0.09 g of iron was converted to the title compound: :MP = 215°C (dec)

Example 346

N-{4-[(3-Bromo-4-fluorophenyl)amino]-3-cyano-7-methoxy-6-quinolinyl}-4-bromo-2-butenamide

[0428] By using the method described in Example 172 and not reacting with dimethylamine, a portion of 6-amino-

4-(3-bromo-4-fluoro-phenylamino)-7-methoxy-quinoline-3-carbonitrile was converted to the title compound: mass spectrum (electrospray, m/e,): 532.8, 534.8, 536.8 (M+H)⁺

Example 347

N-{4-[(3-Bromophenyl)amino]-3-cyano-7-methoxy-6-quinolinyl}-4-chloro-2-butenamide

[0429] In the method described in Example 198, a side product was isolated that proved to be the title compound: mass spectrum (electrospray, m/e,): 471.25, 473.3(M+H)⁺

Example 348

N-{3-Cyano-4-[(3-iodophenyl)amino]-6-quinolinyl}-2-butyneamide

[0430] Dissolved 275 mg (3.27 mmol) 2-butyneic acid in 20 ml THF under N₂ and chilled to 0°C. Added 420 µl (3.23 mmol) isobutyl chloroformate and 355 µl (3.24 mmol) N-methylmorpholine and stirred for 10 minutes. Added dropwise a solution of 500 mg (1.30 mmol) 6-amino-4-[(3-iodophenyl)amino]-3-quinolinecarbonitrile and after 15 minutes, removed ice bath and stirred overnight at 25°C. Stripped solvent, washed with water and collected solids. Boiled in ethyl acetate, collected, and dried in vacuo, giving 228 mg of orange-brown solid: mass spectrum (electrospray m/e): M+H = 453.1.

Example 349

N-{3-Cyano-4-[(3-methylphenyl)amino]-6-quinolinyl}-2-propenamide

[0431] Dissolved 500 mg (1.82 mmol) of 6-amino-4-[(3-methylphenyl)amino]-3-quinolinecarbonitrile in 1.0 ml DMF and 6 ml THF and chilled to 0°C under N₂. Added 280 µl (2.00 mmol) triethylamine and 166 µl (2.00 mmol) acryloyl chloride. Removed ice bath at 15 minutes and at 1 hour, stripped solvent and slurried residue with dilute sodium bicarbonate. Collected crystals and washed with water. Boiled solids in ethyl acetate, collected and dried in vacuo, giving 238 mg of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 329.1.

Example 350

N-{4-[(4-Bromophenyl)amino]-3-cyano-6-quinolinyl}-2-butyneamide

[0432] Dissolved 310 mg (3.68 mmol) 2-butyneic acid in 20 ml THF and chilled to 0°C under N₂. Added 480 µl (3.68 mmol) isobutyl chloroformate and 410 µl (3.72 mmol) N-methylmorpholine. Stirred for 20 minutes and dropwise added a solution of 500 mg (1.47 mmol) 6-amino-4-[(4-bromophenyl)amino]-3-quinolinecarbonitrile in 1 ml DMF and 10 ml THF. Removed ice bath after 15 minutes and stirred at 25°C overnight. Stripped solvent, slurried residue with water and collected solids. Boiled solids in ethyl acetate, collected, and dried in vacuo, giving 341 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 405.1, 407.1.

Example 351

N-{4-[(3-Chloro-4-thiophenoxyphenyl)amino]-3-cyano-6-quinolinyl}-2-propenamide

[0433] Dissolved 1.00 g (2.48 mmol) 6-amino-4-[(3-chloro-4-thiophenoxyphenyl)amino]-3-quinolinecarbonitrile in 2.0 ml DMF and 12 ml THF and chilled to 0°C under N₂. Added 380 µl (2.73 mmol) triethylamine and 227 µl (2.73 mmol) acryloyl chloride. Removed ice bath at 15 minutes and at 1.5 hours stripped solvent and slurried residue with dilute sodium bicarbonate. Collected solids and washed with water. Recrystallized from ethyl acetate and dried in vacuo, giving 293 mg of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 457.3, 459.3.

Example 352

N-{3-Cyano-4-[(3,4-difluorophenyl)amino]-6-quinolinyl}-2-butyneamide

[0434] Dissolved 425 mg (5.06 mmol) 2-butyneic acid in 40 ml THF and chilled to 0°C under N₂. Added 556 µl (5.06 mmol) N-methylmorpholine and 658 µl (5.06 mmol) isobutyl chloroformate and stirred for 10 minutes. Added dropwise

a solution of 1.00 g (3.37 mmol) 6-amino-4-[(3,4-difluorophenyl)amino]-3-quinolinecarbonitrile in 2.0 ml hot DMF and 20 ml THF. Removed ice bath at 15 minutes and stirred at 25°C overnight. Stripped solvent, slurried residue with water, and collected solids. Boiled in ethyl acetate, collected solids, and dried in vacuo, giving 735 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 363.3

Example 353

N-{4-[(3-Chlorophenyl)amino]-3-cyano-6-quinoliny]-2-butyramide

[0435] Dissolved 428 mg (5.09 mmol) 2-butyric acid in 40 ml THF and chilled to 0°C under N₂. Added 560 µl (5.09 mmol) N-methylmorpholine and 662 µl (5.09 mmol) isobutyl chloroformate and stirred for 10 minutes. Added dropwise a solution of 1.00 g (3.39 mmol) 6-amino-4-[(3-chlorophenyl)amino]-3-quinolinecarbonitrile in 2 ml DMF and 20 ml THF. Removed ice bath at 15 minutes and stirred at 25°C overnight. Stripped solvent, slurried residue with water and collected solids. Boiled in ethyl acetate, collected and dried in vacuo, giving 975 mg of yellow solid: mass spectrum (electrospray m/e): M+H = 361.1, 363.2.

Example 354

N-{3-Cyano-4-[(3-isopropylphenyl)amino]-6-quinoliny]-2-butyramide

[0436] Dissolved 695 mg (8.27 mmol) 2-butyric acid in 40 ml THF and chilled to 0°C under N₂. Added 1.08 ml (8.30 mmol) isobutyl chloroformate and 910 µl (8.27 mmol) N-methylmorpholine and stirred for 10 minutes. Dropwise added a solution of 1.00 g (3.31 mmol) 6-amino-4-[(3-isopropylphenyl)amino]-3-quinolinecarbonitrile in 2.0 ml DMF and 15 ml THF. Removed ice bath at 15 minutes and stirred at 25°C overnight. Stripped solvent, slurried residue with water, and collected solid. Recrystallized from ethyl acetate and dried in vacuo, giving 329 mg of yellow-green solid: mass spectrum (electrospray m/e): M+H = 369.2.

Example 355

N-{3-Cyano-4-[(3-isopropylphenyl)amino]-6-quinoliny]-2-propenamide

[0437] Dissolved 1.00 g (3.31 mmol) 6-amino-4-[(3-isopropylphenyl)amino]-3-quinolinecarbonitrile in 2.0 ml hot DMF, added 12 ml THF, and chilled to 0°C under N₂. Added 507 µl (3.64 mmol) triethylamine and 303 µl (3.64 mmol) acryloyl chloride. Removed ice bath at 15 minutes and at 1 hour stripped solvent. Slurried residue with dilute sodium bicarbonate, collected solids and washed with water. Recrystallized from ethyl acetate and dried in vacuo, giving 366 mg of orange solid: mass spectrum (electrospray m/e): M+H = 357.1.

Example 356

6-Amino-4-[(3-isopropylphenyl)amino]-3-quinolinecarbonitrile

[0438] Added 0.5 g 10% palladium on carbon to a flask under N₂ and covered with 250 ml ethanol. To this added 4.818 g (14.5 mmol) 4-[(3-isopropylphenyl)amino]-6-nitro-3-quinolinecarbonitrile and 1.14 ml (36.2 mmol) anhydrous hydrazine and heated to reflux. At 1.5 hours, filtered hot mixture through celite, stripped solvent, and dried in vacuo, giving 4.30 g of yellow solid: mass spectrum (electrospray m/e): M+H = 303.1.

Example 357

4-[(3-Isopropylphenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0439] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 200 ml ethanol, and 3.48 g (25.8 mmol) 3-isopropylaniline was heated to reflux under N₂. At 4 hours, removed heat and made basic with saturated sodium bicarbonate. Stripped solvents and azeotroped with ethanol. Slurried residue with hexane and collected solids. Dissolved in ethyl acetate, stirred with Darco, filtered through celite, stripped solvent and dried in vacuo, giving 5.289 g of yellow solid: mass spectrum (electrospray m/e): M+H = 333.1.

Example 3584-(3-Bromo-phenylamino)-6-(3-pyrrolidin-1-yl-propylamino)-quinoline-3-carbonitrile

[0440] Dissolved 0.64 g (3.69 mmol) 3-(pyrrolidin-1-yl)propionaldehyde dimethyl acetal in 10 ml water and acidified to pH 1 with concentrated HCl. Heated to 40°C for 90 minutes, removed heat and neutralized with sodium bicarbonate. Dissolved 500 mg (1.47 mmol) 6-amino-4-(3-bromo-phenylamino)-quinoline-3-carbonitrile in 100 ml ethanol and added acetic acid until pH was 3 to 4. Added the deprotected aldehyde to the amine solution and stirred at 25°C for 0.5 hour. Gradually added 94 mg (1.47 mmol) sodium cyanoborohydride and stirred overnight. Stripped solvent, partitioned between chloroform and water. Washed organic layer with brine and dried with sodium sulfate. Stripped solvent and filtered through a pad of silica gel, first with 10% methanol/chloroform, then 20% methanol/chloroform/1% ammonium hydroxide. Stripped solvent and dried in vacuo, giving 143 mg of yellow-brown solid: mass spectrum (electrospray m/e): M+H = 450, 452.1.

Example 3594-(3-Azido-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0441] Dissolved 643 mg (2.00 mmol) 4-(3-amino-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile in 25 ml 80% acetic acid in water. Chilled to 0°C and added 152 mg (2.21 mmol) sodium nitrite in 2.2 ml water. After 10 minutes, added 144 mg (2.21 mmol) sodium azide in 2.2 ml water. At 1.5 hours stripped solvent and dissolved residue in hot ethyl acetate. Washed with saturated sodium bicarbonate, water and brine and dried with sodium sulfate. Stripped solvent and redissolved in 60% ethyl acetate/methylene chloride and filtered through a pad of silica gel. Stripped solvent and dried in vacuo, giving 526 mg of brown solid: mass spectrum (electrospray m/e): M+H = 347.1.

Example 3606-Amino-4[(4-Chloro-2-fluorophenyl)amino]-7-methoxy-3-quinolinecarbonitrile

[0442] A mixture of 500 mg (1.34 mmol) 4-[(4-chloro-2-fluorophenyl)amino]-7-methoxy-6-nitro-3-quinolinecarbonitrile, 20 ml ethanol and 1.52 ml (6.71 mmol) tin chloride dihydrate was heated to reflux under N₂. At 3 hours, removed heat, added ice water and made basic with sodium bicarbonate. Stirred for several hours and extracted with chloroform. Dried organic layer with sodium sulfate, stripped solvent and dried in vacuo, giving 350 mg of green solid: mass spectrum (electrospray m/e): M+H = 342.9, 344.8.

Example 3614-[(4-Chloro-2-fluorophenyl)amino]-7-methoxy-6-nitro-3-quinolinecarbonitrile

[0443] A mixture of 5.017 g (19.0 mmol) 4-chloro-7-methoxy-6-nitro-3-quinolinecarbonitrile, 250 ml ethanol, and 2.55 ml 22.8 mmol) 4-chloro-2-fluoroaniline was heated to reflux under N₂. At 3.5 hours, removed heat and made basic with saturated sodium bicarbonate. Stripped solvents and azeotroped with ethanol. Slurried residue with hexane, collected solids, and washed with water. Dissolved in ethyl acetate, stirred with Darco, filtered, stripped solvent, and dried in vacuo, giving 6.54 g of yellow solid: mass spectrum (electrospray m/e): M+H = 372.8, 374.8.

Example 3624-[(3,4-dichlorophenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0444] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 250 ml ethanol, and 4.17 g (25.6 mmol) 3,4-dichloroaniline was heated to reflux under N₂. At 3.5 hours, removed head and made basic with saturated sodium bicarbonate. Stripped solvents and azeotroped with ethanol. Slurried residue with hexane, collected solids and washed with water. Dissolved in ethyl acetate, stirred with Darco, filtered, stripped solvent and dried in vacuo, giving 2.106 g of yellow solid: mass spectrum (electrospray m/e): M+H = 359.1, 361.0.

Example 3636-Amino-4-[(3-methylsulfanylphenyl)amino]-3-quinolinecarbonitrile

[0445] A mixture of 4.55 g (13.5 mmol) 4-[(3-methylsulfanylphenyl)amino]-6-nitro-3-quinolinecarbonitrile, 250 ml ethanol, 0.46 g 10% palladium on carbon, and 1.06 ml (33.8 mmol) anhydrous hydrazine was heated to reflux. At 4 hours, added 0.5 equivalents of hydrazine, and at 5 hours, filtered the hot mixture through celite. Stripped the solvent and dried in vacuo, giving 4.068 g brown solid: mass spectrum (electrospray m/e): M+H = 307.1.

Example 3644-[(3-Methylsulfanylphenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0446] A mixture of 5.00g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 200 ml ethanol, and 3.18 ml (25.8 mmol) 3-methylsulfanylaniline was heated to reflux under N₂. At 2 hours, removed heat and made basic with saturated sodium bicarbonate. Stripped solvents and air dried. Washed residue with hexane, collected solids and washed with water. Dissolved in ethyl acetate, stirred with Darco, stripped solvent and dried in vacuo, giving 4.848 g of yellow solid: mass spectrum (electrospray m/e): M+H = 337.1.

Example 3654-[(3-Trifluoromethoxyphenyl)amino]-6-nitro-3-quinolinecarbonitrile

[0447] A mixture of 5.00 g (21.5 mmol) 4-chloro-6-nitro-3-quinolinecarbonitrile, 200 ml ethanol, and 3.4 ml (25.3 mmol) 3-trifluoromethoxyaniline was heated to reflux. At 5 hours, removed heat and made basic with saturated sodium bicarbonate. Stripped solvents, slurried residue with hexane, collected, and washed with water. Dissolved in ethyl acetate, stirred with Darco, filtered, stripped solvent, and dried in vacuo, giving 4.537 g of yellow-orange solid: mass spectrum (electrospray m/e): M+H = 374.8.

Example 3664-(3-Dimethylamino-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0448] A 1.25 gram (5 mmole) portion of 4-chloro, 6,7-dimethoxy-quinoline-3-carbonitrile and a 1.05 gram (5 mmole) portion of N, N-dimethyl-1,3-phenylenediamine in 10ml of 2-methoxyethanol were refluxed for 2 hours in an oil bath at 154 deg. Cooling gave a solid which was recrystallized from water to give 0.4 grams (19%) of 4-(3-Dimethylamino-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile which melted at 246-249°C. : mass spectrum (electrospray m/e): (M+H)=349.2., (M+2H)⁺=174.9.

Example 3676,7-Dimethoxy-4-(4-methoxy-2-meth-phenylamino)-quinoline-3-carbonitrile

[0449] A reaction mixture of 248.7 mg (1mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 164.6 mg (1.2 mmol) of 4-methoxy-2-methyl-aniline and 115.6 mg (1 mmol) of pyridine hydrochloride in 10 mL of 2-ethoxyethanol was refluxed under N₂ for 3 hr. After removal of the solvent, the residue was diluted with water and neutralized to pH 7-8 with diluted sodium carbonate solution. The precipitate was filtered and washed with water and ether. After drying in vacuo. this yielded 250.2 mg (71.7 %) of the product as a off red solid, m.p. >131° C(dec.), mass (electrospray, m/e): M+H 349.9.

Example 3683-(3-Cyano-6,7-dimethoxy-quinolin-4-ylamino)-2-methyl-benzoic acid

[0450] Using an analogous procedure to that described in Example 367, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 12 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 196.5 mg (1.3 mmol) of 3-amino-2-methylbenzoic acid to give 89.6 mg (24.7 %) of the product as a gray solid, m.p. 242-245° C, mass (electrospray, m/e): M+H 364.0.

Example 3694-(3-Hydroxy-4-methoxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0451] Using an analogous procedure to that described in Example 367, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 10 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 167.0 mg (1.2 mmol) of 5-amino-2-methoxyphenol to give 313.3 mg (89.3 %) of the product as a gray solid, m.p. 254-256° C, mass (electrospray, m/e): M+H 351.2.

Example 3704-(3-Chloro-4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3 carbonitrile

[0452] Using an analogous procedure to that described in Example 367, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 10 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 170.0 mg (1.2 mmol) of 2-chloro-4-amino-toluene to give 350.9 mg (99.4 %) of the product as a yellow solid, m.p. >250° C, mass (electrospray, m/e): M+H 353.9, 355.8.

Example 3716,7-Dimethoxy-4-(4-phenoxy-phenylamino)-quinoline-3-carbonitrile

[0453] Using an analogous procedure to that described in Example 367, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 12 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 222.3 mg (1.2 mmol) of 4-phenoxyaniline to give 283.0 mg (71.3 %) of the product as a light yellow solid, m.p. 239-241° C, mass (electrospray, m/e): M+H 397.9.

Example 3724-(5-Chloro-2-methoxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0454] Using an analogous procedure to that described in Example 367, 248.7 mg (1 mmol) of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile in 12 mL of 2-ethoxyethanol and in the presence of 115.6 mg (1 mmol) of pyridine hydrochloride was reacted with 189.1 mg (1.2 mmol) of 5-chloro-o-anisidine to give 240.5 mg (65.0 %) of the product as a cream solid, m.p. 200-202° C, mass (electrospray, m/e): M+H 369.9, 371.8.

Example 3734-(4-Chloro-2-fluoro-phenylamino)-6,7-dihydroxy-quinoline-3-carbonitrile

[0455] A mixture of 0.358 g of 4-(4-chloro-2-fluoro-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile and 3 g of pyridine hydrochloride was stirred under nitrogen at 210-220°C for 20 minutes. The mixture was cooled and added to 50 ml of 3% ammonium hydroxide solution. The product was collected, washed with water, and dried to give 0.302 g of 4-(4-chloro-2-fluoro-phenylamino)-6,7-dihydroxy-quinoline-3-carbonitrile as a solid, mp 270-272°C; mass spectrum (EI, m/e): M 329.0363.

Example 3744-(3-Hydroxy-2-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0456] A mixture of 0.249 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.123 g of 3-amino-o-cresol, 20 mg of pyridine hydrochloride, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 40 ml of water. To this mixture was added sodium carbonate and concentrated hydrogen chloride to adjust pH to 7. The product was collected, washed with water, and dried to give 0.174 g of 4-(3-hydroxy-2-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile as a solid, mp 255-257°C; mass spectrum (electrospray, m/e): M+H 335.9.

Example 3754-(3-Chloro-4-methoxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile

[0457] A mixture of 0.249 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.158 g of 3-chloro-p-anisidine, 20 mg of pyridine hydrochloride, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 40 ml of water. To this mixture was added sodium carbonate and concentrated hydrogen chloride to adjust pH to 7. The product was collected, washed with water, and dried to give 0.324 g of 4-(3-chloro-4-methoxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile as a solid, mp 278-280°C; mass spectrum (EI, m/e): M 369.0860.

Example 3766,7-Dimethoxy-4-(4-trifluoromethyl-phenylamino)-quinoline-3-carbonitrile

[0458] A mixture of 0.249 g of 4-chloro-6,7-dimethoxy-3-quinolinecarbonitrile, 0.322 g of 4-(trifluoromethyl)aniline, 20 mg of pyridine hydrochloride, and 10 ml of ethoxyethanol was stirred under nitrogen, at reflux temperature for 30 minutes. The mixture was cooled and added to 40 ml of water. To this mixture was added sodium carbonate and concentrated hydrogen chloride to adjust pH to 7. The product was collected, washed with water, and dried to give 0.268 g of 6,7-dimethoxy-4-(4-trifluoromethylphenylamino)-quinoline-3-carbonitrile as a solid, mp 116-118°C; mass spectrum (EI, m/e): M 373.1031.

Example 3774-(3,4-Dibromophenylamino)-6-nitroquinoline-3-carbonitrile

[0459] A mixture of 6.20g (26.6 mmol) of 4-chloro-6-nitroquinoline-3-carbonitrile and 8.00 g (31.9 mmol) of 3,4-dibromoaniline in 160 mL of EtOH was refluxed under N₂ for 5 hr. Satd NaHCO₃ was added and volatile material was removed. The residue was slurried with hexane, collected, washed with hexane and H₂O and dried. The insoluble material was repeatedly extracted with boiling EtOAc and the solution was then filtered through silica gel. The solvent was removed to give 3.80 g of 4-(3,4-dibromophenylamino)-6-nitroquinoline-3-carbonitrile as a green solid: mass spectrum (electrospray, m/e): M+H 448.9.

Example 3786-Amino-4-(3-trifluoromethylphenylamino)quinoline-3-carbonitrile

[0460] A mixture of 6.0 g (16.8 mmol) of 6-nitro-4-(3-trifluoromethylphenylamino)quinoline-3-carbonitrile and 18.9 g (83.8 mmol) of SnCl₂·2H₂O in 240 mL of EtOH was refluxed under N₂ for 1 hr. Ice water was added followed by NaHCO₃ to pH 8. The mixture was stirred for 2 hr and then extracted with CHCl₃. Darco was added and the extracts were filtered through anhyd MgSO₄ and evaporated. The residue was filtered through silica gel with 10% MeOH in CHCl₃. Solvent evaporation and drying in vacuo (40°C) gave 4.87 g of 6-amino-4-(3-trifluoromethylphenylamino)quinoline-3-carbonitrile as a brown solid: mass spectrum (electrospray, m/e): M+H 329.1.

Example 3796-Amino-4-(3,4-dibromophenylamino)quinoline-3-carbonitrile

[0461] Prepared from 4.90 g of 4-(3,4-dibromophenylamino)-6-nitroquinoline-3-carbonitrile and 12.4 g of SnCl₂·2H₂O in the same manner as Example 378. There was obtained 1.25 g of 6-amino-4-(3,4-dibromophenylamino)quinoline-3-carbonitrile as a brown solid: mass spectrum (electrospray, m/e): M+H 416.9, 418.9.

Example 380N-[3-Cyano-4-(3,4-dibromophenylamino)quinolin-6-yl]acrylamide

[0462] 6-Amino-4-(3,4-dibromophenylamino)quinoline-3-carbonitrile (0.750 g, 1.79 mmol) in 10 mL of THF was treated with 0.217 g (2.15 mmol) of Et₃N and 0.195 g (2.15 mmol) of acryloyl chloride at 0°C under N₂. After stirring overnight

at 25°C, the solvent was evaporated and the residue was slurried with water and collected. The residue was boiled twice with EtOAc and then dried in vacuo (50°C) to give 0.609 g of N-[3-cyano-4-(3,4-dibromophenylamino)quinolin-6-yl]acrylamide as a brown solid: mass spectrum (electrospray, m/e): 470.9, 472.9.

Example 381

N-[4-(3-Bromophenylamino)-3-cyanoquinolin-6-yl]propionamide

[0463] Prepared from 1.00 g of 6-amino-4-(3-bromophenylamino)quinoline-3-carbonitrile, 0.359 g of Et₃N and 0.328 g of propionyl chloride in the same manner as Example 380. The yield of N-[4-(3-bromophenylamino)-3-cyanoquinolin-6-yl]propionamide was 0.722 g as a yellow solid: mass spectrum (electrospray, m/e): M+H 395.1, 397.0.

Example 382

(E)-But-2-enoic Acid [4-(3-Bromophenylamino)-3-cyanoquinolin-6-yl]amide

[0464] A solution of 0.637 g (7.40 mmol) of E-but-2-enoic acid in 25 mL of THF under N₂ was chilled in ice. Isobutyl chloroformate (1.01 g, 7.40 mmol) and N-methylmorpholine (0.747 g, 7.40 mmol) were added and the solution was stirred cold for 10 min. A slurry of 1.00 g (2.96 mmol) of 6-amino-4-(3-bromophenylamino)-quinoline-3-carbonitrile in 15 mL of THF was added and the mixture was stirred at 25°C overnight. The mixture was evaporated and the residue was slurried in water, collected and dried. The residue was boiled twice with EtOAc and dried in vacuo (50°C) to give 0.965 g of (E)-but-2-enoic acid [4-(3-bromophenylamino)-3-cyanoquinolin-6-yl]amide as a yellow solid: mass spectrum (electrospray, m/e): M+H 406.9, 408.9.

Example 383

N-[4-(3-Bromophenylamino)-3-cyanoquinolin-6-yl]-2-methylacrylamide

[0465] Prepared from 0.500 g of 6-amino-4-(3-bromophenylamino)quinoline-3-carbonitrile, 0.194 g of Et₃N and 0.202 g of methacryloyl chloride in the same manner as Example 380. There was obtained 0.317 g of N-[4-(3-bromophenylamino)-3-cyanoquinolin-6-yl]-2-methylacrylamide as a yellow solid: mass spectrum (electrospray, rule): M+H 406.8, 408.8.

Example 384

4-(3-Fluorophenylamino)-6-nitroquinoline-3-carbonitrile

[0466] Prepared from 5.00 g of 4-chloro-6-nitroquinoline-3-carbonitrile and 2.86 g of 3-fluoroaniline in the same manner as Example 377. The crude product was dissolved in a large volume of EtOAc, treated with Darco and filtered through Celite. Solvent removal and drying in vacuo (50°C) gave 5.77 g of 4-(3-fluorophenylamino)-6-nitroquinoline-3-carbonitrile as a yellow-orange solid: mass spectrum (electrospray, m/e): M+H 309.2.

Example 385

6-Amino-4-(3-fluorophenylamino)quinoline-3-carbonitrile

[0467] Prepared from 5.04 g of 4-(3-fluorophenylamino)-6-nitroquinoline-6-carbonitrile and 18.5 g of SnCl₂·2H₂O in the same manner as Example 378. Filtration through silica was unnecessary. There was obtained 4.30 g of 6-amino-4-(3-fluorophenylamino)-quinoline-3-carbonitrile as yellow-brown crystals: mass spectrum (electrospray, m/e): M+H 279.1.

Example 386

4-(3-Dimethylaminophenylamino)-6-nitroquinoline-3-carbonitrile

[0468] Prepared from 5.00 g of 4-chloro-6-nitroquinoline-3-carbonitrile, 5.38 g of 3-dimethylaminoaniline dihydrochloride and 5.17 g of triethylamine in the same manner as Example 377. The crude product was taken up in EtOAc, treated with Darco, filtered through Celite, evaporated and dried in vacuo (50°C). The yield of 4-(3-dimethylaminophenylamino)-6-nitroquinoline-3-carbonitrile was 5.62 g as brick red crystals: mass spectrum (electrospray, m/e): M+H

334.2.

Example 3874-(4-Dimethylaminophenylamino)-6-nitroquinoline-3-carbonitrile

[0469] Prepared from 5.00 g of 4-chloro-6-nitroquinoline-3-carbonitrile, 5.38 g of 4-dimethylaminoaniline dihydrochloride and 5.17 g of triethylamine in the same manner as Example 386. The yield of 4-(4-dimethylaminophenylamino)-6-nitroquinoline-3-carbonitrile was 5.58 g as brick red crystals: mass spectrum (electrospray, m/e): M+H 334.2.

Example 3886-Amino-4-(3-dimethylaminophenylamino)quinoline-3-carbonitrile

[0470] A mixture of 5.00 g (15.0 mmol) of 4-(3-dimethylaminophenylamino)-6-nitroquinoline-3-carbonitrile, 1.20 g (37.5 mmol) of anhyd hydrazine and 0.5 g of 10% Pd/C in 250 mL of EtOH was refluxed under N₂ for 1.3 hr. The reaction was filtered through Celite, the Celite was washed with EtOH and the filtrate and washes were combined. Solvent evaporation and drying in vacuo (50°C) gave 6-amino-4-(3-dimethylaminophenylamino)quinoline-3-carbonitrile as a red brown solid: mass spectrum (electrospray, m/e): 303.9.

Example 3896-Amino-4-(4-dimethylaminophenylamino)quinoline-3-carbonitrile

[0471] Prepared from 4-(4-dimethylaminophenylamino)-6-nitroquinoline-3-carbonitrile (5.00 g), 1.20 g of anhyd hydrazine and 0.500 g of 10% Pd/C in the same manner as Example 388 155179. After washing first with MeOH (discarded), the product was eluted with DMF. The latter solvent was collected separately, evaporated and the residue was dried in vacuo (50°C). The yield of 6-amino-4-(4-dimethylaminophenylamino)quinoline-3-carbonitrile was 4.00 g as a yellow solid: mass spectrum (electrospray, m/e): M+H 303.9.

Example 390But-2-ynoic Acid [4-(3-Fluorophenylamino)-3-cyanoquinolin-6-yl]amide

[0472] Prepared from 0.756 g of but-2-ynoic acid, 1.23 g of isobutyl chloroformate, 0.908 g of N-methylmorpholine and 1.00 g of 6-amino-4-(3-fluorophenylamino)quinoline-3-carbonitrile in the same manner as Example 382. The yield of but-2-ynoic acid [4-(3-fluorophenylamino)-3-cyanoquinolin-6-yl]amide was 1.07 g as a yellow solid: mass spectrum (electrospray, m/e): 345.1.

Example 391N-[3-Cyano-4-(3-dimethylaminophenylamino)quinolin-6-yl]acrylamide

[0473] Prepared from 1.00 g of 6-amino-4-(3-dimethylaminophenylamino)quinoline-3-carbonitrile, 0.400 g of triethylamine and 0.360 g of acryloyl chloride in the same manner as Example 88. The yield of N-[3-cyano-4-(3-dimethylaminophenylamino)-quinolin-6-yl]acrylamide was 0.880 g as an orange solid: mass spectrum (electrospray, m/e): 358.1.

Example 392N-[3-Cyano-4-(4-dimethylaminophenylamino)quinolin-6-yl]acrylamide

[0474] Prepared from 1.00 g of 6-amino-4-(4-dimethylaminophenylamino)quinoline-3-carbonitrile, 0.400 g of triethylamine and 0.360 g of acryloyl chloride in the same manner as Example 380. The yield of N-[3-cyano-4-(4-dimethylaminophenylamino)-quinolin-6-yl]acrylamide was 0.990 g of brown-orange solid: mass spectrum (electrospray, m/e): 358.2.

Example 393

But-2-ynoic Acid [3-Cyano-4-(3-dimethylaminophenylamino)quinolin-6-yl]amide

[0475] Prepared from 0.694 g of but-2-ynoic acid, 1.13 g of isobutyl chloroformate, 0.833 g of N-methylmorpholine and 1.00 g of 6-amino-4-(3-dimethylaminophenylamino)-quinoline-3-carbonitrile in the same manner as Example 382. The yield of but-2-ynoic acid [3-cyano-4-(3-dimethylaminophenylamino)quinolin-6-yl]amide was 0.967 g as an orange solid: mass spectrum (electrospray, m/e): M+H 370.2.

Example 394

But-2-ynoic Acid [3-Cyano-4-(4-dimethylaminophenylamino)quinolin-6-yl]amide

[0476] Prepared from 0.694 g of but-2-ynoic acid, 1.13 g of isobutyl chloroformate, 0.833 g of N-methylmorpholine and 1.00 g of 4-(4-dimethylaminophenylamino)quinoline-3-carbonitrile in the same manner as Example 382. The yield of but-2-ynoic acid [3-cyano-4-(4-dimethylaminophenylamino)quinolin-6-yl]amide was 1.13 g as a brick red solid: mass spectrum (electrospray, m/e): M+H 370.2.

Example 395

4-(3-Bromophenylamino)-6-dimethylaminoquinoline-3-carbonitrile Hydrochloride

[0477] Prepared from 0.400 g of 4-chloro-6-dimethylaminoquinoline-3-carbonitrile and 3-bromoaniline in the same manner as Example 377. The crude product was boiled twice with EtOAc and dried in vacuo (50°C). The yield of 4-(3-bromophenylamino)-6-dimethylaminoquinoline-3-carbonitrile hydrochloride was 0.621 g as a brown powder: mass spectrum (electrospray, m/e) M+H 366, 368.9.

Example 396

6-Dimethylamino-4-(3-methoxyphenylamino)quinoline-3-carbonitrile Hydrochloride

[0478] Prepared from 0.400 g of 4-chloro-6-dimethylaminoquinoline-3-carbonitrile and 0.256 g of 3-methoxyaniline in the same manner as Example 395. The yield of 6-dimethylamino-4-(3-methoxyphenylamino)quinoline-3-carbonitrile was 0.532 g of brown powder: mass spectrum (electrospray, m/e): M+H 318.9.

Example 397

2-Bromo-N-[4-(3-bromophenylamino)-3-cyanoquinolin-6-yl]acetamide

[0479] Prepared from 1.50 g of 6-amino-4-(3-bromophenylamino)quinoline-3-carbonitrile, 0.538 g of triethylamine and 1.08 g of bromoacetyl bromide in the same manner as Example 380. The yield of 2-bromo-N-[4-(3-bromophenylamino)-3-cyanoquinolin-6-yl]acetamide was 1.55 g as a yellow-brown solid: mass spectrum (electrospray, m/e): M+H 458.9, 460.9.


Example 398

6-Iodo-4-(3-methoxyphenylamino)quinoline-3-carbonitrile

[0480] Prepared from 1.00 g of 4-chloro-6-iodoquinoline-3-carbonitrile and 0.469 g of 3-methoxyaniline in the same manner as Example 377. The crude product was filtered through silica gel with 20% EtOAc in CH₂Cl₂, evaporated and dried in vacuo (50°C). The yield of 6-iodo-4-(3-methoxyphenylamino)quinoline-3-carbonitrile was 1.09 g as yellow crystals: mass spectrum (electrospray, m/e): M+H 401.9.

Claims

1. A compound of the formula



15 wherein:



20 X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally monodi-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxy-alkyl of 1-6 carbon atoms, halomethyl, alkoxyethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;






25 n is 0-1;

Y is -NH-, -O-, -S-, or -NR-;

R is alkyl of 1-6 carbon atoms;

30 R₁, R₂, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynyloxymethyl of 4-9 carbon atoms, alkoxyethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphanyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, aminoalkyl of 1-4 carbon atoms, N-alkylaminoalkyl of 2-7 carbon atoms, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino,





R_5 is alkyl of 1-6 carbon atoms, alkyl optionally substituted with one or more halogen atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, nitro, cyano, or alkyl of 1-6 carbon atoms groups;

R_6 is hydrogen, alkyl of 1-6 carbon atoms, or alkenyl of 2-6 carbon atoms;

R_7 is chloro or bromo

R_8 is hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy

of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, or bromo;
 Z is amino, hydroxy, alkoxy of 1-6 carbon atoms, alkylamino wherein the alkyl moiety is of 1-6 carbon atoms,
 dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, morpholino, piperazino, N-alkylpiper-
 azino wherein the alkyl moiety is of 1-6 carbon atoms, or pyrrolidino;
 m = 1-4, q = 1-3, and p = 0-3;

any of the substituents R₁, R₂, R₃, or R₄ that are located on contiguous carbon atoms can together be the divalent radical -O-C(R₈)₂-O-;

or a pharmaceutically acceptable salt thereof, provided that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, then X is not 2-methylphenyl, and further provided that when Y is -NH-, R₃ is chlorine, R₁, R₂ and R₄ are hydrogen, and n is 0, then X is not phenyl or 3-chlorophenyl, and further provided that when Y is -NH-, R₁, R₂, and R₃ are hydrogen, R₄ is R₅-CONH(CH₂)_p-, R₅ is 2,6-dichlorophenyl, n is 1, and p is 0, then X is not pyridin-2-yl.

2. The compound according to claim 1 wherein Y is -NH- and n = 0 or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2 wherein X is optionally substituted phenyl or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 3 wherein R₁ and R₄ are hydrogen or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1 which is 4-[(3-bromophenyl)amino]-6,7-diethoxy-3-quinolinecarbonitrile or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 1 which is 4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 1 which is 4-diethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 1 which is 4-dimethylamino-but-2-enoic acid [4-(3-bromo-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 1 which is 4-dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof.
10. The compound according to claim 1 which is 4-diethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 1 which is 4-morpholin-4-yl-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof.
12. The compound according to claim 1 which is 4-dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt thereof.
13. The compound according to claim 1 which is N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinolinyl]4-methoxy-2-butyramide or a pharmaceutically acceptable salt thereof.
14. The compound according to claim 1 which is N-{4-[(3-chloro-4-fluorophenyl)-amino]-3-cyano-6-quinolinyl}-4-dimethylamino-2-butenamide or a pharmaceutically acceptable salt thereof.
15. A compound according to claim 1 which is
 - a) 4-[(3-bromophenyl)amino]-7-methoxy-3-quinolinecarbonitrile;
 - b) 4-[(3-bromophenyl)amino]-7-methoxy-6-nitro-3-quinolinecarbonitrile;
 - c) 6-amino-4-[(3-bromophenyl)amino]-7-methoxy-3-quinolinecarbonitrile;
 - d) N-[4-[(3-bromophenyl)amino]-3-cyano-7-methoxy-6-quinolinyl]-2-butyramide;
 - e) N-[4-[(3-bromophenyl)amino]-3-cyano-7-methoxy-6-quinolinyl]-2-propenamide;
 - f) 4-[(3-bromophenyl)amino]-6-nitro-3-quinolinecarbonitrile;

g) 6-amino-4-[(3-bromophenyl)amino]-3-quinolinecarbonitrile;
 h) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-2-butyramide;
 i) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny] acetamide;
 j) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny] butanamide;
 5 k) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-2-propenamide;
 l) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-2-chloroacetamide;
 m) 4-[(3,4-dibromophenyl)amino]-6-nitro-3-quinolinecarbonitrile;
 n) 6-amino-4-[(3,4-dibromophenyl)amino]-3-quinolinecarbonitrile;
 o) N-[4-[(3,4-dibromophenyl)amino]-3-cyano-6-quinoliny]-2-butyramide;
 10 p) 6-nitro-4-[(3-trifluoromethylphenyl)amino]-3-quinolinecarbonitrile;
 q) 6-amino-4-[(3-trifluoromethylphenyl)amino]-3-quinolinecarbonitrile;
 r) N-[4-[(3-trifluoromethylphenyl)amino]-3-cyano-6-quinoliny]-2-butyramide;
 s) 4-[(3-bromophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 t) 4-[(3-fluorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 15 u) 4-(cyclohexylamino)-6,7-dimethoxy-3-quinolinecarbonitrile;
 v) 4-[(3-bromophenyl)amino]-6,7-dihydroxy-3-quinolinecarbonitrile;
 w) 8-[(3-bromophenyl)amino]-[1,3]-dioxolo[4,5-g]quinoline-7-carbonitrile;
 x) 4-[(3-chlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 y) 4-[(3-trifluoromethylphenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 20 z) 4-[(3,4-dimethoxyphenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 aa) 4-[(methylphenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 bb) 4-[(3-cyanophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 cc) 4-[(4-fluorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 dd) 4-[(3-(hydroxymethyl)phenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 25 ee) 4-(3-bromophenoxy)-6,7-dimethoxy-3-quinolinecarbonitrile;
 ff) 4-[(4-bromophenyl)sulfanyl]-6,7-dimethoxy-3-quinolinecarbonitrile;
 gg) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-3(E)-chloro-2-propenamide;
 hh) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-3(Z)-chloro-2-propenamide;
 ii) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-2-methyl-2-propenamide;
 30 jj) N-[4-[(3,4-dibromophenyl)amino]-3-cyano-6-quinoliny]-2-propenamide; kk) N-[4-[(5-bromo-3-pyridinyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 ll) 4-[(3-bromophenyl)amino]-6,7-bis(methoxymethoxy)-3-quinolinecarbonitrile;
 mm) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-hydroxy-2-butyramide;
 nn) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-morpholino-2-butyramide;
 35 oo) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-2-butyramide;
 pp) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-methoxy-2-butyramide;
 qq) 4-(3-bromophenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 rr) 4-(3-phenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 ss) 4-(3,4-dimethoxyphenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 40 tt) 4-(3,4-dichlorophenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 uu) 4-methoxy-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide;
 vv) 4-(4-chloro-2-fluoro-phenylamino)-7-(3-chloro-propoxy)-6-methoxyquinoline-3-carbonitrile;
 ww) 4-(4-chloro-2-fluoro-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile;
 xx) 7-(2-dimethylamino-ethoxy)-4-(3-hydroxy-4-methyl-phenylamino)-6-methoxy-quinoline-3-carbonitrile;
 45 yy) 4-(3-hydroxy-4-methyl-phenylamino)-6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinoline-3-carbonitrile; or
 zz) 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-7-(3-dimethylaminopropoxy)-6-methoxy-quinoline-3-carbonitrile;

or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 1 which is

- a) 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile;
 55 b) 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-7-(2-dimethylamino-ethoxy)-6-methoxy-quinoline-3-carbonitrile;
 c) 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinoline-3-carbonitrile;

d) N-[3-cyano-4-(3-fluorophenylamino)quinolin-6-yl]acrylamide;
 e) 6,7-dimethoxy-4-(3-nitrophenylamino)quinoline-3-carbonitrile;
 f) 4-(3-bromophenylamino)-6-ethoxy-7-methoxyquinoline-3-carbonitrile;
 g) 6-ethoxy-4-(3-hydroxy-4-methylphenylamino)-7-methoxyquinoline-3-carbonitrile;
 5 h) 4-dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyanoquinolin-6-yl]-amide;
 i) 4-diethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyanoquinolin-6-yl]-amide;
 j) 4-methylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyanoquinolin-6-yl]-amide;
 k) 4-[(3-bromophenyl)amino]-8-methyl-6-nitro-3-quinolinecarbonitrile;
 l) 4-[(3-bromophenyl)amino]-8-dimethylaminomethyl-6-nitro-3-quinolinecarbonitrile;
 10 m) 6-amino-4-[(3-bromophenyl)amino]-8-dimethylaminomethyl-3-quinolinecarbonitrile;
 n) N-{4-[(3-bromophenyl)amino]-3-cyano-8-dimethylaminomethyl-6-quinoliny}-2-butyramide;
 o) N-{4-[(3-bromophenyl)amino]-3-cyano-8-dimethylaminomethyl-6-quinoliny}-2-propenamide;
 p) N-{4-[(3-bromophenyl)amino]-3-cyano-8-dimethylaminomethyl-6-quinoliny}acetamide;
 q) 4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-(morpholinopropoxy)-3-quinolinecarbonitrile;
 15 r) 4-[(3-bromophenyl)amino]-7-methoxy-6-(morpholinopropoxy)-3-quinolinecarbonitrile;
 s) 4-[(4-chloro-2-fluorophenyl)amino]-7-methoxy-6-(morpholinopropoxy)-3-quinolinecarbonitrile;
 t) 4-[(3-hydroxy-4-methylphenyl)amino]-7-methoxy-6-(morpholinopropoxy)-3-quinolinecarbonitrile;
 u) N-{3-cyano-4-[(3-iodophenyl)amino]-6-quinoliny}-2-propenamide;
 v) 6-amino-4-[(3-iodophenyl)amino]-3-quinolinecarbonitrile;
 20 w) 4-[(3-iodophenyl)amino]-6-nitro-3-quinolinecarbonitrile;
 x) N-{3-cyano-4-[(3-methylphenyl)amino]-6-quinoliny}-2-butyramide;
 y) 6-amino-4-[(3-methylphenyl)amino]-3-quinolinecarbonitrile;
 z) 6-nitro-4-[(3-methylphenyl)amino]-3-quinolinecarbonitrile;
 aa) N-{4-[(3-chlorophenyl)amino]-3-cyano-6-quinoliny}-2-propenamide;
 25 bb) 6-amino-4-[(3-chlorophenyl)amino]-3-quinolinecarbonitrile;
 cc) 4-[(3-chlorophenyl)amino]-6-nitro-3-quinolinecarbonitrile;
 dd) N-{3-cyano-4-[(3-methoxyphenyl)amino]-6-quinoliny}-2-propenamide;
 ee) N-{3-cyano-4-[(3-methoxyphenyl)amino]-6-quinoliny}-2-butyramide;
 ff) N-{3-cyano-4-[(3-methoxyphenyl)amino]-6-quinoliny}-4-piperidino-2-butyramide;
 30 gg) 6-amino-4-[(3-methoxyphenyl)amino]-3-quinolinecarbonitrile;
 hh) 4-[(3-methoxyphenyl)amino]-6-nitro-3-quinolinecarbonitrile;
 ii) N-{4-[(3-chloro-4-fluoro-phenyl)amino]-3-cyano-6-quinoliny}-2-butyramide;
 jj) N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny}-2-propenamide;
 kk) N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny}-4-diethylamino-2-butenamide;
 35 ll) N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny}-4-morpholino-2-butenamide;
 mm) N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny}-2-morpholin-4-ylmethyl-2-propenamide;
 nn) 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-3-quinolinecarbonitrile;
 oo) 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-3-quinolinecarbonitrile;
 pp) N-{4-[(4-bromophenyl)amino]-3-cyano-6-quinoliny}-2-propenamide;
 40 qq) 6-amino-4-[(4-bromophenyl)amino]-3-quinolinecarbonitrile;
 rr) [(4-bromophenyl)amino]-6-nitro-3-quinolinecarbonitrile;
 ss) N-{3-cyano-4-[(3,4-difluorophenyl)amino]-6-quinoliny}-2-propenamide;
 tt) 6-amino-4-[(3,4-difluorophenyl)amino]-3-quinolinecarbonitrile;
 uu) 4-[(3,4-difluorophenyl)amino]-6-nitro-3-quinolinecarbonitrile;
 45 ww) N-{4-[(3-chloro-4-thiophenoxyphenyl)amino]-3-cyano-6-quinoliny}-2-butyramide;
 xx) 6-amino-4-[(3-chloro-4-thiophenoxyphenyl)amino]-3-quinolinecarbonitrile;
 yy) 4-[(3-chloro-4-thiophenoxyphenyl)amino]-6-nitro-3-quinolinecarbonitrile; or
 zz) N-{3-cyano-4-[(3-cyanophenyl)amino]-6-quinoliny}-2-propenamide; or a pharmaceutically acceptable salt thereof.

17. A compound according to claim 1 which is

- a) N-{3-cyano-4-[(3-cyanophenyl)amino]-6-quinoliny}-4-piperidino-2-butyramide;
 b) 6-amino-4-[(3-cyanophenyl)amino]-3-quinolinecarbonitrile;
 55 c) 4-[(3-cyanophenyl)amino]-6-nitro-3-quinolinecarbonitrile;
 d) N-{3-cyano-4-[(3-ethynylphenyl)amino]-6-quinoliny}-2-butyramide;
 e) N-{3-cyano-4-[(3-ethynylphenyl)amino]-6-quinoliny}-2-propenamide;
 f) N-{3-cyano-4-[(3-ethynylphenyl)amino]-6-quinoliny}-4-piperidino-2-butyramide;

g) 6-amino-4-[(3-ethynylphenyl)amino]-3-quinolinecarbonitrile;
h) 4-[(3-ethynylphenyl)amino]-6-nitro-3-quinolinecarbonitrile;
i) N-{4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-piperidino-2-butyramide;
j) N-{4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-dipropylamino-2-butyramide;
5 k) N-{4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-2-morpholin-4-ylmethyl-2-propenamide;
l) N-{4-[(3-bromo-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-2-butenamide;
m) N-{4-[(3-bromo-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-diethylamino-2-butenamide;
n) N-{4-[(3-bromo-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-morpholino-2-butenamide;
o) N-{4-[(3-bromo-4-fluorophenyl)amino]-3-cyano-7-methoxy-6-quinoliny]-4-morpholino-2-butenamide;
10 p) 4-[(3-bromophenyl)amino]-7-ethoxy-6-methoxy-3-quinolinecarbonitrile;
q) 7-ethoxy-4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-3-quinolinecarbonitrile;
r) N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-(z)-2-butenamide;
s) N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-methoxy-(z)-2-butenamide;
t) 4-[[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]amino]-2-methylene-4-oxo-butanoic acid;
15 u) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-diethylamino-2-butyramide;
v) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-(n-ethylpiperazino)-2-butyramide;
w) N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-diethylamino-2-butyramide;
x) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-(n-methylpiperazino)-2-butyramide;
y) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-(n-isopropyl-n-methylamino)-2-butyramide;
20 z) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinoliny]-4-diisopropylamino-2-butyramide;
aa) N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-2-butyramide;
bb) N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-methoxy-2-butyramide;
cc) 4-[(3-bromo-4-fluorophenyl)amino]-6-nitro-3-quinolinecarbonitrile;
dd) 6-amino-4-[(3-bromo-4-fluorophenyl)amino]-3-quinolinecarbonitrile;
25 ee) N-[4-[(3-bromo-4-fluorophenyl)amino]-3-cyano-6-quinoliny]-4-dimethylamino-2-butyramide;
ff) 4-diethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide;
gg) 4-morpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide;
hh) 4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-6-nitro-quinoline-3-carbonitrile;
ii) 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinoline-3-carbonitrile;
30 jj) 4-(3-bromo-4-fluoro-phenylamino)-7-methoxy-6-nitro-quinoline-3-carbonitrile;
kk) 6-amino-4-(3-bromo-4-fluoro-phenylamino)-7-methoxy-quinoline-3-carbonitrile;
ll) 4-diethylamino-but-2-enoic acid [4-(3-bromo-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide;
mm) 4-(3-bromo-phenylamino)-7-ethoxy-6-nitro-quinoline-3-carbonitrile;
35 nn) 6-amino-4-(3-bromo-phenylamino)-7-ethoxy-quinoline-3-carbonitrile;
oo) 4-bromo-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide;
pp) 4-morpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide;
qq) 6-amino-4-(3-bromo-phenylamino)-8-methoxy-quinoline-3-carbonitrile;
rr) 6-amino-4-(3-bromo-phenylamino)-8-methoxy-quinoline-3-carbonitrile;
40 ss) 4-bromo-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-8-methoxy-quinolin-6-yl]-amide;
tt) 4-dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-8-methoxy-quinolin-6-yl]-amide;
uu) 4-diethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-8-methoxy-quinolin-6-yl]-amide;
vv) 4-morpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-8-methoxy-quinolin-6-yl]-amide;
ww) 4-dimethylamino-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinol-6-yl]-amide;
45 xx) 4-(4-chloro-2-fluoro-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
yy) 4-(3-hydroxy-4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile; or
zz) 4-(3-dimethylamino-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile;

or a pharmaceutically acceptable salt thereof.

18. A compound according to claim 1 which is

a) 4-(3-hydroxy-4-methyl-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile;
b) 4-(4-chloro-2-fluoro-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile;
55 c) 4-(4-chloro-2-fluoro-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile;
d) 4-(3-hydroxy-4-methyl-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile;
e) 4-(3-bromo-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile;
f) 4-(3-bromo-phenylamino)-6,7,8-trimethoxy-quinoline-3-carbonitrile;

g) 4-(3-dimethylamino-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile;
 h) 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-5,8-dimethoxy-quinoline-3-carbonitrile;
 i) 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-6,7,8-trimethoxyquinoline-3-carbonitrile;
 j) 4-(3-hydroxy-2-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 5 k) 4-(2-hydroxy-6-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 l) 4-(3-bromo-4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 m) 4-(3-chloro-4-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 n) 6,7-dimethoxy-4-(2-methylsulfanyl-phenylamino)-quinoline-3-carbonitrile;
 o) 1,4-dihydroquinoline-6,7-diethoxy-4-oxo-3-carbonitrile;
 10 p) 4-[3-chloro-4-(phenylthio)phenylamino]-6,7-diethoxy-3-quinolinecarbonitrile;
 q) 4-[3-chloro-4-(phenylthio)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 r) 4-(3-chloro-4-fluorophenylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 s) 4-(3-acetylphenylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 t) 4-(n-methylphenylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 15 u) 4-(phenylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 v) 4-(4-fluorophenylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 w) 4-(4-fluoro-2-methylphenylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 x) 4-(3-chlorophenylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 y) 4-(3-fluorophenylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 20 z) 4-(3-aminophenylamino)-6,7-dimethoxy-3-quinolinecarbonitrile;
 aa) 4-(3-acetamidophenylamino)-6,7-dimethoxy-3-quinolinecarbonitrile;
 bb) 4-[3-(2-butyrylamino)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 cc) 4-[3-(hydroxymethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 dd) 4-[3-(chloromethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 25 ee) 4-[3-(acetylthiomethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 ff) 4-[3-(thiomethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile;
 gg) 4-[(3-bromophenyl)amino]-8-methoxy-3-quinolinecarbonitrile;
 hh) 4-(4-chloro-2-fluoro-phenylamino)-8-methoxy-quinoline-3-carbonitrile;
 ii) 4-(3-hydroxy-4-methyl-phenylamino)-8-methoxy-quinoline-3-carbonitrile;
 30 jj) 4-(3-dimethylamino-phenylamino)-8-methoxy-quinoline-3-carbonitrile;
 kk) 4-(4-bromo-3-hydroxy-phenylamino)-8-methoxy-quinoline-3-carbonitrile;
 ll) 4-(3-hydroxy-4-methoxy-phenylamino)-8-methoxy-quinoline-3-carbonitrile;
 mm) 8-methoxy-4-(2,4,6-trifluoro-phenylamino)-quinoline-3-carbonitrile;
 nn) 4-(3-hydroxy-4-methyl-phenylamino)-7-methoxy-quinoline-3-carbonitrile;
 35 oo) 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-7-methoxy-quinoline-3-carbonitrile;
 pp) 4-(4-chloro-2-fluoro-phenylamino)-6-methoxy-quinoline-3-carbonitrile;
 qq) 4-(3-hydroxy-4-methyl-phenylamino)-6-methoxy-quinoline-3-carbonitrile;
 rr) 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-6-methoxy-quinoline-3-carbonitrile;
 ss) 4-(3,5-dichloro-4-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 40 tt) 4-(2-hydroxy-4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 uu) 4-(4-hydroxy-3,5-dimethyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 vv) 4-(5-chloro-2-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 ww) 4-(3,5-dibromo-4-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 xx) 4-(4-hydroxy-2-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 45 yy) 6,7-dimethoxy-4-(pyridin-3-ylamino)-quinoline-3-carbonitrile; or
 zz) 6,7-dimethoxy-4-(3-methylsulfanyl-phenylamino)-quinoline-3-carbonitrile;

or a pharmaceutically acceptable salt thereof.

19. A compound according to claim 1 which is

a) 4-(2-hydroxy-5-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 b) 4-(2-chloro-4-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 c) 6,7-dimethoxy-4-(4-methylsulfanyl-phenylamino)-quinoline-3-carbonitrile;
 55 d) 4-[4-(2-hydroxy-ethyl)-phenylamino]-6,7-dimethoxy-quinoline-3-carbonitrile;
 e) 4-(2,4-dihydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 f) 4-[2-(2-hydroxy-ethyl)-phenylamino]-6,7-dimethoxy-quinoline-3-carbonitrile;
 g) 4-(3-bromophenylamino)-6,7-dihydroxy-3-quinolinecarbonitrile;

- h) 4-(3-bromophenylamino)-6,7-di-n-propoxy-3-quinolinecarbonitrile;
 i) 4-[(3-bromophenyl)-n-acetylamino]-6,7-dihydroxy-3-quinolinecarbonitrile;
 j) 4-(3-bromophenylamino)-6,7-di-n-butoxy-3-quinolinecarbonitrile ;
 k) 4-(4-chloro-2-fluorophenylamino)-7-methoxy-3-quinolinecarbonitrile;
 l) 4-(4-chloro-2-fluorophenylamino)-7-hydroxy-3-quinolinecarbonitrile;
 m) 4-[(4-chloro-2-fluorophenylamino)-n-acetylamino]-7-hydroxy-3-quinolinecarbonitrile;
 n) 4-(4-chloro-2-fluorophenylamino)-7-ethoxy-3-quinolinecarbonitrile;
 o) 4-[(3-bromophenyl)amino]-6,7-bis(2-methoxyethoxy)-3-quinolinecarbonitrile;
 p) 4-(2-aminophenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 q) 4-(3,4-difluorophenylmethylamino)-6,7-diethoxy-3-quinolinecarbonitrile;
 r) 4-methoxy-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide;
 s) 7-benzyloxy-4-(4-chloro-2-fluoro-phenylamino)-6-methoxy-quinoline-3-carbonitrile;
 t) 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-7-methoxy-6-(3-morpholin-4-yl)-propoxyl-quinoline-3-carbonitrile;
 u) N-[4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-3-chloro-(e) acrylamide;
 v) N-[4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-3-chloro-(z)-acrylamide;
 w) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinolinyl]-4-morpholino-2-butyramide;
 x) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinolinyl]-4-dimethylamino-2-butyramide;
 y) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinolinyl]-4-t-butyl dimethylsiloxy-2-butyramide;
 z) N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinolinyl]-4-hydroxy-2-butyramide;
 aa) 4-(3-hydroxymethyl-2-methylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile;
 bb) 4-(2-amino-4,5-dimethylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile;
 cc) 4-(4-ethylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile;
 dd) 4-(4-chloro-2-methylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile;
 ee) 6,7-dimethoxy-4-(3-phenoxyphenylamino)quinoline-3-carbonitrile;
 ff) 4-(4-chloro-3-trifluoromethylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile;
 gg) 4-(3-hydroxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 hh) 4-(4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 ii) 4-(3-hydroxy-4-methyl-phenylamino)-8-methoxy-6-nitro-quinoline-3-carbonitrile;
 jj) 4-(4-chloro-2-fluoro-phenylamino)-8-methoxy-6-nitro-quinoline-3-carbonitrile;
 kk) 4-(3-hydroxy-4-methoxy-phenylamino)-8-methoxy-6-nitro-quinoline-3-carbonitrile;
 ll) 6-amino-4-(3-hydroxy-4-methyl-phenylamino)-8-methoxy-quinoline-3-carbonitrile;
 mm) 6-amino-4-(3-hydroxy-4-methoxy-phenylamino)-8-methoxy-quinoline-3-carbonitrile;
 nn) N-[4-[(3-bromo-4-fluorophenyl)amino]-3-cyano-7-methoxy-6-quinolinyl]-4-bromo-2-butenamide;
 oo) N-[4-[(3-bromophenyl)amino]-3-cyano-7-methoxy-6-quinolinyl]-4-chloro-2-butenamide;
 pp) N-[3-cyano-4-[(3-iodophenyl)amino]-6-quinolinyl]-2-butyramide;
 qq) N-[3-cyano-4-[(3-methylphenyl)amino]-6-quinolinyl]-2-propenamide;
 rr) N-[4-[(4-bromophenyl)amino]-3-cyano-6-quinolinyl]-2-butyramide;
 ss) N-[4-[(3-chloro-4-thiophenoxyphenyl)amino]-3-cyano-6-quinolinyl]-2-propenamide;
 tt) N-[3-cyano-4-[(3,4-difluorophenyl)amino]-6-quinolinyl]-2-butyramide;
 uu) N-[4-[(3-chlorophenyl)amino]-3-cyano-6-quinolinyl]-2-butyramide;
 vv) N-[3-cyano-4-[(3-isopropylphenyl)amino]-6-quinolinyl]-2-butyramide;
 ww) N-[3-cyano-4-[(3-isopropylphenyl)amino]-6-quinolinyl]-2-propenamide;
 xx) 6-amino-4-[(3-isopropylphenyl)amino]-3-quinolinecarbonitrile;
 yy) 4-[(3-isopropylphenyl)amino]-6-nitro-3-quinolinecarbonitrile; or
 zz) 4-(3-bromo-phenylamino)-6-(3-pyrrolidin-1-yl-propylamino)-quinoline-3-carbonitrile;

or a pharmaceutically acceptable salt thereof.


20. A compound according to claim 1 which is

- a) 4-(3-azido-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 b) 6-amino-4-[(4-chloro-2-fluorophenyl)amino]-7-methoxy-3-quinolinecarbonitrile;
 c) 4-[(4-chloro-2-fluorophenyl)amino]-7-methoxy-6-nitro-3-quinolinecarbonitrile;
 d) 4-[(3-dichlorophenyl)amino]-6-nitro-3-quinolinecarbonitrile;
 e) 6-amino-4-[(3-methylsulfanylphenyl)amino]-3-quinolinecarbonitrile;
 f) 4-[(3-methylsulfanylphenyl)amino]-6-nitro-3-quinolinecarbonitrile;
 g) 4-[(3-trifluoromethoxyphenyl)amino]-6-nitro-3-quinolinecarbonitrile;

h) 4-(3-dimethylamino-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 i) 6,7-dimethoxy-4-(4-methoxy-2-methyl-phenylamino)-quinoline-3-carbonitrile;
 j) 4-(3-hydroxy-4-methoxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 k) 4-(3-chloro-4-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 l) 6,7-dimethoxy-4-(4-phenoxy-phenylamino)-quinoline-3-carbonitrile;
 m) 4-(5-chloro-2-methoxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 n) 3-(3-cyano-6,7-dimethoxy-quinolin-4-ylamino)-2-methyl-benzoic acid;
 o) 4-(4-chloro-2-fluoro-phenylamino)-6,7-dihydroxy-quinoline-3-carbonitrile;
 p) 4-(3-hydroxy-2-methyl-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 q) 4-(3-chloro-4-methoxy-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile;
 r) 6,7-dimethoxy-4-(4-trifluoromethyl-phenylamino)-quinoline-3-carbonitrile;
 s) 4-(3,4-dibromophenylamino)-6-nitroquinoline-3-carbonitrile;
 t) 6-amino-4-(3-trifluoromethylphenylamino)quinoline-3-carbonitrile;
 u) 6-amino-4-(3,4-dibromophenylamino)quinoline-3-carbonitrile;
 v) N-[3-cyano-4-(3,4-dibromophenylamino)quinolin-6-yl]acrylamide;
 w) N-[4-(3-bromophenylamino)-3-cyanoquinolin-6-yl]propionamide;
 x) (e)-but-2-enoic acid [4-(3-bromophenylamino)-3-cyanoquinolin-6-yl]amide;
 y) N-[4-(3-bromophenylamino)-3-cyanoquinolin-6-yl]-2-methylacrylamide;
 z) 4-(3-fluorophenylamino)-6-nitroquinoline-3-carbonitrile;
 aa) 6-amino-4-(3-fluorophenylamino)quinoline-3-carbonitrile;
 bb) 4-(3-dimethylaminophenylamino)-6-nitroquinoline-3-carbonitrile;
 cc) 4-(4-dimethylaminophenylamino)-6-nitroquinoline-3-carbonitrile;
 dd) 6-amino-4-(3-dimethylaminophenylamino)quinoline-3-carbonitrile;
 ee) 6-amino-4-(4-dimethylaminophenylamino)quinoline-3-carbonitrile;
 ff) but-2-ynoic acid [4-(3-fluorophenylamino)-3-cyanoquinolin-6-yl]amide;
 gg) N-[3-cyano-4-(3-dimethylaminophenylamino)quinolin-6-yl]acrylamide;
 hh) N-[3-cyano-4-(4-dimethylaminophenylamino)quinolin-6-yl]acrylamide;
 ii) but-2-ynoic acid [3-cyano-4-(3-dimethylaminophenylamino)quinolin-6-yl]amide;
 jj) but-2-ynoic acid [3-cyano-4-(4-dimethylaminophenylamino)quinolin-6-yl]amide;
 kk) 4-(3-bromophenylamino)-6-dimethylaminoquinoline-3-carbonitrile hydrochloride;
 ll) 6-dimethylamino-4-(3-methoxyphenylamino)quinoline-3-carbonitrile hydrochloride;
 mm) 2-bromo-n-[4-(3-bromophenylamino)-3-cyanoquinolin-6-yl]acetamide;
 nn) 6-iodo-4-(3-methoxyphenylamino)quinoline-3-carbonitrile;
 oo) 4-(4-hydroxy-2-methyl-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile;
 pp) 4-(3-bromo-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile;
 qq) 6-methoxy-4-(2-methylsulfonyl-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile; or
 rr) 4-(4-hydroxy-3,5-dimethyl-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile;

or a pharmaceutically acceptable salt thereof.

21. A compound of the formula



wherein:


X is phenyl ring which may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;

n is 0-1;

Y is -NH-;

R₁ and R₄ are hydrogen;

R₂ is



R₃ is hydrogen, alkoxy of 1-6 carbon atoms, or Z-(C(R₆)₂)_qY-;

R₆ is hydrogen or alkyl of 1-6 carbon atoms;

R₈ is hydrogen, alkyl of 1-6 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, or morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms;


Z is dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, or morpholino;

q= 1-4, and p= 0-3;

or a pharmaceutically acceptable salt thereof.

22. The compound according to claims 21 wherein X is phenyl optionally mono-, di-, or tri-substituted with halogen and q is 2-4.

23. A pharmaceutical composition which comprises a compound having the formula



wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxy-alkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino,






benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;



n is 0-1;

Y is -NH-, -O-, -S-, or -NR-;

R is alkyl of 1-6 carbon atoms;

R₁, R₂, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphanyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, aminoalkyl of 1-4 carbon atoms, N-alkylaminoalkyl of 2-7 carbon atoms, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino,





R_5 is alkyl of 1-6 carbon atoms, alkyl optionally substituted with one or more halogen atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, nitro, cyano, or alkyl of 1-6 carbon atoms groups;

R_6 is hydrogen, alkyl of 1-6 carbon atoms, or alkenyl of 2-6 carbon atoms;

R_7 is chloro or bromo ;

R_8 is hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, or bromo;


Z is amino, hydroxy, alkoxy of 1-6 carbon atoms, alkylamino wherein the alkyl moiety is of 1-6 carbon atoms, dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, morpholino, piperazino, N-alkylpiperazino wherein the alkyl moiety is of 1-6 carbon atoms, or pyrrolidino;

$m = 1-4$, $q = 1-3$, and $p = 0-3$;

any of the substituents R_1 , R_2 , R_3 , or R_4 that are located on contiguous carbon atoms can together be the divalent radical $-\text{O}-\text{C}(\text{R}_8)_2-\text{O}-$;

or a pharmaceutically acceptable salt thereof provided that when Y is $-\text{NH}-$, R_1 , R_2 , R_3 , and R_4 are hydrogen, and n is 0, then X is not 2-methylphenyl, and further provided that when Y is $-\text{NH}-$, R_1 , R_2 , and R_3 are hydrogen, R_4 is $\text{R}_5-\text{CONH}(\text{CH}_2)_p-$, R_5 is 2,6-dichlorophenyl, n is 1, and p is 0, then X is not pyridin-2-yl; and a pharmaceutically acceptable carrier.

24. A compound of Formula



wherein:





X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxy-alkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;




n is 0-1;

Y is -NH-, -O-, -S-, or -NR-;

R is alkyl of 1-6 carbon atoms;

R₁, R₂, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, aminoalkyl of 1-4 carbon atoms, N-alkylaminoalkyl of 2-7 carbon atoms, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino,





R₅ is alkyl of 1-6 carbon atoms, alkyl optionally substituted with one or more halogen atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, nitro, cyano, or alkyl of 1-6 carbon atoms groups;

R₆ is hydrogen, alkyl of 1-6 carbon atoms, or alkenyl of 2-6 carbon atoms;

R₇ is chloro or bromo

R₈ is hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, or bromo;

Z is amino, hydroxy, alkoxy of 1-6 carbon atoms, alkylamino wherein the alkyl moiety is of 1-6 carbon atoms, dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, morpholino, piperazino, N-alkylpiperazino wherein the alkyl moiety is of 1-6 carbon atoms, or pyrrolidino;

m = 1-4, q = 1-3, and p = 0-3;

any of the substituents R₁, R₂, R₃, or R₄ that are located on contiguous carbon atoms can together be the divalent radical -O-C(R₈)₂-O-;

or a pharmaceutically acceptable salt thereof, provided that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, then X is not 2-methylphenyl, and further provided that when Y is -NH-, R₁, R₂, and R₃ are hydrogen, R₄ is R₅-CONH(CH₂)_p-, R₅ is 2,6-dichlorophenyl, n is 1, and p is 0, then X is not pyridin-2-yl; for use as a therapeutic agent.

25. A compound of Formula 1 as defined in claim 24 for use in inhibiting the biological effects of a deregulated protein kinase in a mammal in need thereof.

26. A compound of Formula 1 as defined in claim 24 for use in treating, inhibiting the growth of, or eradicating a neoplasm in a mammal in need thereof.

27. A compound of Formula 1 as defined in claim 26 wherein the neoplasm expresses EGFR.

28. A compound of Formula 1 as defined in claim 26 wherein the neoplasm expresses MAPK.


29. A compound of Formula 1 as defined in claim 26 wherein the neoplasm expresses ECK.

30. A compound of Formula 1 as defined in claim 26 wherein the neoplasm expresses KDR.

31. A compound of Formula 1 as defined in claim 26 wherein the neoplasm is selected from the group consisting of breast, kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, and lung.

32. A compound of Formula 1 as defined in any of claim 24 for use in treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal.

33. Use of compound of the formula



wherein:








X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxy-alkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;

n is 0-1;

Y is -NH-, -O-, -S-, or -NR- ;

R is alkyl of 1-6 carbon atoms;

R₁, R₂, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, aminoalkyl of 1-4 carbon atoms, N-alkylaminoalkyl of 2-7 carbon atoms, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino,



R_5 is alkyl of 1-6 carbon atoms, alkyl optionally substituted with one or more halogen atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, nitro, cyano, or alkyl of 1-6 carbon atoms groups;

R₆ is hydrogen, alkyl of 1-6 carbon atoms, or alkenyl of 2-6 carbon atoms;

R₇ is chloro or bromo;

R₈ is hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, or bromo;


Z is amino, hydroxy, alkoxy of 1-6 carbon atoms, alkylamino wherein the alkyl moiety is of 1-6 carbon atoms, dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, morpholino, piperazino, N-alkylpiperazino wherein the alkyl moiety is of 1-6 carbon atoms, or pyrrolidino;

m= 1-4, q = 1-3, and p= 0-3;

any of the substituents R₁, R₂, R₃, or R₄ that are located on contiguous carbon atoms can together be the divalent radical -O-C(R₈)₂-O-;

or a pharmaceutically acceptable salt thereof, provided that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, then X is not 2-methylphenyl, and further provided that when Y is -NH-, R₁, R₂, and R₃ are hydrogen, R₄ is R₅-CONH(CH₂)_p-, R₅ is 2,6-dichlorophenyl, n is 1, and p is 0, then X is not pyridin-2-yl; in the preparation of a medicament for treating, inhibiting the growth of, or eradicating a neoplasm in a mammal in need thereof; or inhibiting the biological effects of a deregulated protein kinase in a mammal in need thereof.

34. Use of a compound of the formula



wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;







n is 0-1;


Y is -NH-, -O-, -S-, or -NR-;

R is alkyl of 1-6 carbon atoms;

R₁, R₂, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of

1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, aminoalkyl of 1-4 carbon atoms, N-alkylaminoalkyl of 2-7 carbon atoms, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino,





R₅ is alkyl of 1-6 carbon atoms, alkyl optionally substituted with one or more halogen atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, nitro, cyano, or alkyl of 1-6 carbon atoms groups;

R₆ is hydrogen, alkyl of 1-6 carbon atoms, or alkenyl of 2-6 carbon atoms;

R₇ is chloro or bromo;

R₈ is hydrogen, alkyl of 1-6 carbon atoms, amino alkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, or bromo;


Z is amino, hydroxy, alkoxy of 1-6 carbon atoms, alkylamino wherein the alkyl moiety is of 1-6 carbon atoms, dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, morpholino, piperazino, N-alkylpiperazino wherein the alkyl moiety is of 1-6 carbon atoms, or pyrrolidino;

m = 1-4, q = 1-3, and p = 0-3;

any of the substituents R₁, R₂, R₃, or R₄ that are located on contiguous carbon atoms can together be the divalent radical -O-C(R₈)₂-O-;


or a pharmaceutically acceptable salt thereof, provided that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, then X is not 2-methylphenyl; in the preparation of a medicament for use in treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal.

35. Process for the preparation of compounds of Formula




wherein Y and n are as defined in Claim 1 and X' is cycloalkyl or phenyl optionally substituted with one or more substituents selected from the group consisting of hydrogen, halogeno, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, halomethyl, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, trifluoromethyl, cyano, nitro, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, dialkylamino of 2 to 12 carbon atoms; R₁', R₂', R₃', and R₄' are each, independently, hydrogen, halogeno, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, trifluoromethyl, cyano, nitro, carboxy, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, alkoxyamino of 1-4 carbon atoms, dialkylamino of 2 to 12 carbon atom, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino, N-alkylcarbamoyl of 1-6 carbon atoms, N,N-dialkylcarbamoyl of 2-12 carbon atoms; or any of the substituents R₁', R₂', R₃', and R₄' that are located on contiguous carbon atoms can together be the divalent radical -O-C(R₈)₂-O-; provided that when Y is -NH-, R₁', R₂', R₃', and R₄' are hydrogen,


and n is 0, then X' is not 2-methylphenyl; comprising hydrolysing an acid ester of Formula 2



where R' is an alkyl radical containing 1-6 carbon atoms, with base to form the compound of Formula 3,




then converting the carboxylic acid group of Formula 3 to an acyl imidazole by heating it with carbonylimidazole in an inert solvent followed by the addition of ammonia to give the amide of Formula 4,




and further reacting with a dehydrating agent to provide the compound of Formula 5 above; and optionally thereafter forming a pharmaceutically acceptable salt thereof.


36. Process for the preparation of the compounds of Formula 10 or Formula 11





or




wherein Y, p, and n are as defined in Claim 1 and X" is selected from the group consisting of cycloalkyl or phenyl optionally substituted with one or more substituents selected from the group consisting of hydrogen, halogeno, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino, R₉ is independently hydrogen, phenyl, or alkyl of 1-6 carbon atoms, the moieties (R₁₀)_k represent 1 to 3 substituents on the aromatic ring that can be the same or different and are selected independently from the group hydrogen, halogeno, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphanyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, trifluoromethyl, cyano, nitro, carboxy, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, alkoxyamino of 1-4 carbon atoms, dialkylamino of 2 to 12 carbon atom, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino, N-alkylcarbamoyl of 1-6 carbon atoms, N,N-dialkylcarbamoyl of 2-12 carbon atoms. R₁₁ is a radical and is selected from the group:





20


wherein q, m, R₅, R₆, R₇, and R₈ are as defined in Claim 1; which comprises acylation of the compound of Formula 6



35

40

with either an acid chloride of Formula 8 or a mixed anhydride of Formula 9 where R''' is alkyl from 1 to 6 carbon atoms




50

in the presence of an organic base to give the compound of Formula 11; or alternately, acylation of the compound of Formula 6 with a cyclic anhydride of Formula 7




in the presence of a basic catalyst to provide the compound of Formula 10; and optionally thereafter forming a pharmaceutically acceptable salt thereof.


37. Process for the preparation of the compounds Formula 18




X, Y, n are as defined in Claim 1 and R₁', R₂', R₃', and R₄' are as defined in Claim 35, provided that when Y is -NH-, R₁', R₂', R₃', and R₄' are hydrogen, and n is 0, then X is not 2-methylphenyl; which comprises heating a substituted aniline of Formula 12




with a reagent of Formula 13




to give a compound of Formula 14




which is then thermolysed in a high boiling solvent to give a compound of Formula 15;



then heating the compound of Formula 15 with a chlorinating agent to give a compound of Formula 16



which is condensed with a compound of Formula 17




30

to provide the compounds of Formula 18; and optionally thereafter forming a pharmaceutically acceptable salt thereof.


35

38. Process for the preparation of compound of Formula 15




50

in which R₁', R₂', R₃' and R₄' are as defined in claim 35 comprising heating the compound of Formula 19




15 with dimethylformamide dimethyl acetal to give a compound of Formula 20



which is then reacted with acetonitrile in the presence of a base gives the compounds of Formula 15.

- 30 **39.** Process for the preparation of compounds of Formula 22 wherein R_1 , R_2 , R_3 , R_4 and n are as defined in Claim 1 and X' is defined in Claim 35:



which comprises:

- 50 where one or more of R_1 , R_2 , R_3 , or R_4 is a nitro group, converting to the corresponding amino group using a reducing agent;
 where one or more of R_1 , R_2 , R_3 , or R_4 is an amino group, converting to the corresponding dialkylamino group of 2 to 12 carbon atoms by alkylation with an alkyl halide of 1 to 6 carbon atoms;
 55 where one or more of R_1 , R_2 , R_3 , or R_4 is a methoxy group, converting to the corresponding hydroxy group by reaction with a demethylating agent or pyridinium chloride;
 where one or more of R_1 , R_2 , R_3 , or R_4 is an amino group, converting to the corresponding alkylsulfonamido, alkenylsulfonamido, or alkynylsulfonamido group of 2 to 6 carbon atoms by the reaction with an alkylsulfonyl chloride, alkenylsulfonyl chloride, or alkynylsulfonyl chloride, respectively, using a basic catalyst;

when one or more of R_1 , R_2 , R_3 , or R_4 is an amino group, converting to the corresponding alkenylsulfonamido group by reaction with a reagent $C_1-C(R'_6)_2-CH(R'_6)SO_2Cl$, wherein R'_6 is hydrogen or alkyl of 1-4 carbon atoms using an excess of an organic base;

where two of R_1 , R_2 , R_3 , or R_4 are contiguous methoxy groups, converting to the compound with contiguous hydroxy groups by reaction with a demethylating agent or by heating with pyridinium chloride;

where two of R_1 , R_2 , R_3 , or R_4 are contiguous hydroxy groups, converting to the compound where together the two contiguous R_1 , R_2 , R_3 , or R_4 groups are the divalent radical $-O-C(R_8)_2-O-$ wherein R_8 is defined in Claim 1 by the reaction with $J-C(R_8)_2-J$, wherein J is chloro, bromo, or iodo, and each J can be the same or different, using a base;

where one or more of R_1 , R_2 , R_3 , or R_4 is an amino group, converting to the corresponding alkyamino group of 1 to 6 carbon atoms by alkylation with alkyl halide of 1 to 6 carbon atoms or by reductive alkylation using an aldehyde of 1 to 6 carbon atoms and a reducing agent;

where one or more of R_1 , R_2 , R_3 , or R_4 is hydroxy, converting to the corresponding alkanoyloxy group of 1-6 carbon atoms by reaction with an appropriate carboxylic acid chloride, anhydride, or mixed anhydride in an inert solvent with a catalyst;

where one or more of R_1 , R_2 , R_3 , or R_4 is hydroxy, converting to the corresponding alkenoyloxy group of 1-6 carbon atoms by reaction with an appropriate carboxylic acid chloride, anhydride, or mixed anhydride in an inert solvent with a catalyst;


where one or more of R_1 , R_2 , R_3 , or R_4 is hydroxy, it can be converted to the corresponding alkynoyloxy group of 1-6 carbon atoms by reaction with an appropriate carboxylic acid chloride, anhydride, or mixed anhydride in an inert solvent with a catalyst;

where one or more of R_1 , R_2 , R_3 , or R_4 is carboxy or a carboalkoxy group of 2-7 carbon atoms, converting to the corresponding hydroxymethyl group by reduction with a reducing agent; optionally converting the hydroxymethyl group to the corresponding halomethyl group by reaction with a halogenating reagent; or optionally acylating the hydroxymethyl group with an acid chloride, anhydride, or mixed anhydride in an inert solvent with a catalyst to give the corresponding alkanoyloxymethyl group of 2-7 carbon atoms, alkenoyloxymethyl group of 2-7 carbon atoms, or alkynoyloxymethyl group of 2-7 carbon atoms;

where one or more of R_1 , R_2 , R_3 , or R_4 is a halomethyl group, converting to an alkoxymethyl group of 2-7 carbon atoms by displacing the halogen atom with a sodium alkoxide in an inert solvent;


where one or more of R_1 , R_2 , R_3 , or R_4 is a halomethyl group, converting to an aminomethyl group, N-alkylaminomethyl group of 2-7 carbon atoms or N,N-dialkylaminomethyl group of 3-14 carbon atoms by displacing the halogen atom with ammonia, a primary, or secondary amine, respectively, in an inert solvent;

where one or more of R_1 , R_2 , R_3 , or R_4 is a $H_2N(CH_2)_p-$ group, converting to the corresponding groups:




wherein R_5 and p are as defined in Claim 1 by reacting with phosgene in an inert solvent in the presence of a base to give an isocyanate which is treated with an excess of the alcohol R_5-OH or amines R_5-NH_2 or $(R_5)_2NH$, respectively;

where one or more of R_1 , R_2 , R_3 , or R_4 is a $HO-(CH_2)_p-$ group, converting to the corresponding groups:



wherein R_5 and p are as defined above by reaction, in an inert solvent using a basic catalyst with an appropriate alkyl or phenyl chloroformate, $R_5-OCOCl$, alkyl or phenyl substituted isocyanate, $R_5-N=C=O$, or alkyl or phenyl substituted carboxylic acid chloride, R_5-COCl , respectively;


where one or more of R_1 , R_2 , R_3 , or R_4 is a $HO-(CH_2)_p-$ group, converting to the corresponding group:



wherein R_5 and p are as defined above by reaction, in an inert solvent using a basic catalyst with a reagent $(R_5)_2NCOCl$.

Patentansprüche

1. Verbindung der Formel



worin:

X für Cycloalkyl mit 3 bis 7 Kohlenstoffatomen steht, welches gegebenenfalls substituiert sein kann mit einem oder mehreren Alkyl mit 1 bis 6 Kohlenstoffatomgruppen; oder einen Pyridinyl-, Pyrimidinyl- oder Phenylring darstellt; wobei der Pyridinyl-, Pyrimidinyl- oder Phenylring gegebenenfalls mono-, di- oder trisubstituiert sein kann mit einem Substituenten, ausgewählt aus der Gruppe bestehend aus Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Azido, Hydroxyalkyl mit 1-6 Kohlenstoffatomen, Halogenmethyl, Alkoxyethyl mit 2-7 Kohlenstoffatomen, Alkanoyloxyethyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Hydroxy, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzoyl, Benzyl, Amino, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Phenylamino, Benzylamino, Alkanoylamino mit 1-6 Kohlenstoffatomen, Alkanoylamino mit 3-8 Kohlenstoffatomen, Alkinoyl mit 3-8 Kohlenstoffatomen und Benzoylamino;







n 0-1 ist;


Y für -NH-, -O-, -S- oder -NR- steht;

R für Alkyl mit 1-6 Kohlenstoffatomen steht;

R_1 , R_2 , R_3 und R_4 jeweils unabhängig Wasserstoff, Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Alkenyloxy mit 2-6 Kohlenstoffatomen, Alkinyloxy mit 2-6 Kohlenstoffatomen, Hydroxymethyl, Halogenmethyl, Alkanoyloxy mit 1-6 Kohlenstoffatomen, Alkenoyloxy mit 3-8 Kohlenstoffatomen, Alkinoyloxy mit 3-8 Kohlenstoffatomen, Alkanoyloxyethyl mit 2-7 Kohlenstoffatomen, Alkenoyloxyethyl mit 4-9 Kohlenstoffatomen, Alkinoyloxyethyl mit 4-9 Kohlenstoffatomen, Alkoxy-methyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Alkylsulfonil mit 1-6 Kohlenstoffatomen, Alkylsulfonil mit 1-6 Kohlenstoffatomen, Alkylsulfonamido mit 1-6 Kohlenstoffatomen, Alkenylsulfonamido mit 2-6 Kohlenstoffatomen, Alkylsulfonamido mit 2-6 Kohlenstoffatomen, Hydroxy, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzyl, Amino, Hydroxyamino, Alkoxyamino mit 1-4 Kohlenstoffatomen, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Aminoalkyl mit 1-4 Kohlenstoffatomen, N-Alkylaminoalkyl mit 2-7 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit

3-14 Kohlenstoffatomen, Phenylamino, Benzylamino,





darstellt,

R_5 Alkyl mit 1-6 Kohlenstoffatomen, Alkyl gegebenenfalls substituiert mit einem oder mehreren Halogenatomen, Phenyl oder Phenyl, gegebenenfalls substituiert mit einem oder mehreren Halogenen, Alkoxy mit 1-6 Kohlenstoffatomen, Trifluormethyl, Amino, Nitro, Cyano oder Alkyl mit 1-6 Kohlenstoffatomgruppen darstellt; R_6 Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen oder Alkenyl mit 2-6 Kohlenstoffatomen darstellt;

R_7 Chlor oder Brom darstellt;

R_8 Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen, Aminoalkyl mit 1-6 Kohlenstoffatomen, N-Alkylaminoalkyl mit 2-9 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-12 Kohlenstoffatomen, N-Cycloalkylaminoalkyl mit 4-12 Kohlenstoffatomen, N-Cycloalkyl-N-alkylaminoalkyl mit 5-18 Kohlenstoffatomen, N,N-Dicycloalkylaminoalkyl mit 7-18 Kohlenstoffatomen, Morpholino-N-Alkyl, worin die Alkylgruppe 1-6 Kohlenstoffatome hat, Piperidino-N-alkyl, worin die Alkylgruppe 1-6 Kohlenstoffatome hat, N-Alkyl-piperidino-N-alkyl, worin jede Alkylgruppe 1-6 Kohlenstoffatome hat, Azacycloalkyl-N-alkyl mit 3-11 Kohlenstoffatomen, Hydroxyalkyl mit 1-6 Kohlenstoffatomen, Alkoxyalkyl mit 2-8 Kohlenstoffatomen, Carboxy, Carboalkoxy mit 1-6 Kohlenstoffatomen, Phenyl, Carboalkyl mit 2-7 Kohlenstoffatomen, Chlor, Fluor oder Brom darstellt;

Z Amino, Hydroxy, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylamino, worin die Alkylkomponente aus 1-6 Kohlenstoffatomen besteht, Dialkylamino, worin jede der Alkylkomponenten aus 1-6 Kohlenstoffatomen besteht, Morpholino, Piperazino, N-Alkylpiperazino, worin die Alkylkomponente aus 1-6 Kohlenstoffatomen besteht, oder Pyrrolidino darstellt;

$m = 1-4$, $q = 1-3$ und $p = 0-3$;

jede der Substituenten R_1 , R_2 , R_3 oder R_4 , die sich an benachbarten Kohlenstoffatomen befinden, zusammen den bivalenten Rest $-\text{O}-\text{C}(\text{R}_6)_2-\text{O}-$ darstellen können;

oder ein pharmazeutisch annehmbares Salz davon, vorausgesetzt, dass wenn Y für -NH- steht, R_1 , R_2 , R_3 und R_4 Wasserstoff darstellen und $n = 0$ ist, X nicht für 2-Methylphenyl steht, und ferner vorausgesetzt, dass wenn Y für -NH- steht, R_3 Chlor darstellt, R_1 , R_2 und R_4 Wasserstoff darstellen und $n = 0$ ist, X nicht für Phenyl oder 3-Chlorphenyl steht und ferner vorausgesetzt, dass wenn Y für -NH- steht, R_1 , R_2 und R_3 Wasserstoff darstellen, R_4 für $\text{R}_5-\text{CONH}(\text{CH}_2)_p-$ steht, R_5 für 2,6-Dichlorphenyl steht, $n = 1$ ist und $p = 0$ ist, X nicht für Pyridin-2-yl steht.

2. Verbindung gemäß Anspruch 1, worin Y für -NH- steht und $n = 0$ oder ein pharmazeutisch annehmbares Salz davon.

3. Verbindung gemäß Anspruch 2, worin X gegebenenfalls substituiertes Phenyl darstellt, oder ein pharmazeutisch annehmbares Salz davon.

4. Verbindung gemäß Anspruch 3, worin R_1 und R_4 Wasserstoff darstellen, oder ein pharmazeutisch annehmbares Salz davon.

5. Verbindung gemäß Anspruch 1, welche 4-[(3-Bromphenyl)amino]-6,7-diethoxy-3-chinolincarbonitril ist, oder ein pharmazeutisch annehmbares Salz davon.

6. Verbindung gemäß Anspruch 1, welche 4-Dimethylamino-but-2-ensäure-[4-(3-chlor-4-fluor-phenylamino)-3-cyano-7-methoxy-chinolin-6-yl]-amid ist, oder ein pharmazeutisch annehmbares Salz davon.

7. Verbindung gemäß Anspruch 1, welche 4-Diethylamino-but-2-ensäure-[4-(3-chlor-4-fluor-phenylamino)-3-cyano-7-methoxy-chinolin-6-yl]-amid ist, oder ein pharmazeutisch annehmbares Salz davon.

8. Verbindung gemäß Anspruch 1, welche 4-Dimethylamino-but-2-ensäure-[4-(3-brom-4-fluor-phenylamino)-3-cyano-7-methoxy-chinolin-6-yl]-amid ist, oder ein pharmazeutisch annehmbares Salz davon.

9. Verbindung gemäß Anspruch 1, welche 4-Dimethylamino-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-7-ethoxy-chinolin-6-yl]-amid ist, oder ein pharmazeutisch annehmbares Salz davon.

10. Verbindung gemäß Anspruch 1, welche 4-Diethylamino-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-7-ethoxy-chinolin-6-yl]-amid ist, oder ein pharmazeutisch annehmbares Salz davon.

11. Verbindung gemäß Anspruch 1, welche 4-Morpholin-4-yl-but-2-ensäure-[4-(3-chlor-4-fluor-phenylamino)-3-cyano-7-methoxy-chinolin-6-yl]-amid ist, oder ein pharmazeutisch annehmbares Salz davon.

12. Verbindung gemäß Anspruch 1, welche 4-Dimethylamino-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-7-methoxy-chinolin-6-yl]-amid ist, oder ein pharmazeutisch annehmbares Salz davon.

13. Verbindung gemäß Anspruch 1, welche N-[4-[(3-Bromphenyl)-amino]-3-cyano-6-chinoliny]-4-methoxy-2-butanamid ist, oder ein pharmazeutisch annehmbares Salz davon.

14. Verbindung gemäß Anspruch 1, welche N-[4-[(3-Chlor-4-fluorphenyl)-amino]-3-cyano-6-chinoliny]-4-dimethylamino-2-butanamid ist, oder ein pharmazeutisch annehmbares Salz davon.

15. Verbindung gemäß Anspruch 1, welche ist:

- a) 4-[(3-Bromphenyl)amino]-7-methoxy-3-chinolincarbonitril;
- b) 4-[(3-Bromphenyl)amino]-7-methoxy-6-nitro-3-chinolincarbonitril;
- c) 6-Amino-4-[(3-bromphenyl)amino]-7-methoxy-3-chinolincarbonitril;
- d) N-[4-[(3-Bromphenyl)amino]-3-cyano-7-methoxy-6-chinoliny]-2-butanamid;
- e) N-[4-[(3-Bromphenyl)amino]-3-cyano-7-methoxy-6-chinoliny]-2-propenamid;
- f) 4-[(3-Bromphenyl)amino]-6-nitro-3-chinolincarbonitril;
- g) 6-Amino-4-[(3-bromphenyl)amino]-3-chinolincarbonitril;
- h) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-2-butanamid;
- i) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]acetamid;
- j) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]butanamid;
- k) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-2-propenamid;
- l) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-2-chloracetamid;
- m) 4-[(3,4-Dibromphenyl)amino]-6-nitro-3-chinolincarbonitril;
- n) 6-Amino-4-[(3,4-dibromphenyl)amino]-3-chinolincarbonitril;
- o) N-[4-[(3,4-Dibromphenyl) amino]-3-cyano-6-chinoliny]-2-butanamid;
- p) 6-Nitro-4-[(3-trifluormethylphenyl) amino]-3-chinolincarbonitril;
- q) 6-Amino-4-[(3-trifluormethylphenyl)amino]-3-chinolincarbonitril;
- r) N-[4-[(3-Trifluormethylphenyl)amino]-3-cyano-6-chinoliny]-2-butanamid;
- s) 4-[(3-Bromphenyl)amino]-6,7-dimethoxy-3-chinolincarbonitril;
- t) 4-[(3-Fluorphenyl)amino]-6,7-dimethoxy-3-chinolincarbonitril;
- u) 4-(Cyclohexylamino)-6,7-dimethoxy-3-chinolincarbonitril;
- v) 4-[(3-Bromphenyl)amino]-6,7-dihydroxy-3-chinolincarbonitril;
- w) 8-[(3-Bromphenyl)amino]-[1,3]-dioxolo[4,5-g]chinolin-7-carbonitril;
- x) 4-[(3-Chlorphenyl)amino]-6,7-dimethoxy-3-chinolincarbonitril;
- y) 4-[(3-Trifluormethylphenyl)amino]-6,7-dimethoxy-3-chinolincarbonitril;
- z) 4-[(3,4-Dimethoxyphenyl)amino]-6,7-dimethoxy-3-chinolincarbonitril;
- aa) 4-[(Methylphenyl)amino]-6,7-dimethoxy-3-chinolincarbonitril;
- bb) 4-[(3-Cyanophenyl)amino]-6,7-dimethoxy-3-chinolincarbonitril;
- cc) 4-[(4-Fluorphenyl)amino]-6,7-dimethoxy-3-chinolincarbonitril;
- dd) 4-[(3-(Hydroxymethyl)phenyl)amino]-6,7-dimethoxy-3-chinolincarbonitril;
- ee) 4-(3-Bromphenoxy)-6,7-dimethoxy-3-chinolincarbonitril;
- ff) 4-[(4-Bromphenyl)sulfanyl]-6,7-dimethoxy-3-chinolincarbonitril
- gg) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-3(E)-chlor-2-propenamid;
- hh) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-3(Z)-chlor-2-propenamid;
- ii) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-2-methyl-2-propenamid;
- jj) N-[4-[(3,4-Dibromphenyl)amino]-3-cyano-6-chinoliny]-2-propenamid;
- kk) N-[4-[(5-Brom-3-pyridinyl)amino]-6,7-dimethoxy-3-chinolincarbonitril;
- ll) 4-[(3-Bromphenyl)amino]-6,7-bis(methoxymethoxy)-3-chinolincarbonitril;
- mm) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-hydroxy-2-butanamid;
- nn) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-morpholino-2-butanamid;
- oo) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-dimethylamino-2-butanamid;

pp) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-methoxy-2-butanamid;
 qq) 4-(3-Bromphenylmethylamino)-6,7-diethoxy-3-chinolincarbonitril;
 rr) 4-(3-Phenylmethylamino)-6,7-diethoxy-3-chinolincarbonitril;
 ss) 4-(3,4-Dimethoxyphenylmethylamino)-6,7-diethoxy-3-chinolincarbonitril;
 5 tt) 4-(3,4-Dichlorphenylmethylamino)-6,7-diethoxy-3-chinolincarbonitril;
 uu) 4-Methoxy-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-chinolin-6-yl]-amid;
 vv) 4-(4-Chlor-2-fluor-phenylamino)-7-(3-chlor-propoxy)-6-methoxy-chinolin-3-carbonitril;
 ww) 4-(4-Chlor-2-fluor-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-chinolin-3-carbonitril;
 xx) 7-(2-Dimethylamino-ethoxy)-4-(3-hydroxy-4-methyl-phenylamino)-6-methoxy-chinolin-3-carbonitril;
 10 yy) 4-(3-Hydroxy-4-methyl-phenylamino)-6-methoxy-7-(2-morpholin-4-yl-ethoxy)-chinolin-3-carbonitril; oder
 zz) 4-(4-Chlor-2-fluor-5-hydroxy-phenylamino)-7-(3-dimethylamino-propoxy)-6-methoxy-chinolin-3-carbonitril;

oder ein pharmazeutisch annehmbares Salz davon.

16. Verbindung gemäß Anspruch 1, welche ist:

- a) 4-(4-Chlor-2-fluor-5-hydroxy-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-chinolin-3-carbonitril;
 b) 4-(4-Chlor-2-fluor-5-hydroxy-phenylamino)-7-(2-dimethylamino-ethoxy)-6-methoxy-chinolin-3-carbonitril;
 20 c) 4-(4-Chlor-2-fluor-5-hydroxy-phenylamino)-6-methoxy-7-(2-morpholin-4-yl-ethoxy)-chinolin-3-carbonitril;
 d) N-[3-Cyano-4-(3-fluorphenylamino)chinolin-6-yl]acrylamid;
 e) 6,7-Dimethoxy-4-(3-nitrophenylamino)chinolin-3-carbonitril;
 f) 4-(3-Bromphenylamino)-6-ethoxy-7-methoxychinolin-3-carbonitril;
 g) 6-Ethoxy-4-(3-hydroxy-4-methylphenylamino)-7-methoxychinolin-3-carbonitril;
 25 h) 4-Dimethylamino-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-chinolin-6-yl]-amid;
 i) 4-Diethylamino-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-chinolin-6-yl]-amid;
 j) 4-Methylamino-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-chinolin-6-yl]-amid;
 k) 4-[(3-Bromphenyl)amino]-8-methyl-6-nitro-3-chinolincarbonitril ;
 l) 4-[(3-Bromphenyl)amino]-8-dimethylaminomethyl-6-nitro-3-chinolincarbonitril;
 30 m) 6-Amino-4-[(3-bromphenyl)amino]-8-dimethylaminomethyl-3-chinolincarbonitril;
 n) N-[4-[(3-Bromphenyl)amino]-3-cyano-8-dimethylaminomethyl-6-chinoliny]-2-butanamid;
 o) N-[4-[(3-Bromphenyl)amino]-3-cyano-8-dimethylaminomethyl-6-chinoliny]-2-propenamid;
 p) N-[4-[(3-Bromphenyl)amino]-3-cyano-8-dimethylaminomethyl-6-chinoliny]acetamid;
 q) 4-[(3-Chlor-4-fluorphenyl)amino]-7-methoxy-6-(morpholinopropoxy)-3-chinolincarbonitril;
 35 r) 4-[(3-Bromphenyl)amino]-7-methoxy-6-(morpholinopropoxy)-3-chinolincarbonitril;
 s) 4-[(4-Chlor-2-fluorphenyl)amino]-7-methoxy-6-(morpholinopropoxy) -3-chinolincarbonitril;
 t) 4-[(3-Hydroxy-4-methylphenyl)amino]-7-methoxy-6-(morpholinopropoxy) -3-chinolincarbonitril;
 u) N-[3-Cyano-4-[(3-iodphenyl)amino]-6-chinoliny]-2-propenamid;
 v) 6-Amino-4-[(3-iodphenyl)amino]-3-chinolincarbonitril;
 40 w) 4-[(3-iodphenyl)amino]-6-nitro-3-chinolincarbonitril;
 x) N-[3-Cyano-4-[(3-methylphenyl)amino]-6-chinoliny]-2-butanamid;
 y) 6-Amino-4-[(3-methylphenyl)amino]-3-chinolincarbonitril;
 z) 6-Nitro-4-[(3-methylphenyl)amino]-3-chinolincarbonitril;
 aa) N-[4-[(3-Chlorphenyl)amino]-3-cyano-6-chinoliny]-2-propenamid;
 45 bb) 6-Amino-4-[(3-chlorphenyl)amino]-3-chinolincarbonitril;
 cc) 4-[(3-Chlorphenyl)amino]-6-nitro-3-chinolincarbonitril;
 dd) N-[3-Cyano-4-[(3-methoxyphenyl)amino]-6-chinoliny]-2-propenamid;
 ee) N-[3-Cyano-4-[(3-methoxyphenyl)amino]-6-chinoliny]-2-butanamid;
 ff) N-[3-Cyano-4-[(3-methoxyphenyl)amino]-6-chinoliny]-4-piperidino-2-butanamid;
 50 gg) 6-Amino-4-[(3-methoxyphenyl)amino]-3-chinolincarbonitril;
 hh) 4-[(3-Methoxyphenyl)amino]-6-nitro-3-chinolincarbonitril;
 ii) N-[4-[(3-Chlor-4-fluor-phenyl)amino]-3-cyano-6-chinoliny]-2-butanamid;
 jj) N-[4-[(3-Chlor-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-2-propenamid;
 kk) N-[4-[(3-Chlor-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-diethylamino-2-butanamid;
 55 ll) N-[4-[(3-Chlor-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-morpholino-2-butanamid;
 mm) N-[4-[(3-Chlor-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-2-morpholin-4-ylmethyl-2-propenamid;
 nn) 6-Amino-4-[(3-chlor-4-fluorphenyl)amino]-3-chinolincarbonitril;
 oo) 4-[(3-Chlor-4-fluorphenyl)amino]-6-nitro-3-chinolincarbonitril;

pp) N-{4-[(4-Bromphenyl)amino]-3-cyano-6-chinoliny]-2-propenamid;
 qq) 6-Amino-4-[(4-bromphenyl)amino]-3-chinolincarbonitril;
 rr) [(4-Bromphenyl)amino]-6-nitro-3-chinolincarbonitril;
 ss) N-{3-Cyano-[(3,4-difluorphenyl) amino]-6-chinoliny]-2-propenamid;
 5 tt) 6-Amino-4-[(3,4-difluorphenyl)amino]-3-chinolincarbonitril;
 uu) 4-[(3,4-Difluorphenyl) amino]-6-nitro-3-chinolincarbonitril;
 ww) N-{4-[(3-chlor-4-thiophenoxyphenyl)amino]-3-cyano-6-chinoliny]-2-butanamid;
 xx) 6-Amino-4-[(3-chlor-4-thiophenoxyphenyl)amino]-3-chinolincarbonitril;
 yy) 4-[(3-Chlor-4-thiophenoxyphenyl)amino]-6-nitro-3-chinolincarbonitril; oder
 10 zz) N-{3-Cyano-4-[(3-cyanophenyl)amino]-6-chinoliny]-2-propenamid;

oder ein pharmazeutisch annehmbares Salz davon.

17. Verbindung gemäß Anspruch 1, welche ist:

15 a) N-{3-Cyano-4-[(3-cyanophenyl)amino]-6-chinoliny]-4-piperidino-2-butanamid;
 b) 6-Amino-4-[(3-cyanophenyl)amino]-3-chinolincarbonitril;
 c) 4-[(3-Cyanophenyl)amino]-6-nitro-3-chinolincarbonitril;
 d) N-{3-Cyano-4-[(3-ethinylphenyl)amino]-6-chinoliny]-2-butanamid;
 20 e) N-{3-Cyano-4-[(3-ethinylphenyl)amino]-6-chinoliny]-2-propenamid;
 f) N-{3-Cyano-4-[(3-ethinylphenyl)amino]-6-chinoliny]-4-piperidino-2-butanamid;
 g) 6-Amino-4-[(3-ethinylphenyl)amino]-3-chinolincarbonitril;
 h) 4-[(3-Ethinylphenyl)amino]-6-nitro-3-chinolincarbonitril;
 i) N-{4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-piperidino-2-butanamid;
 25 j) N-{4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-dipropylamino-2-butanamid;
 k) N-{4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-2-morpholin-4-ylmethyl-2-propenamid;
 l) N-{4-[(3-Brom-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-dimethylamino-2-butanamid;
 m) N-{4-[(3-Brom-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-diethylamino-2-butanamid;
 n) N-{4-[(3-Brom-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-morpholin-2-butanamid;
 30 o) N-{4-[(3-Brom-4-fluorphenyl)amino]-3-cyano-7-methoxy-6-chinoliny]-4-morpholin-2-butanamid;
 p) 4-[(3-Bromphenyl)amino]-7-ethoxy-6-methoxy-3-chinolincarbonitril;
 q) 7-Ethoxy-4-[(3-hydroxy-4-methylphenyl)-amino]-6-methoxy-3-chinolincarbonitril;
 r) N-{4-[(3-Chlor-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-dimethylamino-(z)-2-butanamid;
 s) N-{4-[(3-Chlor-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-methoxy-(z)-2-butanamid;
 35 t) 4-[[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]amino]-2-methylen-4-oxo-butansäure;
 u) N-{4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-diethylamino-2-butanamid;
 v) N-{4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-(n-ethylpiperazino)-2-butanamid;
 w) N-{4-[(3-Chlor-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-diethylamino-2-butanamid;
 x) N-{4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-(n-methylpiperazino)-2-butanamid;
 40 y) N-{4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-(n-isopropyl-n-methylamino)-2-butanamid;
 z) N-{4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-diisopropylamino-2-butanamid;
 aa) N-{4-[(3-Chlor-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-dimethylamino-2-butanamid;
 bb) N-{4-[(3-Chlor-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-methoxy-2-butanamid;
 cc) 4-[(3-Brom-4-fluorphenyl)amino]-6-nitro-3-chinolincarbonitril;
 45 dd) 6-Amino-4-[(3-brom-4-fluorphenyl)amino]-3-chinolincarbonitril;
 ee) N-{4-[(3-Brom-4-fluorphenyl)amino]-3-cyano-6-chinoliny]-4-dimethylamino-2-butanamid;
 ff) 4-Diethylamino-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-7-methoxy-chinolin-6-yl]-amid;
 gg) 4-Morpholin-4-yl-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-7-methoxy-chinolin-6-yl]-amid;
 hh) 4-(3-Chlor-4-fluor-phenylamino)-7-methoxy-6-nitro-chinolin-3-carbonitril;
 50 ii) 6-Amino-4-(3-chlor-4-fluor-phenylamino)-7-methoxy-chinolin-3-carbonitril;
 jj) 4-(3-Brom-4-fluor-phenylamino)-7-methoxy-6-nitro-chinolin-3-carbonitril;
 kk) 6-Amino-4-(3-brom-4-fluor-phenylamino)-7-methoxy-chinolin-3-carbonitril;
 ll) 4-Diethylamino-but-2-ensäure-[4-(3-brom-4-fluor-phenylamino)-3-cyano-7-methoxy-chinolin-6-yl]-amid;
 mm) 4-(3-Brom-phenylamino)-7-ethoxy-6-nitro-chinolin-3-carbonitril;
 55 nn) 6-Amino-4-(3-brom-phenylamino)-7-ethoxy-chinolin-3-carbonitril;
 oo) 4-Brom-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-7-ethoxy-chinolin-6-yl]-amid;
 pp) 4-Morpholin-4-yl-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-7-ethoxy-chinolin-6-yl]-amid;
 qq) 6-Amino-4-(3-brom-phenylamino)-8-methoxy-chinolin-3-carbonitril;

rr) 6-Amino-4-(3-brom-phenylamino)-8-methoxy-chinolin-3-carbonitril;
 ss) 4-Brom-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-8-methoxy-chinolin-6-yl]-amid;
 tt) 4-Dimethylamino-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-8-methoxy-chinolin-6-yl]-amid;
 uu) 4-Diethylamino-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-8-methoxy-chinolin-6-yl]-amid;
 vv) 4-Morpholin-4-yl-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-8-methoxy-chinolin-6-yl]-amid;
 ww) 4-Dimethylamino-but-2-ensäure-[4-(3-brom-phenylamino)-3-cyano-7-methoxy-chinolin-6-yl]-amid;
 xx) 4-(4-Chlor-2-fluor-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 yy) 4-(3-Hydroxy-4-methyl-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril; oder
 zz) 4-(3-Dimethylamino-phenylamino)-6,7,8-trimethoxy-chinolin-3-carbonitril;

oder ein pharmazeutisch annehmbares Salz davon.

18. Verbindung gemäß Anspruch 1, welche ist:

a) 4-(3-Hydroxy-4-methyl-phenylamino)-6,7,8-trimethoxy-chinolin-3-carbonitril ;
 b) 4-(4-Chlor-2-fluor-phenylamino)-6,7,8-trimethoxy-chinolin-3-carbonitril;
 c) 4-(4-Chlor-2-fluor-phenylamino)-5,8-dimethoxy-chinolin-3-carbonitril;
 d) 4-(3-Hydroxy-4-methyl-phenylamino)-5,8-dimethoxy-chinolin-3-carbonitril;
 e) 4-(3-Brom-phenylamino)-5,8-dimethoxy-chinolin-3-carbonitril;
 f) 4-(3-Brom-phenylamino)-6,7,8-trimethoxy-chinolin-3-carbonitril;
 g) 4-(3-Dimethylamino-phenylamino)-5,8-dimethoxy-chinolin-3-carbonitril;
 h) 4-(4-Chlor-2-fluor-5-hydroxy-phenylamino)-5,8-dimethoxy-chinolin-3-carbonitril;
 i) 4-(4-Chlor-2-fluor-5-hydroxy-phenylamino)-6,7,8-trimethoxy-chinolin-3-carbonitril;
 j) 4-(3-Hydroxy-2-methyl-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 k) 4-(2-Hydroxy-6-methyl-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 l) 4-(3-Brom-4-methyl-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 m) 4-(3-Chlor-4-hydroxy-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 n) 6,7-Dimethoxy-4-(2-methylsulfanyl-phenylamino)-chinolin-3-carbonitril;
 o) 1,4-Dihydrochinolin-6,7-diethoxy-4-oxo-3-carbonitril;
 p) 4-[3-Chlor-4-(phenylthio)phenylamino]-6,7-diethoxy-3-chinolin-carbonitril;
 q) 4-[3-Chlor-4-(phenylthio)phenylamino]-6,7-dimethoxy-3-chinolin-carbonitril;
 r) 4-(3-Chlor-4-fluorphenylamino)-6,7-diethoxy-3-chinolincarbonitril;
 s) 4-(3-Acetylphenylamino)-6,7-diethoxy-3-chinolincarbonitril;
 t) 4-(n-Methylphenylamino)-6,7-diethoxy-3-chinolincarbonitril;
 u) 4-(Phenylamino)-6,7-diethoxy-3-chinolincarbonitril;
 v) 4-(4-Fluorphenylamino)-6,7-diethoxy-3-chinolincarbonitril;
 w) 4-(4-Fluor-2-methylphenylamino)-6,7-diethoxy-3-chinolincarbonitril;
 x) 4-(3-Chlorphenylamino)-6,7-diethoxy-3-chinolincarbonitril;
 y) 4-(3-Fluorphenylamino)-6,7-diethoxy-3-chinolincarbonitril;
 z) 4-(3-Aminophenylamino)-6,7-dimethoxy-3-chinolincarbonitril;
 aa) 4-(3-Acetamidophenylamino)-6,7-dimethoxy-3-chinolincarbonitril;
 bb) 4-[3-(2-Butinoylamino)phenylamino]-6,7-dimethoxy-3-chinolin-carbonitril;
 cc) 4-[3-(Hydroxymethyl)phenylamino]-6,7-dimethoxy-3-chinolincarbonitril;
 dd) 4-[3-(Chlormethyl)phenylamino]-6,7-dimethoxy-3-chinolincarbonitril;
 ee) 4-[3-(Acetylthiomethyl)phenylamino]-6,7-dimethoxy-3-chinolin-carbonitril ;
 ff) 4-[3-(Thiomethyl)phenylamino]-6,7-dimethoxy-3-chinolincarbonitril;
 gg) 4-[3-(3-Bromphenyl)amino]-8-methoxy-3-chinolincarbonitril;
 hh) 4-(4-Chlor-2-fluor-phenylamino)-8-methoxy-chinolin-3-carbonitril;
 ii) 4-(3-Hydroxy-4-methyl-phenylamino)-8-methoxy-chinolin-3-carbonitril;
 jj) 4-(3-Dimethylamino-phenylamino)-8-methoxy-chinolin-3-carbonitril;
 kk) 4-(4-Brom-3-hydroxy-phenylamino)-8-methoxy-chinolin-3-carbonitril;
 ll) 4-(3-Hydroxy-4-methoxy-phenylamino)-8-methoxy-chinolin-3-carbonitril;
 mm) 8-Methoxy-4-(2,4,6-trifluor-phenylamino)-chinolin-3-carbonitril;
 nn) 4-(3-Hydroxy-4-methyl-phenylamino)-7-methoxy-chinolin-3-carbonitril;
 oo) 4-(4-Chlor-2-fluor-5-hydroxy-phenylamino)-7-methoxy-chinolin-3-carbonitril;
 pp) 4-(4-Chlor-2-fluor-phenylamino)-6-methoxy-chinolin-3-carbonitril;
 qq) 4-(3-Hydroxy-4-methyl-phenylamino)-6-methoxy-chinolin-3-carbonitril;
 rr) 4-(4-Chlor-2-fluor-5-hydroxy-phenylamino)-6-methoxy-chinolin-3-carbonitril;

ss) 4-(3,5-Dichlor-4-hydroxy-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 tt) 4-(2-Hydroxy-4-methyl-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 uu) 4-(4-Hydroxy-3,5-dimethyl-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 vv) 4-(5-Chlor-2-hydroxy-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 ww) 4-(3,5-Dibrom-4-hydroxy-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 xx) 4-(4-Hydroxy-2-methyl-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 yy) 6,7-Dimethoxy-4-(pyridin-3-ylamino)-chinolin-3-carbonitril; oder
 zz) 6,7-Dimethoxy-4-(3-methylsulfanyl-phenylamino)-chinolin-3-carbonitril;

oder ein pharmazeutisch annehmbares Salz davon.

19. Verbindung gemäß Anspruch 1, welche ist:

a) 4-(2-Hydroxy-5-methyl-phenylamino) -6,7-dimethoxy-chinolin-3-carbonitril;
 b) 4-(2-Chlor-4-hydroxy-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 c) 6,7-Dimethoxy-4-(4-methylsulfanyl-phenylamino)-chinolin-3-carbonitril;
 d) 4-[4-(2-Hydroxy-ethyl)-phenylamino] -6,7-dimethoxy-chinolin-3-carbonitril ;
 e) 4-(2,4-Dihydroxy-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 f) 4-[2-(2-Hydroxy-ethyl)-phenylamino]-6,7-dimethoxy-chinolin-3-carbonitril;
 g) 4-(3-Bromphenylamino)-6,7-dihydroxy-3-chinolincarbonitril;
 h) 4-(3-Bromphenylamino)-6,7-di-n-propoxy-3-chinolincarbonitril;
 i) 4-[(3-Bromphenyl)-n-acetylamino]-6,7-dihydroxy-3-chinolincarbonitril;
 j) 4-(3-Bromphenylamino)-6,7-di-n-butoxy-3-chinolincarbonitril;
 k) 4-(4-Chlor-2-fluorphenylamino)-7-methoxy-3-chinolincarbonitril;
 l) 4-(4-Chlor-2-fluorphenylamino)-7-hydroxy-3-chinolincarbonitril;
 m) 4-[(4-Chlor-2-fluorphenylamino)-n-acetylamino]-7-hydroxy-3-chinolincarbonitril;
 n) 4-(4-Chlor-2-fluorphenylamino)-7-ethoxy-3-chinolincarbonitril;
 o) 4-[(3-Bromphenyl)amino]-6,7-bis(2-methoxyethoxy)-3-chinolincarbonitril;
 p) 4-(2-Aminphenylmethylamino)-6,7-diethoxy-3-chinolincarbonitril;
 q) 4-(3,4-Difluorphenylmethylamino) 6,7 diethoxy-3-chinolin carbonitril;
 r) 4-Methoxy-but-2-ensäure-[4-(3-brom-phenylamino)-chinazolin-6-yl]-amid;
 s) 7-Benzoyloxy-4-(4-chlor-2-fluor-phenylamino)-6-methoxy-chinolin-3-carbonitril;
 t) 4-(4-Chlor-2-fluor-5-hydroxy-phenylamino)-7-methoxy-6-(3-morpholin-4-yl)-propoxyl-chinolin-3-carbonitril;
 u) N-[4-(3-Brom-phenylamino)-3-cyano-chinolin-6-yl]-3-chlor-(e) acrylamid,
 v) N-[4-(3-Brom-phenylamino)-3-cyano-chinolin-6-yl]-3-chlor-(z)-acrylamid;
 w) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-morpholino-2-butanamid;
 x) N-[4-[(3-Bromphenyl) amino] -3-cyano-6-chinoliny]-4-dimethylamino-2-butanamid;
 y) N-[4-[(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-t-butylidimethylsiloxy-2-butanamid;
 z) N-[4- [(3-Bromphenyl)amino]-3-cyano-6-chinoliny]-4-hydroxy-2-butanamid;
 aa) 4- (3 -Hydroxymethyl-2 -methylphenylamino) -6, 7-dimethoxychinolin-3-carbonitril;
 bb) 4-(2-Amino-4,5-dimethylphenylamino)-6,7-dimethoxychinolin-3-carbonitril;
 cc) 4-(4-Ethylphenylamino)-6,7-dimethoxychinolin-3-carbonitril;
 dd) 4-(4-Chlor-2-methylphenylamino)-6,7-dimethoxychinolin-3-carbonitril;
 ee) 6,7-Dimethoxy-4-(3-phenoxyphenylamino) chinolin-3-carbonitril;
 ff) 4-(4-Chlor-3-trifluormethylphenylamino)-6,7-dimethoxychinolin-3-carbonitril;
 gg) 4-(3-Hydroxy-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 hh) 4-(4-Methyl-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 ii) 4-(3-Hydroxy-4-methyl-phenylamino)-8-methoxy-6-nitro-chinolin-3-carbonitril ;
 jj) 4-(4-Chlor-2-fluor-phenylamino)-8-methoxy-6-nitro-chinolin-3-carbonitril;
 kk) 4-(3-Hydroxy-4-methoxy-phenylamino)-8-methoxy-6-nitro-chinolin-3-carbonitril ;
 ll) 6-Amino-4-(3-hydroxy-4-methyl-phenylamino) -8-methoxy-chinolin-3-carbonitril;
 mm) 6-Amino-4-(3-hydroxy-4-methoxy-phenylamino)-4-methoxy-chinolin-3-carbonitril;
 nn) N-{4-[(3-Brom-4-fluorphenyl)amino]-3-cyano-7-methoxy-6-chinoliny}-4-brom-2-butanamid;
 oo) N-{4-[(3-Bromphenyl)amino]-3-cyano-7-methoxy-6-chinoliny}-4-chlor-2-butanamid;
 pp) N-{3-Cyano-4-[(3-iodphenyl)amino]-6-chinoliny}-2-butanamid;
 qq) N-{3-Cyano-4-[(3-methylphenyl) amino] -6-chinoliny} -2-propenamid;
 rr) N-{4-[(4-Bromphenyl)amino]-3-cyano-6-chinoliny}-2-butanamid;
 ss) N-{4-[(3-Chlor-4-thiophenoxyphenyl)amino]-3-cyano-6-chinoliny}-2-propenamid;

tt) N-{3-Cyano-4-[(3,4-difluorphenyl)amino]-6-chinoliny]-2-butanamid;
 uu) N-{4-[(3-Chlorphenyl)amino]-3-cyano-6-chinoliny]-2-butanamid;
 vv) N-{3-Cyano-4-[(3-isopropylphenyl)amino]-6-chinoliny]-2-butanamid;
 ww) N-{3-Cyano-4-[(3-isopropylphenyl)amino]-6-chinoliny]-2-propenamid;
 5 xx) 6-Amino-4-[(3-isopropylphenyl)amino]-3-chinolincarbonitril;
 yy) 4-[(3-Isopropylphenyl)amino]-6-nitro-3-chinolincarbonitril; oder
 zz) 4-(3-Brom-phenylamino)-6-(3-pyrrolidin-1-yl-propylamino)-chinolin-3-carbonitril;


oder ein pharmazeutisch annehmbares Salz davon.

20. Verbindung gemäß Anspruch 1, welche ist:

a) 4-(3-Azido-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 b) 6-Amino-4-[(4-chlor-2-fluorphenyl)amino]-7-methoxy-3-chinolincarbonitril ;
 15 c) 4-[(4-Chlor-2-fluorphenyl)amino]-7-methoxy-6-nitro-3-chinolincarbonitril;
 d) 4-[(3,4-Dichlorphenyl)amino]-6-nitro-3-chinolincarbonitril;
 e) 6-Amino-4-[(3-methylsulfanylphenyl)amino]-3-chinolincarbonitril;
 f) 4-[(3-Methylsulfanylphenyl)-amino]-6-nitro-3-chinolincarbonitril;
 g) 4-[(3-Trifluormethoxyphenyl)amino]-6-nitro-3-chinolincarbonitril;
 20 h) 4-(3-Dimethylamino-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 i) 6,7-Dimethoxy-4-(4-methoxy-2-methyl-phenylamino)-chinolin-3-carbonitril;
 j) 4-(3-Hydroxy-4-methoxy-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 k) 4-(3-Chlor-4-methyl-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril; l) 6,7-Dimethoxy-4-(4-phenoxy-phenylamino)-chinolin-3-carbonitril;
 25 m) 4-(5-Chlor-2-methoxy-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 n) 3-(3-Cyano-6,7-dimethoxy-chinolin-4-ylamino)-2-methyl-benzoesäure;
 o) 4-(4-Chlor-2-fluor-phenylamino)-6,7-dihydroxy-chinolin-3-carbonitril;
 p) 4-(3-Hydroxy-2-inethyl-phenylarnino) -6, 7-dimethoxy-chinolin-3-carbonitril;
 q) 4-(3-Chlor-4-methoxy-phenylamino)-6,7-dimethoxy-chinolin-3-carbonitril;
 30 r) 6,7-Dimethoxy-4-(4-trifluormethyl-phenylamino)-chinolin-3-carbonitril;
 s) 4-(3,4-Dibromphenylamino)-6-nitrochinolin-3-carbonitril;
 t) 6-Amino-4-(3-trifluormethylphenylamino)chinolin-3-carbonitril;
 u) 6-Amino-4-(3,4-dibromphenylamino) chinolin-3-carbonitril;
 v) N-[3-Cyano-4-(3,4-dibromphenylamino)chinolin-6-yl]acrylamid;
 35 w) N-[4-(3-Bromphenylamino)-3-cyanochinolin-6-yl]propionamid;
 x) (e) -But-2-ensäure-[4-(3-bromphenylamino)-3-cyanochinolin-6-yl]amid;
 y) N-[4-(3-Bromphenylamino)-3-cyanochinolin-6-yl]-2-methylacrylamid;
 z) 4-(3-Fluorphenylamino)-6-nitrochinolin-3-carbonitril;
 aa) 6-Amino-4-(3-fluorphenylamino)chinolin-3-carbonitril;
 40 bb) 4-(3-Dimethylaminophenylamino)-6-nitrochinolin-3-carbonitril;
 cc) 4-(4-Dimethylaminophenylamino)-6-nitrochinolin-3-carbonitril;
 dd) 6-Amino-4-(3-dimethylaminophenylamino)chinolin-3-carbonitril;
 ee) 6-Amino-4-(4-dimethylaminophenylamino)chinolin-3-carbonitril;
 ff) But-2-ensäure-[4-(3-fluorphenylamino)-3-cyanochinolin-6-yl]amid;
 45 gg) N-[3-Cyano-4-(3-dimethylaminophenylamino)chinolin-6-yl]-acrylamid;
 hh) N-[3-Cyano-4-(4-dimethylaminophenylamino)chinolin-6-yl]-acrylamid;
 ii) But-2-ensäure-[3-cyano-4-(3-dimethylaminophenylamino)chinolin-6-yl]amid;
 jj) But-2-ensäure-[3-cyano-4-(4-dimethylaminophenylamino)chinolin-6-yl]amid;
 kk) 4-(3-Bromphenylamino)-6-dimethylaminochinolin-3-carbonitril hydrochlorid;
 50 ll) 6-Dimethylamino-4-(3-methoxyphenylamino)chinolin-3-carbonitril-hydrochlorid;
 mm) 2-Brom-n-[4-(3-bromphenylamino)-3-cyanochinolin-6-yl] acetamid;
 nn) 6-Iod-4-(3-methoxyphenylamino)chinolin-3-carbonitril;
 oo) 4-(4-Hydroxy-2-methyl-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-chinolin-3-carbonitril;
 pp) 4-(3-Brom-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-chinolin-3-carbonitril;
 55 qq) 6-Methoxy-4-(2-methylsulfanyl-phenylamino)-7-(3-morpholin-4-yl-propoxy)-chinolin-3-carbonitril; oder
 rr) 4-(4-Hydroxy-3,5-dimethyl-phenylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-chinolin-3-carbonitril;

oder ein pharmazeutisch annehmbares Salz davon.

21. Verbindung der Formel



worin:


X einen Phenylring darstellt, welche gegebenenfalls mono-, di- oder trisubstituiert sein kann mit einem Substituenten, ausgewählt aus der Gruppe bestehend aus Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Azido, Hydroxyalkyl mit 1-6 Kohlenstoffatomen, Halogenmethyl, Alkoxymethyl mit 2-7 Kohlenstoffatomen, Alkanoyloxymethyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Hydroxy, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzoyl, Benzyl, Amino, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Phenylamino, Benzylamino, Alkanoylamino mit 1-6 Kohlenstoffatomen, Alkenoylamino mit 3-8 Kohlenstoffatomen, Alkinoylamino mit 3-8 Kohlenstoffatomen und Benzoylamino;

n 0-1 ist;

Y für -NH- steht;

R₁ und R₄ Wasserstoff darstellen;

R₂ für



steht;

R₃ für Wasserstoff, Alkoxy mit 1-6 Kohlenstoffatomen oder Z-(C(R₆)₂)_qY- steht ;

R₆ Wasserstoff oder Alkyl mit 1-6 Kohlenstoffatomen darstellt;

R₈ Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-12 Kohlenstoffatomen oder Morpholino-N-alkyl darstellt, worin die Alkylgruppe 1-6 Kohlenstoffatome hat;


Z Dialkylamino darstellt, worin jede der Alkylkomponenten aus 1-6 Kohlenstoffatomen besteht, oder Morpholino;

q = 1-4 und p = 0-3;

oder ein pharmazeutisch annehmbares Salz davon.

22. Verbindung gemäß Anspruch 21, worin X Phenyl darstellt, gegebenenfalls mono-, di- oder trisubstituiert mit Halogen, und q 2-4 ist.

23. Pharmazeutische Zusammensetzung, welche eine Verbindung mit der Formel



umfasst, worin:

20 X Cycloalkyl mit 3 bis 7 Kohlenstoffatomen darstellt, welches gegebenenfalls substituiert sein kann mit einem oder mehreren Alkyl mit 1 bis 6 Kohlenstoffatomgruppen; oder einen Pyridinyl-, Pyrimidinyl- oder Phenylring darstellt; worin der Pyridinyl-, Pyrimidinyl- oder Phenylring gegebenenfalls mono-, di- oder trisubstituiert sein kann mit einem Substituenten, ausgewählt aus der Gruppe bestehend aus Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Azido, Hydroxyalkyl mit 1-6 Kohlenstoffatomen, Halogenmethyl, Alkoxymethyl mit 2-7 Kohlenstoffatomen, Alkanoyloxymethyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Hydroxy, Trifluor-

25 methyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzoyl, Benzyl, Amino, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Phenylamino, Benzylamino, Alkanoylamino mit 1-6 Kohlenstoffatomen, Alkenoylamino mit 3-8 Kohlenstoffatomen, Alkinoylamino mit 3-8 Kohlenstoffatomen und Benzoylamino;



30 n 0-1 ist;


Y für -NH-, -O-, -S- oder -NR- steht;

R Alkyl mit 1-6 Kohlenstoffatomen darstellt;

35 R₁, R₂, R₃ und R₄ jeweils unabhängig Wasserstoff, Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Alkenyloxy mit 2-6-Kohlenstoffatomen, Alkinyloxy mit 2-6 Kohlenstoffatomen, Hydroxymethyl, Halogenmethyl, Alkanoyloxy mit 1-6 Kohlenstoffatomen, Alkenoyloxy mit 3-8 Kohlenstoffatomen, Alkinoyloxy mit 3-8 Kohlenstoffatomen, Alkanoyloxymethyl mit 2-7 Kohlenstoffatomen, Alkenoyloxymethyl mit 4-9 Kohlenstoffatomen, Alkinoyloxymethyl mit 4-9 Kohlenstoffatomen, Alkoxy-methyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Alkylsulfinyl mit 1-6 Kohlenstoffatomen, Alkylsulfonyl mit 1-6 Kohlenstoffatomen, Alkylsulfonamido mit 1-6 Koh-

40 lenstoffatomen, Alkenylsulfonamido mit 2-6 Kohlenstoffatomen, Alkynylsulfonamido mit 2-6 Kohlenstoffatomen, Hydroxy, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzyl, Amino, Hydroxyamino, Alkoxyamino mit 1-4 Kohlenstoffatomen, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Aminoalkyl mit 1-4 Kohlenstoffatomen, N-Alkylaminoalkyl mit 2-7 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-14 Kohlenstoffatomen, Phenylamino, Benzylamino,





darstellt.

R₅ Alkyl mit 1-6 Kohlenstoffatomen, Alkyl gegebenenfalls substituiert mit einem oder mehreren Halogenatomen, Phenyl oder Phenyl, gegebenenfalls substituiert mit einem oder mehreren Halogen, Alkoxy mit 1-6 Kohlenstoffatomen, Trifluormethyl, Amino, Nitro, Cyano oder Alkyl mit 1-6 Kohlenstoffatomgruppen darstellt;

R₆ Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen oder Alkenyl mit 2-6 Kohlenstoffatomen darstellt;

R₇ Chlor oder Brom darstellt;

R₈ Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen, Aminoalkyl mit 1-6 Kohlenstoffatomen, N-Alkylaminoalkyl mit 2-9 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-12 Kohlenstoffatomen, N-Cycloalkylaminoalkyl mit 4-12 Kohlenstoffatomen, N-Cycloalkyl-N-alkylaminoalkyl mit 5-18 Kohlenstoffatomen, N,N-Dicycloalkylaminoalkyl mit 7-18 Kohlenstoffatomen, Morpholino-N-Alkyl, worin die Alkylgruppe 1-6 Kohlenstoffatome hat, Piperidino-N-alkyl, worin die Alkylgruppe 1-6 Kohlenstoffatome hat, N-Alkyl-piperidino-N-alkyl, worin jede Alkylgruppe 1-6 Kohlenstoffatome hat, Azacycloalkyl-N-alkyl mit 3-11 Kohlenstoffatomen, Hydroxyalkyl mit 1-6

Kohlenstoffatomen, Alkoxyalkyl mit 2-8 Kohlenstoffatomen, Carboxy, Carboalkoxy mit 1-6 Kohlenstoffatomen, Phenyl, Carboalkyl mit 2-7 Kohlenstoffatomen, Chlor, Fluor oder Brom darstellt;


Z Amino, Hydroxy, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylamino, worin die Alkylkomponente aus 1-6 Kohlenstoffatomen besteht, Dialkylamino, worin jede der Alkylkomponenten aus 1-6 Kohlenstoffatomen besteht, Morpholino, Piperazino, N-Alkylpiperazino, worin die Alkylkomponente aus 1-6 Kohlenstoffatomen besteht, oder Pyrrolidino darstellt;

m = 1-4, q = 1-3 und p = 0-3;

jede der Substituenten R_1 , R_2 , R_3 oder R_4 , die sich an benachbarten Kohlenstoffatomen befinden, zusammen den bivalenten Rest $-O-C(R_8)_2-O-$ darstellen können;

oder ein pharmazeutisch annehmbares Salz davon, vorausgesetzt, dass wenn Y für -NH- steht, R_1 , R_2 , R_3 und R_4 Wasserstoff darstellen und n 0 ist, X nicht für 2-Methylphenyl steht, und ferner vorausgesetzt, dass wenn Y für -NH- steht, R_1 , R_2 und R_3 Wasserstoff darstellen, R_4 für $R_5-CONH(CH_2)_p-$ steht, R_5 für 2,6-Dichlorphenyl steht, n 1 ist und p 0 ist, X nicht für Pyridin-2-yl steht; und einen pharmazeutisch annehmbaren Träger umfasst.

24. Verbindung der Formel



worin:







X Cycloalkyl mit 3 bis 7 Kohlenstoffatomen darstellt, welches gegebenenfalls substituiert sein kann mit einem oder mehreren Alkyl mit 1 bis 6 Kohlenstoffatomgruppen; oder einen Pyridinyl-, Pyrimidinyl- oder Phenylring darstellt; worin der Pyridinyl-, Pyrimidinyl- oder Phenylring gegebenenfalls mono-, di- oder trisubstituiert sein kann mit einem Substituenten, ausgewählt aus der Gruppe bestehend aus Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkinyl mit 2-6 Kohlenstoffatomen, Azido, Hydroxyalkyl mit 1-6 Kohlenstoffatomen, Halogenmethyl, Alkoxyethyl mit 2-7 Kohlenstoffatomen, Alkanoyloxymethyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Hydroxy, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzoyl, Benzyl, Amino, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Phenylamino, Benzylamino, Alkanoylamino mit 1-6 Kohlenstoffatomen, Alkanoylamino mit 3-8 Kohlenstoffatomen, Alkinoylamino mit 3-8 Kohlenstoffatomen und Benzoylamino; n 0-1 ist;


Y für -NH-, -O-, -S- oder -NR- steht;

R Alkyl mit 1-6 Kohlenstoffatomen darstellt;

R_1 , R_2 , R_3 und R_4 jeweils unabhängig Wasserstoff, Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkinyl mit 2-6 Kohlenstoffatomen, Alkenyloxy mit 2-6 Kohlenstoffatomen, Alkinyloxy mit 2-6 Kohlenstoffatomen, Hydroxymethyl, Halogenmethyl, Alkanoyloxy mit 1-6 Kohlenstoffatomen, Alkenoyloxy mit 3-8 Kohlenstoffatomen, Alkinoyloxy mit 3-8 Kohlenstoffatomen, Alkanoyloxymethyl mit 2-7 Kohlenstoffatomen, Alkenoyloxymethyl mit 4-9 Kohlenstoffatomen, Alkinoyloxymethyl mit 4-9 Kohlenstoffatomen, Alkoxy-methyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Alkylsulfonamido mit 1-6 Kohlenstoffatomen, Alkylsulfonamido mit 1-6 Kohlenstoffatomen, Alkylsulfonamido mit 2-6 Kohlenstoffatomen, Alkylsulfonamido mit 2-6 Kohlenstoffatomen, Hydroxy, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzyl, Amino, Hydroxyamino, Alkoxyamino mit 1-4

Kohlenstoffatomen, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Aminoalkyl mit 1-4 Kohlenstoffatomen, N-Alkylaminoalkyl mit 2-7 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-14 Kohlenstoffatomen, Phenylamino, Benzylamino,





darstellt,

R₅ Alkyl mit 1-6 Kohlenstoffatomen, Alkyl gegebenenfalls substituiert mit einem oder mehreren Halogenatomen, Phenyl oder Phenyl, gegebenenfalls substituiert mit einem oder mehreren Halogenen, Alkoxy mit 1-6 Kohlenstoffatomen, Trifluormethyl, Amino, Nitro, Cyano oder Alkyl mit 1-6 Kohlenstoffatomgruppen darstellt; R₆ Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen oder Alkenyl mit 2-6 Kohlenstoffatomen darstellt;

R₇ Chlor oder Brom darstellt;

R₈ Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen, Aminoalkyl mit 1-6 Kohlenstoffatomen, N-Alkylaminoalkyl mit 2-9 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-12 Kohlenstoffatomen, N-Cycloalkylaminoalkyl mit 4-12 Kohlenstoffatomen, N-Cycloalkyl-N-alkylaminoalkyl mit 5-18 Kohlenstoffatomen, N,N-Dicycloalkylaminoalkyl mit 7-18 Kohlenstoffatomen, Morpholino-N-alkyl, worin die Alkylgruppe 1-6 Kohlenstoffatome hat, Piperidino-N-alkyl, worin die Alkylgruppe 1-6 Kohlenstoffatome hat, N-Alkyl-piperidino-N-alkyl, worin jede Alkylgruppe 1-6 Kohlenstoffatome hat, Azacycloalkyl-N-alkyl mit 3-11 Kohlenstoffatomen, Hydroxyalkyl mit 1-6 Kohlenstoffatomen, Alkoxyalkyl mit 2-8 Kohlenstoffatomen, Carboxy, Carboalkoxy mit 1-6 Kohlenstoffatomen, Phenyl, Carboalkyl mit 2-7 Kohlenstoffatomen, Chlor, Fluor oder Brom darstellt;

Z Amino, Hydroxy, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylamino, worin die Alkylkomponente aus 1-6 Kohlenstoffatomen besteht, Dialkylamino, worin jede der Alkylkomponenten aus 1-6 Kohlenstoffatomen besteht, Morpholino, Piperazino, N-Alkylpiperazino, worin die Alkylkomponente aus 1-6 Kohlenstoffatomen besteht, oder Pyrrolidino darstellt;

m = 1-4, q = 1-3 und p = 0-3;

jede der Substituenten R₁, R₂, R₃ oder R₄, die sich an benachbarten Kohlenstoffatomen befinden, zusammen den bivalenten Rest -O-C(R₈)₂-O- darstellen können;

oder ein pharmazeutisch annehmbares Salz davon, vorausgesetzt, dass wenn Y für -NH- steht, R₁, R₂, R₃ und R₄ Wasserstoff darstellen und n 0 ist, X nicht für 2-Methylphenyl steht, und ferner vorausgesetzt, dass wenn Y für -NH- steht, R₁, R₂ und R₃ Wasserstoff darstellen, R₄ für R₅-CONH(CH₂)_p- steht, R₅ für 2,6-Dichlorphenyl steht, n 1 ist und p 0 ist, X nicht für Pyridin-2-yl steht; zur Verwendung als therapeutischen Wirkstoff.

25. Verbindung der Formel 1, wie in Anspruch 24 definiert, zur Verwendung beim Hemmen der biologischen Wirkungen einer deregulierten Proteinkinase in einem Säuger, der dessen bedarf.

26. Verbindung der Formel 1, wie in Anspruch 24 definiert, zur Verwendung beim Behandeln, Hemmen des Wachstums von oder Ausmerzen eines Neoplasma in einem Säuger, der dessen bedarf.

27. Verbindung der Formel 1, wie in Anspruch 26 definiert, wobei das Neoplasma EGFR exprimiert.

28. Verbindung der Formel 1, wie in Anspruch 26 definiert, wobei das Neoplasma MAPK exprimiert.


29. Verbindung der Formel 1, wie in Anspruch 26 definiert, wobei das Neoplasma ECK exprimiert.

30. Verbindung der Formel 1, wie in Anspruch 26 definiert, wobei das Neoplasma KDR exprimiert.

31. Verbindung der Formel 1, wie in Anspruch 26 definiert, wobei das Neoplasma ausgewählt wird aus der Gruppe bestehend aus Brust, Niere, Blase, Mund, Larynx, Ösophagus, Magen, Dickdarm, Eierstock und Lunge.

32. Verbindung der Formel 1, wie in einem der Ansprüche 24 definiert, zur Verwendung beim Behandeln, Hemmen des Fortschreitens von oder Ausmerzen von polyzystischer Nierenerkrankung in einem Säuger.

33. Verwendung einer Verbindung der Formel



worin:


X Cycloalkyl mit 3 bis 7 Kohlenstoffatomen darstellt, welches gegebenenfalls substituiert sein kann mit einem oder mehreren Alkyl mit 1 bis 6 Kohlenstoffatomgruppen; oder einen Pyridinyl-, Pyrimidinyl- oder Phenylring darstellt; worin der Pyridinyl-, Pyrimidinyl- oder Phenylring gegebenenfalls mono-, di- oder trisubstituiert sein kann mit einem Substituenten, ausgewählt aus der Gruppe bestehend aus Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Azido, Hydroxyalkyl mit 1-6 Kohlenstoffatomen, Halogenmethyl, Alkoxymethyl mit 2-7 Kohlenstoffatomen, Alkanoyloxymethyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Hydroxy, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzoyl, Benzyl, Amino, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Phenylamino, Benzylamino, Alkanoylamino mit 1-6 Kohlenstoffatomen, Alkenoylamino mit 3-8 Kohlenstoffatomen, Alkinoylamino mit 3-8 Kohlenstoffatomen und Benzoylamino;







n 0-1 ist;

Y für -NH-, -O-, -S- oder -NR- steht;

R Alkyl mit 1-6 Kohlenstoffatomen darstellt;

R₁, R₂, R₃ und R₄ jeweils unabhängig Wasserstoff, Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Alkenyloxy mit 2-6 Kohlenstoffatomen, Alkinoyloxy mit 2-6 Kohlenstoffatomen, Hydroxymethyl, Halogenmethyl, Alkanoyloxy mit 1-6 Kohlenstoffatomen, Alkenoyloxy mit 3-8 Kohlenstoffatomen, Alkinoyloxy mit 3-8 Kohlenstoffatomen, Alkanoyloxymethyl mit 2-7 Kohlenstoffatomen, Alkenoyloxymethyl mit 4-9 Kohlenstoffatomen, Alkinoyloxymethyl mit 4-9 Kohlenstoffatomen, Alkoxy-methyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Alkylsulfinyl mit 1-6 Kohlenstoffatomen, Alkylsulfonyl mit 1-6 Kohlenstoffatomen, Alkylsulfonamido mit 1-6 Kohlenstoffatomen, Alkenylsulfonamido mit 2-6 Kohlenstoffatomen, Alkinylsulfonamido mit 2-6 Kohlenstoffatomen, Hydroxy, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzyl, Amino, Hydroxyamino, Alkoxyamino mit 1-4 Kohlenstoffatomen, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Aminoalkyl mit 1-4 Kohlenstoffatomen, N-Alkylaminoalkyl mit 2-7 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-14 Kohlenstoffatomen, Phenylamino, Benzylamino,





darstellt,

R_5 Alkyl mit 1-6 Kohlenstoffatomen, Alkyl gegebenenfalls substituiert mit einem oder mehreren Halogenatomen, Phenyl oder Phenyl, gegebenenfalls substituiert mit einem oder mehreren Halogenen, Alkoxy mit 1-6

Kohlenstoffatomen, Trifluormethyl, Amino, Nitro, Cyano oder Alkyl mit 1-6 Kohlenstoffatomgruppen darstellt;
 R_6 Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen oder Alkenyl mit 2-6 Kohlenstoffatomen darstellt;

R_7 Chlor oder Brom darstellt;


R_8 Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen, Aminoalkyl mit 1-6 Kohlenstoffatomen, N-Alkylaminoalkyl mit 2-9 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-12 Kohlenstoffatomen, N-Cycloalkylaminoalkyl mit 4-12 Kohlenstoffatomen, N-Cycloalkyl-N-alkylaminoalkyl mit 5-18 Kohlenstoffatomen, N,N-Dicycloalkylaminoalkyl mit 7-18 Kohlenstoffatomen, Morpholino-N-Alkyl, worin die Alkylgruppe 1-6 Kohlenstoffatome hat, Piperidino-N-alkyl, worin die Alkylgruppe 1-6 Kohlenstoffatome hat, N-Alkyl-piperidino-N-alkyl, worin jede Alkylgruppe 1-6 Kohlenstoffatome hat, Azacycloalkyl-N-alkyl mit 3-11 Kohlenstoffatomen, Hydroxyalkyl mit 1-6 Kohlenstoffatomen, Alkoxyalkyl mit 2-8 Kohlenstoffatomen, Carboxy, Carboalkoxy mit 1-6 Kohlenstoffatomen, Phenyl, Carboalkyl mit 2-7 Kohlenstoffatomen, Chlor, Fluor oder Brom darstellt;

Z Amino, Hydroxy, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylamino, worin die Alkylkomponente aus 1-6 Kohlenstoffatomen besteht, Dialkylamino, worin jede der Alkylkomponenten aus 1-6 Kohlenstoffatomen besteht, Morpholino, Piperazino, N-Alkylpiperazino, worin die Alkylkomponente aus 1-6 Kohlenstoffatomen besteht, oder Pyrrolidino darstellt;

$m = 1-4$, $q = 1-3$ und $p = 0-3$; jede der Substituenten R_1 , R_2 , R_3 oder R_4 , die sich an benachbarten Kohlenstoffatomen befinden, zusammen den bivalenten Rest $-O-C(R_8)_2-O-$ darstellen können;

oder ein pharmazeutisch annehmbares Salz davon, vorausgesetzt, dass wenn Y für $-NH-$ steht, R_1 , R_2 , R_3 und R_4 Wasserstoff darstellen und n 0 ist, X nicht für 2-Methylphenyl steht, und ferner vorausgesetzt, dass wenn Y für $-NH-$ steht, R_1 , R_2 und R_3 Wasserstoff darstellen, R_4 für $R_5-CONH(CH_2)_p-$ steht, R_5 für 2,6-Dichlorphenyl steht, n 1 ist und p 0 ist, X nicht für Pyridin-2-yl steht; bei der Herstellung eines Medikaments zum Behandeln, Hemmen des Wachstums von oder Ausmerzen eines Neoplasma in einem Säuger, der dessen bedarf; oder Hemmen der biologischen Wirkungen einer deregulierten Proteinkinase in einem Säuger, der dessen bedarf.

34. Verwendung einer Verbindung der Formel








worin:



X Cycloalkyl mit 3 bis 7 Kohlenstoffatomen darstellt, welches gegebenenfalls substituiert sein kann mit einem oder mehreren Alkyl mit 1 bis 6 Kohlenstoffatomgruppen; oder einen Pyridinyl-, Pyrimidinyl- oder Phenylring darstellt; worin der Pyridinyl-, Pyrimidinyl- oder Phenylring gegebenenfalls mono-, di- oder trisubstituiert sein kann mit einem Substituenten, ausgewählt aus der Gruppe bestehend aus Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkinyl mit 2-6 Kohlenstoffatomen, Azido, Hydroxyalkyl mit 1-6 Kohlenstoffatomen, Halogenmethyl, Alkoxymethyl mit 2-7 Kohlenstoffatomen, Alkanoyloxymethyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Hydroxy, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzoyl, Benzyl, Amino, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Phenylamino, Benzylamino, Alkanoylamino mit 1-6 Kohlenstoffatomen, Alkanoylamino mit 3-8 Kohlenstoffatomen, Alkinoylamino mit 3-8 Kohlenstoffatomen und Benzoylamino; n 0-1 ist;

Y für -NH-, -O-, -S- oder -NR- steht;

R Alkyl mit 1-6 Kohlenstoffatomen darstellt;

R₁, R₂, R₃ und R₄ jeweils unabhängig Wasserstoff, Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Alkenyloxy mit 2-6 Kohlenstoffatomen, Alkinyloxy mit 2-6 Kohlenstoffatomen, Hydroxymethyl, Halogenmethyl, Alkanoyloxy mit 1-6 Kohlenstoffatomen, Alkenoyloxy mit 3-8 Kohlenstoffatomen, Alkinoyloxy mit 3-8 Kohlenstoffatomen, Alkanoyloxymethyl mit 2-7 Kohlenstoffatomen, Alkenoyloxymethyl mit 4-9 Kohlenstoffatomen, Alkinoyloxymethyl mit 4-9 Kohlenstoffatomen, Alkoxy-methyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Alkylsulfinyl mit 1-6 Kohlenstoffatomen, Alkylsulfonyl mit 1-6 Kohlenstoffatomen, Alkylsulfonamido mit 1-6 Kohlenstoffatomen, Alkenylsulfonamido mit 2-6 Kohlenstoffatomen, Alkinylsulfonamido mit 2-6 Kohlenstoffatomen, Hydroxy, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzyl, Amino, Hydroxyamino, Alkoxyamino mit 1-4 Kohlenstoffatomen, Alkylamino mit 1-6 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Aminoalkyl mit 1-4 Kohlenstoffatomen, N-Alkylaminoalkyl mit 2-7 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-14 Kohlenstoffatomen, Phenylamino, Benzylamino,





darstellt,

R_5 Alkyl mit 1-6 Kohlenstoffatomen, Alkyl gegebenenfalls substituiert mit einem oder mehreren Halogenatomen, Phenyl oder Phenyl, gegebenenfalls substituiert mit einem oder mehreren Halogenen, Alkoxy mit 1-6 Kohlenstoffatomen, Trifluormethyl, Amino, Nitro, Cyano oder Alkyl mit 1-6 Kohlenstoffatomgruppen darstellt; R_6 Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen oder Alkenyl mit 2-6 Kohlenstoffatomen darstellt;

R_7 Chlor oder Brom darstellt;

R_8 Wasserstoff, Alkyl mit 1-6 Kohlenstoffatomen, Aminoalkyl mit 1-6 Kohlenstoffatomen, N-Alkylaminoalkyl mit 2-9 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-12 Kohlenstoffatomen, N-Cycloalkylaminoalkyl mit 4-12 Kohlenstoffatomen, N-Cycloalkyl-N-alkylaminoalkyl mit 5-18 Kohlenstoffatomen, N,N-Dicycloalkylaminoalkyl mit 7-18 Kohlenstoffatomen, Morpholino-N-Alkyl, worin die Alkylgruppe 1-6 Kohlenstoffatome hat, Piperidino-N-alkyl, worin die Alkylgruppe 1-6 Kohlenstoffatome hat, N-Alkyl-piperidino-N-alkyl, worin jede Alkylgruppe 1-6 Kohlenstoffatome hat, Azacycloalkyl-N-alkyl mit 3-11 Kohlenstoffatomen, Hydroxyalkyl mit 1-6 Kohlenstoffatomen, Alkoxyalkyl mit 2-8 Kohlenstoffatomen, Carboxy, Carboalkoxy mit 1-6 Kohlenstoffatomen, Phenyl, Carboalkyl mit 2-7 Kohlenstoffatomen, Chlor, Fluor oder Brom darstellt;


Z Amino, Hydroxy, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylamino, worin die Alkylkomponente aus 1-6 Kohlenstoffatomen besteht, Dialkylamino, worin jede der Alkylkomponenten aus 1-6 Kohlenstoffatomen besteht, Morpholino, Piperazino, N-Alkylpiperazino, worin die Alkylkomponente aus 1-6 Kohlenstoffatomen besteht, oder Pyrrolidino darstellt;

$m = 1-4$, $q = 1-3$ und $p = 0-3$;

jede der Substituenten R_1 , R_2 , R_3 oder R_4 , die sich an benachbarten Kohlenstoffatomen befinden, zusammen den bivalenten Rest $-\text{O}-\text{C}(\text{R}_6)_2-\text{O}-$ darstellen können;


oder ein pharmazeutisch annehmbares Salz davon, vorausgesetzt, dass wenn Y für $-\text{NH}-$ steht, R_1 , R_2 , R_3 und R_4 Wasserstoff darstellen und n 0 ist, X nicht für 2-Methylphenyl steht; bei der Herstellung eines Medikaments zur Verwendung beim Behandeln, Hemmen des Fortschreitens von oder Ausmerzen von polyzystischer Nierenerkrankung in einem Säuger.

35. Verfahren für die Herstellung von Verbindungen der Formel




5


worin Y und n wie in Anspruch 1 definiert sind und X' für Cycloalkyl oder Phenyl steht, gegebenenfalls substituiert mit einem oder mehreren Substituenten, ausgewählt aus der Gruppe bestehend aus Wasserstoff, Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Halogenmethyl, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Trifluormethyl, Cyano, Nitro, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzyl, Dialkylamino mit 2 bis 12 Kohlenstoffatomen; R₁', R₂', R₃' und R₄' jeweils unabhängig Wasserstoff, Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Alkenyloxy mit 2-6 Kohlenstoffatomen, Alkynyloxy mit 2-6 Kohlenstoffatomen, Halogenmethyl, Alkoxymethyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Alkylsulfinyl mit 1-6 Kohlenstoffatomen, Alkylsulfonyl mit 1-6 Kohlenstoffatomen, Alkylsulfonamido mit 1-6 Kohlenstoffatomen, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzyl, Alkoxyamino mit 1-4 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, N,N-Dialkylaminoalkyl mit 3-14 Kohlenstoffatomen, Phenylamino, Benzylamino, N-Alkylcarbamoyl mit 1-6 Kohlenstoffatomen, N,N-Dialkylcarbamoyl mit 2-12 Kohlenstoffatomen darstellen; oder jede der Substituenten R₁', R₂', R₃' und R₄', die sich an benachbarten Kohlenstoffatomen befinden, zusammen den bivalenten Rest -O-C(R₃)₂-O- darstellen können; vorausgesetzt, dass wenn Y für -NH- steht, R₁', R₂', R₃' und R₄' Wasserstoff darstellen und n 0 ist, X' nicht 2-Methylphenyl darstellt; welches umfasst: Hydrolysieren eines Säureesters der Formel 2



worin R' einen Alkylrest darstellt, welcher 1-6 Kohlenstoffatome enthält, mit Base, um die Verbindung der Formel 3




zu bilden, dann Umwandeln der Carbonsäuregruppe der Formel 3 in ein Acylimidazol durch Erhitzen mit Carbo-nylimidazol in einem inerten Lösungsmittel, gefolgt von der Zugabe von Ammoniak, um das Amid der Formel 4




zu ergeben und ferner Umsetzen mit einem Dehydratisierungsmittel, um die Verbindung der Formel 5 oben vorzusehen, und gegebenenfalls danach Bilden eines pharmazeutisch annehmbaren Salzes davon.

36. Verfahren für die Herstellung der Verbindungen der Formel 10 oder 11











oder




worin Y, p und n wie in Anspruch 1 definiert sind und X'' ausgewählt wird aus der Gruppe bestehend aus Cycloalkyl oder Phenyl, gegebenenfalls substituiert mit einem oder mehreren Substituenten, ausgewählt aus der Gruppe bestehend aus Wasserstoff, Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Halogenmethyl, Alkoxyethyl, Alkoxyethyl mit 2-7 Kohlenstoffatomen, Alkanoyloxy-methyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Trifluor-methyl, Cyano, Nitro, Carboxy, Carboalkoxy mit 2-7 Kohlenstoffatomen, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzoyl, Benzyl, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, Phenylamino, Benzylamino, Alkanoylamino mit 1-6 Kohlenstoffatomen, Alkenoylamino mit 3-8 Kohlenstoffatomen, Alkinoylamino mit 3-8 Kohlenstoffatomen und Benzoylamino, R₉ unabhängig Wasserstoff, Phenyl oder Alkyl mit 1-6 Kohlenstoffato-

men darstellt, die Komponenten $(R_{10})_k$ 1 bis 3 Substituenten an dem aromatischen Ring darstellen, die gleich oder unterschiedlich sein können und unabhängig ausgewählt werden aus der Gruppe von Wasserstoff, Halogen, Alkyl mit 1-6 Kohlenstoffatomen, Alkenyl mit 2-6 Kohlenstoffatomen, Alkynyl mit 2-6 Kohlenstoffatomen, Alkenyloxy mit 2-6 Kohlenstoffatomen, Alkynyloxy mit 2-6 Kohlenstoffatomen, Halogenmethyl, Alkoxyethyl mit 2-7 Kohlenstoffatomen, Alkoxy mit 1-6 Kohlenstoffatomen, Alkylthio mit 1-6 Kohlenstoffatomen, Alkylsulfinyl mit 1-6 Kohlenstoffatomen, Alkylsulfonyl mit 1-6 Kohlenstoffatomen, Trifluormethyl, Cyano, Nitro, Carboxy, Carboalkyl mit 2-7 Kohlenstoffatomen, Phenoxy, Phenyl, Thiophenoxy, Benzyl, Alkoxyamino mit 1-4 Kohlenstoffatomen, Dialkylamino mit 2 bis 12 Kohlenstoffatomen, N,N-Dialkyl-aminoalkyl mit 3-14 Kohlenstoffatomen, Phenylamino, Benzylamino, N-Alkylcarbamoyl mit 1-6 Kohlenstoffatomen, N,N-Dialkylcarbamoyl mit 2-12 Kohlenstoffatomen, R_{11} einen Rest darstellt und ausgewählt wird aus der Gruppe:







worin q, m, R_5 , R_6 , R_7 und R_8 wie in Anspruch 1 definiert sind; welches umfasst: Acylierung der Verbindung der Formel 6



mit entweder einem Säurechlorid der Formel 8 oder einem gemischten Anhydrid der Formel 9, wo R''' Alkyl mit 1 bis 6 Kohlenstoffatomen darstellt,




in Gegenwart einer organischen Base, um die Verbindung der Formel 11 zu ergeben; oder alternativ Acylierung der Verbindung der Formel 6 mit einem cyclischen Anhydrid der Formel 7




in Gegenwart eines basischen Katalysators, um die Verbindung der Formel 10 vorzusehen; und gegebenenfalls danach Bilden eines pharmazeutisch annehmbaren Salzes davon.


37. Verfahren zur Herstellung der Verbindungen der Formel 18




15 worin X, Y, n wie in Anspruch 1 definiert sind und R₁' , R₂' , R₃' und R₄' wie in Anspruch 35 definiert sind, vorausgesetzt, dass wenn Y für -NH- steht, R₁' , R₂' , R₃' und R₄' Wasserstoff darstellen und n 0 ist, X nicht 2-Methylphenyl darstellt; welches umfasst: Erhitzen eines substituierten Anilins der Formel 12




35 mit einem Reagenz der Formel 13




45 um eine Verbindung der Formel 14




zu ergeben, welche dann in einem hoch siedenden Lösungsmittel thermolysiert wird, um eine Verbindung der Formel 15



zu ergeben, dann Erhitzen der Verbindung der Formel 15 mit einem Chlorierungsmittel, um eine Verbindung der Formel 16




zu ergeben, welche mit einer Verbindung der Formel 17




kondensiert wird, um die Verbindungen der Formel 18 vorzusehen; und gegebenenfalls danach Bilden eines pharmazeutisch annehmbaren Salzes davon.


38. Verfahren für die Herstellung von Verbindung der Formel 15

**15**

worin R_1' , R_2' , R_3' und R_4' wie in Anspruch 35 definiert sind, welches umfasst: Erhitzen der Verbindung der Formel 19


**19**

mit Dimethylformamid-dimethylacetal, um eine Verbindung der Formel 20

**20**

zu ergeben, welche dann mit Acetonitril in Gegenwart einer Base umgesetzt wird, um die Verbindungen der Formel 15 zu ergeben.

39. Verfahren zur Herstellung von Verbindungen der Formel 22, worin R_1 , R_2 , R_3 , R_4 und n wie in Anspruch 1 definiert sind und X' in Anspruch 35 definiert ist:

**22**

welches umfasst:

wo eines oder mehr von R₁, R₂, R₃ oder R₄ eine Nitrogruppe darstellen, Umwandeln der entsprechenden Aminogruppe unter Verwendung eines Reduktionsmittels;

wo eines oder mehr von R₁, R₂, R₃ oder R₄ eine Aminogruppe darstellen, Umwandeln zur entsprechenden Dialkylaminogruppe mit 2 bis 12 Kohlenstoffatomen durch Alkylierung mit einem Alkylhalogenid mit 1 bis 6 Kohlenstoffatomen;

wo eines oder mehr von R₁, R₂, R₃ oder R₄ eine Methoxygruppe darstellen, Umwandeln zur entsprechenden Hydroxygruppe durch Umsetzung mit einem Demethylierungsmittel oder Pyridiniumchlorid;

wo eines oder mehr von R₁, R₂, R₃ oder R₄ eine Aminogruppe darstellen, Umwandeln zur entsprechenden Alkylsulfonamido-, Alkenylsulfonamido- oder Alkynylsulfonamido-Gruppe mit 2 bis 6 Kohlenstoffatomen durch die Umsetzung mit einem Alkylsulfonylchlorid, Alkenylsulfonylchlorid oder Alkynylsulfonylchlorid unter Verwendung eines basischen Katalysators;

wenn eines oder mehr von R₁, R₂, R₃ oder R₄ eine Aminogruppe darstellen, Umwandeln zur entsprechenden Alkenylsulfonamido-Gruppe durch Umsetzung mit einem Reagenz Cl-C(R'₆)₂-CHR'₆SO₂Cl, worin R'₆ Wasserstoff darstellt oder Alkyl mit 1-4 Kohlenstoffatomen, unter Verwendung eines Überschusses an organischer Base;

wo zwei von R₁, R₂, R₃ oder R₄ benachbarte Methoxygruppen darstellen, Umwandeln zur Verbindung mit benachbarten Hydroxygruppen durch Umsetzung mit einem Demethylierungsmittel oder durch Erhitzen mit Pyridiniumchlorid;

wo zwei von R₁, R₂, R₃ oder R₄ benachbarte Hydroxygruppen darstellen, Umwandeln zur Verbindung, wo die zwei benachbarten R₁, R₂, R₃ oder R₄ Gruppen zusammen den bivalenten Rest -O-C(R₈)₂-O- darstellen, worin R₈ wie in Anspruch 1 definiert ist, durch die Umsetzung mit J-C(R₈)₂-J, worin J für Chlor, Brom oder Iod steht und jedes J gleich oder unterschiedlich sein kann, unter Verwendung einer Base;

wo eines oder mehr von R₁, R₂, R₃ oder R₄ eine Aminogruppe darstellen, Umwandeln zur entsprechenden Alkylaminogruppe mit 1 bis 6 Kohlenstoffatomen durch Alkylierung mit einem Alkylhalogenid mit 1 bis 6 Kohlenstoffatomen oder durch reduktive Alkylierung unter Verwendung eines Aldehyds mit 1 bis 6 Kohlenstoffatomen und eines Reduktionsmittels;

wo eines oder mehr von R₁, R₂, R₃ oder R₄ Hydroxy darstellen, Umwandeln in die entsprechende Alkanoyloxygruppe mit 1-6 Kohlenstoffatomen durch Umsetzung mit einem passenden Carbonsäurechlorid, Anhydrid oder gemischten Anhydrid in einem inerten Lösungsmittel mit einem Katalysator;

wo eines oder mehr von R₁, R₂, R₃ oder R₄ Hydroxy darstellen, Umwandeln in die entsprechende Alkenoyloxygruppe mit 1-6 Kohlenstoffatomen durch Umsetzung mit einem passenden Carbonsäurechlorid, Anhydrid oder gemischten Anhydrid in einem inerten Lösungsmittel mit einem Katalysator;


wo eines oder mehr von R₁, R₂, R₃ oder R₄ Hydroxy darstellen, kann es durch Umsetzung mit einem passenden Carbonsäurechlorid, Anhydrid oder gemischten Anhydrid in einem inerten Lösungsmittel mit einem Katalysator zur entsprechenden Alkinoyloxygruppe mit 1-6 Kohlenstoffatomen umgewandelt werden;

wo eines oder mehr von R₁, R₂, R₃ oder R₄ Carboxy oder eine Carboalkoxygruppe mit 2-7 Kohlenstoffatomen darstellen, Umwandeln zur entsprechenden Hydroxymethylgruppe durch Reduktion mit einem Reduktionsmittel; gegebenenfalls Umwandeln der Hydroxymethylgruppe zur entsprechenden Halogenmethylgruppe durch Umsetzung mit einem halogenierenden Reagenz; oder gegebenenfalls Acylierung der Hydroxymethylgruppe mit einem Säurechlorid, Anhydrid oder gemischten Anhydrid in einem inerten Lösungsmittel mit einem

Katalysator, um die entsprechende Alkanoyloxymethylgruppe mit 2-7 Kohlenstoffatomen, Alkenoyloxymethylgruppe mit 2-7 Kohlenstoffatomen oder Alkinoyloxymethylgruppe mit 2-7 Kohlenstoffatomen zu ergeben;
 wo eines oder mehr von R_1 , R_2 , R_3 oder R_4 eine Halogenmethylgruppe darstellen, Umwandeln in eine Alkoxy-methylgruppe mit 2-7 Kohlenstoffatomen durch Ersetzen des Halogenatoms mit einem Natriumalkoxid in einem inerten Lösungsmittel;


wo eines oder mehr von R_1 , R_2 , R_3 oder R_4 eine Halogenmethylgruppe darstellen, Umwandeln in eine Aminomethylgruppe, N-Alkylaminomethylgruppe mit 2-7 Kohlenstoffatomen oder N,N-Dialkylaminomethylgruppe mit 3-14 Kohlenstoffatomen durch Ersetzen des Halogenatoms mit Ammoniak, einem primären oder sekundären Amin in einem inerten Lösungsmittel;

wo eines oder mehr von R_1 , R_2 , R_3 oder R_4 für eine $H_2N(CH_2)_p$ -Gruppe stehen, Umwandeln in die entsprechenden Gruppen:




worin R_5 und p wie in Anspruch 1 definiert sind, durch Umsetzung mit Phosgen in einem inerten Lösungsmittel in Gegenwart einer Base, um ein Isocyanat zu ergeben, welches mit einem Überschuss des Alkohols R_5-OH oder der Amine R_5-NH_2 oder $(R_5)_2NH$ behandelt wird;

wo eines oder mehr von R_1 , R_2 , R_3 oder R_4 eine $HO-(CH_2)_p$ -Gruppe darstellen, Umwandeln in die entsprechenden Gruppen:




worin R_5 und p wie oben definiert sind, durch Umsetzung in einem inerten Lösungsmittel unter Verwendung eines basischen Katalysators mit einem passenden Alkyl oder Phenylchlorformat, $R_5-OCOCl$, Alkyl oder Phenyl substituierten Isocyanat, $R_5-N=C=O$ oder Alkyl oder Phenyl substituierten Carbonsäurechlorid, R_5-COCl ;
 wo eines oder mehr von R_1 , R_2 , R_3 oder R_4 eine $HO(CH_2)_p$ -Gruppe darstellen, Umwandeln zur entsprechenden Gruppe:



worin R_5 und p wie oben definiert sind, durch Umsetzung in einem inerten Lösungsmittel unter Verwendung eines basischen Katalysators mit einem Reagenz $(R_5)_2NCOCl$.

Revendications

1. Composé de formule



dans laquelle :



X est cycloalkyle de 3 à 7 atomes de carbone qui peut être facultativement substitué avec un ou plusieurs groupements alkyle de 1 à 6 atomes de carbone ; ou est un cycle pyridinyle, pyrimidinyle ou phényle ; où le cycle pyridinyle, pyrimidinyle ou phényle peut être facultativement mono-, di- ou trisubstitué avec un substituant choisi parmi le groupe constitué d'halogène, d'alkyle de 1-6 atomes de carbone, d'alcényle de 2-6 atomes de carbone, d'alcynyle de 2-6 atomes de carbone, d'azido, d'hydroxyalkyle de 1-6 atomes de carbone, d'halométhyle, d'alkoxyméthyle de 2-7 atomes de carbone, d'alcanoyloxyméthyle de 2-7 atomes de carbone, d'alkoxy de 1-6 atomes de carbone, d'alkylthio de 1-6 atomes de carbone, d'hydroxy, de trifluorométhyle, de cyano, de nitro, de carboxy, de carboalkoxy de 2-7 atomes de carbone, de carboalkyle de 2-7 atomes de carbone, de phénoxy, de phényle, de thiophénoxy, de benzoyle, de benzyle, d'amino, d'alkylamino de 1-6 atomes de carbone, de dialkylamino de 2 à 12 atomes de carbone, de phénylamino, de benzylamino, d'alcanoylamino de 1-6 atomes de carbone, d'alcénoylamino de 3-8 atomes de carbone, d'alcynoylamino de 3-8 atomes de carbone et de benzylamino ;






n est 0-1 ;

Y est -NH-, -O-, -S- ou -NR- ;

R est alkyle de 1-6 atomes de carbone ;

R₁, R₂, R₃ et R₄ sont chacun, indépendamment, hydrogène, halogène, alkyle de 1-6 atomes de carbone, alcényle de 2-6 atomes de carbone, alcynyle de 2-6 atomes de carbone, alcényloxy de 2-6 atomes de carbone, alcynyloxy de 2-6 atomes de carbone, hydroxyméthyle, halométhyle, alcanoyloxy de 1-6 atomes de carbone, alcénoyloxy de 3-8 atomes de carbone, alcynoyloxy de 3-8 atomes de carbone, alcanoyloxyméthyle de 2-7 atomes de carbone, alcénoyloxyméthyle de 4-9 atomes de carbone, alcynoyloxyméthyle de 4-9 atomes de carbone, alkoxyméthyle de 2-7 atomes de carbone, alkoxy de 1-6 atomes de carbone, alkylthio de 1-6 atomes de carbone, alkylsulfinyle de 1-6 atomes de carbone, alkylsulfonyl de 1-6 atomes de carbone, alkylsulfonamido de 1-6 atomes de carbone, alcénylsulfonamido de 2-6 atomes de carbone, alcynylsulfonamido de 2-6 atomes de carbone, hydroxy, trifluorométhyle, cyano, nitro, carboxy, carboalkoxy de 2-7 atomes de carbone, carboalkyle de 2-7 atomes de carbone, phénoxy, phényle, thiophénoxy, benzyle, amino, hydroxyamino, alkoxamino de 1-4 atomes de carbone, alkylamino de 1-6 atomes de carbone, dialkylamino de 2 à 12 atomes de carbone, aminoalkyle de 1-4 atomes de carbone, N-alkylaminoalkyle de 2-7 atomes de carbone, N,N-dialkylaminoalkyle de 3-14 atomes de carbone, phénylamino, benzylamino,





R₅ est alkyle de 1-6 atomes de carbone, alkyle facultativement substitué avec un ou plusieurs atomes d'halogène, groupements phényle ou phényle facultativement substitué avec un ou plusieurs halogènes, alkoxy de 1-6 atomes de carbone, trifluorométhyle, amino, nitro, cyano ou alkyle de 1-6 atomes de carbone ;

R₆ est hydrogène, alkyle de 1-6 atomes de carbone ou alcényle de 2-6 atomes de carbone ;

R₇ est chloro ou bromo ;

R₈ est hydrogène, alkyle de 1-6 atomes de carbone, aminoalkyle de 1-6 atomes de carbone, N-alkylaminoalkyle de 2-9 atomes de carbone, N,N-dialkylaminoalkyle de 3-12 atomes de carbone, N-cycloalkylaminoalkyle de 4-12 atomes de carbone, N-cycloalkyl-N-alkylaminoalkyle de 5-18 atomes de carbone, N,N-dicycloalkylaminoalkyle de 7-18 atomes de carbone, morpholino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone, pipéridino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone, N-alkylpipéridino-N-alkyle où chaque groupement alkyle est de 1-6 atomes de carbone, azacycloalkyl-N-alkyle de 3-11 atomes de carbone, hydroxyalkyle de 1-6 atomes de carbone, alkoxyalkyle de 2-8 atomes de carbone, carboxy, carboalkoxy de 1-6 atomes de carbone, phényle, carboalkyle de 2-7 atomes de carbone, chloro, fluoro ou bromo ;

Z est amino, hydroxy, alkoxy de 1-6 atomes de carbone, alkylamino où la partie alkyle est de 1-6 atomes de carbone, dialkylamino où chacune des parties alkyle est de 1-6 atomes de carbone, morpholino, pipérazino, N-alkylpipérazino où la partie alkyle est de 1-6 atomes de carbone ou pyrrolidino ;
m = 1-4, q = 1-3 et p = 0-3 ;

n'importe lequel des substituants R_1 , R_2 , R_3 ou R_4 qui sont situés sur des atomes de carbone contigus peuvent conjointement être le radical divalent $-O-C(R_8)_2-O-$;

ou un sel pharmaceutiquement acceptable de celui-ci, à condition que, quand Y est $-NH-$, R_1 , R_2 , R_3 et R_4 sont hydrogène, et n est 0, alors X n'est pas 2-méthylphényle, et à condition en outre que, quand Y est $-NH-$, R_3 est chlore, R_1 , R_2 et R_4 sont hydrogène, et n est 0, alors X n'est pas phényle ou 3-chlorophényle, et à condition en outre que, quand Y est $-NH-$, R_1 , R_2 , R_3 sont hydrogène, R_4 est $R_5-CONH(CH_2)_p-$, R_5 est 2,6-dichlorophényle, n est 1 et p est 0, alors X n'est pas pyridin-2-yle.

2. Composé selon la revendication 1 dans lequel Y est $-NH-$ et n = 0 ou un sel pharmaceutiquement acceptable de celui-ci.

3. Composé selon la revendication 2 dans lequel X est phényle facultativement substitué ou un sel pharmaceutiquement acceptable de celui-ci.

4. Composé selon la revendication 3 dans lequel R_1 et R_4 sont hydrogène ou un sel pharmaceutiquement acceptable de celui-ci.

5. Composé selon la revendication 1 qui est le 4-[(3-bromophényl)amino]-6,7-diéthoxy-3-quinoléinecarbonitrile ou un sel pharmaceutiquement acceptable de celui-ci.

6. Composé selon la revendication 1 qui est le [4-(3-chloro-4-fluorophénylamino)-3-cyano-7-méthoxyquinolin-6-yl]amide de l'acide 4-diméthylamino-but-2-énoïque ou un sel pharmaceutiquement acceptable de celui-ci.

7. Composé selon la revendication 1 qui est le [4-(3-chloro-4-fluorophénylamino)-3-cyano-7-méthoxyquinolin-6-yl]amide de l'acide 4-diéthylamino-but-2-énoïque ou un sel pharmaceutiquement acceptable de celui-ci.

8. Composé selon la revendication 1 qui est le [4-(3-bromo-4-fluorophénylamino)-3-cyano-7-méthoxyquinolin-6-yl]amide de l'acide 4-diméthylamino-but-2-énoïque ou un sel pharmaceutiquement acceptable de celui-ci.

9. Composé selon la revendication 1 qui est le [4-(3-bromophénylamino)-3-cyano-7-éthoxyquinolin-6-yl]amide de l'acide 4-diméthylamino-but-2-énoïque ou un sel pharmaceutiquement acceptable de celui-ci.

10. Composé selon la revendication 1 qui est le [4-(3-bromophénylamino)-3-cyano-7-éthoxyquinolin-6-yl]amide de l'acide 4-diéthylamino-but-2-énoïque ou un sel pharmaceutiquement acceptable de celui-ci.

11. Composé selon la revendication 1 qui est le [4-(3-chloro-4-fluorophénylamino)-3-cyano-7-méthoxyquinolin-6-yl]amide de l'acide 4-morpholin-4-ylbut-2-énoïque ou un sel pharmaceutiquement acceptable de celui-ci.

12. Composé selon la revendication 1 qui est le [4-(3-bromophénylamino)-3-cyano-7-méthoxy-quinolin-6-yl]amide de l'acide 4-diméthylaminobut-2-énoïque ou un sel pharmaceutiquement acceptable de celui-ci.

13. Composé selon la revendication 1 qui est le N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-méthoxy-2-butyname ou un sel pharmaceutiquement acceptable de celui-ci.

14. Composé selon la revendication 1 qui est le N-[4-[(3-chloro-4-fluorophényl)amino]-3-cyano-6-quinoliny]-4-diméthylamino-2-butyname ou un sel pharmaceutiquement acceptable de celui-ci.

15. Composé selon la revendication 1 qui est

- a) 4-[(3-bromophényl)amino]-7-méthoxy-3-quinoléinecarbonitrile;
- b) 4-[(3-bromophényl)amino]-7-méthoxy-6-nitro-3-quinoléinecarbonitrile;
- c) 6-amino-4-[(3-bromophényl)amino]-7-méthoxy-3-quinoléinecarbonitrile;
- d) N-[4-[(3-bromophényl)amino]-3-cyano-7-méthoxy-6-quinoliny]-2-butyname;

e) N-[4-[(3-bromophényl)amino]-3-cyano-7-méthoxy-6-quinoliny] -2-propénamide;
 f) 4-[(3-bromophényl)amino]-6-nitro-3-quinoléinecarbonitrile;
 g) 6-amino-4-[(3-bromophényl)amino]-3-quinoléinecarbonitrile;
 h) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-2-butynamide;
 i) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny] acétamide;
 j) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny] butanamide;
 k) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-2-propénamide;
 l) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-2-chloroacétamide;
 m) 4-[(3,4-dibromophényl)amino]-6-nitro-3-quinoléinecarbonitrile;
 n) 6-amino-4-[(3,4-dibromophényl)amino]-3-quinoléinecarbonitrile;
 o) N-[4-[(3,4-dibromophényl)amino]-3-cyano-6-quinoliny]-2-butynamide;
 p) 6-nitro-4-[(3-trifluorométhylphényl)amino]-3-quinoléinecarbonitrile;
 q) 6-amino-4-[(3-trifluorométhylphényl)amino]-3-quinoléinecarbonitrile;
 r) N-[4-[(3-trifluorométhylphényl)amino]-3-cyano-6-quinoliny] -2-butynamide;
 s) 4-[(3-bromophényl)amino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 t) 4-[(3-fluorophényl)amino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 u) 4-(cyclohexylamino)-6,7-diméthoxy-3-quinoléinecarbonitrile;
 v) 4-[(3-bromophényl)amino]-6,7-dihydroxy-3-quinoléinecarbonitrile;
 w) 8-[(3-bromophényl)amino]-[1,3]-dioxolo[4,5-g]-quinoléine-7-carbonitrile;
 x) 4-[(3-chlorophényl)amino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 y) 4-[(3-trifluorométhylphényl)amino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 z) 4-[(3,4-diméthoxyphényl)amino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 aa) 4-[(méthylphényl)amino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 bb) 4-[(3-cyanophényl)amino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 cc) 4-[(4-fluorophényl)amino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 dd) 4-[(3-(hydroxyméthyl)phényl)amino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 ee) 4-[(3-bromophénoxy)-6,7-diméthoxy-3-quinoléinecarbonitrile;
 ff) 4-[(4-bromophényl) sulfanyl]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 gg) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-3(E)-chloro-2-propénamide;
 hh) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-3(Z)-chloro-2-propénamide;
 ii) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-2-méthyl-2-propénamide;
 jj) N-[4-[(3,4-dibromophényl)amino]-3-cyano-6-quinoliny]-2-propénamide;
 kk) N-[4-[(5-bromo-3-pyridinyl)amino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
 ll) 4-[(3-bromophényl)amino]-6,7-bis(méthoxyméthoxy)-3-quinoléinecarbonitrile;
 mm) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-hydroxy-2-butynamide;
 nn) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-morpholino-2-butynamide;
 oo) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-diméthylamino-2-butynamide;
 pp) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-méthoxy-2-butynamide;
 qq) 4-(3-bromophénylméthylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
 rr) 4-(3-phénylméthylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
 ss) 4-(3,4-diméthoxyphénylméthylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
 tt) 4-(3,4-dichlorophénylméthylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
 uu) [4-(3-bromophénylamino)-3-cyanoquinolin-6-yl]amide de l'acide 4-méthoxy-but-2-énoïque;
 vv) 4-(4-chloro-2-fluorophénylamino)-7-(3-chloropropoxy)-6-méthoxyquinoléine-3-carbonitrile;
 ww) 4-(4-chloro-2-fluorophénylamino)-6-méthoxy-7-(3-morpholin-4-ylpropoxy)quinoléine-3-carbonitrile;
 xx) 7-(2-diméthylaminoéthoxy)-4-(3-hydroxy-4-méthylphénylamino)-6-méthoxyquinoléine-3-carbonitrile;
 yy) 4-(3-hydroxy-4-méthylphénylamino)-6-méthoxy-7-(2-morpholin-4-yléthoxy)quinoléine-3-carbonitrile; ou
 zz) 4-(4-chloro-2-fluoro-5-hydroxyphénylamino)-7-(3-diméthylaminopropoxy)-6-méthoxyquinoléine-3-carbonitrile;

ou un sel pharmaceutiquement acceptable de celui-ci.

16. Composé selon la revendication 1 qui est

- a) 4-(4-chloro-2-fluoro-5-hydroxyphénylamino)-6-méthoxy-7-(3-morpholin-4-ylpropoxy)quinoléine-3-carbonitrile;
 b) 4-(4-chloro-2-fluoro-5-hydroxyphénylamino)-7-(2-diméthylaminoéthoxy)-6-méthoxyquinoléine-3-carbonitrile ;

c) 4-(4-chloro-2-fluoro-5-hydroxyphénylamino)-6-méthoxy-7-(2-morpholin-4-yléthoxy)quinoléine-3-carbonitrile;

d) N-[3-cyano-4-(3-fluorophénylamino)quinoléin-6-yl]acrylamide;

e) 6,7-diméthoxy-4-(3-nitrophénylamino)quinoléine-3-carbonitrile;

f) 4-(3-bromophénylamino)-6-éthoxy-7-méthoxyquinoléine-3-carbonitrile;

g) 6-éthoxy-4-(3-hydroxy-4-méthylphénylamino)-7-méthoxyquinoléine-3-carbonitrile;

h) [4-(3-bromophénylamino)-3-cyanoquinoléin-6-yl]amide de l'acide 4-diméthylaminobut-2-énoïque;

i) [4-(3-bromophénylamino)-3-cyanoquinoléin-6-yl]amide de l'acide 4-diéthylaminobut-2-énoïque;

j) [4-(3-bromophénylamino)-3-cyanoquinoléin-6-yl]amide de l'acide 4-méthylaminobut-2-énoïque;

k) 4-[(3-bromophényl)amino]-8-méthyl-6-nitro-3-quinoléinecarbonitrile;

l) 4-[(3-bromophényl)amine]-8-diméthylaminométhyl-6-nitro-3-quinoléinecarbonitrile;

m) 6-amino-4-[(3-bromophényl)amino]-8-diméthylaminométhyl-3-quinoléinecarbonitrile;

n) N-{4-[(3-bromophényl)amine]-3-cyano-8-diméthylaminométhyl-6-quinoliny}-2-butynamide;

o) N-{4-[(3-bromophényl)amino]-3-cyano-8-diméthylaminométhyl-6-quinoliny}-2-propénamide;

p) N-{4-[(3-bromophényl)amino]-3-cyano-8-diméthylaminométhyl-6-quinoliny}acétamide;

q) 4-[(3-chloro-4-fluorophényl)amino]-7-méthoxy-6-(morpholinopropoxy)-3-quinoléinecarbonitrile;

r) 4-[(3-bromophényl)amino]-7-méthoxy-6-(morpholinopropoxy)-3-quinoléinecarbonitrile;

s) 4-[(4-chloro-2-fluorophényl)amino]-7-méthoxy-6-(morpholinopropoxy)-3-quinoléinecarbonitrile;

t) 4-[(3-hydroxy-4-méthylphényl)amino]-7-méthoxy-6-(morpholinopropoxy)-3-quinoléinecarbonitrile;

u) N-{3-cyano-4-[(3-iodophényl)amino]-6-quinoliny}-2-propénamide;

v) 6-amino-4-[(3-iodophényl)amino]-3-quinoléinecarbonitrile;

w) 4-[(3-iodophényl)amino]-6-nitro-3-quinoléinecarbonitrile;

x) N-{3-cyano-4-[(3-méthylphényl)amino]-6-quinoliny}-2-butynamide;

y) 6-amino-4-[(3-méthylphényl)amino]-3-quinoléinecarbonitrile;

z) 6-nitro-4-[(3-méthylphényl)amino]-3-quinoléinecarbonitrile;

aa) N-{4-[(3-chlorophényl)amino]-3-cyano-6-quinoliny}-2-propénamide;

bb) 6-amino-4-[(3-chlorophényl)amino]-3-quinoléinecarbonitrile;

cc) 4-[(3-chlorophényl)amino]-6-nitro-3-quinoléinecarbonitrile;

dd) N-{3-cyano-4-[(3-méthoxyphényl)amino]-6-quinoliny}-2-propénamide;

ee) N-{3-cyano-4-[(3-méthoxyphényl)amino]-6-quinoliny}-2-butynamide;

ff) N-{3-cyano-4-[(3-méthoxyphényl)amino]-6-quinoliny}-4-pipéridino-2-butynamide;

gg) 6-amino-4-[(3-méthoxyphényl)amino]-3-quinoléinecarbonitrile;

hh) 4-[(3-méthoxyphényl)amino]-6-nitro-3-quinoléinecarbonitrile;

ii) N-{4-[(3-chloro-4-fluorophényl)amino]-3-cyano-6-quinoliny}-2-butynamide;

jj) N-{4-[(3-chloro-4-fluorophényl)amino]-3-cyano-6-quinoliny}-2-propénamide;

kk) N-4-[(3-chloro-4-fluorophényl)amino]-3-cyano-6-quinoliny-4-diéthylamino-2-buténamide;

ll) N-4-[(3-chloro-4-fluorophényl)amino]-3-cyano-6-quinoliny-4-morpholino-2-buténamide;

mm) N-4-[(3-chloro-4-fluorophényl)amino]-3-cyano-6-quinoliny-2-morpholin-4-ylméthyl-2-propénamide;

nn) 6-amino-4-[(3-chloro-4-fluorophényl)amino]-3-quinoléinecarbonitrile;

oo) 4-[(3-chloro-4-fluorophényl)amino]-6-nitro-3-quinoléinecarbonitrile;

pp) N-{4-[(4-bromophényl)amino]-3-cyano-6-quinoliny}-2-propénamide;

qq) 6-amino-4-[(4-bromophényl)amino]-3-quinoléinecarbonitrile;

rr) [(4-bromophényl)amino]-6-nitro-3-quinoléinecarbonitrile;

ss) N-{3-cyano-4-[(3,4-difluorophényl)amino]-6-quinoliny}-2-propénamide;

tt) 6-amino-4-[(3,4-difluorophényl)amino]-3-quinoléinecarbonitrile;

uu) 4-[(3,4-difluorophényl)amino]-6-nitro-3-quinoléinecarbonitrile;

ww) N-{4-[(3-chloro-4-thiophénoxyphényl)amino]-3-cyano-6-quinoliny}-2-butynamide;

xx) 6-amino-4-[(3-chloro-4-thiophénoxyphényl)amino]-3-quinoléinecarbonitrile;

yy) 4-[(3-chloro-4-thiophénoxyphényl)amino]-6-nitro-3-quinoléinecarbonitrile; ou

zz) N-{3-cyano-4-[(3-cyanophényl)amino]-6-quinoliny}-2-propénamide;

ou un sel pharmaceutiquement acceptable de celui-ci.

17. Composé selon la revendication 1 qui est

a) N-{3-cyano-4-[(3-cyanophényl)amino]-6-quinoliny}-4-pipéridino-2-butynamide;

b) 6-amino-4-[(3-cyanophényl)amino]-3-quinoléinecarbonitrile;

c) 4-[(3-cyanophényl)amino]-6-nitro-3-quinoléinecarbonitrile;

- d) N-{3-cyano-4-[(3-éthynylphényl)amino]-6-quinoliny]-2-butynamide;
e) N-{3-cyano-4-[(3-éthynylphényl)amino]-6-quinoliny]-2-propénamide;
f) N-{3-cyano-4-[(3-éthynylphényl) amino]-6-quinoliny]-4-pipéridino-2-butynamide;
g) 6-amino-4-[(3-éthynylphényl)amino]-3-quinoléinecarbonitrile;
5 h) 4-[(3-éthynylphényl)amino]-6-nitro-3-quinoléinecarbonitrile;
i) N-{4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-pipéridino-2-butynamide;
j) N-{4-[(3-bromophényl) amino]-3-cyano-6-quinoliny]-4-dipropylamino-2-butynamide;
k) N-{4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-2-morpholin-4-ylméthyl-2-propénamide;
l) N-{4-[(3-bromo-4-fluorophényl)amino]-3-cyano-6-quinoliny]-4-diméthylamino-2-buténamide;
10 m) N-{4-[(3-bromo-4-fluorophényl)amino]-3-cyano-6-quinoliny]-4-diéthylamino-2-buténamide;
n) N-{4-[(3-bromo-4-fluorophényl)amino]-3-cyano-6-quinoliny]-4-morpholino-2-buténamide;
o) N-{4-[(3-bromo-4-fluorophényl)amino]-3-cyano-7-méthoxy-6-quinoliny]-4-morpholino-2-buténamide;
p) 4-[(3-bromophényl)amino]-7-éthoxy-6-méthoxy-3-quinoléinecarbonitrile;
q) 7-éthoxy-4-[(3-hydroxy-4-méthylphényl)amino]-6-méthoxy-3-quinoléinecarbonitrile;
15 r) N-{4-[(3-chloro-4-fluorophényl)amino]-3-cyano-6-quinoliny]-4-diméthylamino-(z)-2-buténamide;
s) N-{4-[(3-chloro-4-fluorophényl)amino]-3-cyano-6-quinoliny]-4-méthoxy-(z)-2-buténamide;
t) acide 4-{[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]amino}-2-méthylène-4-oxobutanoïque;
u) N-{4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-diéthylamino-2-butynamide;
v) N-{4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-(n-éthylpipérazino)-2-butynamide;
20 w) N-{4-[(3-chloro-4-fluorophényl) amino]-3-cyano-6-quinoliny]-4-diéthylamino-2-butynamide;
x) N-{4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-(n-méthylpipérazino)-2-butynamide;
y) N-{4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-(n-isopropyl-n-méthylamino)-2-butynamide;
z) N-{4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-diisopropylamino-2-butynamide;
aa) N-{4-[(3-chloro-4-fluorophényl)amino]-3-cyano-6-quinoliny]-4-diméthylamino-2-butynamide;
25 bb) N-{4-[(3-chloro-4-fluorophényl)amino]-3-cyano-6-quinoliny]-4-méthoxy-2-butynamide;
cc) 4-[(3-bromo-4-fluorophényl) amino]-6-nitro-3-quinoléinecarbonitrile;
dd) 6-amino-4-[(3-bromo-4-fluorophényl)amino]-3-quinoléinecarbonitrile;
ee) N-{4-[(3-bromo-4-fluorophényl)amino]-3-cyano-6-quinoliny]-4-diméthylamino-2-butynamide;
ff) [4-[(3-bromophénylamino)-3-cyano-7-méthoxyquinolin-6-yl]amide de l'acide 4-diéthylamino-but-2-énoïque;
30 gg) [4-[(3-bromophénylamino)-3-cyano-7-méthoxyquinolin-6-yl]amide de l'acide 4-morpholin-4-ylbut-2-énoïque;
hh) 4-(3-chloro-4-fluorophénylamino)-7-méthoxy-6-nitroquinoléine-3-carbonitrile;
ii) 6-amino-4-(3-chloro-4-fluorophénylamino)-7-méthoxyquinoléine-3-carbonitrile;
jj) 4-(3-bromo-4-fluorophénylamino)-7-méthoxy-6-nitroquinoléine-3-carbonitrile;
35 kk) 6-amino-4-(3-bromo-4-fluorophénylamino)-7-méthoxyquinoléine-3-carbonitrile;
ll) [4-(3-bromo-4-fluorophénylamino)-3-cyano-7-méthoxyquinolin-6-yl]amide de l'acide 4-diéthylamino-but-2-énoïque;
mm) 4-(3-bromophénylamino)-7-éthoxy-6-nitroquinoléine-3-carbonitrile;
nn) 6-amino-4-(3-bromophénylamino)-7-éthoxyquinoléine-3-carbonitrile;
40 oo) [4-(3-bromophénylamino)-3-cyano-7-éthoxyquinolin-6-yl]amide de l'acide 4-bromobut-2-énoïque;
pp) [4-(3-bromophénylamino)-3-cyano-7-éthoxyquinolin-6-yl]amide de l'acide 4-morpholin-4-ylbut-2-énoïque;
qq) 6-amino-4-(3-bromophénylamino)-8-méthoxyquinoléine-3-carbonitrile;
rr) 6-amino-4-(3-bromophénylamino)-8-méthoxyquinoléine-3-carbonitrile;
ss) [4-(3-bromophénylamino)-3-cyano-8-méthoxyquinolin-6-yl]amide de l'acide 4-bromobut-2-énoïque;
45 tt) [4-(3-bromophénylamino)-3-cyano-8-méthoxyquinolin-6-yl]amide de l'acide 4-diméthylaminobut-2-énoïque;
uu) [4-(3-bromophénylamino)-3-cyano-8-méthoxyquinolin-6-yl]amide de l'acide 4-diéthylaminobut-2-énoïque;
vv) [4-(3-bromophénylamino)-3-cyano-8-méthoxyquinolin-6-yl]amide de l'acide 4-morpholin-4-ylbut-2-énoïque;
50 ww) [4-(3-bromophénylamino)-3-cyano-7-méthoxyquinol-6-yl]amide de l'acide 4-diméthylamino-but-2-ynoïque;
xx) 4-(4-chloro-2-fluorophénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
yy) 4-(3-hydroxy-4-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile; ou
zz) 4-(3-diméthylaminophénylamino)-6,7,8-triméthoxyquinoléine-3-carbonitrile;

ou un sel pharmaceutiquement acceptable de celui-ci.

18. Composé selon la revendication 1 qui est

- a) 4-(3-hydroxy-4-méthylphénylamino)-6,7,8-triméthoxyquinoléine-3-carbonitrile;
- b) 4-(4-chloro-2-fluorophénylamino)-6,7,8-triméthoxyquinoléine-3-carbonitrile;
- c) 4-(4-chloro-2-fluorophénylamino)-5,8-diméthoxyquinoléine-3-carbonitrile;
- d) 4-(3-hydroxy-4-méthylphénylamino)-5,8-diméthoxyquinoléine-3-carbonitrile;
- e) 4-(3-bromophénylamino)-5,8-diméthoxyquinoléine-3-carbonitrile;
- f) 4-(3-bromophénylamino)-6,7,8-triméthoxyquinoléine-3-carbonitrile;
- g) 4-(3-diméthylaminophénylamino)-5,8-diméthoxyquinoléine-3-carbonitrile;
- h) 4-(4-chloro-2-fluoro-5-hydroxyphénylamino)-5,8-diméthoxyquinoléine-3-carbonitrile;
- i) 4-(4-chloro-2-fluoro-5-hydroxyphénylamino)-6,7,8-triméthoxyquinoléine-3-carbonitrile;
- j) 4-(3-hydroxy-2-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
- k) 4-(2-hydroxy-6-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
- l) 4-(3-bromo-4-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
- m) 4-(3-chloro-4-hydroxyphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
- n) 4-(3-diméthoxy-4-(2-méthylsulfanylphénylamino)-quinoléine-3-carbonitrile;
- o) 1,4-dihydroquinoléine-6,7-diéthoxy-4-oxo-3-carbonitrile;
- p) 4-[3-chloro-4-(phénylthio)phénylamino]-6,7-diéthoxy-3-quinoléinecarbonitrile;
- q) 4-[3-chloro-4-(phénylthio)phénylamino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
- r) 4-(3-chloro-4-fluorophénylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
- s) 4-(3-acétylphénylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
- t) 4-(n-méthylphénylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
- u) 4-(phénylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
- v) 4-(4-fluorophénylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
- w) 4-(4-fluoro-2-méthylphénylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
- x) 4-(3-chlorophénylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
- y) 4-(3-fluorophénylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
- z) 4-(3-aminophénylamino)-6,7-diméthoxy-3-quinoléinecarbonitrile;
- aa) 4-(3-acétamidophénylamino)-6,7-diméthoxy-3-quinoléinecarbonitrile;
- bb) 4-[3-(2-butynoylamino)phénylamino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
- cc) 4-[3-(hydroxyméthyl)phénylamino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
- dd) 4-[3-(chlorométhyl)phénylamino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
- ee) 4-[3-(acétylthiométhyl)phénylamino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
- ff) 4-[3-(thiométhyl)phénylamino]-6,7-diméthoxy-3-quinoléinecarbonitrile;
- gg) 4-[(3-bromophényl)amino]-8-méthoxy-3-quinoléinecarbonitrile;
- hh) 4-(4-chloro-2-fluorophénylamino)-8-méthoxyquinoléine-3-carbonitrile;
- ii) 4-(3-hydroxy-4-méthylphénylamino)-8-méthoxyquinoléine-3-carbonitrile;
- jj) 4-(3-diméthylaminophénylamino)-8-méthoxyquinoléine-3-carbonitrile;
- kk) 4-(4-bromo-3-hydroxyphénylamino)-8-méthoxyquinoléine-3-carbonitrile;
- ll) 4-(3-hydroxy-4-méthoxyphénylamino)-8-méthoxyquinoléine-3-carbonitrile;
- mm) 8-méthoxy-4-(2,4,6-trifluorophénylamino)quinoléine-3-carbonitrile;
- nn) 4-(3-hydroxy-4-méthylphénylamino)-7-méthoxyquinoléine-3-carbonitrile;
- oo) 4-(4-chloro-2-fluoro-5-hydroxyphénylamino)-7-méthoxyquinoléine-3-carbonitrile;
- pp) 4-(4-chloro-2-fluorophénylamino)-6-méthoxyquinoléine-3-carbonitrile;
- qq) 4-(3-hydroxy-4-méthylphénylamino)-6-méthoxyquinoléine-3-carbonitrile;
- rr) 4-(4-chloro-2-fluoro-5-hydroxyphénylamino)-6-méthoxyquinoléine-3-carbonitrile;
- ss) 4-(3,5-dichloro-4-hydroxyphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
- tt) 4-(2-hydroxy-4-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
- uu) 4-(4-hydroxy-3,5-diméthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
- vv) 4-(5-chloro-2-hydroxyphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
- ww) 4-(3,5-dibromo-4-hydroxyphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
- xx) 4-(4-hydroxy-2-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
- yy) 6,7-diméthoxy-4-(pyridin-3-ylamino)quinoléine-3-carbonitrile; ou
- zz) 6,7-diméthoxy-4-(3-méthylsulfanylphénylamino)-quinoléine-3-carbonitrile;

ou un sel pharmaceutiquement acceptable de celui-ci.

19. Composé selon la revendication 1 qui est

- a) 4-(2-hydroxy-5-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;

- b) 4-(2-chloro-4-hydroxyphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 c) 6,7-diméthoxy-4-(4-méthylsulfanylphénylamino)-quinoléine-3-carbonitrile;
 d) 4-[4-(2-hydroxyéthyl)phénylamino]-6,7-diméthoxyquinoléine-3-carbonitrile;
 e) 4-(2,4-dihydroxyphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 5 f) 4-[2-(2-hydroxyéthyl)phénylamino]-6,7-diméthoxyquinoléine-3-carbonitrile;
 g) 4-(3-bromophénylamino)-6,7-dihydroxy-3-quinoléinecarbonitrile;
 h) 4-(3-bromophénylamino)-6,7-di-n-propoxy-3-quinoléinecarbonitrile;
 i) 4-[(3-bromophényl)-n-acétylamino]-6,7-dihydroxy-3-quinoléinecarbonitrile;
 j) 4-(3-bromophénylamino)-6,7-di-n-butoxy-3-quinoléinecarbonitrile;
 10 k) 4-(4-chloro-2-fluorophénylamino)-7-méthoxy-3-quinoléinecarbonitrile;
 l) 4-(4-chloro-2-fluorophénylamino)-7-hydroxy-3-quinoléinecarbonitrile;
 m) 4-[(4-chloro-2-fluorophénylamino)-n-acétamino]-7-hydroxy-3-quinoléinecarbonitrile;
 n) 4-(4-chloro-2-fluorophénylamino)-7-éthoxy-3-quinoléinecarbonitrile;
 o) 4-[(3-bromophényl)amino]-6,7-bis(2-méthoxyéthoxy)-3-quinoléinecarbonitrile;
 15 p) 4-(2-aminophénylméthylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
 q) 4-(3,4-difluorophénylméthylamino)-6,7-diéthoxy-3-quinoléinecarbonitrile;
 r) [4-(3-bromophénylamino)quinazolin-6-yl]amide de l'acide 4-méthoxybut-2-énoïque;
 s) 7-benzyloxy-4-(4-chloro-2-fluorophénylamino)-6-méthoxyquinoléine-3-carbonitrile;
 t) 4-(4-chloro-2-fluoro-5-hydroxyphénylamino)-7-méthoxy-6-(3-morpholin-4-yl)propoxylquinoléine-3-carbonitrile;
 20 u) N-[4-(3-bromophénylamino)-3-cyanoquinolin-6-yl]-3-chloro-(e)acrylamide;
 v) N-[4-(3-bromophénylamino)-3-cyanoquinolin-6-yl]-3-chloro-(z)-acrylamide;
 w) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-morpholino-2-butynamide;
 x) N-4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-diméthylamino-2-butynamide;
 25 y) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-t-butyl diméthylsiloxy-2-butynamide;
 z) N-[4-[(3-bromophényl)amino]-3-cyano-6-quinoliny]-4-hydroxy-2-butynamide;
 aa) 4-(3-hydroxyméthyl-2-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 bb) 4-(2-amino-4,5-diméthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 cc) 4-(4-éthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 30 dd) 4-(4-chloro-2-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 ee) 6,7-diméthoxy-4-(3-phénoxyphénylamino)quinoléine-3-carbonitrile;
 ff) 4-(4-chloro-3-trifluorométhylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 gg) 4-(3-hydroxyphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 hh) 4-(4-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 35 ii) 4-(3-hydroxy-4-méthylphénylamino)-8-méthoxy-6-nitroquinoléine-3-carbonitrile;
 jj) 4-(4-chloro-2-fluorophénylamino)-8-méthoxy-6-nitroquinoléine-3-carbonitrile;
 kk) 4-(3-hydroxy-4-méthoxyphénylamino)-8-méthoxy-6-nitroquinoléine-3-carbonitrile;
 ll) 6-amino-4-(3-hydroxy-4-méthylphénylamino)-8-méthoxyquinoléine-3-carbonitrile;
 mm) 6-amino-4-(3-hydroxy-4-méthoxyphénylamino)-8-méthoxyquinoléine-3-carbonitrile;
 40 nn) N-[4-[(3-bromo-4-fluorophényl)amino]-3-cyano-7-méthoxy-6-quinoliny]-4-bromo-2-buténamide;
 oo) N-[4-[(3-bromophényl)amino]-3-cyano-7-méthoxy-6-quinoliny]-4-chloro-2-buténamide;
 pp) N-[3-cyano-4-[(3-iodophényl)amino]-6-quinoliny]-2-butynamide;
 qq) N-[3-cyano-4-[(3-méthylphényl)amino]-6-quinoliny]-2-propénamide;
 rr) N-[4-[(4-bromophényl)amino]-3-cyano-6-quinoliny]-2-butynamide;
 45 ss) N-[4-[(3-chloro-4-thiophénoxyphényl)amino]-3-cyano-6-quinoliny]-2-propénamide;
 tt) N-[3-cyano-4-[(3,4-difluorophényl)amino]-6-quinoliny]-2-butynamide;
 uu) N-[4-[(3-chlorophényl)amino]-3-cyano-6-quinoliny]-2-butynamide;
 vv) N-[3-cyano-4-[(3-isopropylphényl)amino]-6-quinoliny]-2-butynamide;
 ww) N-[3-cyano-4-[(3-isopropylphényl)amino]-6-quinoliny]-2-propénamide;
 50 xx) 6-amino-4-[(3-isopropylphényl)amino]-3-quinoléinecarbonitrile;
 yy) 4-[(3-isopropylphényl)amino]-6-nitro-3-quinoléinecarbonitrile; ou
 zz) 4-(3-bromophénylamino)-6-(3-pyrrolidin-1-yl-propylamino)quinoléine-3-carbonitrile;

ou un sel pharmaceutiquement acceptable de celui-ci.


20. Composé selon la revendication 1 qui est

- a) 4-(3-azidophénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;

b) 6-amino-4-[(4-chloro-2-fluorophényl)amino]-7-méthoxy-3-quinoléinecarbonitrile;
 c) 4-[(4-chloro-2-fluorophényl)amino]-7-méthoxy-6-nitro-3-quinoléinecarbonitrile;
 d) 4-[(3,4-dichlorophényl)amino]-6-nitro-3-quinoléinecarbonitrile;
 e) 6-amino-4-[(3-méthylsulfanylphényl)amino]-3-quinoléinecarbonitrile;
 5 f) 4-[(3-méthylsulfanylphényl)amino]-6-nitro-3-quinoléinecarbonitrile;
 g) 4-[(3-trifluorométhoxyphényl)amino]-6-nitro-3-quinoléinecarbonitrile;
 h) 4-(3-diméthylaminophénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 i) 6,7-diméthoxy-4-(4-méthoxy-2-méthylphénylamino)-quinoléine-3-carbonitrile;
 j) 4-(3-hydroxy-4-méthoxyphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 10 k) 4-(3-chlore-4-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 l) 6,7-diméthoxy-4-(4-phenoxyphénylamino)quinoléine-3-carbonitrile;
 m) 4-(5-chloro-2-méthoxyphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 n) acide 3-(3-cyano-6,7-diméthoxyquinolin-4-ylamino)-2-méthylbenzoïque;
 o) 4-(4-chloro-2-fluorophénylamino)-6,7-dihydroxyquinoléine-3-carbonitrile;
 15 p) 4-(3-hydroxy-2-méthylphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 q) 4-(3-chloro-4-méthoxyphénylamino)-6,7-diméthoxyquinoléine-3-carbonitrile;
 r) 6,7-diméthoxy-4-(4-trifluorométhylphénylamino)-quinoléine-3-carbonitrile;
 s) 4-(3,4-dibromophénylamino)-6-nitroquinoléine-3-carbonitrile;
 t) 6-amino-4-(3-trifluorométhylphénylamino)quinoléine-3-carbonitrile;
 20 u) 6-amino-4-(3,4-dibromophénylamino)quinoléine-3-carbonitrile;
 v) N-[3-cyano-4-(3,4-dibromophénylamino)quinolin-6-yl]acrylamide;
 w) N-[4-(3-bromophénylamino)-3-cyanoquinolin-6-yl]propionamide;
 x) [4-(3-bromophénylamino)-3-cyanoquinolin-6-yl] amide de l'acide (e) -but-2-énoïque;
 y) N-[4-(3-bromophénylamino)-3-cyanoquinolin-6-yl]-2-méthylacrylamide;
 25 z) 4-(3-fluorophénylamino)-6-nitroquinoléine-3-carbonitrile;
 aa) 6-amino-4-(3-fluorophénylamino)quinoléine-3-carbonitrile;
 bb) 4-(3-diméthylaminophénylamino)-6-nitroquinoléine-3-carbonitrile;
 cc) 4-(4-diméthylaminophénylamino)-6-nitroquinoléine-3-carbonitrile;
 dd) 6-amino-4-(3-diméthylaminophénylamino)quinoléine-3-carbonitrile;
 30 ee) 6-amino-4-(4-diméthylaminophénylamino)quinoléine-3-carbonitrile;
 ff) [4-(3-fluorophénylamino)-3-cyanoquinolin-6-yl]amide de l'acide but-2-ynoïque;
 gg) N-[3-cyano-4-(3-diméthylaminophénylamino)quinolin-6-yl]acrylamide;
 hh) N-[3-cyano-4-(4-diméthylaminophénylamino)quinolin-6-yl]acrylamide;
 ii) [3-cyano-4-(3-diméthylaminophénylamino)quinolin-6-yl]amide de l'acide but-2-ynoïque;
 35 jj) [3-cyano-4-(4-diméthylaminophénylamino)quinolin-6-yl]amide de l'acide but-2-ynoïque;
 kk) chlorhydrate de 4-(3-bromophénylamino)-6-diméthylaminoquinoléine-3-carbonitrile;
 ll) chlorhydrate de 6-diméthylamino-4-(3-méthoxyphénylamino)quinoléine-3-carbonitrile;
 mm) 2-bromo-n-[4-(3-bromophénylamino)-3-cyanoquinolin-6-yl] acétamide;
 nn) 6-iodo-4-(3-méthoxyphénylamino)quinoléine-3-carbonitrile;
 40 oo) 4-(4-hydroxy-2-méthylphénylamino)-6-méthoxy-7-(3-morpholin-4-yl-propoxy)quinoléine-3-carbonitrile;
 pp) 4-(3-bromophénylamino)-6-méthoxy-7-(3-morpholin-4-ylpropoxy)quinoléine-3-carbonitrile;
 qq) 6-méthoxy-4-(2-méthylsulfanylphénylamino)-7-(3-morpholin-4-ylpropoxy)quinoléine-3-carbonitrile; ou
 rr) 4-(4-hydroxy-3, 5-diméthylphénylamino)-6-méthoxy-7-(3-morpholin-4-ylpropoxy)quinoléine-3-carbonitrile;
 45 le;

ou un sel pharmaceutiquement acceptable de celui-ci.

21. Composé de formule



15 dans laquelle :


20 X est un cycle phényle qui peut être facultativement mono-, di- ou trisubstitué avec un substituant choisi parmi le groupe constitué d'halogène, d'alkyle de 1-6 atomes de carbone, d'alcényle de 2-6 atomes de carbone, d'alcynyle de 2-6 atomes de carbone, d'azido, d'hydroxyalkyle de 1-6 atomes de carbone, d'halométhyle, d'alkoxyméthyle de 2-7 atomes de carbone, d'alcanoyloxyméthyle de 2-7 atomes de carbone, d'alkoxy de 1-6 atomes de carbone, d'alkylthio de 1-6 atomes de carbone, d'hydroxy, de trifluorométhyle, de cyano, de nitro, de carboxy, de carboalkoxy de 2-7 atomes de carbone, de carboalkyle de 2-7 atomes de carbone, de phénoxy, de phényle, de thiophénoxy, de benzoyle, de benzyle, d'amino, d'alkylamino de 1-6 atomes de carbone, de dialkylamino de 2 à 12 atomes de carbone, de phénylamino, de benzylamino, d'alcanoylamino de 1-6 atomes de carbone, d'alcénoylamino de 3-8 atomes de carbone, d'alcynoylamino de 3-8 atomes de carbone et de benzoylamino ;

25 n est 0-1 ;

Y est -NH- ;

R₁ et R₄ sont hydrogène ;

30 R₂ est



40 R₃ est hydrogène, alkoxy de 1-6 atomes de carbone ou Z-(C(R₆)₂)_qY-;

R₆ est hydrogène ou alkyle de 1-6 atomes de carbone ;

45 R₈ est hydrogène, alkyle de 1-6 atomes de carbone,

N,N-dialkylaminoalkyle de 3-12 atomes de carbone ou morpholino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone ;


Z est dialkylamino où chacun des groupements alkyle est de 1-6 atomes de carbone ou morpholino ;

q = 1-4, et p = 0-3

45 ou un sel pharmaceutiquement acceptable de celui-ci.

22. Composé selon la revendication 21 dans lequel X est phényle facultativement mono-, di- ou trisubstitué avec un halogène et q est 2-4.

23. Composition pharmaceutique qui comprend un composé ayant la formule



dans laquelle :


X est cycloalkyle de 3 à 7 atomes de carbone qui peut être facultativement substitué avec un ou plusieurs groupements alkyle de 1 à 6 atomes de carbone ; ou est un cycle pyridinyle, pyrimidinyle ou phényle ; où le cycle pyridinyle, pyrimidinyle ou phényle peut être facultativement mono-, di- ou trisubstitué avec un substituant choisi parmi le groupe constitué d'halogène, d'alkyle de 1-6 atomes de carbone, d'alcényle de 2-6 atomes de carbone, d'alcynyle de 2-6 atomes de carbone, d'azido, d'hydroxyalkyle de 1-6 atomes de carbone, d'halométhyle, d'alkoxyméthyle de 2-7 atomes de carbone, d'alcanoyloxyméthyle de 2-7 atomes de carbone, d'alkoxy de 1-6 atomes de carbone, d'alkylthio de 1-6 atomes de carbone, d'hydroxy, de trifluorométhyle, de cyano, de nitro, de carboxy, de carboalkoxy de 2-7 atomes de carbone, de carboalkyle de 2-7 atomes de carbone, de phénoxy, de phényle, de thiophénoxy, de benzoyle, de benzyle, d'amino, d'alkylamino de 1-6 atomes de carbone, de dialkylamino de 2 à 12 atomes de carbone, de phénylamino, de benzylamino, d'alcanoylamino de 1-6 atomes de carbone, d'alcénoylamino de 3-8 atomes de carbone, d'alcinoylamino de 3-8 atomes de carbone, et de benzylamino ;






n est 0-1 ;


Y est -NH-, -O-, -S- ou -NR- ;

R est alkyle de 1-6 atomes de carbone ;

R₁, R₂, R₃ et R₄ sont chacun, indépendamment, hydrogène, halogène, alkyle de 1-6 atomes de carbone, alcényle de 2-6 atomes de carbone, alcynyle de 2-6 atomes de carbone, alcényloxy de 2-6 atomes de carbone, alcynyloxy de 2-6 atomes de carbone, hydroxyméthyle, halométhyle, alcanoyloxy de 1-6 atomes de carbone, alcénoyloxy de 3-8 atomes de carbone, alcynoyloxy de 3-8 atomes de carbone, alcanoyloxyméthyle de 2-7 atomes de carbone, alcénoyloxyméthyle de 4-9 atomes de carbone, alcynoyloxyméthyle de 4-9 atomes de carbone, alkoxyméthyle de 2-7 atomes de carbone, alkoxy de 1-6 atomes de carbone, alkylthio de 1-6 atomes de carbone, alkylsulfinyle de 1-6 atomes de carbone, alkylsulfonyl de 1-6 atomes de carbone, alkylsulfonamido de 1-6 atomes de carbone, alcénylsulfonamido de 2-6 atomes de carbone, alcynylsulfonamido de 2-6 atomes de carbone, hydroxy, trifluorométhyle, cyano, nitro, carboxy, carboalkoxy de 2-7 atomes de carbone, carboalkyle de 2-7 atomes de carbone, phénoxy, phényle, thiophénoxy, benzyle, amino, hydroxyamino, alkoxamino de 1-4 atomes de carbone, alkylamino de 1-6 atomes de carbone, dialkylamino de 2 à 12 atomes de carbone, aminoalkyle de 1-4 atomes de carbone, N-alkylaminoalkyle de 2-7 atomes de carbone, N,N-dialkylaminoalkyle de 3-14 atomes de carbone, phénylamino, benzylamino,







R₅ est alkyle de 1-6 atomes de carbone, alkyle facultativement substitué avec un ou plusieurs atomes d'halogène, groupements phényle ou phényle facultativement substitué avec un ou plusieurs halogènes, alkoxy de 1-6 atomes de carbone, trifluorométhyle, amino, nitro, cyano ou alkyle de 1-6 atomes de carbone ;

R₆ est hydrogène, alkyle de 1-6 atomes de carbone ou alcényle de 2-6 atomes de carbone ;

R₇ est chloro ou bromo ;

R₈ est hydrogène, alkyle de 1-6 atomes de carbone, aminoalkyle de 1-6 atomes de carbone, N-alkylaminoalkyle de 2-9 atomes de carbone, N,N-dialkylaminoalkyle de 3-12 atomes de carbone, N-cycloalkylaminoalkyle de 4-12 atomes de carbone, N-cycloalkyl-N-alkylaminoalkyle de 5-18 atomes de carbone, N,N-dicycloalkylaminoalkyle de 7-18 atomes de carbone, morpholino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone, pipéridino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone, N-alkylpipéridino-N-alkyle où chaque groupement alkyle est de 1-6 atomes de carbone, azacycloalkyl-N-alkyle de 3-11 atomes de carbone, hydroxyalkyle de 1-6 atomes de carbone, alkoxyalkyle de 2-8 atomes de carbone, carboxy, carboalkoxy de 1-6 atomes de carbone, phényle, carboalkyle de 2-7 atomes de carbone, chloro, fluoro ou bromo ;


Z est amino, hydroxy, alkoxy de 1-6 atomes de carbone, alkylamino où la partie alkyle est de 1-6 atomes de carbone, dialkylamino où chacune des parties alkyle est de 1-6 atomes de carbone, morpholino, pipérazino, N-alkylpipérazino où la partie alkyle est de 1-6 atomes de carbone ou pyrrolidino ;

m = 1-4, q = 1-3 et p = 0-3 ;

n'importe lequel des substituants R₁, R₂, R₃ ou R₄ qui sont situés sur des atomes de carbone contigus peuvent conjointement être le radical divalent -O-C(R₈)₂-O- ;

ou un sel pharmaceutiquement acceptable de celui-ci, à condition que, quand Y est -NH-, R₁, R₂, R₃ et R₄ sont hydrogène, et n est 0, alors X n'est pas 2-méthylphényle, et à condition en outre que, quand Y est -NH-, R₁, R₂ et R₃ sont hydrogène, R₄ est R₅-CONH (CH₂)_p-, R₅ est 2,6-dichlorophényle, n est 1 et p est 0, alors X n'est pas pyridin-2-yle ; et un excipient pharmaceutiquement acceptable.

24. Composé de formule



dans laquelle :

X est cycloalkyle de 3 à 7 atomes de carbone qui peut être facultativement substitué avec un ou plusieurs groupements alkyle de 1 à 6 atomes de carbone ; ou est un cycle pyridinyle, pyrimidinyle ou phényle ; où le cycle pyridinyle, pyrimidinyle ou phényle peut être facultativement mono-, di- ou trisubstitué avec un substituant choisi parmi le groupe constitué d'halogène, d'alkyle de 1-6 atomes de carbone, d'alcényle de 2-6 atomes de





carbone, d'alcynyle de 2-6 atomes de carbone, d'azido, d'hydroxyalkyle de 1-6 atomes de carbone, d'halométhyle, d'alkoxyméthyle de 2-7 atomes de carbone, d'alcanoyloxyméthyle de 2-7 atomes de carbone, d'alkoxy de 1-6 atomes de carbone, d'alkylthio de 1-6 atomes de carbone, d'hydroxy, de trifluorométhyle, de cyano, de nitro, de carboxy, de carboalkoxy de 2-7 atomes de carbone, de carboalkyle de 2-7 atomes de carbone, de phénoxy, de phényle, de thiophénoxy, de benzoyle, de benzyle, d'amino, d'alkylamino de 1-6 atomes de carbone, de dialkylamino de 2 à 12 atomes de carbone, de phénylamino, de benzylamino, d'alcanoylamino de 1-6 atomes de carbone, d'alcénoylamino de 3-8 atomes de carbone, d'alcinoylamino de 3-8 atomes de carbone et de benzylamino ;




n est 0-1 ;

Y est -NH-, -O-, -S- ou -NR- ;

R est alkyle de 1-6 atomes de carbone ;

R₁, R₂, R₃ et R₄ sont chacun, indépendamment, hydrogène, halogène, alkyle de 1-6 atomes de carbone, alcényle de 2-6 atomes de carbone, alcynyle de 2-6 atomes de carbone, alcényloxy de 2-6 atomes de carbone, alcynyloxy de 2-6 atomes de carbone, hydroxyméthyle, halométhyle, alcanoyloxy de 1-6 atomes de carbone, alcénoylxy de 3-8 atomes de carbone, alcynoyloxy de 3-8 atomes de carbone, alcanoyloxyméthyle de 2-7 atomes de carbone, alcénoylloxyméthyle de 4-9 atomes de carbone, alcynoyloxyméthyle de 4-9 atomes de carbone, alkoxyméthyle de 2-7 atomes de carbone, alkoxy de 1-6 atomes de carbone, alkylthio de 1-6 atomes de carbone, alkyisulfinyle de 1-6 atomes de carbone, alkyisulfonyl de 1-6 atomes de carbone, alkylsulfonamido de 1-6 atomes de carbone, alcénylsulfonamido de 2-6 atomes de carbone, alcynylsulfonamido de 2-6 atomes de carbone, hydroxy, trifluorométhyle, cyano, nitro, carboxy, carboalkoxy de 2-7 atomes de carbone, carboalkyle de 2-7 atomes de carbone, phénoxy, phényle, thiophénoxy, benzyle, amino, hydroxyamino, alkoxyamino de 1-4 atomes de carbone, alkylamino de 1-6 atomes de carbone, dialkylamino de 2 à 12 atomes de carbone, aminoalkyle de 1-4 atomes de carbone, N-alkylaminoalkyle de 2-7 atomes de carbone, N,N-dialkylaminoalkyle de 3-14 atomes de carbone, phénylamino, benzylamino,





R₅ est alkyle de 1-6 atomes de carbone, alkyle facultativement substitué avec un ou plusieurs atomes d'halogène, groupements phényle ou phényle facultativement substitué avec un ou plusieurs halogènes, alkoxy de 1-6 atomes de carbone, trifluorométhyle, amino, nitro, cyano ou alkyle de 1-6 atomes de carbone ;

R₆ est hydrogène, alkyle de 1-6 atomes de carbone ou alcényle de 2-6 atomes de carbone ;

R₇ est chloro ou bromo ;

R₈ est hydrogène, alkyle de 1-6 atomes de carbone, aminoalkyle de 1-6 atomes de carbone, N-alkylaminoalkyle de 2-9 atomes de carbone, N,N-dialkylaminoalkyle de 3-12 atomes de carbone, N-cycloalkylaminoalkyle de 4-12 atomes de carbone, N-cycloalkyl-N-alkylaminoalkyle de 5-18 atomes de carbone, N,N-dicycloalkylaminoalkyle de 7-18 atomes de carbone, morpholino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone, pipéridino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone, N-alkylpipéridino-N-alkyle où chaque groupement alkyle est de 1-6 atomes de carbone, azacycloalkyl-N-alkyle de 3-11 atomes de carbone, hydroxyalkyle de 1-6 atomes de carbone, alkoxyalkyle de 2-8 atomes de carbone, carboxy, carboalkoxy de 1-6 atomes de carbone, phényle, carboalkyle de 2-7 atomes de carbone, chloro, fluoro ou bromo ;

Z est amino, hydroxy, alkoxy de 1-6 atomes de carbone, alkylamino où la partie alkyle est de 1-6 atomes de carbone, dialkylamino où chacune des parties alkyle est de 1-6 atomes de carbone, morpholino, pipérazino, N-alkylpipérazino où la partie alkyle est de 1-6 atomes de carbone ou pyrrolidino ;

m = 1-4, q = 1-3 et p = 0-3 ;

n'importe lequel des substituants R₁, R₂, R₃ ou R₄ qui sont situés sur des atomes de carbone contigus peuvent conjointement être le radical divalent -O-C(R₈)₂-O- ;

ou un sel pharmaceutiquement acceptable de celui-ci, à condition que, quand Y est -NH-, R₁, R₂, R₃ et R₄ sont hydrogène, et n est 0, alors X n'est pas 2-méthylphényle, et à condition en outre que, quand Y est -NH-, R₁, R₂, R₃ sont hydrogène, R₄ est R₅-CoNH(CH₂)_p-, R₅ est 2,6-dichloro-phényle, n est 1 et p est 0, alors X n'est pas pyridin-2-yle ; pour utilisation comme agent thérapeutique.

25. Composé de formule 1 comme défini dans la revendication 24 pour utilisation dans l'inhibition des effets biologiques d'une protéine kinase dérégulée chez un mammifère qui en a besoin.

26. Composé de formule 1 comme défini dans la revendication 24 pour utilisation dans le traitement, l'inhibition de

croissance ou l'éradication d'un néoplasme chez un mammifère qui en a besoin.

27. Composé de formule 1 comme défini dans la revendication 26 dans lequel le néoplasme exprime EGFR.

28. Composé de formule 1 comme défini dans la revendication 26 dans lequel le néoplasme exprime MAPK.


29. Composé de formule 1 comme défini dans la revendication 26 dans lequel le néoplasme exprime ECK.

30. Composé de formule 1 comme défini dans la revendication 26 dans lequel le néoplasme exprime KDR.

31. Composé de formule 1 comme défini dans la revendication 26 où le néoplasme est choisi parmi le groupe constitué du néoplasme du sein, du rein, de la vessie, de la bouche, du larynx, de l'oesophage, de l'estomac, du colon, de l'ovaire et du poumon.

32. Composé de formule 1 comme défini dans la revendication 24 pour utilisation dans le traitement, l'inhibition de la progression ou l'éradication de la maladie polykystique des reins chez un mammifère.

33. Utilisation d'un composé de formule



dans laquelle :

X est cycloalkyle de 3 à 7 atomes de carbone qui peut être facultativement substitué avec un ou plusieurs groupements alkyle de 1 à 6 atomes de carbone ; ou est un cycle pyridinyle, pyrimidinyle ou phényle ; où le cycle pyridinyle, pyrimidinyle ou phényle peut être facultativement mono-, di- ou trisubstitué avec un substituant choisi parmi le groupe constitué d'halogène, d'alkyle de 1-6 atomes de carbone, d'alcényle de 2-6 atomes de carbone, d'alcynyle de 2-6 atomes de carbone, d'azido, d'hydroxyalkyle de 1-6 atomes de carbone, d'halométhyle, d'alkoxyméthyle de 2-7 atomes de carbone, d'alcanoyloxyméthyle de 2-7 atomes de carbone, d'alkoxy de 1-6 atomes de carbone, d'alkylthio de 1-6 atomes de carbone, d'hydroxy, de trifluorométhyle, de cyano, de nitro, de carboxy, de carboalkoxy de 2-7 atomes de carbone, de carboalkyle de 2-7 atomes de carbone, de phénoxy, de phényle, de thiophénoxy, de benzoyle, de benzyle, d'amino, d'alkylamino de 1-6 atomes de carbone, de dialkylamino de 2 à 12 atomes de carbone, de phénylamino, de benzylamino, d'alcanoylamino de 1-6 atomes de carbone, d'alcénoylamino de 3-8 atomes de carbone, d'alcinoylamino de 3-8 atomes de carbone et de benzylamino ;







n est 0-1 ;


Y est -NH-, -O-, -S- ou -NR- ;

R est alkyle de 1-6 atomes de carbone ;

R₁, R₂, R₃ et R₄ sont chacun, indépendamment, hydrogène, halogène, alkyle de 1-6 atomes de carbone, alcényle de 2-6 atomes de carbone, alcynyle de 2-6 atomes de carbone, alcényloxy de 2-6 atomes de carbone, alcynioxy de 2-6 atomes de carbone, hydroxyméthyle, halométhyle, alcanoyloxy de 1-6 atomes de carbone, alcénoyloxy de 3-8 atomes de carbone, alcynoyloxy de 3-8 atomes de carbone, alcanoyloxyméthyle de 2-7 atomes de carbone, alcénoyloxyméthyle de 4-9 atomes de carbone, alcynoyloxyméthyle de 4-9 atomes de carbone, alkoxyméthyle de 2-7 atomes de carbone, alkoxy de 1-6 atomes de carbone, alkylthio de 1-6 atomes de carbone, alkylsulfinyle de 1-6 atomes de carbone, alkylsulfonyl de 1-6 atomes de carbone, alkylsulfonamido de 1-6 atomes de carbone, alcénylsulfonamido de 2-6 atomes de carbone, alcynylsulfonamido de 2-6

atomes de carbone, hydroxy, trifluorométhyle, cyano, nitro, carboxy, carboalkoxy de 2-7 atomes de carbone, carboalkyle de 2-7 atomes de carbone, phénoxy, phényle, thiophénoxy, benzyle, amino, hydroxyamino, alkoxyamino de 1-4 atomes de carbone, alkylamino de 1-6 atomes de carbone, dialkylamino de 2 à 12 atomes de carbone, aminoalkyle de 1-4 atomes de carbone, N-alkylaminoalkyle de 2-7 atomes de carbone, N,N-dialkylaminoalkyle de 3-14 atomes de carbone, phénylamino, benzylamino,





R₅ est alkyle de 1-6 atomes de carbone, alkyle facultativement substitué avec un ou plusieurs atomes d'halogène, groupements phényle ou phényle facultativement substitué avec un ou plusieurs halogènes, alkoxy de 1-6 atomes de carbone, trifluorométhyle, amino, nitro, cyano ou alkyle de 1-6 atomes de carbone ;

R₆ est hydrogène, alkyle de 1-6 atomes de carbone ou alcényle de 2-6 atomes de carbone ;

R₇ est chloro ou bromo ;

R₈ est hydrogène, alkyle de 1-6 atomes de carbone, aminoalkyle de 1-6 atomes de carbone, N-alkylaminoalkyle de 2-9 atomes de carbone, N,N-dialkylaminoalkyle de 3-12 atomes de carbone, N-cycloalkylaminoalkyle de 4-12 atomes de carbone, N-cycloalkyl-N-alkylaminoalkyle de 5-18 atomes de carbone, N,N-dicycloalkylaminoalkyle de 7-18 atomes de carbone, morpholino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone, pipéridino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone, N-alkylpipéridino-N-alkyle où chaque groupement alkyle est de 1-6 atomes de carbone, azacycloalkyl-N-alkyle de 3-11 atomes de carbone, hydroxyalkyle de 1-6 atomes de carbone, alkoxyalkyle de 2-8 atomes de carbone, carboxy, carboalkoxy de 1-6 atomes de carbone, phényle, carboalkyle de 2-7 atomes de carbone, chloro, fluoro ou bromo ;


Z est amino, hydroxy, alkoxy de 1-6 atomes de carbone, alkylamino où la partie alkyle est de 1-6 atomes de carbone, dialkylamino où chacune des parties alkyle est de 1-6 atomes de carbone, morpholino, pipérazino, N-alkylpipérazino où la partie alkyle est de 1-6 atomes de carbone ou pyrrolidino ;

m = 1-4, q = 1-3 et p = 0-3 ;

n'importe lequel des substituants R₁, R₂, R₃ ou R₄ qui sont situés sur des atomes de carbone contigus peuvent conjointement être le radical divalent -O-C(R₈)₂-O- ;

ou un sel pharmaceutiquement acceptable de celui-ci, à condition que, quand Y est -NH-, R₁, R₂, R₃ et R₄ sont hydrogène, et n est 0, alors X n'est pas 2-méthylphényle, et à condition en outre que, quand Y est -NH-, R₁, R₂, R₃ sont hydrogène, R₄ est R₅-CONH(CH₂)_p-, R₅ est 2,6-dichloro-phényle, n est 1 et p est 0, alors X n'est pas pyridin-2-yle ; dans la préparation d'un médicament pour le traitement, l'inhibition de la croissance ou l'éradication d'un néoplasme chez un mammifère qui en a besoin ; ou pour l'inhibition des effets biologiques d'une protéine kinase dérégulée chez un mammifère qui en a besoin.

34. Utilisation d'un composé de formule



dans laquelle :

X est cycloalkyle de 3 à 7 atomes de carbone, qui peut être facultativement substitué avec un ou plusieurs groupements alkyle de 1 à 6 atomes de carbone ; ou est un cycle pyridinyle, pyrimidinyle ou phényle ; où le cycle pyridinyle, pyrimidinyle ou phényle peut être facultativement mono-, di- ou trisubstitué avec un substituant choisi parmi le groupe constitué d'halogène, d'alkyle de 1-6 atomes de carbone, d'alcényle de 2-6 atomes de carbone, d'alcynyle de 2-6 atomes de carbone, d'azido, d'hydroxyalkyle de 1-6 atomes de carbone, d'halométhyle, d'alkoxyméthyle de 2-7 atomes de carbone, d'alcanoyloxyméthyle de 2-7 atomes de carbone, d'alkoxy





de 1-6 atomes de carbone, d'alkylthio de 1-6 atomes de carbone, d'hydroxy, de trifluorométhyle, de cyano, de nitro, de carboxy, de carboalkoxy de 2-7 atomes de carbone, de carboalkyle de 2-7 atomes de carbone, de phénoxy, de phényle, de thiophénoxy, de benzoyle, de benzyle, d'amino, d'alkylamino de 1-6 atomes de carbone, de dialkylamino de 2 à 12 atomes de carbone, de phénylamino, de benzylamino, d'alcanoylamino de 1-6 atomes de carbone, d'alcénoylamino de 3-8 atomes de carbone, d'alcinoylamino de 3-8 atomes de carbone et de benzylamino ;




n est 0-1 ;

Y est -NH-, -O-, -S- ou -NR- ;

R est alkyle de 1-6 atomes de carbone ;

R₁, R₂, R₃ et R₄ sont chacun, indépendamment, hydrogène, halogène, alkyle de 1-6 atomes de carbone, alcényle de 2-6 atomes de carbone, alcynyle de 2-6 atomes de carbone, alcényloxy de 2-6 atomes de carbone, alcynyloxy de 2-6 atomes de carbone, hydroxyméthyle, halométhyle, alcanoyloxy de 1-6 atomes de carbone, alcénoyloxy de 3-8 atomes de carbone, alcynoyloxy de 3-8 atomes de carbone, alcanoyloxyméthyle de 2-7 atomes de carbone, alcénoyloxyméthyle de 4-9 atomes de carbone, alcynoyloxyméthyle de 4-9 atomes de carbone, alkoxy de 1-6 atomes de carbone, alkylthio de 1-6 atomes de carbone, alkylsulfinyle de 1-6 atomes de carbone, alkylsulfonyl de 1-6 atomes de carbone, alkylsulfonamido de 1-6 atomes de carbone, alcénylsulfonamido de 2-6 atomes de carbone, alcynylsulfonamido de 2-6 atomes de carbone, hydroxy, trifluorométhyle, cyano, nitro, carboxy, carboalkoxy de 2-7 atomes de carbone, carboalkyle de 2-7 atomes de carbone, phénoxy, phényle, thiophénoxy, benzyle, amino, hydroxyamino, alkoxyamino de 1-4 atomes de carbone, alkylamino de 1-6 atomes de carbone, dialkylamino de 2 à 12 atomes de carbone, aminoalkyle de 1-4 atomes de carbone, N-alkylaminoalkyle de 2-7 atomes de carbone, N,N-dialkylaminoalkyle de 3-14 atomes de carbone, phénylamino, benzylamino,





R₅ est alkyle de 1-6 atomes de carbone, alkyle facultativement substitué avec un ou plusieurs atomes d'halogène, groupements phényle ou phényle facultativement substitué avec un ou plusieurs halogènes, alkoxy de 1-6 atomes de carbone, trifluorométhyle, amino, nitro, cyano ou alkyle de 1-6 atomes de carbone ;

R₆ est hydrogène, alkyle de 1-6 atomes de carbone ou alcényle de 2-6 atomes de carbone ;

R₇ est chloro ou bromo ;

R₈ est hydrogène, alkyle de 1-6 atomes de carbone, aminoalkyle de 1-6 atomes de carbone, N-alkylaminoalkyle de 2-9 atomes de carbone, N,N-dialkylaminoalkyle de 3-12 atomes de carbone, N-cycloalkylaminoalkyle de 4-12 atomes de carbone, N-cycloalkyl-N-alkylaminoalkyle de 5-18 atomes de carbone, N,N-dicycloalkylaminoalkyle de 7-18 atomes de carbone, morpholino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone, pipéridino-N-alkyle où le groupement alkyle est de 1-6 atomes de carbone, N-alkylpipéridino-N-alkyle où chaque groupement alkyle est de 1-6 atomes de carbone, azacycloalkyl-N-alkyle de 3-11 atomes de carbone, hydroxyalkyle de 1-6 atomes de carbone, alkoxyalkyle de 2-8 atomes de carbone, carboxy, carboalkoxy de 1-6 atomes de carbone, phényle, carboalkyle de 2-7 atomes de carbone, chloro, fluoro ou bromo ;


Z est amino, hydroxy, alkoxy de 1-6 atomes de carbone, alkylamino où la partie alkyle est de 1-6 atomes de carbone, dialkylamino où chacune des parties alkyle est de 1-6 atomes de carbone, morpholino, pipérazino, N-alkylpipérazino où la partie alkyle est de 1-6 atomes de carbone ou pyrrolidino ;

m = 1-4, q = 1-3 et p = 0-3 ;


n'importe lequel des substituants R₁, R₂, R₃ ou R₄ qui sont situés sur des atomes de carbone contigus peuvent conjointement être le radical divalent -O-C(R₈)₂-O- ;

ou un sel pharmaceutiquement acceptable de celui-ci, à condition que quand Y est -NH-, R₁, R₂, R₃ et R₄ sont hydrogène, et n est 0, alors X n'est pas 2-méthylphényle ; dans la préparation d'un médicament pour le traitement, l'inhibition de la progression ou l'éradication de la maladie polykystique des reins chez un mammifère.


35. Procédé pour la préparation de composés de formule




dans laquelle Y et n sont comme définis dans la revendication 1 et X' est cycloalkyle ou phényle facultativement substitué avec un ou plusieurs substituants choisis parmi le groupe consistant en hydrogène, halogène, alkyle de 1-6 atomes de carbone, alcényle de 2-6 atomes de carbone, alcynyle de 2-6 atomes de carbone, halométhyle, alkoxy de 1-6 atomes de carbone, alkylthio de 1-6 atomes de carbone, trifluorométhyle, cyano, nitro, carboalkyle de 2-7 atomes de carbone, phénoxy, phényle, thiophénoxy, benzyle, dialkylamino de 2 à 12 atomes de carbone ; R₁', R₂', R₃' et R₄' sont chacun, indépendamment, hydrogène, halogène, alkyle de 1-6 atomes de carbone, alcényle de 2-6 atomes de carbone, alcynyle de 2-6 atomes de carbone, alcényloxy de 2-6 atomes de carbone, alcynyloxy de 2-6 atomes de carbone, halométhyle, alkoxyméthyle de 2-7 atomes de carbone, alkoxy de 1-6 atomes de carbone, alkylthio de 1-6 atomes de carbone, alkylsulfinyle de 1-6 atomes de carbone, alkylsulfonyl de 1-6 atomes de carbone, alkylsulfonamido de 1-6 atomes de carbone, trifluorométhyle, cyano, nitro, carboxy, carboalkyle de 2-7 atomes de carbone, phénoxy, phényle, thiophénoxy, benzyle, alkoxyamino de 1-4 atomes de carbone, dialkylamino de 2 à 12 atomes de carbone, N,N-dialkylaminoalkyle de 3-14 atomes de carbone, phénylamino, benzylamino, N-alkylcarbamoyl de 1-6 atomes de carbone, N,N-dialkylcarbamoyl de 2-12 atomes de carbone ; ou n'importe lequel des substituants R₁', R₂', R₃' et R₄' qui sont situés sur des atomes de carbone contigus peuvent conjointement être le radical divalent -O-C(R₈)₂-O- ; à condition que, quand Y est -NH-, R₁', R₂', R₃' et R₄' sont hydrogène et n est 0, alors X' n'est pas 2-méthylphényle ; comprenant l'hydrolyse d'un ester d'acide de formule 2



où R' est un radical alkyle contenant 1-6 atomes de carbone, avec une base pour former le composé de formule 3




puis la conversion du groupement d'acide carboxylique de la formule 3 en un acylimidazole en le chauffant avec du carbonylimidazole dans un solvant inerte suivi par l'addition d'ammoniaque pour donner l'amide de formule 4




puis la réaction avec un agent déshydratant pour fournir le composé de formule 5 ci-dessus ; et facultativement après cela, la formation d'un sel pharmaceutiquement acceptable de celui-ci.

36. Procédé pour la préparation des composés de formule 10 ou 11













ou




dans lesquelles Y, p et n sont comme définis dans la revendication 1 et X'' est choisi parmi le groupe consistant en cycloalkyle ou phényle facultativement substitué avec un ou plusieurs substituants choisis parmi le groupe consistant en hydrogène, halogène, alkyle de 1-6 atomes de carbone, alcényle de 2-6 atomes de carbone, alcynyle de 2-6 atomes de carbone, halométhyle, alcoxyméthyle de 2-7 atomes de carbone, alcanoyloxyméthyle de 2-7 atomes de carbone, alkoxy de 1-6 atomes de carbone, alkylthio de 1-6 atomes de carbone, trifluorométhyle, cyano, nitro, carboxy, carboalkoxy de 2-7 atomes de carbone, carboalkyle de 2-7 atomes de carbone, phénoxy, phényle, thiophénoxy, benzoyle, benzyle, dialkylamino de 2 à 12 atomes de carbone, phénylamino, benzylamino, alcanoylamino de 1-6 atomes de carbone, alcénoylamino de 3-8 atomes de carbone, alcynoylamino de 3-8 atomes de carbone et benzoylamino, R₉ est indépendamment hydrogène, phényle ou alkyle de 1-6 atomes de carbone, les parties (R₁₀)_k représentent 1 à 3 substituants sur le cycle aromatique qui peuvent être identiques ou différentes et sont choisis indépendamment parmi le groupe consistant en hydrogène, halogène, alkyle de 1-6 atomes de carbone, alcényle de 2-6 atomes de carbone, alcynyle de 2-6 atomes de carbone, alcényloxy de 2-6 atomes de carbone, alcoxyméthyle de 2-7 atomes de carbone, alkoxy de 1-6 atomes de carbone, alkylthio de 1-6 atomes de carbone, alkylsulfinyle de 1-6 atomes de carbone, alkylsulfonyl de 1-6 atomes de carbone, trifluorométhyle, cyano, nitro, carboxy, carboalkyle de 2-7 atomes de carbone,


phénoxy, phényle, thiophénoxy, benzyle, alkoxyamino de 1-4 atomes de carbone, dialkylamino de 2 à 12 atomes de carbone, N,N-dialkylaminoalkyle de 3-14 atomes de carbone, phénylamino, benzylamino, N-alkylcarbamoyle de 1-6 - atomes de carbone, N , N-dialkylcarbamoyle de 2-12 atomes de carbone. R_{11} est un radical et est choisi parmi le groupe :




où q, m, R_5 , R_6 , R_7 et R_8 sont comme définis dans la revendication 1 ; qui comprend l'acylation du composé de formule 6



15 avec soit le chlorure d'acide de formule 8 soit un anhydride mixte de formule 9 où R''' est alkyle de 1 à 6 atomes de carbone




25 en présence d'une base organique pour donner le composé de formule 11 ; ou en variante l'acylation du composé de formule 6 avec un anhydride cyclique de formule 7




35 en présence d'un catalyseur basique pour fournir le composé de formule 10 ; et facultativement après cela, la formation d'un sel pharmaceutiquement acceptable de celui-ci.


40 **37.** Procédé pour la préparation des composés de formule 18




55 X, Y, n sont comme définis dans la revendication 1 et R1', R2', R3' et R4' sont comme définis dans la revendication 35, à condition que, quand Y est -NH-, R1', R2', R3' et R4' sont hydrogène, et n est 0, alors X n'est pas 2-méthylphényle ; qui comprend le chauffage d'une aniline substituée de formule 12

**12**


avec un réactif de formule 13

**13**


pour donner un composé de formule 14

**14**


qui est ensuite thermolysé dans un solvant à point d'ébullition élevé pour donner un composé de formule 15 ;

**15**

ensuite le chauffage du composé de formule 15 avec un agent de chloration pour donner un composé de formule 16


**16**

qui est condensé avec un composé de formule 17




pour donner les composés de formule 18 ; et facultativement après cela, la formation d'un sel pharmaceutiquement acceptable de celui-ci.


38. Procédé pour la préparation du composé de formule 15

**15**

dans laquelle R₁' , R₂' , R₃' et R₄' sont comme définis dans la revendication 35 comprenant le chauffage du composé de formule 19


**19**

avec le diméthylacétal de diméthylformamide pour donner un composé de formule 20



qui est ensuite mis à réagir avec de l'acétonitrile en présence d'une base pour donner un composé de formule 15.

39. Procédé pour la préparation de composés de formule 22 dans laquelle R_1 , R_2 , R_3 et R_4 et n sont comme définis dans la revendication 1 et X' est défini dans la revendication 35 :



qui comprend :

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement nitro, la conversion en groupement amino correspondant en utilisant un agent réducteur ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement amino, la conversion en groupement dialkylamino correspondant de 2 à 12 atomes de carbone par alkylation avec un halogénure d'alkyle de 1 à 6 atomes de carbone ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement méthoxy, la conversion en groupement hydroxy correspondant par réaction avec un agent de déméthylation ou le chlorure de pyridinium ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est un groupement amino, la conversion en groupement correspondant alkylsulfonamido, alcénysulfonamido ou alcynylsulfonamido de 2-6 atomes de carbone, par réaction avec un chlorure d'alkylsulfonyl, un chlorure d'alcénysulfonyl ou un chlorure d'alcynylsulfonyl, respectivement, en utilisant un catalyseur basique ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement amino, la conversion en groupement alcénysulfonamido correspondant par réaction avec un réactif de $Cl-C(R_6')_2-CH(R_6')SO_2Cl$ où R_6' est hydrogène ou alkyle de 1-4 atomes de carbone en utilisant un excès d'une base organique ;

si deux des R_1 , R_2 , R_3 et R_4 sont des groupements méthoxy contigus, la conversion en composé avec des groupements hydroxy contigus par réaction avec un agent de déméthylation ou par chauffage avec du chlorure de pyridinium ;

si deux des R_1 , R_2 , R_3 et R_4 sont des groupements hydroxy contigus, la conversion en composé où conjointement les deux groupements R_1 , R_2 , R_3 ou R_4 contigus sont le radical $-O-C(R_8)_2-O-$ divalent où R_8 est défini dans la revendication 1, par la réaction avec $J-C(R_8)_2-J$ où J est chloro, bromo ou iodo et chaque J peut être identique ou différent, en utilisant une base ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement amino, la conversion en groupement alkylamino correspondant de 1 à 6 atomes de carbone par alkylation avec un halogénure d'alkyle de 1 à 6 atomes de carbone ou par alkylation réductrice en utilisant un aldéhyde de 1 à 6 atomes de carbone et un agent réducteur ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement hydroxy, la conversion en groupement alcanoyloxy correspondant de 1-6 atomes de carbone par réaction avec un chlorure, un anhydride ou un anhydride

mixte d'acide carboxylique approprié dans un solvant inerte avec un catalyseur ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement hydroxy, la conversion en groupement alcénoyloxy correspondant de 1-6 atomes de carbone par réaction avec un chlorure, un anhydride ou un anhydride


mixte d'acide carboxylique approprié dans un solvant inerte avec un catalyseur ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement carboxy ou carboalkoxy de 2-7 atomes de carbone, la conversion en groupement hydroxyméthyle correspondant par réduction avec un agent réducteur ; facultativement la conversion du groupement hydroxyméthyle en groupement halométhyle correspondant par réaction avec un agent d'halogénéation ; ou facultativement l'acylation du groupement hydroxyméthyle avec un chlorure, anhydride ou anhydride mixte d'acide dans un solvant inerte avec un catalyseur pour donner les groupements correspondants alcanoyloxyméthyle de 2-7 atomes de carbone, alcénoyloxyméthyle de 2-7 atomes de carbone ou alcynoyloxyméthyle de 2-7 atomes de carbone ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement halométhyle, la conversion en groupement alkoxyméthyle de 2-7 atomes de carbone par déplacement de l'atome d'halogène avec un alcoolate de sodium dans un solvant inerte ;


si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement halométhyle, la conversion en groupement aminométhyle, groupement N-alkylaminométhyle de 2-7 atomes de carbone ou groupement N,N-dialkylaminométhyle de 3-14 atomes de carbone par déplacement de l'atome d'halogène avec l'ammoniaque, une aminé primaire ou secondaire, respectivement dans un solvant inerte ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement $H_2N(CH_2)_p-$, la conversion en groupements correspondants :




où R_5 et p sont comme définis dans la revendication 1, par réaction avec du phosgène dans un solvant inerte en présence d'une base pour donner un isocyanate qui est traité avec un excès d'alcool R_5-OH ou d'amines R_5-NH_2 ou $(R_5)_2NH$, respectivement ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement $HO(CH_2)_p-$, la conversion en groupements correspondants :



où R_5 et p sont comme définis ci-dessus, par réaction dans un solvant inerte en utilisant un catalyseur basique avec un chloroformiate d'alkyle ou de phényle approprié, $R_5-OCOCl$, un isocyanate substitué par alkyle ou phényle, $R_5-N=C-O$, ou un chlorure d'acide carboxylique substitué par alkyle ou phényle, R_5-COCl , respectivement ;

si un ou plusieurs des R_1 , R_2 , R_3 et R_4 est/sont un groupement $HO(CH_2)_p-$, la conversion en groupement correspondant :



EP 0 973 746 B1

où R_5 et p sont comme définis ci-dessus, par réaction dans un solvant inerte en utilisant un catalyseur basique avec un réactif $(R_5)_2NCoCl$.

5

10

15

20

25

30

35

40

45

50

55